Pyrazole derivatives

ABSTRACT

This invention relates to pyrazole derivatives of formula (I)  
                 
 
     or pharmaceutically acceptable salts, solvates or derivatives thereof, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such, the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This non-provisional patent application claims priority to United Kingdom Application No. 0108999.4, filed Apr. 10, 2001, United Kingdom Application No. 0127426.5, filed Nov. 15, 2001, U.S. patent application Ser. No. 289,570, filed May 8, 2001, and U.S. patent application Ser. No. 346,727, filed Jan. 7, 2002, each of which is hereby incorporated in its entirety.

FIELD OF THE INVENTION

[0002] This invention relates to pyrazole derivatives and to processes for the preparation thereof, intermediates used in their preparation, compositions containing them and the uses of such derivatives.

[0003] The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. Reverse transcriptase is implicated in the infectious lifecycle of HIV, and compounds which interfere with the function of this enzyme have shown utility in the treatment of conditions including AIDS. There is a constant need to provide new and better modulators, especially inhibitors, of HIV reverse transcriptase since the virus is able to mutate, becoming resistant to the effects of known modulators.

[0004] The compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).

[0005] European patent application EP 0 786 455 A1 discloses a class of imidazole compounds which inhibit the growth of HIV. A class of N-phenylpyrazoles which act as reverse transcriptase inhibitors are disclosed in J. Med. Chem., 2000, 43,1034. Antiviral activity is ascribed to a class of N-(hydroxyethyl)pyrazole derivatives in U.S. Pat. No. 3,303,200.

[0006] According to the present invention there is provided a compound of the formula

[0007] or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein:

[0008] either R¹ is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl, benzyl, halo, —CN, —OR⁷, —CO₂R¹⁰, —CONR⁵R¹⁰, R⁸ or R⁹, said C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl and benzyl being unsubstituted or substituted by halo, —CN, —OR¹⁰, S(O)XR¹¹, —CO₂R¹⁰, —CONR⁵R¹⁰, —OCONR⁵R¹⁰, —NR⁵CO₂R¹¹, —NR¹⁰R¹⁰R¹¹, —NR⁵COR¹⁰, —SO₂NR⁵R¹⁰, —NR⁵CONR⁵R¹⁰, —NR⁵SO₂R¹⁰ or R¹⁰; and

[0009] R² is H, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, C₃-C₇ cycloalkyl, C₃-C₇ cycloalkenyl, phenyl, benzyl, R⁸ or R⁹, said C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl and benzyl being unsubstituted or substituted by halo, —OR⁵, —OR¹², —CN, —CO₂R⁷, —OCONR⁵R⁵, —CONR⁵R⁵, —C(═NR⁵)NR⁵OR⁵, —CONR⁵NR⁵R⁵, —NR⁶R⁶, —NR⁵R¹², —NR⁵COR⁵, —NR⁵COR⁸, —NR⁵COR¹², —NR⁵CO₂R⁵, —NR⁵CONR⁵R⁵, —SO₂NR⁵R⁵, —NR⁵SO₂R⁵, —NR⁵SO₂NR⁵R⁵, R⁸ or R⁹;

[0010] or, R¹ and R², when taken together, represent unbranched C₃-C₄ alkylene, unsubstituted or substituted by oxo, wherein one methylene group of said C₃-C₄ alkylene may be replaced by an oxygen atom or a nitrogen atom, said nitrogen atom being unsubstituted or substituted by R¹⁰;

[0011] R³ is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl, benzyl, halo, —CN, —OR⁷, —CO₂R⁵, —CONR⁵R⁵, R⁸ or R⁹, said C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl and benzyl being unsubstituted or substituted by halo, —CN, —OR⁵, —CO₂R⁵, —CONR⁵R⁵, —OCONR⁵R⁵, —NR⁵CO₂R⁵, —NR⁶R⁶, —NR⁵COR⁵, —SO₂NR⁵R⁵, —NR⁵CONR⁵R⁵, —NR⁵SO₂R⁵, R⁸ or R⁹;

[0012] R⁴ is phenyl, naphthyl or pyridyl, each being unsubstituted or substituted by R⁸, halo, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl, C₁-C₆ alkoxy, —CONR⁵R⁵, OR¹³, So_(x)R⁶, O—(C₁-C₆ alkylene)-CONR⁵R⁵, O—(C₁-C₆ alkylene)-NR⁵R⁵, or O—(C₁-C₆ alkylene)—OR⁶;

[0013] each R⁵ is independently either H, C₁-C₆ alkyl or C₃-C₇ cycloalkyl or, when two R⁵ groups are attached to the same nitrogen atom, those two groups taken together with the nitrogen atom to which they are attached represent azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl or morpholinyl, said azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl and morpholinyl being unsubstituted or substituted by C₁-C₆ alkyl or C₃-C₇ cycloalkyl;

[0014] each R⁶ is independently either H, C₁-C₆ alkyl or C₃-C₇ cycloalkyl;

[0015] R⁷ is C₁-C₆ alkyl or C₃-C₇ cycloalkyl;

[0016] R⁸ is a five or six-membered, aromatic heterocyclic group containing (i) from 1 to 4 nitrogen heteroatom(s) or (ii) 1 or 2 nitrogen heteroatom(s) and 1 oxygen or 1 sulphur heteroatom or (iii) 1 or 2 oxygen or sulphur heteroatom(s), said heterocyclic group being unsubstituted or substituted by halo, oxo, —CN, —COR⁵, —CONR⁵R⁵, —SO₂NR⁵R⁵, —NR⁵SO₂R⁵, —OR⁵, —NR⁵R⁵, —(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, fluoro(C₁-C₆)alkyl or C₃-C₇ cycloalkyl;

[0017] R⁹ is a four to seven-membered, saturated or partially unsaturated heterocyclic group containing (i) 1 or 2 nitrogen heteroatom(s) or (ii) 1 nitrogen heteroatom and 1 oxygen or 1 sulphur heteroatom or (iii) 1 oxygen or sulphur heteroatom, said heterocyclic group being unsubstituted or substituted by oxo, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, —SO₂R⁵, —CONR⁵R⁵, —COOR⁵, —CO—(C₁-C₆ alkylene)-OR⁵ or —COR⁵ and unsubstituted or substituted on a carbon atom which is not adjacent to a heteroatom by halo, —OR⁵, —NR⁵R⁵, —NR⁵COR⁵, —NR⁵COOR⁵, —NR⁵CONR⁵R⁵, —NR⁵SO₂R⁵ or —CN;

[0018] R¹⁰ is H, R⁸, R⁹, R¹³, C₁-C₆ alkyl, C₃-C₇ cycloalkyl or —(C₁-C₆ alkyl)-(C₃-C₇ cycloalkyl), said C₁-C₆ alkyl and C₃-C₇ cycloalkyl being unsubstituted or substituted by —OR⁵, —OR¹³, R⁸, R⁹, R¹³ or —COR¹³;

[0019] R¹¹ is H, C₁-C₆ alkyl or C₃-C₇ cycloalkyl, said C₁-C₆ alkyl and C₃-C₇ cycloalkyl being unsubstituted or substituted by —OR⁵, —NR⁵R⁵, —NR⁵COR⁵, —CONR⁵R⁵, R⁸ or R⁹;

[0020] R¹² is C₁-C₆ alkyl substituted by R⁸, R⁹, —OR⁵, —CONR⁵R⁵, —NR⁵COR⁵ or —NR⁵R⁵;

[0021] R¹³ is phenyl unsubstituted or substituted by halo, —CN, —COR⁵, —CONR⁵R⁵, —SO₂NR⁵R⁵, —NR⁵SO₂R⁵, —OR⁵, —NR⁵R⁵, —(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, halo(C₁-C₆)alkyl or C₃-C₇ cycloalkyl; and

[0022] x is 0, 1 or 2;

[0023] with the proviso that (a) when R¹ and R³ are both phenyl, R² is not methyl; and (b) when R¹ is ethoxy and R³ is ethoxycarbonyl, R² is not phenyl.

[0024] In the above definitions, halo means fluoro, chloro, bromo or iodo. Unless otherwise stated, alkyl, alkenyl, alkynyl, alkylene and alkoxy groups containing the requisite number of carbon atoms can be unbranched or branched chain. Examples of alkyl include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl and t-butyl. Examples of alkenyl include ethenyl, propen-1-yl, propen-2-yl, propen-3-yl, 1-buten-1-yl, 1-buten-2-yl, 1-buten-3-yl, 1-buten-4-yl, 2-buten-1-yl, 2-buten-2-yl, 2-methylpropen-1-yl or 2-methylpropen-3-yl. Examples of alkynyl include ethynyl, propyn-1-yl, propyn-3-yl, 1-butyn-1-yl, 1-butyn-3-yl, 1-butyn-4-yl, 2-butyn-1-yl. Examples of alkylene include methylene, 1,1-ethylene, 1,2-ethylene, 1,1-propylene, 1,2-propylene, 2,2-propylene and 1,3-propylene. Examples of alkoxy include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, sec-butoxy and t-butoxy. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Where R¹ and R² are taken together, they form, along with the nitrogen atom and the carbon atom of the pyrazole ring to which they are attached, a 5- or 6-membered ring. Where a heterocyclic group R⁸ or R⁹ is attached to an oxygen, sulphur or nitrogen heteroatom the heterocyclic group R⁸ or R⁹ must be linked through a ring carbon atom. Further, where a heterocyclic group R⁹ is attached to an oxygen, sulphur or nitrogen heteroatom the heterocyclic group R⁹ must be linked through a ring carbon atom that is not adjacent to a ring heteratom.

[0025] The pharmaceutically acceptable salts of the compounds of the formula (I) include the acid addition and the base salts thereof.

[0026] Suitable acid addition salts are formed from acids which form non-toxic salts and examples are the hydrochloride, hydrobromide, hydroiodide, sulphate, bisulphate, nitrate, phosphate, hydrogen phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, succinate, saccharate, benzoate, methanesulphonate, ethanesulphonate, benzenesulphonate, para-toluenesulphonate and pamoate salts.

[0027] Suitable base salts are formed from bases which form non-toxic salts and examples are the sodium, potassium, aluminium, calcium, magnesium, zinc and diethanolamine salts.

[0028] For a review on suitable salts see Berge et al, J. Pharm. Sci., 66, 1-19, 1977.

[0029] The pharmaceutically acceptable solvates of the compounds of the formula (I) include the hydrates thereof.

[0030] Also included within the present scope of the compounds of the formula (I) are polymorphs thereof.

[0031] The compounds of formula (I) may be modified to provide pharmaceutically acceptable derivatives thereof at any of the functional groups in the compounds. Examples of such derivatives are described in: Drugs of Today, Volume 19, Number 9, 1983, pp 499-538; Topics in Chemistry, Chapter 31, pp 306-316; and in “Design of Prodrugs” by H. Bundgaard, Elsevier, 1985, Chapter 1 (the disclosures in which documents are incorporated herein by reference) and include: esters, carbonate esters, hemi-esters, phosphate esters, nitro esters, sulfate esters, sulfoxides, amides, sulphonamides, carbamates, azo-compounds, phosphamides, glycosides, ethers, acetals and ketals.

[0032] A compound of the formula (I) may contain one or more asymmetric carbon atoms and therefore exist in two or more stereoisomeric forms. The present invention includes the individual stereoisomers of the compounds of the formula (I) together with, where appropriate, the individual tautomers thereof, and mixtures thereof.

[0033] Separation of diastereoisomers may be achieved by conventional techniques, e.g., by fractional crystallisation, chromatography or high performance liquid chromatography (HPLC) of a stereoisomeric mixture of a compound of the formula (I) or a suitable salt or derivative thereof. An individual enantiomer of a compound of the formula (I) may also be prepared from a corresponding optically pure intermediate or by resolution, such as by HPLC of the corresponding racemate using a suitable chiral support or by fractional crystallisation of the diastereoisomeric salts formed by reaction of the corresponding racemate with a suitable optically active acid or base, as appropriate.

[0034] Preferably, R¹, when taken separately, is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl or —OR⁷, said C₁-C₆ alkyl and C₃-C₇ cycloalkyl being unsubstituted or substituted by halo, —CN, —OR¹⁰, S(O)_(x)R¹⁰, —CO₂R¹⁰, —CONR⁵R¹⁰, —OCONR⁵R¹⁰, —NR⁵CO₂R¹⁰, —NR¹⁰R¹¹, —NR⁵COR¹⁰, —SO₂NR⁵R¹⁰, —NR⁵CONR⁵R¹⁰, —NR⁵SO₂R¹⁰ or R¹⁰.

[0035] Preferably, R¹, when taken separately, is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl or —OR⁷, said C₁-C₆ alkyl being unsubstituted or substituted by halo, —OR¹⁰, —NR¹⁰R¹¹, —NR⁵COR¹⁰ or R¹⁰.

[0036] Preferably, R¹, when taken separately, is H, C₁-C₄ alkyl, cyclopropyl, or —OCH₃, said C₁-C₄ alkyl being unsubstituted or substituted by bromo, —OH, —O(C₁-C₂ alkyl), —NR¹⁰R¹¹, —NHCOR¹³ or R¹⁰.

[0037] Preferably, R¹, when taken separately, is H, —CH₃, —CH₂CH₃, —CH(CH₃)₂, C(CH₃)₃, cyclopropyl, —OCH₃, —CH₂OH, —CH₂OCH₃, —CH₂OCH₂CH₃, —CH₂Br, —CH₂NH₂, —CH₂NHCH₃, —CH₂N(CH₃)₂, —CH₂NHCH₂(cyclopropyl), —CH₂NHCH₂CH₂OCH₃, —CH₂NHCH₂CH₂NHCOCH₃, —CH₂NHCO(4-cyanophenyl), —CH₂NHCO(3-cyanophenyl), —CH₂NHCH₂(4-cyanophenyl), —CH₂NHCH₂(4-fluorophenyl), —CH₂NHCH₂(4-methoxyphenyl), —CH₂NHCH₂(4-aminosulphonylphenyl), —CH₂NHCH₂(4-aminocarbonylphenyl), —CH₂NHCH₂(pyrid-3-yl), —CH₂N(CH₃) (4-cyanophenylmethyl), —CH₂N(CH₂CH₂OH) (4-cyanophenylmethyl), 4-methoxypiperidin-1-ylmethyl, 4-aminocarbonylpiperidin-1-ylmethyl, 4-methylcarbonylaminopiperidin-1-ylmethyl, piperazin-1-ylmethyl, 4-methylpiperazin-1-ylmethyl, 4-methylcarbonylpiperazin-1-ylmethyl, 4-methoxymethylcarbonylpiperazin-1-ylmethyl, 4-methoxycarbonylpiperazin-1-ylmethyl, 4-methylsulphonylpiperazin-1-ylmethyl, morpholin-4-ylmethyl, 2-methylimidazol-1-ylmethyl, pyrazol-1-ylmethyl or 1,2,4-triazol-1-ylmethyl.

[0038] Preferably, R¹, when taken separately, is, —CH₃, —CH₂CH₃, cyclopropyl, —CH₂NHCH₂(4-cyanophenyl), —CH₂NHCH₂(4-fluorophenyl), —CH₂NHCH₂(4-methoxyphenyl), —CH₂NHCH₂(4-aminosulphonylphenyl) or —CH₂NHCH₂(4-aminocarbonylphenyl).

[0039] Preferably, R², when taken separately, is H, C₁-C₆ alkyl, C₃-C₆ alkenyl or R⁹, said C₁-C₆ alkyl being unsubstituted or substituted by halo, —OR⁵, —OR¹², —CN, —CO₂R⁷, —OCONR⁵R⁵, —CONR⁵R⁵, —C(═NR⁵)NR⁵OR⁵, —CONR⁵NR⁵R⁵, —NR⁶R⁶, —NR⁵R¹², —NR⁵COR⁵, —NR⁵COR⁸, —NR⁵COR¹², —NR⁵CO₂R⁵, —NR⁵CONR⁵R⁵, —SO₂NR⁵R⁵, —NR⁵SO₂R⁵, R⁸ or R⁹.

[0040] Preferably, R², when taken separately, is H, C₁-C₆ alkyl, C₃-C₆ alkenyl or R⁹, said C₁-C₆ alkyl being unsubstituted or substituted by —OR⁵, —OR¹², —CN, —CO₂R⁷, —CONR⁵R⁵, —C(═NR⁵)NR⁵OR⁵, —CONR⁵NR⁵R⁵, —NR⁶R⁶, —NR⁵R¹², —NR⁵COR⁸, —NR⁵COR¹², —NR⁵CO₂R⁵, R⁸ or R⁹.

[0041] Preferably, R², when taken separately, is H, C₁-C₃ alkyl, propenyl or R⁹, said C₁-C₃ alkyl being unsubstituted or substituted by —OH, —OCH₃, —OCH₂CH₂NH₂, —CN, —CO₂CH₃, —CO₂CH₂CH₃, —CONH₂, —C(═NH)NHOH, —CONHNH₂, —NH₂, —NHCH₃, —N(CH₃)₂, —NHCH₂CH₂NHCOCH₃, —NHCH₂CH₂OCH₃, —NHCH₂R⁹, —NHCOR⁸, —NHCOCH₂OCH₃, —NHCO₂C(CH₃)₃, R³ or R⁹.

[0042] Preferably, R², when taken separately, is H, methyl, —CH₂CH═CH₂, —CH₂CN, —CH₂OCH₃, —CH₂CONH₂, —CH₂CONHNH₂, —CH₂CO₂CH₃, —CH₂CO₂CH₂CH₃, —CH₂C(═NH)NHOH, —CH₂CH₂OH, —CH₂CH₂OCH₃, —CH₂CH₂NH₂, —CH₂CH₂NHCOCH₂OCH₃, —CH₂CH₂NHCO₂C(CH₃)₃, 2-(pyrid-2-ylcarbonylamino)eth-1-yl, 2-(pyrazin-2-ylcarbonylamino)eth-1-yl, —CH₂CH₂OCH₂CH₂NH₂, —CH₂CH₂NHCH₃, —CH₂CH₂N(CH₃)₂, —CH₂CH₂NHCH₂CH₂NHCOCH₃, —CH₂CH₂NHCH₂CH₂OCH₃, —CH₂CH(OH)CH₃, (3-hydroxypyrazol-5-yl)methyl, 2-hydroxy-1,3,4-oxadiazol-5-ylmethyl, 2-amino-1,3,4-oxadiazol-5-yl, 5-hydroxy-1,2,4-oxadiazol-3-ylmethyl, 6-hydroxy-2-methylpyrimidin-4-ylmethyl, 6-hydroxy-2-aminopyrimidin-4-ylmethyl, 2-(morpholin-4-yl)eth-1-yl, 2-(4-methylcarbonylpiperazin-1-yl)eth-1-yl, morpholin-3-ylmethyl, (2-(tetrahydrofuran-2-ylmethylamino)eth-1-yl, 1-methylazetidin-3-yl or azetidin-3-yl.

[0043] Preferably, R², when taken separately, is H, —CH₂CH₂OH or —CH₂CH₂NH₂.

[0044] Preferably, R¹ and R², when taken together, represent unbranched C₃-C₄ alkylene, unsubstituted or substituted by oxo, wherein one methylene group of said C₃-C₄ alkylene is replaced by an oxygen atom or a nitrogen atom, said nitrogen atom being unsubstituted or substituted by R¹⁰.

[0045] Preferably, R¹ and R², when taken together, represent unbranched propylene wherein one methylene group is replaced by an oxygen atom or unbranched butylene wherein one methylene group is replaced by a nitrogen atom, said propylene and butylene being unsubstituted or substituted by oxo and said nitrogen atom being unsubstituted or substituted by R¹⁰.

[0046] Preferably, R¹ and R², when taken together, represent ^(x)-OCH₂CH₂-^(y), ^(x)-CONHCH₂CH₂-^(y), ^(x)-CH₂NHCH₂CH₂-^(y), ^(x)-CH₂N(CH₃)CH₂CH₂-^(y), ^(x)-CH₂N(4-cyanophenylmethyl)CH₂CH₂-^(y) or ^(x)-CH₂N(4-methoxyphenylmethyl)CH₂CH₂-^(y) wherein ‘x’ represents the point of attachment to the carbon atom of the pyrazole ring and ‘y’ represents the point of attachment to the nitrogen atom of the pyrazole ring.

[0047] Preferably, R³ is H or C₁-C₆ alkyl, said C₁-C₆ alkyl being unsubstituted or substituted by halo, —CN, —OR⁵, —CO₂R⁵, —CONR⁵R⁵, —OCONR⁵R⁵, —NR⁵CO₂R⁵, —NR⁶R⁶, —NR⁵COR⁵, —SO₂NR⁵R⁵, —NR⁵CONR⁵R⁵, —NR⁵SO₂R⁵, R⁸ or R⁹.

[0048] Preferably, R³ is H or C₁-C₆ alkyl.

[0049] Preferably, R³ is H or C₁-C₄ alkyl.

[0050] Preferably, R³ is H, —CH₃, —CH₂CH₃, —CH(CH₃)₂ or —C(CH₃)₃.

[0051] Preferably, R³ is —CH₃, —CH₂CH₃, —CH(CH₃)₂ or cyclopropyl.

[0052] Preferably, R⁴ is phenyl unsubstituted or substituted by R⁸, halo, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl or C₁-C₆ alkoxy.

[0053] Preferably, R⁴ is phenyl substituted by R⁸, halo, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl or C₁-C₆ alkoxy.

[0054] Preferably, R⁴ is phenyl substituted by halo, —CN or C₁-C₆ alkyl.

[0055] Preferably, R⁴ is phenyl substituted by fluoro, chloro, —CN or methyl.

[0056] Preferably, R⁴ is 3-cyanophenyl, 4-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 3-fluorophenyl, 2-fluorophenyl, 3,5-dichlorophenyl, 2,6-dichlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-difluorophenyl, 2,3-difluorophenyl, 3,5-difluorophenyl, 2,5-difluorophenyl, 3,5-dicyanophenyl, 3,5-dimethylphenyl, 4-fluoro-3-methylphenyl, 3-cyano-4-fluorophenyl, 3-cyano-5-fluorophenyl, 2-chloro-4-cyanophenyl, 3-chloro-5-cyanophenyl, 3-cyano-5-methylphenyl or 4-cyano-2,6-dimethylphenyl.

[0057] Preferably, R⁴ is 3,5-dicyanophenyl, 3-cyano-5-fluorophenyl, 3-chloro-5-cyanophenyl or 3-cyano-5-methylphenyl. In an alternative set of preferences:

[0058] Preferably, R⁴ is phenyl unsubstituted or substituted by R⁸, halo, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl, C₁-C₆ alkoxy, —CONR⁵R⁵, OR¹³, So_(x)R⁶, O—(C₁-C₆ alkylene)-CONR⁵R⁵, O—(C₁-C₆ alkylene)-NR⁵R⁵, or O—(C₁-C₆ alkylene)-OR⁶; or naphthyl.

[0059] Preferably, R⁴ is phenyl substituted by R⁸, halo, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl, C₁-C₆ alkoxy, —CONR⁵R⁵, OR¹³, So_(x)R⁵, O—(C₁-C₆ alkylene)—CONR⁵R⁵, O—(C₁-C₆ alkylene)-NR⁵R⁵, or O—(C₁-C₆ alkylene)-OR⁶.

[0060] Preferably, R⁸ is pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, furanyl, thienyl, pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl, each being unsubstituted or substituted by halo, —CN, —COR⁵, —CONR⁵R⁵, —SO₂NR⁵R⁵,

[0061] —NR⁵SO₂R⁵, —OR⁵, —NR⁵R⁵, —(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, fluoro(C₁-C₆)alkyl or C₃-C₇ cycloalkyl.

[0062] Preferably, R⁸ is imidazolyl, pyrazolyl, 1,2,4-triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrazinyl or pyrimidinyl, each being unsubstituted or substituted by halo, —CN, —COR⁵, —CONR⁵R⁵, —SO₂NR⁵R⁵, —NR⁵SO₂R⁵, —OR⁵, —NR⁵R⁵, —(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, fluoro(C₁-C₆)alkyl or C₃-C₇ cycloalkyl.

[0063] Preferably, R⁸ is imidazolyl, pyrazolyl, 1,2,4-triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrazinyl or pyrimidinyl, each being unsubstituted or substituted by —OR⁵, —NR⁵R⁵ or C₁-C₆ alkyl.

[0064] Preferably, R⁸ is imidazolyl, pyrazolyl, 1,2,4-triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrazinyl or pyrimidinyl, each being unsubstituted or substituted by —OH, —NH₂ or methyl.

[0065] Preferably, R⁸ is pyrazol-1-yl, 2-methylimidazol-1-yl, 1,2,4-triazol-1-yl, 3-hydroxypyrazol-5-yl, 2-hydroxy-1,3,4-oxadiazol-5-yl, 2-amino-1,3,4-oxadiazol-5-yl, 5-hydroxy-1,2,4-oxadiazol-3-yl, 2-methyl-4-hydroxypyrimidin-6-yl, 2-amino-4-hydroxypyrimidin-6-yl, pyridin-3-yl, pyridin-2-yl or pyrazin-2-yl.

[0066] Preferably, R⁹ is azetidinyl, tetrahydropyrrolyl, piperidinyl, azepinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, oxepinyl, morpholinyl, piperazinyl or diazepinyl, each being unsubstituted or substituted by oxo, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, —SO₂R⁵, —CONR⁵R⁵, —COOR⁵, —CO—(C₁-C₆ alkylene)-OR⁵ or —COR⁵ and unsubstituted or substituted on a carbon atom which is not adjacent to a heteroatom by halo, —OR⁵, —NR⁵R⁵, —NR⁵COR⁵, —NR⁵COOR⁵, —NR⁵CONR⁵R⁵, —NR⁵SO₂R⁵ or —CN.

[0067] Preferably, R⁹ is azetidinyl, piperidinyl, tetrahydrofuranyl, piperazinyl or morpholinyl, each being optionally substituted by oxo, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, —SO₂R⁵, —CONR⁵R⁵, —COOR⁵, —CO—(C₁-C₆ alkylene)-OR⁵ or —COR⁵ and unsubstituted or substituted on a carbon atom which is not adjacent to a heteroatom by halo, —OR⁵, —NR⁵R⁵, —NR⁵COR⁵, —NR⁵COOR⁵, —NR⁵CONR⁵R⁵, —NR⁵SO₂R⁵ or —CN.

[0068] Preferably, R⁹ is azetidinyl, piperidinyl, tetrahydrofuranyl, piperazinyl or morpholinyl, each being unsubstituted or substituted by C₁-C₆ alkyl, —SO₂R⁵, —CONR⁵R⁵, —COOR⁵, —CO—(C₁-C₆ alkylene)-OR⁵ or —COR⁵ and unsubstituted or substituted on a carbon atom which is not adjacent to a heteroatom by —OR⁵ or —NR⁵COR⁵.

[0069] Preferably, R⁹ is azetidinyl, piperidinyl, tetrahydrofuranyl, piperazinyl or morphoninyl, each being unsubstituted or substituted by —CH₃, —SO₂CH₃, —CONH₂, —COOCH₃, —COCH₂OCH₃ or —COCH₃ and unsubstituted or substituted on a carbon atom which is not adjacent to a heteroatom by —OCH₃ or —NHCOCH₃.

[0070] Preferably, R⁹ is 4-methoxypiperidin-1-yl, 4-aminocarbonylpiperidin-1-yl, 4-methylcarbonylaminopiperidin-1-yl, piperazin-1-yl, 4-methylpiperazin-1-yl, 4-methylcarbonylpiperazin-1-yl, 4-methoxymethylcarbonylpiperazin-1-yl, 4-methoxycarbonylpiperazin-1-yl, 4-methylsulphonylpiperazin-1-yl, morpholin-4-yl, tetrahydrofuran-2-yl, morpholin-3-yl, azetidin-3-yl or 1-methylazetidin-3-yl.

[0071] Preferably, R¹⁰ is H, R⁸, R⁹, R¹³, C₁-C₆ alkyl or —(C₁-C₆ alkyl)-(C₃-C₇ cycloalkyl), said C₁-C₆ alkyl being unsubstituted or substituted by —OR⁵, —OR¹³, R⁸, R⁹, R¹³ or

[0072] Preferably, R¹⁰ is H, R⁸, R⁹, R¹³, C₁-C₆ alkyl or —(C₁-C₆ alkyl)-(C₃-C₇ cycloalkyl), said C₁-C₆ alkyl being unsubstituted or substituted by —OR⁵ or R¹³.

[0073] Preferably, R¹⁰ is H, R⁸, R⁹, R¹³, —CH₃, —CH₂CH₃ or —CH₂(cyclopropyl), said —CH₃ and —CH₂CH₃ being unsubstituted or substituted by —OCH₃ or R¹³.

[0074] Preferably, R¹⁰ is H, R⁸, R⁹, R¹³, —CH₃, —CH₂CH₃, —CH₂CH₂OCH₃, —CH₂(cyclopropyl), 4-cyanophenylmethyl, 4-fluorophenylmethyl, 4-methoxyphenylmethyl, 4-aminosulphonylphenylmethyl or 4-aminocarbonylphenylmethyl.

[0075] Preferably, R¹¹ is H or C₁-C₆ alkyl, said C₁-C₆ alkyl being unsubstituted or substituted by —OR⁵, —NR⁵R⁵, —NR⁵COR⁵, —CONR⁵R⁵, R⁸ or R⁹.

[0076] Preferably, R¹¹ is H or C₁-C₆ alkyl, said C₁-C₆ alkyl being unsubstituted or substituted by —OR⁵ or —NR⁵COR⁵.

[0077] Preferably, R¹¹ is H, —CH₃ or —CH₂CH₃, said —CH₃ and —CH₂CH₃ being unsubstituted or substituted by —OH or —NHCOCH₃.

[0078] Preferably, R¹¹ is H, —CH₃, —CH₂CH₂NHCOCH₃ or —CH₂CH₂OH.

[0079] Preferably, R¹² is C₁-C₄ alkyl substituted by R⁸, R⁹, —OR⁵, —CONR⁵R⁵, —NR⁵COR⁵ or —NR⁵R⁵.

[0080] Preferably, R¹² is C₁-C₄ alkyl substituted by R⁹, —OR⁵, —NR⁵COR⁵ or —NR⁵R⁵.

[0081] Preferably, R¹² is C₁-C₂ alkyl substituted by tetrahydrofuranyl, —OCH₃, —NHCOCH₃ or —NH₂.

[0082] Preferably, R¹² is —CH₂CH₂NH₂, —CH₂CH₂OCH₃, tetrahydrofuran-2-ylmethyl, —CH₂CH₂NHCOCH₃ or —CH₂OCH₃.

[0083] Preferably, R¹³ is phenyl substituted by halo, —CN, —COR⁵, —CONR⁵R⁵, —SO₂NR⁵R⁵, —NR⁵SO₂R⁵, —OR⁵, —NR⁵R⁵, —(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, halo(C₁-C₆)alkyl or C₃-C₇ cycloalkyl.

[0084] Preferably, R¹³ is phenyl substituted by halo, —CN, —CONR⁵R⁵, —SO₂NR⁵R⁵ or —OR⁵.

[0085] Preferably, R¹³ is phenyl substituted by fluoro, —CN, —CONH₂, —SO₂NH₂ or —OCH₃.

[0086] Preferably, R¹³ is 4-cyanophenyl, 3-cyanophenyl, 4-fluorophenyl, 4-methoxyphenyl, 4-aminocarbonylphenyl or 4-aminosulphonylphenyl.

[0087] Preferred groups of compounds according to the invention include all combinations of the preferred definitions for individual substituents given above.

[0088] Also preferred according to the invention are the compounds of formula (I)

[0089] or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein:

[0090] R¹ is H, C₁-C₆ alkyl, —OC₁-C₆ alkyl, —OC₃-C₇ cycloalkyl, said C₁-C₆ alkyl being unsubstituted or substituted by R¹⁵;

[0091] R² is H, C₁-C₃ alkyl, propenyl or C-linked R¹⁵, said C₁-C₃ alkyl being unsubstituted or substituted by —OH, —OCH₃, —OCH₂CH₂NH₂, —CN, —CO₂CH₃, —CONH₂, —C(═NH)NH₂, —CONHNH₂, —NH₂, —NHCH₃, —N(CH₃)₂, —NHCH₂CH₂NHCOCH₃, —NHCH₂CH₂OCH₃, —NHCH₂R¹⁵, —NHCOR¹⁵, —NHCOCH₂OCH₃, or R¹⁵

[0092] R³ is C₁-C₆ alkyl;

[0093] R⁴ is phenyl unsubstituted or substituted by halo, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl or C₁-C₆ alkoxy; and

[0094] R¹⁵ is azetidinyl, tetrahydrofuranyl, morpholinyl, piperazinyl, pyrazolyl, oxadiazolyl, pyridinyl or pyrimidinyl each being unsubstituted or substituted by —OH, —NH₂, oxo or C₁-C₆ alkyl or —CO(C₁-C₆ alkyl).

[0095] Preferred individual compounds according to the invention include the Examples below, particularly Examples 117, 118, 119, 120, 122, 123, 124, 125, 126, 127 and 128, and the pharmaceutically acceptable salts and solvates thereof.

[0096] All of the compounds of the formula (I) can be prepared by conventional routes such as the procedures described in the general methods presented below or by the specific methods described in the Examples section, or by similar methods thereto. The present invention also encompasses any one or more of these processes for preparing the compounds of formula (I), in addition to any novel intermediates used therein.

[0097] In the following general methods, R¹, R², R³ and R⁴ are as previously defined for a compound of the formula (I) unless otherwise stated.

[0098] Except where either R¹ or R³ is halo, —OR⁸ or —CN, compounds of the formula (I) may be prepared using the route shown in Scheme 1 that follows.

[0099] In Scheme 1, compounds of the formula (I) may be prepared by the condensation of a compound of the formula (II) with a compound of the formula

H₂NNHR²  (V),

[0100] or a salt or hydrate thereof, optionally in the presence of an acid or a base, the base preferably being a tertiary amine base such as triethylamine and the acid preferably being acetic acid. In a typical procedure, a solution of the compound of the formula (II) in a suitable solvent, such as ethanol, is treated with the compound of the formula (V), or the salt or hydrate thereof, and, if used, the appropriate acid or base, at a temperature of from room temperature to the reflux temperature of the solvent. In a preferred procedure, the reaction mixture is heated under reflux.

[0101] Functional equivalents of compounds of the formula (II) may also be used in this reaction. These include compounds of the formula (VI) or (VII), in which L¹ and L², respectively, are each suitable leaving groups, preferably —N(C₁-C₆ alkyl)₂, Most preferably —N(CH₃)₂.

[0102] Thus, a compound of the formula (I) may be prepared by the condensation of a compound of the formula (VI) or (VII) with a compound of the formula (V), or a salt or hydrate thereof, optionally in the presence of an acid or a base, the base preferably being a tertiary amine base such as triethylamine and the acid preferably being acetic acid. In a typical procedure, a solution of the compound of the formula (VI) or (VII) in a suitable solvent, such as ethanol, is treated with the compound of the formula (V), or the salt or hydrate thereof, and, if used, the appropriate acid or base, at a temperature of from room temperature to the reflux temperature of the solvent. In a preferred procedure, the reaction mixture is heated under reflux. Compounds of the formula (VI) or (VII) are particularly suitable for the synthesis of compounds of the formula (I) in which R¹ or R³, respectively, is H.

[0103] Compounds of the formula (VI) in which R¹ is H and L¹ is dimethylamino may be prepared by the reaction of a compound of the formula (VIII) with dimethylformamide dimethylacetal at an elevated temperature, preferably at about 100° C. Compounds of the formula (VII) in which R¹ is H and L¹ is dimethylamino may be prepared by the reaction of a compound of the formula (IX) under the same conditions. Other compounds of the formula (VI) or (VII) in which L¹ or L² is dimethylamino may be prepared analogously.

[0104] Compounds of the formula (VIII) are either commercially available or may be prepared by the reaction of a compound of the formula

R³COCH₂Br  (X)

[0105] with a compound of the formula

R⁴OH  (XI).

[0106] In a typical procedure, a solution of the compound of the formula (XI) in a suitable solvent, such as acetone, is treated with a suitable base, such as caesium carbonate, and the compound of the formula (X). In a preferred procedure, the reaction mixture is heated, for example under reflux. Optionally, a nucleophilic catalyst such as sodium iodide or tetrabutylammonium iodide may be added.

[0107] Compounds of the formula (IX) are either commercially available or may be prepared from a compound of the formula

R¹COCH₂Br  (XII)

[0108] and a compound of the formula (XI) in the same way that a compound of the formula (VIII) may be prepared from a compound of the formula (X).

[0109] Compounds of the formula (II) may be prepared by the reaction of a compound of the formula (III) with a compound of the formula (XI).

[0110] In a typical procedure, a solution of the compound of the formula (III) in a suitable solvent such as acetone is treated with a compound of the formula (XI) and a suitable base, such as potassium or caesium carbonate, and heated, preferably under reflux. Optionally, a nucleophilic catalyst such as sodium iodide or tetrabutylammonium iodide may be added.

[0111] Compounds of the formula (III) are either commercially available or may be prepared by the reaction of a compound of the formula (IV) with a chlorinating reagent. In a typical procedure, a cooled solution of the compound of the formula (IV) in a suitable solvent such as acetonitrile is treated first with tetrabutylammonium bromide and chlorotrimethylsilane and then dry dimethylsulphoxide. In another typical procedure, the compound of the formula (IV) is treated with sulphuryl chloride, optionally in the presence of a suitable solvent such as dichloromethane.

[0112] Compounds of the formula (I) in which R¹ or R³ is —OR⁸ may be prepared using the route shown in Scheme 2 that follows, in which R^(a) is C₁-C₆ alkyl and L³ is a suitable leaving group, preferably trifluoromethanesulphonate.

[0113] In Scheme 2, compounds of the formula (I) in which R¹ is —OR⁸ may be prepared by the reaction of a compound of the formula (XIII) with an alcohol of the formula

R⁸OH  (XXI)

[0114] in the presence of a suitable palladium catalyst and carbon monoxide. In a typical procedure a mixture of the compound of the formula (XIII), a suitable palladium catalyst such as 1,1′-bis(diphenylphosphino)ferrocenepalladium(II)chloride, the alcohol of the formula (XXI) and, optionally, a suitable solvent such as N,N-dimethylformamide is heated, preferably to about 50° C., under an atmosphere of carbon monoxide, preferably at a pressure of 345 kPa.

[0115] Compounds of the formula (XIII) may be prepared by the derivatisation of a compound of the formula (XV). In the case where L³ is trifluoromethanesulphonate, a suitable derivatising agent is phenyltriflamide. In a typical procedure, where L³ is trifluoromethanesulphonate, a solution of the compound of the formula (XV) and a suitable base, preferably a trialkylamine base such as triethylamine, in a suitable solvent such as dichloromethane is treated with phenyltriflamide.

[0116] Compound of the formula (XV) may be prepared by the reaction of a compound of the formula (XVII) with a compound of the formula (V), or a salt or hydrate thereof, optionally in the presence of an acid or a base, the base preferably being a tertiary amine base such as triethylamine and the acid preferably being acetic acid. In a typical procedure, a solution of the compound of the formula (XVII) in a suitable solvent, such as ethanol, is treated with the compound of the formula (V), or the salt or hydrate thereof, and, if used, the appropriate acid or base, at a temperature of from room temperature to the reflux temperature of the solvent. In a preferred procedure, the reaction mixture is heated under reflux.

[0117] Compounds of the formula (XVII) may be prepared by the reaction of a compound of the formula (XIX) with a compound of the formula (XI). In a typical procedure, a solution of the compound of the formula (XVII) in a suitable solvent such as acetone is treated with a compound of the formula (XI) and a suitable base, such as potassium or caesium carbonate, and heated, preferably under reflux. Optionally, a nucleophilic catalyst such as sodium iodide or tetrabutylammonium iodide may be added.

[0118] In Scheme 2, compounds of the formula (I) in which R³ is —OR⁸ may be prepared from a compound of the formula (XX) in the same way that a compound of the formula (I) in which R¹ is —OR⁸ is prepared from a compound of the formula (XIX), as set out above, mutatis mutandis.

[0119] Chloroketoesters of the formula (XIX) and (XX) are either commercially available or may be prepared by the chlorination of the corresponding ketoesters, for instance using sulphonyl chloride.

[0120] Alternatively, compounds of the formula (I) in which R¹ or R³ is —OR⁸ may be prepared from compounds of the formula (XV) or (XVI), respectively, by reaction with a compound of the formula (XXI) under dehydrating conditions, e.g., using the Mitsunobu reaction. In a typical procedure, a solution of the compound of the formula (XV) or (XVI) in a suitable solvent, such as tetrahydrofuran is treated with diethylazodicarboxylate, triphenylphosphine and a compound of the formula (XXI).

[0121] Compounds of the formula (I) in which R¹ or R³ is halo can be prepared by the reaction, respectively, of a compound of the formula (XV) or a compound of the formula (XVI) with a suitable halogenating agent. In a typical procedure, the compound of the formula (XV) or (XVI) is treated with POCl₃, optionally in the presence of a suitable solvent such as dimethylformamide, to give a compound of the formula (I) in which R¹ or R³, respectively, is chloro.

[0122] It will be appreciated by those skilled in the art that, in many cases, compounds of the formula (I) may be converted into other compounds of the formula (I) by functional group transformations. For instance:

[0123] (a) compounds of the formula (I) in which R² is H may be converted into compounds of the formula (I) in which R² is optionally substituted C₁-C₆ alkyl by reaction with an appropriate alkylating agent. In a typical procedure, a solution of a compound of the formula (I) in which R² is H in a suitable solvent such as ethanol or N,N-dimethylformamide is treated with an alkyl bromide and a base such as sodium ethoxide or sodium hydride and heated at a temperature of from room temperature to the reflux temperature of the solvent. A preferred combination is N,N-dimethylformamide as the solvent, sodium hydride as the base and room temperature as the temperature. Examples of specific alkylating agents include bromoacetonitrile, ethyl 4-chloroacetoacetate, methyl bromoacetate and chloroethylamine hydrochloride. The use of further specific alkylating agents is illustrated by the Examples below;

[0124] (b) compounds of the formula (I) in which R¹, R² or R³ contains an ester functionality may be reduced with a suitable reducing agent, such as lithium aluminium hydride, to give corresponding compounds of the formula (I) in which R¹, R² or R³ contains a hydroxy group. In a typical procedure, a solution of the compound of the formula (I), in which R¹, R² or R³ contains an ester group, in a suitable solvent, such as diethyl ether, is treated with lithium aluminium hydride, preferably with cooling to a temperature of from −78° C. to 0° C.;

[0125] (c) compounds of the formula (I) in which R¹, R² or R³ are substituted by a heterocycle of the formula R⁶ may be prepared by standard heterocycle-forming reactions well known to the skilled man (see, for example, Advanced Organic Chemistry, 3rd Edition, by Gerry March or Comprehensive Heterocyclic Chemistry, A. R. Katritzky, C. W. Rees, E. F. V. Scriven, Volumes 1-11). For instance, compounds of the formula (I) in which R² is (2-amino-6-hydroxypyrimidin-4-yl)methyl may be prepared by the sequential reaction of a compound of the formula (I) in which R² is H with chloroacetoacetate and then guanidine hydrochloride. This and other similar heterocycle-forming reactions are illustrated by the Examples below;

[0126] (d) compounds of the formula (I) in which R¹ or R³ is —CO₂R⁵, wherein R⁵ is other than H, may be converted into compounds of the formula (I) in which R¹ or R³, respectively, is —CO₂H by hydrolysis. Typically the reaction will be carried out in a suitable solvent, such as aqueous ethanol, or aqueous 1,4-dioxan and in the presence of a base such as sodium hydroxide. Such an acid may be converted to a primary amide by reaction with ammonia and a suitable coupling agent, such as a carbodiimide, e.g. dicyclohexylcarbodiimide. Such a primary amide may then be converted into a nitrile by dehydration with a suitable dehydrating agent, such as phosphoryl chloride; and

[0127] (e) compounds of the formula (I) in which R¹ or R³ is C₁-C₆ alkyl may be converted into the compounds of the formula (I) in which R¹ or R³, respectively, is C₁-C₆ alkyl substituted by halo (such as bromo), by halogenation, using a suitable halogenating agent. Conveniently the reaction is effected in the presence of a solvent, such as a haloalkane (e.g. dichloromethane) and at ambient temperature. Suitable halogenating agents include halogens (e.g. bromine) or N-halosuccinimides (e.g. N-bromsuccinimide).

[0128] Compounds of the formula (I) containing an —OH, —NH— or —NH₂ group may be prepared by the deprotection of the corresponding compound bearing an —OP¹, —NP¹— or —NHP¹ group, respectively, wherein the group P¹ is a suitable protecting group. Examples of suitable protecting groups will be apparent to the skilled person [see, for instance, ‘Protecting groups in Organic Synthesis (Second Edition)’ by Theodora W. Green and Peter G. M. Wuts, 1991, John Wiley and Sons]. Such compounds bearing an —OP¹, —NP¹— or —NHP¹ group may be prepared using the routes described above, mutatis mutandis.

[0129] Compounds of the formula (IV), (V) and (XXI) are either commercially available or easily prepared by methods well known to those skilled in the art.

[0130] The compounds of the formula (I) can be administered alone but will generally be administered in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.

[0131] For example, the compounds of the formula (I) can be administered orally, buccally or sublingually in the form of tablets, capsules, multi-particulates, gels, films, ovules, elixirs, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications. The compounds of the formula (I) may also be administered as fast-dispersing or fast-dissolving dosage forms or in the form of a high energy dispersion or as coated particles. Suitable formulations of the compounds of the formula (I) may be in coated or uncoated form, as desired.

[0132] Such solid pharmaceutical compositions, for example, tablets, may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate, glycine and starch (preferably corn, potato or tapioca starch), disintegrants such as sodium starch glycolate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.

GENERAL EXAMPLE

[0133] A formulation of the tablet could typically contain from 0.01 mg to 500 mg of active compound whilst tablet fill weights may range from 50 mg to 1000 mg. An example of a formulation for a 10 mg tablet is illustrated below: Ingredient % w/w Compound of the formula (I) or salt 10.000* Lactose 64.125 Starch 21.375 Croscarmellose sodium 3.000 Magnesium Stearate 1.500

[0134] The tablets are manufactured by a standard process, for example, direct compression or a wet or dry granulation process. The tablet cores may be coated with appropriate overcoats.

[0135] Solid compositions of a similar type may also be employed as fillers in gelatin or HPMC capsules. Preferred excipients in this regard include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, the compounds of the formula (I) may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.

[0136] The compounds of the formula (I) can also be administered parenterally, for example, intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly or subcutaneously, or they may be administered by infusion or needleless injection techniques. For such parenteral administration they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.

[0137] For oral and parenteral administration to human patients, the daily dosage level of the compounds of the formula (I) will usually be from 0.01 to 30 mg/kg, preferably from 0.01 to 5 mg/kg (in single or divided doses).

[0138] Thus tablets or capsules of the compound of the formula (I) may contain from 1 to 500 mg of active compound for administration singly or two or more at a time, as appropriate. The physician in any event will determine the actual dosage which will be most suitable for any individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention. The skilled person will appreciate that, in the treatment of certain conditions the compounds of the formula (I) may be taken as a single dose as needed or desired.

[0139] The compounds of formula (I) can also be administered intranasally or by inhalation and are conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray, atomiser or nebuliser, with or without the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as 1,1,1,2-tetrafluoroethane (HFA 134A [trade mark]) or 1,1,1,2,3,3,3-heptafluoropropane (HFA 227EA [trade mark]), carbon dioxide or other suitable gas. In the case of a pressurised aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurised container, pump, spray, atomiser or nebuliser may contain a solution or suspension of the active compound, e.g. using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g. sorbitan trioleate. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of a compound of the formula (I) and a suitable powder base such as lactose or starch.

[0140] Alternatively, the compounds of the formula (I) can be administered in the form of a suppository or pessary, or they may be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder. The compounds of the formula (I) may also be dermally or transdermally administered, for example, by the use of a skin patch. They may also be administered by the pulmonary or rectal routes.

[0141] They may also be administered by the ocular route. For ophthalmic use, the compounds can be formulated as micronised suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.

[0142] For application topically to the skin, the compounds of the formula (I) can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, they can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyidodecanol, benzyl alcohol and water.

[0143] The compounds of the formula (I) may also be used in combination with a cyclodextrin. Cyclodextrins are known to form inclusion and non-inclusion complexes with drug molecules. Formation of a drug-cyclodextrin complex may modify the solubility, dissolution rate, bioavailability and/or stability property of a drug molecule. Drug-cyclodextrin complexes are generally useful for most dosage forms and administration routes. As an alternative to direct complexation with the drug the cyclodextrin may be used as an auxiliary additive, e.g. as a carrier, diluent or solubiliser. Alpha-, beta- and gamma-cyclodextrins are most commonly used and suitable examples are described in WO-A-91/11172, WO-A-94/02518 and WO-A-98/55148.

[0144] It is to be appreciated that all references herein to treatment include curative, palliative and prophylactic treatment.

[0145] Oral administration is preferred.

[0146] Included within the scope of the present invention are embodiments comprising the co-administration of a compound of the present invention with one or more additional therapeutic agents, and compositions containing a compound of the present invention along with one or more additional therapeutic agents. Such a combination therapy is especially useful for the prevention and/or treatment of infection by HIV and related retroviruses which may evolve rapidly into strains resistant to any monotherapy. Alternatively, additional therapeutic agents may be desirable to treat diseases and conditions which result from or accompany the disease being treated with the compound of the present invention. For example, in the treatment of an HIV or related retroviral infection, it may be desirable to additionally treat opportunistic infections, neoplasms and other conditions which occur as a result of the immuno-compromised state of the patient being treated.

[0147] Preferred combinations of the present invention include simultaneous or sequential treatment with a compound of the formula (I), as defined above, or a pharmaceutically acceptable salt thereof, and:

[0148] (a) one or more reverse transcriptase inhibitors such as zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir and adefovir;

[0149] (b) one or more non-nucleoside reverse transcriptase inhibitors such as nevirapine, delavirdine and efavirenz;

[0150] (c) one or more HIV protease inhibitors such as indanivir, ritonavir, saquinavir and nelfinavir;

[0151] (d) one or more CCR5 antagonists such as TAK-779;

[0152] (e) one or more CXCR4 antagonists such as AMD-3100;

[0153] (f) one or more integrase inhibitors;

[0154] (g) one or more inhibitors of viral fusion such as T-20;

[0155] (h) one or more investigational drugs such as trizivir, KNI-272, amprenavir, GW-33908, FTC, PMPA, S-1153, MKC-442, MSC-204, MSH-372, DMP450, PNU-140690, ABT-378, KNI-764, DPC-083, TMC-120 or TMC-125; or

[0156] (i) one or more antifungal or antibacterial agents such as fluconazole.

[0157] The activity of the compounds of the invention as reverse transcriptase inhibitors and as agents for treating HIV infections may be measured using the following assays.

[0158] A. Inhibition of HIV-1 Reverse Transcriptase Enzyme

[0159] The reverse transcriptase activity of the compounds of the invention may be assayed as following. Using the purified recombinant HIV-1 reverse transcriptase (RT, EC, 2.7.7.49) obtained by expression in Escherichia Coli, a 96-well plate assay system was established for assaying a large number of samples using either the Poly(rA)-oligo(dT) Reverse Transcriptase [3H]-SPA enzyme assay system (Amersham NK9020) or the [3H]-flashplate enzyme assay system (NEN—SMP 103) and following the manufacturer's recommendations. The compounds were dissolved in 100% DMSO and diluted with the appropriate buffer to a 5% final DMSO concentration. The inhibitory activity was expressed in percent inhibition relative to the DMSO control. The concentration at which the compound inhibited the reverse transcriptase by 50% was expressed as the IC₅₀ of the compound. The compounds of examples 7, 20 and 51, when tested according to the above procedure, had IC₅₀ values of, respectively, 39000, 3200 and 248 nanomolar.

[0160] B. Anti-Human Immunodeficiency Virus (HIV-1) Cell Culture Assay

[0161] The anti-HIV activity of selected Examples of the invention was assayed by the following procedures.

[0162] 1) SupT1 cells were cultured in an RPMI-1640 medium supplemented with 10% foetal calf serum and were split so that they were in growth phase on the day of use.

[0163] 2) The compounds were dissolved in 100% DMSO and diluted with the above culture medium to predetermined concentrations and distributed in 20 μl aliquots into a 96-well microtiter plate (0.1% DMSO final concentration).

[0164] 3) To prepare infected cells, 100 μl of R^(F) viruses (TCID50 of 10⁷/ml) were added to 106 cells and incubated for 1 hour at 37° C. The cells were then washed twice in PBS and resuspended in the culture medium at a density of 2.2×10⁵ cells/ml. 180 μl of these infected cells was transferred to wells of the 96 well plate containing the compounds.

[0165] 4) The plate was incubated in a CO₂ incubator at 37° C. for 4 days. The cell survival rates were measured following the manufacturer's recommendations (CellTiter 96® AQ_(ueous) Non-Radioactive Assay—Promega (cat no: G5430)). The concentration at which the compound inhibited the cytotoxic effect of the virus by 50% was expressed as the EC₅₀.

[0166] Thus the invention provides:

[0167] (i) a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof;

[0168] (ii) a process for the preparation of a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof;

[0169] (iii) a pharmaceutical composition including a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, together with a pharmaceutically acceptable excipient, diluent or carrier;

[0170] (iv) a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or composition thereof, for use as a medicament;

[0171] (v) a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or composition thereof, for use as a reverse transcriptase inhibitor or modulator;

[0172] (vi) a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or composition thereof, for use in the treatment of an HIV, or genetically-related retroviral, infection or a resulting acquired immune deficiency syndrome (AIDS);

[0173] (vii) the use of a compound of the formula (I) or of a pharmaceutically acceptable salt, solvate or composition thereof, for the manufacture of a medicament having reverse transcriptase inhibitory or modulating activity;

[0174] (viii) the use of a compound of the formula (I) or of a pharmaceutically acceptable salt, solvate or composition thereof, for the manufacture of a medicament for the treatment of an HIV, or genetically-related retroviral, infection or a resulting acquired immune deficiency syndrome (AIDS);

[0175] (ix) a method of treatment of a mammal, including a human being, with a reverse transcriptase inhibitor or modulator including treating said mammal with an effective amount of a compound of the formula (I) or with a pharmaceutically acceptable salt, solvate or composition thereof;

[0176] (x) a method of treatment of a mammal, including a human being, to treat an HIV, or genetically-related retroviral, infection or a resulting acquired immune deficiency syndrome (AIDS) including treating said mammal with an effective amount of a compound of the formula (I) or with a pharmaceutically acceptable salt, solvate or composition thereof; and

[0177] (xi) certain novel intermediates disclosed herein.

[0178] The following Examples illustrate the preparation of the compounds of the formula (I). The synthesis of certain intermediates used therein are described in the Preparations section that follows the Examples.

[0179]¹H Nuclear magnetic resonance (NMR) spectra were in all cases consistent with the proposed structures. Characteristic chemical shifts (6) are given in parts-per-million downfield from tetramethylsilane using conventional abbreviations for designation of major peaks: e.g. s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. The following abbreviations have been used: HRMS, high resolution mass spectrometry; hpic, high performance liquid chromatography; nOe, nuclear Overhauser effect; m.p., melting point; CDCl₃, deuterochloroform; D₆-DMSO, deuterodimethylsulphoxide; CD₃OD, deuteromethanol. Where thin layer chromatography (TLC) has been used it refers to silica gel TLC using silica gel 60 F₂₅₄ plates, R_(f) is the distance travelled by a compound divided by the distance travelled by the solvent front on a TLC plate.

Example 1

[0180] 2-[4-(3,5-Dichlorophenoxy)-3,5-dimethyl-1H-pyrazol-1-yl]ethanol

[0181] 2-Hydroxyethyl hydrazine (21.5 μL, 0.316 mmol) was added to a stirred solution of the β-diketone of Preparation 1 (75 mg, 0.287 mmol) in ethanol (2.9 ml) at room temperature under nitrogen and the resulting orange solution was heated under reflux for 18 hours. After cooling, the mixture was concentrated under reduced pressure. The residue was dissolved in dichloromethane (20 ml) and washed with 2M hydrochloric acid (10 ml) and brine (10 ml) and then dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a viscous orange oil. The crude product was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (10:1, by volume) then dichloromethane to provide the title compound (32 mg) as a white powder, m.p. 114-115° C.

[0182]¹H-NMR (400 MHz, CDCl₃): δ=2.08 (s, 3H), 2.10 (s, 3H), 3.30 (t, 1H), 4.06 (m, 4H), 6.79 (s, 2H), 7.01 (s, 1H).

[0183] LRMS (thermospray): m/z [MH⁺] 301.

[0184] Microanalysis: Found: C, 51.76; H, 4.64; N, 9.20. C₁₃H₁₄Cl₂N₂O₂ requires C, 51.85; H, 4.69; N, 9.30%.

Example 2

[0185] 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol

[0186] 3,5-Dichlorophenol (501 mg, 3.07 mmol), potassium carbonate (467 mg, 3.38 mmol) and finally sodium iodide (461 mg, 3.07 mmol) were added sequentially to a stirred solution of the chloroketone of Preparation 2 (500 mg, 3.07 mmol) in acetone (15 ml), at room temperature and under nitrogen, producing an orange/red suspension. The mixture was heated under reflux for 22½ hours producing a yellow suspension. After cooling the mixture was diluted with water (10 ml) and the acetone was removed under reduced pressure in a fumehood (caution: possible residual lachrymator). The residue was diluted with 2M hydrochloric acid and extracted with dichloromethane (1×20 ml, 2×10 ml). The combined organic layers were washed with brine (20 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave crude 4-(3,5-dichlorophenoxy)-3,5-heptanedione as an orange oil (777 mg). A portion of the crude 4-(3,5-dichlorophenoxy)-3,5-heptanedione (250 mg, ca. 0.865 mmol) was dissolved in ethanol (8.6 ml) and treated with 2-hydroxethyl hydrazine (65 μL, 0.951 mmol). The resulting solution was heated under reflux for 16 hours producing a red solution. After cooling, the mixture was concentrated under reduced pressure and the residue was dissolved in dichloromethane (20 ml). The resulting solution was washed with 2M hydrochloric acid (10 ml), 1 N sodium hydroxide solution (10 ml) and brine (10 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave an orange oil (102 mg). The crude product was purified by flash chromatography on silica gel eluting with methanol:dichloromethane (5:95, by volume) to provide the title compound (23 mg) as an orange oil which solidified to a waxy solid on standing.

[0187]¹H-NMR (400 MHz, CDCl₃): δ=1.08 (t, 3H), 1.12 (t, 3H), 2.38 (q, 2H), 2.48 (q, 2H), 3.69 (br.s, 1H), 4.02 (m, 4H), 6.76 (s, 2H), 6.97 (s, 1H).

[0188] LRMS (thermospray): m/z [MH⁺] 329.

Example 3

[0189] 4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazole

[0190] A mixture of the chloroketone of Preparation 2 (5 g, 30.8 mmol), 3,5-dichlorophenol (5 g, 30.8 mmol), caesium carbonate (10 g, 30.8 mmol) and acetone (40 ml) was heated under reflux for 18 hours. After cooling, a solid was removed by filtration and washed with dichloromethane (100 ml). The combined filtrates were concentrated under reduced pressure. The crude product was dissolved in ethanol (20 ml), hydrazine hydrate (1.5 ml, 30.8 mmol) was added and the mixture was heated at 60° C. for 30 minutes under nitrogen. After cooling, the mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with ether:pentane (1:1, by volume) to provide the title compound (5.5 g) as a yellow oil which solidified on standing to leave a yellow solid, m.p. 114-115° C.

[0191]¹H-NMR (300 MHz, CDCl₃): δ=1.15 (6H, t), 2.48 (4H, q), 6.78 (2H, s), 6.95 (1H, s).

[0192] LRMS (thermospray): m/z [MH⁺] 285.

[0193] Microanalysis: Found: C, 54.93; H, 5.05; N, 9.94. C₁₃H₁₄Cl₂N₂O requires C, 54.75; H, 4.95; N, 9.82%.

Example 4

[0194] [4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetonitrile

[0195] Sodium hydride (60% dispersion in oil, 470 mg, 11.8 mmol) was added to a stirred solution of 4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazole (3 g, 10.5 mmol, Example 3) in dry N,N-dimethylformamide (20 ml) at 0° C. under nitrogen. The mixture was stirred for 5 minutes during which time hydrogen was evolved and then bromoacetonitrile (0.81 ml, 11.6 mmol) was added. The yellow solution turned dark brown and a precipitate formed. Further dry N,N-dimethylformamide (5 ml) was added to aid dissolution and after 45 minutes the reaction mixture was quenched by the addition of water (1 ml). The mixture was partitioned between water (150 ml) and diethyl ether (2×150 ml). The combined organic layers were washed with water (50 ml) and brine (100 ml), dried over magnesium sulphate and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane to provide the title compound (3.2 g) as a yellow powder, m.p. 70-72° C.

[0196]¹H-NMR (400 MHz, CDCl₃): δ=1.14 (6H, m), 2.38 (2H, q), 2.56 (2H, q), 4.92 (2H, s), 6.75 (2H, s), 7.00 (1H, s).

[0197] Microanalysis: Found: C, 55.43; H, 4.69; N, 12.71. C₁₅H₁₅Cl₂N₃O requires C, 55.57; H, 4.60; N, 12.96%.

Example 5

[0198] 5-{[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl}-1H-pyrazol-3-ol

[0199] A mixture of the ester (120 mg, 0.29 mmol) of Preparation 3, hydrazine hydrate (16 mg, 0.29 mmol) and ethanol (5 ml) was stirred and heated at 60° C. for 2 hours under nitrogen. After cooling, the mixture was concentrated under reduced pressure and the resulting white solid was stirred in ethyl acetate and then collected by filtration to give the title compound (60 mg) as a white solid, m.p. 142-144° C.

[0200]¹H-NMR (400 MHz, DMSO-d₆): δ=0.89 (3H, t). 0.99 (3H, t), 2.26 (2H, q), 2.45 (2H, q), 5.01 (2H, s), 5.19 (1H, s), 6.88 (2H, s), 7.21 (1H, s).

[0201] LRMS (electrospray): m/z [M−H⁺] 379.

[0202] Microanalysis: Found: C, 55.39; H, 4.72; N, 14.69. C₁₇H₁₈Cl₂N₄O₂ requires C, 53.56; H, 4.76; N, 14.69%.

Example 6

[0203] 6-{[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl}-2-methyl-4 (3H)-pyrimidinone

[0204] A mixture of the ester (140 mg, 0.34 mmol) of Preparation 3, acetamidine hydrochloride (95 mg, 1.0 mmol), sodium ethoxide (68 mg, 1.0 mmol) and ethanol (5 ml) was stirred and heated at 70° C. for 1 hour under nitrogen. After cooling, the mixture was concentrated under reduced pressure. The resulting oil was dissolved in dichloromethane (50 ml), washed with water (20 ml), dried over magnesium sulphate and concentrated under reduced pressure to leave the title compound as a white foam (100 mg).

[0205]¹H-NMR (300 MHz, CDCl₃): δ=1.10 (3H, t), 1.19 (3H, t), 2.48 (7H, m), 5.08 (2H, s), 5.72 (1H, s), 6.82 (2H, s), 7.03 (1H, s).

[0206] LRMS (thermospray): m/z [MH⁺] 407.

Example 7

[0207] 2-Amino-6-{[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl}-4 (3H)-pyrimidinone

[0208] A mixture of the ester (150 mg, 0.365 mmol) from Preparation 3 and guanidine hydrochloride (104 mg, 1.08 mmol) and sodium ethoxide (73 mg, 1.08 mmol) in ethanol (5 ml) was stirred and heated at 70° C. for 3 hours under nitrogen. After cooling the mixture was concentrated under reduced pressure and the resulting oil was dissolved in dichloromethane (50 ml), washed with water (20 ml), dried over magnesium sulphate and concentrated under reduced pressure. The crude product was purified by chromatography on silica gel eluting with dichloromethane:methanol:ammonia (90:10:1, by volume) to give the title compound as a white solid (30 mg), m.p. 238-240° C.

[0209]¹H-NMR (400 MHz, DMSO-d₆): δ=0.91 (3H, t), 0.99 (3H, t), 2.29 (2H, q), 2.44 (2H, q), 4.75 (1H, s), 4.81 (2H, s), 6.58 (2H, br.s), 6.87 (2H, s), 7.22 (1H, s).

[0210] LRMS (thermospray): m/z [MH⁺] 408.

Example 8

[0211] 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]-N-hydroxyethanimidamide

[0212] Hydroxylamine hydrochloride (1.1 g, 15.8 mmol) and potassium carbonate (2.1 g, 15.2 mmol) were added to a suspension of the nitrile (1 g, 3.1 mmol) of Example 4 in a mixture of methanol (25 ml) and water (10 ml) which was then heated under reflux for 3 days. After cooling, the mixture was extracted with dichloromethane (2×250 ml) and the combined organic layers were washed with brine (100 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to afford the product as a white solid (1.1 g), m.p. 128-130° C.

[0213]¹H-NMR (300 MHz, CD₃OD): δ=1.10 (6H, m), 2.40 (2H, q), 2.60 (2H, q), 4.65 (2H, s), 6.90 (2H, s), 7.10 (1H, s).

[0214] LRMS (electrospray): m/z [MH⁺] 357.

Example 9

[0215] Methyl [4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetate

[0216] Methyl bromoacetate (984 μL, 10 mmol) and then sodium hydride (60% dispersion in oil, 801 mg, 20.1 mmol) were added to a stirred solution of the pyrazole (2.6 g, 9.12 mmol) of Example 3 in dry N,N′-dimethylformamide (25 ml) at 0° C. under nitrogen. After stirring for 1 hour at 0° C. ice-water (100 ml) was added and the mixture was extracted with ether (3×50 ml). The combined ether layers were dried over magnesium sulphate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with ethyl acetate:pentane (20:80, by volume) to provide the title compound (780 mg) as a yellow oil which partly crystallised on standing.

[0217]¹H-NMR (400 MHz, CDCl₃): δ=1.10 (6H, m), 2.44 (4H, m), 3.78 (3H, s), 4.80 (2H, s), 6.69 (2H, s), 6.99 (1H, s).

[0218] LRMS (thermospray): m/z [MH⁺] 357.

Example 10

[0219] 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetamide

[0220] 1,1′-Carbonyl diimidazole (71 mg, 0.44 mmol) was added to stirred solution of the acid (125 mg, 0.36 mmol) of Preparation 4 in dry N,N-dimethylformamide at room temperature and the reaction mixture was stirred for 30 minutes. Concentrated aqueous ammonia (d=0.880 g/cm³, ca. 0.1 ml, ca. 1.8 mmol) was added and stirring was continued for 10 minutes. The solvent was removed under reduced pressure and the residue was partitioned between water (10 ml) and ethyl acetate (10 ml). The organic layer was concentrated under reduced pressure and the residue was purified by chromatography on silica gel, eluting with ethyl acetate, to give the title compound as a white solid (60 mg), m.p. 164-166° C.

[0221]¹H-NMR (300 MHz, CDCL₃): δ=1.15 (6H, m), 2.50 (4H, m), 4.70 (2H, s), 5.50 (1H, br. s), 6.21 (1H, br. s), 6.78 (2H, s), 7.04 (1H, s).

[0222] LRMS (thermospray): m/z [MH⁺] 342.

Example 11

[0223] 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetohydrazide

[0224] Hydrazine hydrate (520 μL, 10.9 mmol) was added to a solution of the ester (780 mg, 2.18 mmol) of Example 9 in ethanol (25 ml) and the resulting mixture was heated under reflux for 18 hours. After cooling, the precipitate was collected by filtration and washed with ether (50 ml) to afford the title compound (550 g) as a white solid, m.p. >250° C.

[0225]¹H-NMR (300 MHz, CD₃OD): δ=1.10 (6H, m), 2.39 (2H, q), 2.55 (2H, q), 4.72 (2H, s), 6.93 (2H, s), 7.09 (1H, s).

[0226] LRMS (electrospray): m/z [MH⁺] 357.

Example 12

[0227] 5-{[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl}-1,3,4-oxadiazol-2(3H)-one

[0228] A stirred solution of the hydrazide (275 mg, 0.77 mmol) of Example 11 and 1,1′-carbonyl diimidazole 187 mg, 1.16 mmol) in dioxane (50 ml) was heated under reflux for 18 hours. After cooling, the mixture was concentrated under reduced pressure and the residue was dissolved in dichloromethane (50 ml) and washed with water (25 ml). The organic layer was dried over magnesium sulphate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (95:5, by volume) to afford the title compound (112 mg) as a white solid m.p. 138-142° C.

[0229]¹H-NMR (400 MHz, CDCl₃): δ=1.10 (6H, m), 2.40 (2H, q), 2.55 (2H, q), 5.07 (2H, s), 6.76 (2H, s), 6.98 (1H, s), 10.45 (1H, br. s).

[0230] LRMS (electrospray): m/z [MH⁺] 383.

Example 13

[0231] 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethylamine

[0232] A mixture of the pyrazole (390 mg, 1.37 mmol) of Example 3 and chloroethylamine hydrochloride (238 mg, 2.05 mmol) was stirred and heated at 150° C. for 24 hours. After cooling, the mixture was partitioned between saturated aqueous sodium bicarbonate solution (100 ml) and dichloromethane (2×50 ml). The combined organic layers were washed with brine (30 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The resulting brown oil was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (90:10, by volume) to afford the title compound (244 mg) as a brown oil.

[0233]¹H-NMR (400 MHz, CDCl₃): δ=1.09 (6H, m), 2.41 (2H, q), 2.52 (2H, q), 3.18 (2H, t), 4.02 (2H, t), 6.78 (2H, s), 6.99 (1H, s).

[0234] LRMS (electrospray): m/z [MH⁺] 330.

[0235] Microanalysis: Found: C, 52.28; H, 5.70; N, 11.75. C₁₅H₁₉Cl₂N₃O.H₂O requires C, 52.03; H, 6.11; N, 12.14%.

Example 14

[0236] 3-{[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl}-1,2,4-oxadiazol-5-ol

[0237] Ethylchloroformate (0.30 ml, 3.08 mmol) was added to a stirred solution of the amidoxime of Example 8 (500 mg, 1.39 mmol) in pyridine (8 ml) at 0° C. under nitrogen and the resulting solution was stirred for 10 minutes. The mixture was concentrated under reduced pressure and the residue was dissolved in a mixture of water (4 ml), tetrahydrofuran (4 ml) and 1M aqueous sodium hydroxide solution (2 ml). The mixture was heated under reflux for 1 hour, cooled to room temperature and stirred for a further 2 days. The resulting solution was diluted with 2M aqueous hydrochloric acid (20 ml) and extracted with ethyl acetate (2×50 ml). The combined organic layers were washed with brine (50 ml), dried over magnesium sulphate, filtered and evaporated under reduced pressure to leave a yellow oil. The oil was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (50:50, by volume) to yield a white solid. The solid was dissolved in a mixture of tetrahydrofuran (1 ml) and 1M aqueous sodium hydroxide solution (10 ml) and then heated under reflux for 24 hours. The resulting solution was diluted with 2M hydrochloric acid (20 ml) and extracted with dichloromethane (2×50 ml). The combined organic layers were washed with brine (50 ml), dried over magnesium sulphate, filtered and evaporated under reduced pressure to give the title compound (113 mg) as a white solid m.p. 94-96° C.

[0238]¹H-NMR (400 MHz, CDCl₃): δ=1.14 (m, 6H), 2.56 (m, 4H), 5.06 (s, 2H), 6.75 (s, 2H), 7.03 (s, 1H).

[0239] LRMS (electrospray): m/z [M−(H⁺)] 381.

Example 15

[0240] 5-{[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl}-1,3,4-oxadiazol-2-amine

[0241] Cyanogen bromide (49 mg, 0.462 mmol) was added to a stirred solution of the hydrazide of Example 11 (150 mg, 0.420 mmol) in ethanol (30 ml), at room temperature, under nitrogen and the resulting solution was heated to reflux for 2.5 hours. After cooling, the mixture was concentrated under reduced pressure to leave a brown oil. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (98:1.75:0.25, by volume) to provide the title compound (71 mg) as a white powder, m.p. 226-228° C.

[0242]¹H-NMR (400 MHz, CDCl₃): δ=1.00 (m, 6H), 2.29 (m, 2H), 2.55 (m, 2H), 5.34 (s, 2H), 6.90 (s, 2H), 7.07 (s, 2H), 7.24 (s, 1H).

[0243] LRMS (electrospray): m/z [MH⁺] 382.

[0244] Microanalysis: Found: C, 49.82; H, 4.52; N, 17.81. C₁₆H₁₇Cl₂N₅O₂.0.25H₂O requires C, 49.69; H, 4.56; N, 18.11%.

Example 16

[0245] N-{2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl}-2-methoxyacetamide

[0246] A solution of the pyrazole of Example 13 (53 mg, 0.161 mmol), 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (34 mg, 0.178 mmol) and 4-(dimethylamino)pyridine (22 mg, 0.178 mmol) in dichloromethane (1 ml) was added to a stirred solution of methoxyacetic acid (14.2 μL, 0.178 mmol) in dichloromethane (1 ml) at room temperature. The reaction was stirred for 12 hours and then concentrated under a stream of nitrogen to leave a yellow solid. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound (54 mg) as a brown solid, m.p. 75-76° C.

[0247]¹H-NMR (400 MHz, CDCl₃): δ=1.08 (t, 3H), 1.18 (t, 3H), 2.42 (q, 2H), 2.52 (q, 2H), 3.39 (s, 3H), 3.75 (m, 2H), 3.90 (s, 2H), 4.13 (t, 2H), 6.79 (s, 2H), 6.99 (s, 1H), 7.21 (br s, 1H).

[0248] LRMS (electrospray): m/z [MH⁺] 400; [M−(H⁺)] 398.

[0249] Microanalysis: Found: C, 54.09; H, 5.79; N, 10.39. C₁₈H₂₃Cl₂N₃O₃ requires C, 54.01; H, 5.79; N, 10.50%.

Examples 17 and 18

[0250] The compounds of the following tabulated Examples of the general formula:

[0251] were prepared by a similar method to that of Example 16 using the appropriate acid starting material and the pyrazole of Example 13. Example LRMS No. R (thermospray) Analytical Data 17

m/z [MH⁺] 433 ¹H-NMR (400MHz, CDCl₃): δ = 1.06 (t, 3H), 1.18 # (t, 3H), 2.44 (q, 2H), 2.52 (q, 2H), 3.92 (m, 2H), 4.24 (t, 2H), 6.79 (s, 2H), 6.99 (s, 1H), 7.40 (m, 1H), 7.82 (m, 1H), 8.19 (m, 1H), 8.52 (br s, 2H), 8.55 (m, 1H). Microanalysis: Found: C, 57.01; H, 5.08; N, 11.94. C₂₁H₂₂Cl₂N₄O₂ requires C, 58.21; H, 5.12; N, 12.03%. 18

m/z [MH⁺] 434 ¹H-NMR (400MHz, CDCl₃): δ = 1.08 (t, 3H), 1.18 (t, 3H), 2.42 (q, 2H), 2.52 (q, 2H), 3.96 (m, 2H), 4.24 (t, 2H), 6.79 (s, 2H), 7.01 (s, 1H), 8.22 (br s, 1H), 8.54 (d, 1H), 8.78 (d, 1H), 9.40 (s, 1H).

Example 19

[0252] 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}benzonitrile

[0253] A mixture of the chloroketone of Preparation 2 (243 mg, 1.50 mmol), 3-cyanophenol (155 mg, 1.50 mmol), cesium carbonate (488 mg, 1.50 mmol) and acetone (10 ml) was heated under reflux for 2 hours. After cooling, the solid was removed by filtration and the filtrate was concentrated under reduced pressure to leave a brown oil. The oil was dissolved in ethanol (10 ml), hydroxyethylhydrazine (114 mg, 1.50 mmol) was added and the mixture was heated at 60° C. for 18 hours. After cooling, the mixture was concentrated under reduced pressure. A solution of the residue in dichloromethane (10 ml) was washed with 2M aqueous hydrochloric acid (5 ml) and water (5 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a yellow oil. The crude product was purified by flash column chromatography on silica gel eluting with ethyl acetate to provide the title compound (80 mg) as a colourless oil.

[0254]¹H-NMR (400 MHz, CDCl₃): δ=1.10 (m, 6H), 2.40 (q, 2H), 2.50 (q, 2H), 3.68 (br s, 1H), 4.07 (m, 4H), 7.12 (s, 1H), 7.14 (d, 1H), 7.28 (d, 2H).

[0255] LRMS (electrospray): m/z [MH⁺] 286; [MNa⁺] 308.

Examples 20 to 38

[0256] The compounds of the following tabulated Examples of the general formula:

[0257] were prepared by a similar method to that of Example 19 using the appropriate phenols and the chloroketone of Preparation 2. LRMS Example No. R⁴ (electrospray) Analytical Data 20

m/z [MH⁺] 314. ¹H-NMR (400MHz, CDCl₃): δ =0.99 (t, 3H), 1.09 (t, 3H), 2.18 (s, 6H), 2.25 (q, 2H), 2.40 (q, 2H), 3.78 (br s, 1H), 4.00 (m, 4H), 7.34 (s, 2H). 21

m/z [MH⁺] 320. ¹H-NMR (400MHz, CDCl₃): δ = 1.10 (m, 6H), 2.40 (q, 2H), 2.53 (q, 2H), 3.56 (br s, 1H), 4.04 (m, 2H), 4.08 (m, 2H), 6.80 (d, 1H), 7.44 (d, 1H), 7.72 (s, 1H). Accurate Mass: Found: 320.1165 [MH⁺]; C₁₆H₁₈ClN₃O₂ requires 320.1161 [MH⁺]. 22

m/z [MH⁺] 304. ¹H-NMR (400MHz, CDCl₃): δ =1.10 (m, 6H), 2.39 (q, 2H), 2.50 (q, 2H), 4.60 (m, 4H), 7.05 (m, 1H), 7.14 (m, 2H). 23

m/z [MH⁺] 295. ¹H-NMR (400MHz, CDCl₃): δ = 1.09 (m, 6H), 2.41 (m, 2H), 2.51 (m, 2H), 3.78 (br s, 1H), 4.06 (m, 4H), 6.81 (m, 2H), 7.21 (m, 2H). Microanalysis: Found: C, 60.88; H, 6.49; N, 9.40. C₁₅H₁₉ClN₂O₂ requires C, 61.12; H, 6.50; N, 9.50%. 24

m/z [MH⁺] 295. ¹H-NMR (400MHz, CDCl₃): δ = 1.09 (t, 3H), 1.14 (t, 3H), 2.41, (q, 2H), 2.52 (q, 2H), 3.79 (br s, 1H), 4.05 (m, 4H), 6.78 (d, 1H), 6.88 (s, 1H), 6.98 (d, 1H), 7.19 (t, 1H). 25

M/z [MH⁺] 1 295. ¹H-NMR (400MHz, CDCl₃): δ = 1.08 (t, 3H), 1.15 (t, 3H), 2.44 (q, 2H), 2.54 (q, 2H), 4.02 (m, 2H), 4.09 (m, 2H), 6.69 (d, 1H), 6.94 (t, 1H), 7.10 (t, 1H), 7.40 (d, 1H). 26

M/z [MH⁺] 329. ¹H-NMR (400MHz, CDCl₃): δ = 1.01 (t, 3H), 1.10 (t, 3H), 2.38 (q, 2H), 2.49 (q, 2H), 3.84 (br s, 1H), 3.99 (m, 4H), 7.01 (t, 1H), 7.30 (d, 2H). Accurate Mass: Found: 329.0822 [MH⁺]; C₁₅H₁₈Cl₂N₂O₂ requires 329.0818 [MH⁺]. 27

m/z [M-(H⁺)] 328. ¹H-NMR (400MHz, CDCl₃): δ = 1.09 (t, 3H), 1.14 (t, 3H), 2.41 (q, 2H), 2.51 (q, 2H), 4.03 (m, 2H), 4.07 (m, 2H), 6.60 (d, 1H), 7.04 (t, 1H), 7.10 (t, 1H). 28

m/z [MH⁺] 329. ¹H-NMR (400MHz, CDCl₃): δ = 1.08 (t, 3H), 1.14 (t, 3H), 2.41 (q, 2H), 2.51 (q, 2H), 4.03 (m, 2H), 4.08 (m, 2H), 6.62 (d, 1H), 7.09 (d, 1H). Microanalysis: Found: C, 54.66; H, 29

m/z [MH⁺] 279. ¹H-NMR (400MHz, CDCl₃): δ = 1.10 (t, 3H), 1.14 (t, 3H), 2.44 (q, 2H), 2.55 (q, 2H), 3.79 (br s, 1H), 4.06 (m, 4H), 6.71 (m, 1H), 6.98 (m, 2H), 7.12 (m, 1H). 30

m/z [MH⁺] 279. ¹H-NMR (400MHz, CDCl₃): δ = 1.09 (t, 3H), 1.12 (t, 3H), 2.43 (q, 2H), 2.52 (q, 2H), 3.78 (br s, 1H), 4.04 (m, 4H), 6.59 (m, 1H), 6.75 (m, 2H), 7.20 (m, 2H). 31

m/z [MH⁺] 289. ¹H-NMR (400MHz, CDCl₃): δ = 1.10 (t, 3H), 1.17 (t, 3H), 2.25 (s, 6H), 2.42 (q, 2H), 2.52 (q, 2H), 3.90 (br s, 1H), 4.05 (m, 4H), 6.49 (s, 2H), 6.62 (s, 1H). 32

m/z [MH⁺] 293. ¹H-NMR (400MHz, CDCl₃): δ = 1.09 (t, 3H), 1.14 (t, 3H), 2.22 (s, 3H), 2.42 (q, 2H), 2.31 (q, 2H), 3.83 (br s, 1H), 4.03 (m, 4H), 6.60 (m, 1H), 6.70 (m, 1H), 6.88 (m, 1H). 33

m/z [MH⁺] 329. ¹H-NMR (400MHz, CDCl₃): δ = 1.11 (t, 3H), 1.17 (t, 3H), 2.42 (q, 2H), 2.54 (q, 2H), 4.06 (m, 4H), 6.69 (s, 1H), 6.94 (d, 1H), 7.34 (d, 1H). Microanalysis: Found: C, 54.84; H, 5.67; N, 8.48. C₁₅H₁₈Cl₂N₂O₂ requires C, 54.72; H, 5.51; N, 8.51%. 34

m/z [MH⁺] 297. ¹H-NMR (400MHz, CDCl₃): δ = 1.09 (3, 3H), 1.12 (t, 3H), 2.42 (q, 2H), 2.50 (q, 2H), 3.68 (br s, 1H), 4.01 (m, 4H), 6.47 (m, 1H), 6.77 (m, 1H), 6.86 (m, 1H). Microanalysis: Found: C, 60.57; H, 6.23; N, 9.52. C₁₅H₁₈F₂N₂O₂ requires C, 60.80; H, 6.12; N, 9.45%. 35

m/z [MH⁺] 329. ¹H-NMR (400MHz, CDCl₃): δ = 1.08 (t, 3H), 1.12 (t, 3H), 2.41 (q, 2H), 2.51 (q, 2H), 3.73 (br s, 1H), 4.08 (m, 4H), 6.75 (d, 1H), 6.98 (s, 1H), 7.31 (d, 1H). Microanalysis: Found: C, 54.70; H, 5.54; N, 8.50. C₁₅H₁₈Cl₂N₂O₂requires C, 54.72; H, 5.51; N, 8.51%. 36

m/z [MH⁺] 297. ¹H-NMR (400MHz, CDCl₃): δ =1.08 (t, 3H), 1.12 (t, 3H), 2.49 (q, 2H), 2.60 (q, 2H), 3.81 (br s, 1H), 3.99 (m, 4H), 6.91 (m, 2H), 6.99 (m, 1H). 37

m/z [MH⁺] 297. ¹H-NMR (400MHz, CDCl₃): δ =1.09 (t, 3H), 1.15 (t, 3H), 2.45 (q, 2H), 2.55 (q, 2H), 3.70 (br s, 1H), 4.06 (m, 4H), 6.46 (m, 1H), 6.62 (m, 1H), 7.08 (m, 1H). 38

m/z [MH⁺] 297. ¹H-NMR (400MHz, CDCl₃): δ =1.08 (t, 3H), 1.14 (t, 3H), 2.41 (q, 2H), 2.53 (q, 2H), 3.72 (br s, 1H), 4.05 (m, 4H), 6.43 (m, 3H).

Example 39

[0258] 4-(3,5-Dichlorophenoxy)-3,5-diethyl-1-(2-methoxyethyl)-1H-pyrazole

[0259] Sodium hydride (60% dispersion in oil, 34 mg, 0.850 mmol) was added to a stirred solution of 4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazole of Example 3 (200 mg, 0.701 mmol) and methoxyethyl bromide (117 mg, 0.850 mmol) in dry N,N-dimethylformamide (2 ml) at 0° C. under nitrogen. The mixture was stirred at 0° C. for 45 minutes during which time hydrogen was evolved and the yellow solution turned dark brown. The reaction mixture was quenched by the addition of water (5 ml) and the mixture concentrated under reduced pressure. The residue was dissolved in ethyl acetate (20 ml) and washed with water (10 ml) and brine (10 ml) and then dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a brown oil. The crude product was purified by flash column chromatography on silica gel eluting with pentane:diethyl ether (80:20, by volume) to provide the title compound (140 mg) as a colourless oil.

[0260]¹H-NMR (300 MHz, CDCl₃): δ=1.09-1.15 (m, 6H), 2.41-2.49 (q, 2H), 2.51-2.57 (q, 2H), 3.34 (s, 3H), 3.74-3.78 (t, 2H), 4.15-4.17 (t, 2H), 6.81 (s, 2H), 7.01 (s, 1H).

[0261] LRMS (thermospray): m/z [MH⁺] 343.

[0262] Microanalysis: Found: C, 56.25; H, 5.94; N, 7.95. C₁₆H₂₀Cl₂N₂O₂ requires C, 55.99; H, 5.87; N, 8.16%.

Examples 40 and 41

[0263] The compounds of the following tabulated Examples of the general formula:

[0264] were prepared by a similar method to that of Example 39 using the appropriate halides and the pyrazole of Example 3. LRMS Example (thermo- No. R² spray) Analytical Data 40

m/z [MH⁺]329. ¹H-NMR (300MHz, CDCl₃): δ = 1.13-1.18 (m, 6H), 2.45 (q, 2H), 2.60 (q, 2H), 3.37 (s, 3H), 5.34 (s, 2H), 6.80 (s, 2H), 7.02 (s, 1H). Microanalysis: Found: C, 54.72; H, 5.46; N, 8.40. C₁₅H₁₈Cl₂N₂O₂ requires C, 54.72; H, 5.51; N, 8.51%. 41

m/z [MH⁺]299. ¹H-NMR (300MHz, CDCl₃): δ = 1.15 (m, 6H), 2.48 (m, 4H), 3.79 (s, 3H), 6.82 (s, 2H), 7.01 (s, 1H). Microanalysis: Found: C, 56.08; H, 5.37; N, 9.29. C₁₄H₁₆Cl₂N₂O requires C, 56.20; H, 5.39; N, 9.36%.

Example 42

[0265] 4-(3,5-Dichlorophenoxy)-3-ethyl-1H-pyrazole

[0266] A solution of the enamine of Preparation 6 (2.88 g, 10.0 mmol) and hydrazine hydrate (0.49 ml, 10.0 mmol) in ethanol (10 ml) was heated under reflux for 12 hours. After cooling further hydrazine hydrate (0.49 ml, 10.0 mmol) was added and the reaction was heated under reflux for 3 hours. After cooling the mixture was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel eluting with cyclohexane:ethyl acetate (80:20, by volume) and then cyclohexane:ethyl acetate (60:40, by volume) to provide the title compound (620 mg) as a yellow oil.

[0267]¹H-NMR (400 MHz, CDCl₃): δ=1.23 (t, 3H), 2.66 (q, 2H), 6.87 (s, 2H), 7.02 (s, 1H), 7.40 (s, 1H).

[0268] LRMS (electrospray): m/z [MH⁺] 257; [M−(H⁺)] 255.

Example 43

[0269] 4-{2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl}morpholine

[0270] Osmium tetroxide (1.00 ml of a 2.5% w/v solution in tert-butanol) was added dropwise to a stirred solution of the pyrazole of Example 64 (3.00 g, 9.23 mmol) and sodium periodate (4.93 g, 23.1 mmol) in acetone (90 ml) and water (30 ml) at room temperature. A white precipitate formed after 5 minutes and the suspension was stirred for a further 3 hours. The solid was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was partitioned between ethyl acetate (300 ml) and water (100 ml) and the organic phase was separated, dried over magnesium sulphate, filtered and concentrated under reduced pressure to yield an intermediate aldehyde. An aliquot of the aldehyde (100 mg, 0.305 mmol) was dissolved in dichloromethane (5 ml) and morpholine (30 mg, 0.344 mmol) and glacial acetic acid (17.1 μL, 0.305 mmol) were added. After stirring at room temperature for 5 minutes sodium triacetoxyborohydride (95 mg, 0.451 mmol) was added in one portion and the reaction was stirred for 1 hour. After this time the resultant mixture was diluted with dichloromethane (20 ml) and partitioned between water (30 ml) and dichloromethane (20 ml). The organic phase was washed with 2M aqueous sodium hydroxide solution (10 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (125 mg) as a colourless oil.

[0271]¹H-NMR (400 MHz, CDCl₃): δ=1.06 (m, 6H), 2.12 (m, 8H), 2.75 (t, 2H), 3.64 (m, 4H), 4.04 (t, 2H), 6.73 (s, 2H), 6.95 (s, 1H).

[0272] LRMS (thermospray): m/z [MH⁺] 398.

[0273] Microanalysis: Found: C, 57.18; H, 6.31; N, 10.36. C₁₉H₂₅Cl₂N₃O₂ requires C, 57.29; H, 6.33; N, 10.55%.

Examples 44 to 49

[0274] The compounds of the following tabulated Examples of the general formula:

[0275] were prepared by a similar method to that of Example 43 using the appropriate amine starting material and the pyrazole of Example 64. LRMS Example No. R (thermospray) Analytical Data 44

m/z [MH⁺] 386. ¹H-NMR (300MHz, CDCl₃): δ = 1.09-1.17 (m, 6H), 2.40-2.47 (q, 2H), 2.50-2.56 (q, 2H), 2.80-2.82 (t, 2H), 3.07-3.11 (t, 2H), 3.36 (s, 3H), 3.47-3.51 (t, 2H), 4.09-4.11 (t, 2H), 6.81 (s, 2H), 7.01 (s, 1H). 45

m/z [MH⁺] 439. ¹H-NMR (400MHz, CDCl₃): δ = 1.04 (m, 6H), 2.00 (s, 3H), 2.38 (m, 6H), 2.44 (q, 2H), 2.77 (q, 2H), 3.38 (m, 2H), 3.55 (m, 2H), 4.05 (m, 2H), 6.71 (s, 2H), 6.92 (s, 1H). 46

m/z [MH⁺] 356. ¹H-NMR (400MHz, CDCl₃): δ = 1.05 (m, 6H), 2.23 (s, 6H), 2.38 (q, 2H), 2.45 (q, 2H), 2,69 (m, 2H), 4.03 (m, 2H), 6.75 (s, 2H), 6.95 (s, 1H). 47

m/z [MH⁺] 413. ¹H-NMR (400MHz, CDCl₃): δ = 1.08 (m, 6H), 1.59 (br s, 1H), 1.91 (s, 3H), 2.38 (q, 2H), 2.48 (q, 2H), 2.71 (m, # 2H), 2.99 (m, 2H), 3.28 (m, 2H), 4.02 (m, 2H), 6.09 (br s, 1H), 6.71 (s, 2H), 6.95 (s, 1H). Microanalysis: Found: C, 54.86; H, 6.32; N, 13.33. C₁₉H₂₆Cl₂N₄O₂requires C, 55.21; H, 6.34; N, 13.55%. m.p. 69-70° C. 48

m/z [MH⁺] 342. ¹H-NMR (400MHz, CDCl₃): δ =1.08 (m, 7H), 2.39 (m, 2H), 2.42 (s, 3H), 2.49 (q, 2H), 3.00 (m, 2H), 4.05 (m, 2H), 6.78 (s, 2H), 6.96 (s, 1H). 49

m/z [MH⁺] 412. ¹H-NMR (400MHz, CDCl₃): δ = 1.05 (m, 6H), 1.49 (m, 1H), 1.81 (m, 4H), 2.42 (q, 2H), 2.52 (q, 2H), 2.64 (m, 2H), 3.08 (t, 2H), 3.76 (m, 1H), 3.79 (m, 1H), 4.00 (m, 1H), 6.78 (s, 2H), 6.98 (s, 1H). Microanalysis: Found: C, 57.78; H, 6.68; N, 9.90. C₂₀H₂₇Cl₂N₃O₂requires C, 58.13; H, 6.61; N, 10.17%.

Example 50

[0276] 3-{[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl}morpholine

[0277] Sodium hydride (60% dispersion in oil, 37 mg, 0.925 mmol) was added to a stirred solution of the mesylate of Preparation 11 (273 mg, 0.925 mmol) and the pyrazole of Example 3 (220 mg, 0.772 mmol) in dry N,N-dimethylformamide (4 ml) at 0° C. under nitrogen. The mixture was heated at 50° C. for 3 hours during which time the yellow solution turned dark brown. The reaction mixture was quenched by the addition of water (5 ml) and the mixture was concentrated under reduced pressure. A solution of the residue in ethyl acetate (20 ml) was washed with water (10 ml) and brine (10 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a brown oil. The oil was dissolved in dichloromethane (3 ml), trifluoroacetic acid (1 ml) was added and the reaction was stirred at room temperature for 12 hours. The mixture was concentrated under reduced pressure and the residue was dissolved in ethyl acetate (10 ml) and washed with 1M aqueous hydrochloric acid (2×5 ml). The combined aqueous phases were neutralised with solid sodium carbonate and extracted with ethyl acetate (3×20 ml). The combined ethyl acetate layers were dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (3 mg) as a colourless oil.

[0278]¹H-NMR (400 MHz, CDCl₃): δ=1.15 (m, 6H), 2.41 (q, 2H), 2.51 (q, 2H), 2.89 (m, 2H), 3.30 (m, 2H), 3.58 (m, 1H), 3.78 (m, 2H), 3.87 (d, 2H), 6.88 (s, 2H), 7.00 (1H, s).

[0279] LRMS (thermospray): m/z [MH⁺] 384.

Example 51

[0280] 1-(3-Azetidinyl)-4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazole

[0281] Sodium hydride (60% dispersion in oil, 30 mg, 0.750 mmol) was added to a stirred solution of the pyrazole of Example 3 (200 mg, 0.702 mmol) and 1-benzhydryl-3-azetidinyl methanesulfonate (222 mg, 0.702 mmol) (see J. Org. Chem., 1972, 37, 3953) in N,N-dimethylformamide (5 ml) at 0° C. under nitrogen. The mixture was heated at 50° C. for 4 hours and then cooled to room temperature. The reaction mixture was quenched by the addition of water (30 ml) and the aqueous mixture was extracted with ether (2×50 ml). The combined organic phases were washed with water (10 ml) and brine (10 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a brown oil. The oil was purified by flash column chromatography on silica gel eluting with dichloromethane to provide the intermediate (60 mg) as a yellow oil. The oil was dissolved in dichloromethane (5 ml) and 1-chloroethylchloroformate (20 μL, 0.182 mmol) was added at room temperature under nitrogen. The mixture was heated under reflux for 4 hours, cooled to room temperature and concentrated under reduced pressure to leave a yellow oil. The oil was dissolved in methanol (5 ml) and the resulting solution was heated under reflux for 1 hour, cooled to room temperature and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (17 mg) as a colourless oil.

[0282]¹H-NMR (400 MHz, CDCl₃): δ=1.08 (t, 3H), 1.16 (t, 3H), 2.48 (m, 4H), 3.87 (t, 2H), 4.40 (t, 2H), 5.07 (q, 1H), 6.79 (s, 2H), 7.01 (m, 1H).

[0283] LRMS (thermospray): m/z [MH⁺] 340.

Example 52

[0284] 7-(3,5-Dichlorophenoxy)-6-ethyl-2,3-dihydropyrazolo[5.1-b][1,3]oxazole

[0285] The triflate of Preparation 15 (282 mg, 0.500 mmol), tributylvinyltin (175 μL, 0.600 mmol), palladium dibenzylidene acetone (23 mg, 0.025 mmol), triphenyl arsine (12 mg, 0.040 mmol) and lithium chloride (64 mg, 1.50 mmol) were heated in N,N-dimethylformamide (3 ml) at 80° C. under nitrogen for 12 hours. The reaction was cooled to room temperature and partitioned between water (20 ml) and ethyl acetate (20 ml). The organic layer was washed with brine (10 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (90:10, by volume) to provide the title compound (34 mg) as a colourless oil.

[0286]¹H-NMR (400 MHz, CDCl₃): δ=1.16 (t, 3H), 2.45 (q, 2H), 4.29 (t, 2H), 5.03 (t, 2H), 6.89 (s, 2H), 7.02 (s, 1H).

[0287] LRMS (thermospray): m/z [MH⁺] 299.

Example 53

[0288] 4-(3,5-Dichlorophenoxy)-3,5-dimethyl-1H-pyrazole

[0289] A mixture of 3-chloro-2,4-pentanedione (5.00 g, 37.0 mmol), 3,5-dichlorophenol (6.03 g, 37.0 mmol), cesium carbonate (12.0 g, 37.0 mmol) and acetone (40 ml) was heated under reflux for 18 hours. After cooling the solid was removed by filtration and the filtrate concentrated under reduced pressure. The intermediate was dissolved in ethanol (30 ml) and hydrazine hydrate (1.85 g, 37.0 mmol) was added and the mixture heated at 60° C. for 30 minutes. After cooling the mixture was concentrated under reduced pressure and the residue purified by flash column chromatography on silica gel eluting with ethyl acetate:pentane (30:70, by volume) to provide the title compound (3.00 g) as a yellow oil which solidified on standing to leave a yellow solid, m.p. 85-87° C.

[0290]¹H-NMR (300 MHz, CDCl₃): δ=2.14 (s, 6H), 5.24 (br s, 1H), 6.81 (s, 2H), 7.02 (s, 1H).

[0291] LRMS (thermospray): m/z [MH⁺] 257.

[0292] Microanalysis: Found: C, 49.58; H, 4.06; N, 11.05. C₁₁H₁₀Cl₂N₂O.0.4H₂O requires C, 49.98; H, 4.12; N, 10.60%.

Example 54

[0293] 1-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]-2-propanol

[0294] Osmium tetroxide (1.00 ml of a 2.5% w/v solution in tert-butanol) was added dropwise to a stirred solution of the pyrazole of Example 64 (3.00 g, 9.23 mmol) and sodium periodate (4.93 g, 23.1 mmol) in acetone (90 ml) and water (30 ml) at room temperature. A white precipitate formed after 5 minutes and the suspension was stirred for a further 3 hours. The solid was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was partitioned between ethyl acetate (300 ml) and water (100 ml) and the organic phase was separated, dried over magnesium sulphate, filtered and concentrated under reduced pressure to yield the intermediate aldehyde. An aliquot of the aldehyde (250 mg, 0.765 mmol) was dissolved in tetrahydrofuran (5 ml) and stored under nitrogen. In a separate flask, anhydrous cerium trichloride (377 mg, 1.53 mmol) was added to a stirred solution of methyl magnesium bromide (0.51 ml of a 3M solution in ether, 1.53 mmol) in tetrahydrofuran (5 ml) at room temperature under nitrogen. The mixture was stirred at room temperature for 1.5 hours and the aldehyde in tetrahydrofuran was added dropwise. The mixture was stirred for 12 hours and the reaction was then quenched with 1M aqueous acetic acid at room temperature. The mixture was diluted with dichloromethane (20 ml), washed with water (5 ml) and brine (5 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (70:30, by volume) to provide the title compound (30 mg) as a colourless oil.

[0295]¹H-NMR (400 MHz, CDCl₃): δ=1.05 (t, 3H), 1.10 (t, 3H), 1.21 (d, 2H), 2.40 (q, 2H), 2.47 (q, 2H), 3.79 (dd, 1H), 3.97 (dd, 1H), 4.24 (s, 1H), 6.76 (s, 2H), 6.98 (s, 1H).

[0296] LRMS (thermospray): m/z [MH⁺] 343.

Example 55

[0297] 2-{2-[4-(3,5-Dichlorophenxoy)-3,5-diethyl-1H-pyrazol-1-yl)ethoxy}ethanamine

[0298] Sodium hydride (60% dispersion in oil, 24 mg, 0.600 mmol) was added to a stirred solution of the pyrazole of Example 2 (100 mg, 0.303 mmol) in dry N,N-dimethylformamide (4 ml) at 0° C. under nitrogen. The mixture was stirred at 0° C. for 30 minutes and 2-chloroethylamine hydrochloride (53 mg, 0.455 mmol) was added. The reaction mixture was stirred at 0° C. for 30 minutes and then stirred at room temperature for 30 minutes. The reaction was cooled to 0° C., further sodium hydride (60% dispersion in oil, 24 mg, 0.600 mmol) and 2-chloroethylamine hydrochloride (53 mg, 0.455 mmol) were added and the reaction was stirred for 1 hour. The reaction was quenched by the addition of water (5 ml) and extracted with ether (10 ml). The organic layer was washed with 2M aqueous hydrochloric acid (30 ml). The acid was neutralised with solid sodium carbonate and extracted with ether (3×20 ml). The combined ether layers were dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (21 mg) as a colourless oil.

[0299]¹H-NMR (400 MHz, CDCl₃): δ=1.19 (m, 6H), 2.42 (q, 2H), 2.58 (q, 2H), 2.80 (t, 2H), 3.38 (t, 2H), 3.81 (t, 2H), 4.18 (t, 2H), 6.78 (s, 2H), 7.02 (s, 1H).

[0300] LRMS (thermospray): m/z [MH⁺] 372.

Example 56

[0301] 4-{[4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}morpholine

[0302] Morpholine (1401L, 1.59 mmol) was added in one portion to a stirred solution of the bromide of Preparation 8 (200 mg, 0.531 mmol) in isopropanol (4 ml) at room temperature. The mixture was heated at 50° C. for 1 hour, cooled to room temperature and concentrated under reduced pressure to leave a yellow oil. The crude product was purified by flash column chromatography on silica gel eluting with ethyl acetate to provide the title compound (60 mg) as a colourless oil.

[0303]¹H-NMR (400 MHz, CDCl₃): δ=2.13 (s, 3H), 2.42 (m, 4H), 3.38 (s, 2H), 3.64 (m, 4H), 6.79 (s, 2H), 7.02 (s, 1H).

[0304] LRMS (thermospray): m/z [MH⁺] 342.

Example 57

[0305] 4-(3,5-Dichlorophenoxy)-3-methyl-5-[(2-methyl-1H-imidazol-1-yl)methyl]-1H-pyrazole

[0306] Sodium hydride (60% dispersion in oil, 32 mg, 0.800 mmol) was added to a stirred solution of 2-methylimidazole (65 mg, 0.800 mmol) in N,N-dimethylformamide (5 ml) at 0° C. under nitrogen. The mixture was stirred for 10 minutes and then the bromide of Preparation 8 (100 mg, 0.261 mmol) was added and the reaction was stirred at room temperature for 1 hour. The reaction mixture was quenched by the addition of 1M aqueous sodium hydroxide solution (5 ml) and the mixture was concentrated under reduced pressure. A solution of the residue in ethyl acetate (20 ml) was washed with water (10 ml) and brine (10 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a brown oil. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4.5:0.5, by volume) to provide the title compound (10 mg) as a colourless oil.

[0307]¹H-NMR (300 MHz, CDCl₃): δ=2.14 (s, 3H), 2.35 (s, 3H), 4.89 (s, 2H), 6.68 (s, 2H), 6.78 (s, 1H), 6.82 (s, 1H), 7.03 (s, 1H).

[0308] LRMS (thermospray): m/z [MH⁺] 337.

Example 58

[0309] 2-[4-(3,5-Dichlorophenoxy)-3-ethyl-5-methoxy-1H-pyrazol-1-yl]ethanol

[0310] The triflate of Preparation 15 (282 mg, 0.500 mmol) was dissolved in methanol (3 ml) and 1,1′-bis(diphenylphosphino)ferrocenepalladium(II)chloride (18 mg, 0.025 mmol) was added in one portion at room temperature. The mixture was heated at 50° C. under an atmosphere of carbon monoxide (345 kPa, 50 psi) for 10 hours. The reaction was cooled to room temperature and concentrated under reduced pressure to leave a brown oil. The oil was dissolved in a mixture of tetrahydrofuran (0.5 ml), glacial acetic acid (1.0 ml) and water (0.5 ml) and stirred at room temperature for 12 hours. The solvent was removed under a stream of nitrogen to leave a yellow solid and the crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:acetonitrile (95:5, by volume) and then dichloromethane:acetonitrile (90:10, by volume) to provide the title compound (6 mg) as a colourless oil.

[0311]¹H-NMR (300 MHz, CDCl₃): δ=1.13 (t, 3H), 2.41 (q, 2H), 3.44 (br s, 1H), 3.94 (s, 3H), 4.23 (m, 4H), 6.87 (s, 2H), 7.09 (s, 1H).

[0312] LRMS (thermospray): m/z [MH⁺] 331.

Example 59

[0313] 1-{f[4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}-1H-1,2,4-triazole

[0314] A suspension of the bromide of Preparation 8 (100 mg, 0.264 mmol), 1,2,4-triazole (92 mg, 1.32 mmol) and sodium carbonate (140 mg, 1.32 mmol) in toluene (5 ml) was heated at 100° C. for 12 hours. The suspension was cooled to room temperature and 1M aqueous sodium hydroxide solution (5 ml) was added. The mixture was extracted with ethyl acetate (3×20 ml) and the combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a clear oil. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4.5:0.5, by volume) to provide the title compound (62 mg) as a colourless oil.

[0315]¹H-NMR (300 MHz, CDCl₃): δ=2.16 (s, 3H), 5.25 (s, 2H), 6.70 (s, 2H), 7.04 (s, 1H), 7.89 (s, 1H), 8.04 (s, 1H).

[0316] LRMS (thermospray): m/z [MH⁺] 324.

Example 60

[0317] 3-[(3,5-Diethyl-1H-pyrazol-4-yl)oxy]benzonitrile

[0318] Hydrazine hydrate (153 μL, 3.14 mmol) was added to a stirred solution of the β-diketone of Preparation 9 (771 mg, 3.14 mmol) in ethanol (16 ml) and the resulting solution was heated under reflux for 12 hours. After cooling the mixture was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (75:25, by volume) to provide the title compound (712 mg) as a yellow solid, m.p. 81-84° C.

[0319]¹H-NMR (400 MHz, CDCl₃): δ=1.15 (t, 6H), 2.47 (q, 4H), 7.11 (m, 2H), 7.24 (d, 1H), 7.35 (t, 1H).

[0320] LRMS (thermospray): m/z [MH⁺] 242.

[0321] Microanalysis: Found: C, 69.03; H, 6.43; N, 17.20. C₁₄H₁₅N₃O₃.0.13H₂O requires C, 69.02; H, 6.31; N, 17.25%.

Example 61

[0322] 3-{[1-(2-Aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}benzonitrile

[0323] The pyrazole of Example 60 (200 mg, 0.829 mmol) and 2-chloroethylamine hydrochloride (144 mg, 1.24 mmol) were heated as a melt at 150° C. for 17 hours. After cooling the solid was dissolved in saturated aqueous sodium hydrogencarbonate (15 ml) and extracted with dichloromethane (2×10 ml). The combined organic phases were washed with 2M aqueous hydrochloric acid (20 ml) and the aqueous layer was neutralised with solid sodium carbonate and extracted with dichloromethane (3×10 ml). The combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave an orange gum. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol (90:10) then dichloromethane:methanol:ammonia (90:9:1, by volume) to provide the title compound (124 mg) as a pale yellow oil.

[0324]¹H-NMR (400 MHz, CDCl₃): δ=1.11 (m, 6H), 2.41 (q, 2H), 2.52 (q, 2H), 3.18 (t, 2H), 4.04 (t, 2H), 7.15 (m, 2H), 7.29 (d, 1H), 7.38 (t, 1H).

[0325] LRMS (thermospray): m/z [MH⁺] 285.

Example 62

[0326] 2-[4-(3-Cyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetamide

[0327] A saturated solution of ammonia in methanol (2.3 ml) was added to the ester of Example 63 (75 mg, 0.229 mmol) in a vial at room temperature then the vial was sealed and heated at 75° C. for 17 hours. After cooling to room temperature the mixture was concentrated under reduced pressure to leave a cream solid. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane then dichloromethane:methanol (99:1, by volume) to provide the title compound (49 mg) as a white solid, m.p. 159-160° C.

[0328]¹H-NMR (400 MHz, CDCl₃): δ=1.10 (t, 3H), 1.17 (t, 3H), 2.44 (q, 2H), 2.53 (q, 2H), 4.69 (s, 2H), 5.44 (br s, 1H), 6.22 (br s, 1H), 7.14 (m, 2H), 7.31 (d, 1H), 7.40 (t, 1H).

[0329] LRMS (thermospray): m/z [MH⁺] 299.

[0330] Microanalysis: Found: C, 64.20; H, 6.12; N, 18.79. C₁₆H₁₈N₄O₂ requires C, 64.41; H, 6.08; N, 18.78%.

Example 63

[0331] Ethyl [4-(3-cyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetate

[0332] A solution of ethylhydrazinoacetate (88 mg, 0.571 mmol) in ethanol (2.0 ml) was added to a stirred solution of the β-diketone of Preparation 9 (140 mg, 0.571 mmol) and triethylamine (88 μL, 0.628 ml) in ethanol (1.0 ml) and the resulting solution was heated under reflux for 18 hours. After cooling, the mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane (20 ml) and water (10 ml). The organic layer was separated, washed with brine (10 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (75:25, by volume) and then ethyl acetate to provide the title compound (131 mg) as a yellow oil.

[0333]¹H-NMR (400 MHz, CDCl₃): δ=1.08 (m, 6H), 1.25 (t, 3H), 2.40 (m, 4H), 4.20 (q, 2H), 4.77 (s, 2H), 7.12 (m, 2H), 7.23 (d, 1H), 7.34 (t, 1H).

[0334] LRMS (thermospray): m/z [MH⁺] 328.

Example 64

[0335] 1-Allyl-4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazole

[0336] Sodium hydride (60% dispersion in oil, 770 mg, 19.2 mmol) was added to a stirred solution of allyl bromide (1.70 ml, 19.2 mmol) and the pyrazole of Example 3 (5.00 g, 17.5 mmol) in N,N-dimethylformamide (20 ml) at 0° C. under nitrogen. The reaction was warmed to room temperature and stirred for 1 hour. The reaction mixture was quenched by the addition of water (100 ml) and the aqueous phase was extracted with ether (2×50 ml). The combined organic phases were washed with water (30 ml) and brine (30 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a brown oil. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (80:20, by volume) to provide the title compound (5.00 g) as a yellow oil.

[0337]¹H-NMR (400 MHz, CDCl₃): δ=1.11 (m, 6H), 2.46 (m, 4H), 4.65 (d, 2H), 5.04 (d, 1H), 5.22 (d, 1H), 5.99 (m, 1H), 6.79 (s, 2H), 6.99 (s, 1H).

[0338] LRMS (thermospray): m/z [MH⁺] 325.

Example 65

[0339] N-{[4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}-N-(4-methoxybenzyl)amine

[0340] 4-Methoxybenzylamine (0.104 ml, 0.800 mmol) was added in one portion to a stirred solution of the bromide of Preparation 8 (100 mg, 0.265 mmol) in isopropanol (2 ml) at room temperature. The mixture was heated at 50° C. for 1 hour, cooled to room temperature and concentrated under reduced pressure to leave a yellow oil. The oil was diluted with diethyl ether (20 ml), washed with saturated aqueous sodium hydrogen carbonate (5 ml) and water (5 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (50 mg) as a colourless oil.

[0341]¹H-NMR (300 MHz, CDCl₃): δ=2.13 (s, 3H), 3.68 (s, 2H), 3.71 (s, 2H), 3.80 (s, 3H), 6.83 (m, 4H), 7.03 (s, 1H), 7.17 (m, 2H).

[0342] LRMS (thermospray): m/z [MH⁺] 392.

Examples 66 to 75

[0343] The compounds of the following tabulated Examples of the general formula:

[0344] were prepared by a similar method to that of Example 65 using the appropriate amine starting material and the bromide of Preparation 8. LRMS Example No. R (thermospray) Analytical Data 66

m/z [MH⁺] 326. ¹H-NMR (300MHz, CDCl₃): δ = 0.09 (m, 2H), 0.49 (q, 2H), 0.90 (m, 1H), 2.34 (s, 3H), 2.47 (d, 2H), 3.73 (s, 2H), 6.82 (s, 2H), 7.03 (s, 1H). 67

m/z [MH⁺] 300. ¹H-NMR (400MHz, CDCl₃): δ = 2.08 (s, 3H), 2.20 (s, 6H), 3.31 (s, 2H), 6.76 (s, 2H), 6.97 (s, 1H). 68

m/z [MH⁺] 286. ¹H-NMR (400MHz, CDCl₃): δ = 2.12 (s, 3H), 2.42 (s, 3H), 3.65 (s, 2H), 6.80 (s, 2H), 7.02 (s, 1H). 69

m/z [MH⁺] 355. ¹H-NMR (400MHz, CDCl₃): δ = 2.08 (s, 3H), 2.22 (s, 3H), 2.31 (m, 8H), 3.36 (s, 2H), 6.76 (s, 2H), 6.97 (s, 1H). 70

m/z [MH⁺] 385. ¹H-NMR (400MHz, CDCl₃): δ = 1.50 (m, 2H), 1.60 (m, 2H), 1.90 (m, 4H), 2.41 (m, 2H), 3.25 (s, 2H), 3.75 (m, 2H), 5.52 (s, 1H), 5.80 (s, 1H), 6.67 (s, 2H), 6.86 (s, 1H). 71

m/z [MH⁺] 330. ¹H-NMR (400MHz, CDCl₃): δ = 2.08 (s, 3H), 2.74 (m, 2H), 3.30 (s, 3H), 3.44 (m, 2H), 3.68 (s, 2H), 6.76 (s, 2H), 6.98 (s, 1H). 72

m/z [MH⁺] 383. ¹H-NMR (400MHz, CDCl₃): δ = 2.02 (s, 3H), 2.10 (s, 3H), 2.38 (m, 4H), 3.34 (m, 2H), 3.38 (s, 2H), 3.51 (m, 2H), 6.76 (s, 2H), 6.98 (s, 1H). 73

m/z [MH⁺] 357. ¹H-NMR (400MHz, CDCl₃): δ = 1.92 (s, 3H), 2.09 (s, 3H), 2.70 (m, 2H), 3.29 (m, 2H), 3.65 (s, 2H), 6.01 (s, 1H), 6.76 (s, 2H), 6.99 (s, 1H). 74

m/z [MH⁺] 397. ¹H-NMR (400MHz, CDCl₃): δ = 1.30 (m, 2H), 1.80 (m, 2H), 1.92 (s, 3H), 2.09 (m, 5H), 2.70 (m, 2H), 3.34 (s, 2H), 3.71 (m, 1H), 6.76 (s, 2H), 6.98 (s, 1H). 75

m/z [MH⁺] 370. ¹H-NMR (300MHz, CDCl₃): δ = 1.60 (m, 2H), 1.80 (m, 2H), 2.13 (s, 3H), 2.20 (m, 2H), 2.71 (m, 2H), 3.22 (m, 1H), 3.33 (s, 3H), 3.39 (s, 2H), 6.81 (s, 2H), 7.03 (s, 1H).

Example 76

[0345] 3-Chloro-5-[(3,5-dimethyl-1H-pyrazol-4-yl)oxy]benzonitrile

[0346] Hydrazine hydrate (1.10 ml, 21.9 mol) was added to a stirred solution of the p-diketone of Preparation 16 (5.50 g, 21.9 mmol) in glacial acetic acid (22 ml) and the resulting solution was stirred at room temperature for 14 hours. The mixture was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel eluting with dichloromethane and then dichloromethane:ethyl acetate (85:15, by volume) to provide the title compound (4.80 g) as a yellow solid, m.p. 136-140° C.

[0347]¹H-NMR (400 MHz, CDCl₃): δ 2.09 (s, 6H), 7.02 (m, 1H), 7.10 (m, 1H), 7.25 (m, 1H).

[0348] LRMS (electrospray): m/z [MH⁺] 248.

[0349] Microanalysis: Found: C, 57.91; H, 4.03; N, 16.79. C₁₂H₁₀N₃OCl requires C, 58.19; H, 4.07; N, 16.97%.

Example 77

[0350] 3-{[5-(Aminomethyl)-3-methyl-1H-pyrazol-4-yl]oxy}-5-chlorobenzonitrile

[0351] The bromide of Preparation 18 (300 mg, 0.800 mmol) was added to a saturated solution of ammonia in isopropanol (50 ml) at 0° C. The reaction was stirred for 2 hours and allowed to slowly warm to room temperature. The mixture was concentrated under reduced pressure and the resulting yellow oil was dissolved in dichloromethane (50 ml). The dichloromethane solution was washed with 1M aqueous sodium carbonate solution (20 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to provide the title compound (220 mg) as a white foam.

[0352]¹H-NMR (300 MHz, CDCl₃): δ=2.14 (s, 3H), 3.79 (s, 2H), 7.08 (1H, s), 7.16 (1H, s), 7.31 (1H, s).

[0353] LRMS (thermospray): m/z [MH⁺] 263.

Example 78

[0354]3-Chloro-5-{[3-methyl-5-(1-piperazinylmethyl)-1H-pyrazol-4-yl]oxy}benzonitrile

[0355] t-Butyl-1-piperazinecarboxylate (1.17 g, 6.30 mmol) was added in one portion to a stirred solution of the bromide of Preparation 18 (500 mg, 1.40 mmol) in isopropanol (20 ml) at room temperature. The mixture was heated at 60° C. for 1 hour, cooled to room temperature and concentrated under reduced pressure to leave a yellow oil. The oil was dissolved in dichloromethane (100 ml) and the resulting solution was washed with 1M aqueous sodium carbonate (20 ml) and brine (20 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide a yellow foam. The foam was dissolved in dichloromethane (10 ml), the resulting solution was cooled to 0° C. and trifluoroacetic acid (2 ml) was added. The reaction was allowed to warm to room temperature and stirred for 24 hours. The mixture was diluted with dichloromethane (50 ml), washed with 1M aqueous sodium carbonate (20 ml) and brine (20 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (90:9:1, by volume) to provide the title compound (400 mg) as a white foam.

[0356]¹H-NMR (300 MHz, CDCl₃): δ=2.14 (s, 3H), 2.40 (m, 4H), 2.83 (m, 4H), 3.38 (s, 2H), 7.09 (s, 1H), 7.16 (s, 1H), 7.30 (s, 1H).

[0357] LRMS (thermospray): m/z [MH⁺] 332.

Example 79

[0358] 3-Chloro-5-[(5-{[(4-cyanobenzyl)amino]methyl}-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile

[0359] A mixture of 4-cyanobenzaldehyde (60 mg, 0.460 mmol), the amine of Example 77 (120 mg, 0.460 mmol), magnesium sulphate (500 mg) and dichloromethane (5 ml) was stirred under nitrogen at room temperature for 3 days. The mixture was concentrated under reduced pressure and the crude product was purified by flash column chromatography on silica gel eluting with methanol:ethyl acetate (5:95, by volume) to provide a foam. The foam was dissolved in methanol (5 ml), sodium borohydride (50 mg, 1.31 mmol) was added in one portion at room temperature and the reaction was stirred for 30 minutes. The mixture was concentrated under reduced pressure and the residue was dissolved in dichloromethane (20 ml). The resulting solution was washed with 1 M aqueous sodium carbonate solution (10 ml) and brine (10 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (35 mg) as a white foam.

[0360]¹H-NMR (300 MHz, CDCl₃): δ=2.15 (s, 3H), 3.69 (s, 2H), 3.84 (s, 2H), 7.06 (s, 1H), 7.15 (s, 1H), 7.31 (s, 1H), 7.38 (d, 2H), 7.60 (d, 2H).

[0361] LRMS (thermospray): m/z [MH⁺] 378.

Example 80

[0362] 3-Chloro-5-[(3-methyl-5-{[4-(methylsulfonyl)-1-piperazinyl]methyl}-1H-pyrazol-4-yl)oxy]benzonitrile

[0363] Methanesulphonyl chloride (19 μl, 0.240 mmol) was added dropwise to a stirred solution of the amine of Example 78 (80 mg, 0.240 mmol) and triethylamine (45 μL, 0.288 mmol) in dichloromethane (3 ml) at room temperature under nitrogen. The reaction was stirred for 30 minutes and then concentrated under reduced pressure to leave a yellow oil. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane and then dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (65 mg) as a white foam.

[0364]¹H-NMR (400 MHz, CDCl₃): δ=2.14 (s, 3H), 2.51 (m, 4H), 2.72 (s, 3H), 3.12 (m, 4H), 3.39 (s, 2H), 7.08 (m, 1H), 7.13 (m, 1H), 7.26 (s, 1H).

[0365] LRMS (thermospray): m/z [MH⁺] 410.

Example 81

[0366] 3-Chloro-5-[(5-{[4-(methoxyacetyl)-1-piperazinyl]methyl}-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile

[0367] N-Benzyl-N′-cyclohexylcarbodiimide polymer bound (624 mg of 1.3 mmol/g, 0.480 mmol) was added in one portion to a stirred solution of methoxyacetic acid (37 μL, 0.480 mmol) and the amine of Example 78 (80 mg, 0.240 mmol) in dichloromethane (5 ml) at room temperature under nitrogen. The reaction was stirred for 1 hour and the polymer bound reagent was removed by filtration. The filtrate was concentrated under reduced pressure and the crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (45 mg) as a white foam.

[0368]¹H-NMR (400 MHz, CDCl₃): δ=2.11 (s, 3H), 2.38 (m, 4H), 3.37 (m, 7H), 3.51 (m, 2H), 4.04 (s, 2H), 7.04 (m, 1H), 7.10 (m, 1H), 7.26 (m, 1H).

[0369] LRMS (thermospray): m/z [MH⁺] 404.

Example 82

[0370] Methyl 4-{[4-(3-chloro-5-cyanophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}-1-piperazinecarboxylate

[0371] Methyl chloroformate (19 82 l, 0.240 mmol) was added dropwise to a stirred solution of the amine of Example 78 (80 mg, 0.240 mmol) and triethylamine (45 μl, 0.288 mmol) in dichloromethane (5 ml) at room temperature under nitrogen. The reaction was stirred for 90 minutes and then concentrated under reduced pressure to leave a yellow oil. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane and then dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (55 mg) as a white foam.

[0372]¹H-NMR (400 MHz, CDCl₃): δ=2.09 (s, 3H), 2.34 (m, 4H), 3.36 (m, 6H), 3.64 (s, 3H), 7.02 (m, 1H), 7.10 (m, 1H), 7.25 (m, 1H).

[0373] LRMS (thermospray): m/z [MH⁺] 390.

Example 83

[0374] 4-[({[4-(3-Chloro-5-cyanophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}amino)methyl]benzenesulfonamide

[0375] Triethylamine (125 μl, 0.860 mmol) was added in one portion to a stirred suspension of 4-aminomethylbenzenesulphonamide hydrochloride (144 mg, 0.590 mmol) and the bromide of Preparation 18 (100 mg, 0.270 mmol) in isopropanol (5 ml) at room temperature under nitrogen. The reaction was heated at 70° C. for 1 hour and then cooled to room temperature. The mixture was concentrated under reduced pressure and the crude product was purified by flash column chromatography on silica gel eluting with dichloromethane and then dichloromethane:methanol:ammonia (90:9:1, by volume) to provide a foam. The foam was further purified using a Phenomenex Luna C18 column eluting with diethylamine:methanol (0.1:99.1, by volume) to provide the title compound (8 mg) as a white foam.

[0376]¹H-NMR (400 MHz, CD₃OD): δ 2.06 (s, 3H), 3.27 (s, 2H), 3.62 (s, 2H), 3.79 (s, 2H), 7.17 (s, 1H), 7.21 (s, 1H), 7.40 (m, 3H), 7.77 (d, 2H).

[0377] LRMS (thermospray): m/z [MH⁺] 432.

Example 84

[0378] 4-(3,5-Dichlorophenoxy)-5-(methoxymethyl)-3-methyl-1H-pyrazole

[0379] Tetrakis(triphenylphosphine)palladium (60 mg) was added in one portion to a stirred solution of the bromide of Preparation 8 (590 mg, 1.56 mmol) in methanol (20 ml) and tetrahydrofuran (20 ml) at room temperature. The mixture was heated at 80° C. under an atmosphere of carbon monoxide (690 kPa, 100 psi) for 18 hours. The reaction was cooled to room temperature and concentrated under reduced pressure to leave a brown oil. The oil was dissolved in dichloromethane (100 ml) and the resulting solution was washed with water (50 ml), dried over magnesium sulphate, filtered and evaporated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with ether to provide the title compound (110 mg) as a colourless oil.

[0380]¹H-NMR (400 MHz, CDCl₃): δ=2.15 (s, 3H), 3.34 (s, 3H), 4.35 (s, 2H), 6.83 (s, 2H), 7.03 (s, 1H).

[0381] LRMS (thermospray): m/z [MH⁺] 287.

Example 85

[0382] 3-tert-Butyl-4-(3,5-dichlorophenoxy)-5-methyl-1H-pyrazole

[0383] A mixture of the dione of Preparation 19 (1.00 g, 5.68 mmol), 3,5-dichlorophenol (930 mg, 5.68 mmol), cesium carbonate (1.85 g, 5.68 mmol) and acetone (20 ml) was heated at reflux for 18 hours. After cooling the solid was removed by filtration and the filtrate was concentrated under reduced pressure. The intermediate was dissolved in ethanol (20 ml), hydrazine hydrate (284 mg, 5.68 mmol) was added and the mixture was heated at 60° C. for 1 hour. After cooling the mixture was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel eluting with ethyl acetate:pentane (25:75, by volume) to provide the title compound (200 mg) as a yellow oil.

[0384]¹H-NMR (400 MHz, CDCl₃): δ=1.30 (s, 9H), 2.06 (s, 3H), 6.81 (s, 2H), 7.02 (s, 1H).

[0385] LRMS (thermospray): m/z [MH⁺] 299.

Example 86

[0386] 4-(3,5-Dichlorophenoxy)-3-ethyl-5-methyl-1H-pyrazole

[0387] A mixture of the dione of Preparation 50 (4.50 g, 30.8 mmol), 3,5-dichlorophenol (5.00 g, 30.8 mmol), caesium carbonate (10.0 g, 30.8 mmol) and acetone (40 ml) was heated at reflux for 18 hours. After cooling the solid was removed by filtration and the filtrate was concentrated under reduced pressure. The intermediate was dissolved in ethanol (40 ml), hydrazine hydrate (1.00 ml, 30.8 mmol) was added and the mixture was heated at 60° C. for 1 hour. After cooling the mixture was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel eluting with ethyl acetate:pentane (20:80, by volume) to provide the title compound (1.50 g) as an orange oil.

[0388]¹H-NMR (400 MHz, CDCl₃): δ=1.18 (t, 3H), 2.11 (s, 3H), 2.53 (q, 2H), 6.79 (s, 2H), 7.01 (s, 1H).

[0389] LRMS (thermospray): m/z [MH⁺] 271.

Example 87

[0390] 4-Cyano-N-{[4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}benzamide

[0391] 1-(3-(Dimethylamino)propyl)-3-ethylcarbodiimide (93 mg, 0.490 mmol) was added in one portion to a stirred solution of the amine of Example 109 (120 mg, 0.440 mmol) and 4-cyanobenzoic acid (71 mg, 0.490 mmol) in dichloromethane (5 ml) at room temperature under nitrogen. The reaction was stirred for 20 minutes and then washed with 1M aqueous sodium hydroxide solution (10 ml), 1M aqueous hydrochloric acid (10 ml) and water (10 ml). The organic layer was dried over magnesium sulphate, filtered and evaporated under reduced pressure to leave a yellow foam. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (110 mg) as a white foam.

[0392]¹H-NMR (400 MHz, CDCl₃): δ=2.09 (s, 3H), 4.91 (d, 2H), 6.74 (s, 2H), 6.95 (s, 1H), 6.98 (d, 1H), 7.65 (d, 2H), 7.77 (d, 2H).

[0393] LRMS (thermospray): m/z [MNH₄ ⁺] 418.

Example 88

[0394] 3-Cyano-N-{[4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}benzamide

[0395] 1-(3-(Dimethylamino)propyl)-3-ethylcarbodiimide (93 mg, 0.490 mmol) was added in one portion to a stirred solution of the amine of Example 109 (120 mg, 0.440 mmol) and 3-cyanobenzoic acid (71 mg, 0.490 mmol) in dichloromethane (5 ml) at room temperature under nitrogen. The reaction was stirred for 10 minutes and then washed with 1M aqueous sodium hydroxide solution (10 ml), 1M aqueous hydrochloric acid (10 ml) and brine (10 ml). The organic layer was dried over magnesium sulphate, filtered and evaporated under reduced pressure to leave a cream foam. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (100 mg) as a white foam.

[0396]¹H-NMR (400 MHz, CDCl₃): δ=2.14 (s, 3H), 4.53 (d, 2H), 6.78 (s, 2H), 6.98 (m, 2H), 7.54 (dd, 1H), 7.76 (d, 1H), 7.95 (d, 1H), 7.99 (s, 1H).

[0397] LRMS (thermospray): m/z [MH⁺] 401.

Example 89

[0398] N-{[4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}-N-(3-pyridinylmethyl)amine

[0399] A mixture of 3-pyridinecarboxaldehyde (55 mg, 0.514 mmol), the amine of Example 109 (140 mg, 0.514 mmol), magnesium sulphate (500 mg) and dichloromethane (5 ml) was stirred under nitrogen at room temperature for 18 hours. Sodium triacetoxyborohydride (163 mg, 0.771 mmol) was added in one portion and then acetic acid (3 drops) was added. After 5 minutes the mixture was filtered. The filtrate was washed with 1M aqueous sodium carbonate solution (10 ml), water (10 ml) and brine (10 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a clear oil. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (60 mg) as a colourless oil.

[0400]¹H-NMR (400 MHz, CDCl₃): δ=2.09 (s, 3H), 3.66 (s, 2H), 3.74 (s, 2H), 6.75 (s, 2H), 6.97 (s, 1H), 7.17 (m, 1H), 7.55 (d, 1H), 8.49 (m, 2H).

[0401] LRMS (electrospray): m/z [MH⁺] 363.

Example 90

[0402] 3-({5-[(4-Acetyl-1-piperazinyl)methyl]-3-methyl-1H-pyrazol-4-yl}oxy)-5-chlorobenzonitrile

[0403] N-Acetylpiperazine (104 mg, 0.810 mmol) was added in one portion to a stirred solution of the bromide of Preparation 18 (100 mg, 0.271 mmol) in isopropanol (5 ml) at room temperature. The mixture was heated at 50° C. for 1 hour, cooled to room temperature and concentrated under reduced pressure to leave a yellow oil. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (90 mg) as a colourless oil.

[0404]¹H-NMR (300 MHz, CDCl₃): δ=2.08 (s, 3H), 2.16 (s, 3H), 2.43 (m, 4H), 3.42 (m, 4H), 3.55 (m, 2H), 7.08 (s, 1H), 7.16 (s, 1H), 7.31 (s, 1H).

[0405] LRMS (thermospray): m/z [MH⁺] 374.

Example 91

[0406] 3-Chloro-5-[(5-{[(4-cyanobenzyl) (methyl)amino]methyl}-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile

[0407] The amine of Preparation 20 (127 mg, 0.870 mmol) was added in one portion to a stirred solution of the bromide of Preparation 18 (100 mg, 0.271 mmol) in isopropanol (5 ml) at room temperature. The mixture was heated at 50° C. for 12 hours, cooled to room temperature and concentrated under reduced pressure to leave a yellow oil. The oil was dissolved in 1M hydrochloric acid and the aqueous solution was washed with ethyl acetate (10 ml). Solid sodium carbonate was added until effervescence ceased and the mixture was extracted with ethyl acetate (3×20 ml). The combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (45 mg) as a colourless oil.

[0408]¹H-NMR (300 MHz, CDCl₃): δ=2.14 (s, 3H), 2.17 (s, 3H), 3.45 (s, 2H), 3.55 (s, 2H), 7.05 (s, 1H), 7.14 (s, 1H), 7.31 (m, 3H), 7.59 (d, 2H).

[0409] LRMS (thermospray): m/z [MH⁺] 392.

Example 92

[0410] 3-Chloro-5-[(5-{[(4-cyanobenzyl)(2-hydroxyethyl)amino]methyl}-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile

[0411] The amine of Preparation 21 (153 mg, 0.870 mmol) was added in one portion to a stirred solution of the bromide of Preparation 18 (100 mg, 0.271 mmol) in isopropanol (5 ml) at room temperature. The mixture was heated at 50° C. for 12 hours, cooled to room temperature and concentrated under reduced pressure to leave a yellow oil. The oil was dissolved in 1M aqueous sodium hydroxide solution and the resulting solution was stirred at room temperature for 1 hour. The aqueous was extracted with ethyl acetate (3×20 ml) and the combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (20 mg) as a colourless oil.

[0412]¹H-NMR (300 MHz, CDCl₃): δ=2.14 (s, 3H), 2.71 (m, 2H), 3.50 (s, 1H), 3.58 (s, 2H), 3.67 (m, 2H), 3.72 (s, 2H), 6.99 (s, 1H), 7.09 (s, 1H), 7.31 (s, 1H), 7.41 (d, 2H), 7.58 (d, 2H).

[0413] LRMS (thermospray): m/z [MH⁺] 422.

Example 93

[0414] 3-Chloro-5-({3-methyl-5-[(2-methyl-1H-imidazol-1-yl)methyl]-1H-pyrazol-4-yl}oxy)benzonitrile

[0415] A suspension of the bromide of Preparation 18 (100 mg, 0.264 mmol), 2-methylimidazole (111 mg, 1.35 mmol) and sodium carbonate (143 mg, 1.35 mmol) in toluene (5 ml) was heated at 100° C. for 12 hours. The suspension was cooled to room temperature, 1M aqueous sodium hydroxide solution (5 ml) was added and the mixture was stirred for 1 hour. The mixture was extracted with ethyl acetate (3×20 ml) and the combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a white solid. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4.5:0.5, by volume) to provide the title compound (77 mg) as a white solid, m.p. 212-214° C.

[0416]¹H-NMR (300 MHz, CDCl₃): δ=2.14 (s, 3H), 2.33 (s, 3H), 4.92 (s, 2H), 6.76 (s, 1H), 6.79 (s, 1H), 6.86 (s, 1H), 7.27 (s, 2H).

[0417] LRMS (thermospray): m/z [MH⁺] 328.

Example 94

[0418] 2-(4-(3,5-Dichlorophenoxy)-3-methyl-5-{[(3-pyridinylmethyl)amino]methyl}-1H-pyrazol-1-yl)ethanol

[0419] Tetrabutylammonium fluoride (0.58 ml of a 1.0M solution in tetrahydrofuran, 0.580 mmol) was added in one portion to a stirred solution of the amine of Preparation 22 (150 mg, 0.290 mmol) in dichloromethane (5 ml) at room temperature. The reaction was stirred for 12 hours and concentrated under reduced pressure to leave a colourless oil. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (100 mg) as a colourless oil.

[0420]¹H-NMR (400 MHz, CDCl₃): δ=2.07 (s, 3H), 3.65 (s, 2H), 3.76 (s, 2H), 3.96 (m, 2H), 4.24 (m, 2H), 6.76 (s, 2H), 7.02 (s, 1H), 7.26 (m, 1H), 7.59 (d, 1H), 8.50 (m, 2H).

[0421] LRMS (thermospray): m/z [MH⁺] 407.

Example 95

[0422] 5-[(3-Isopropyl-5-methyl-1H-pyrazol-4-yl)oxy]isophthalonitrile

[0423] Hydrazine hydrate (110 μl, 2.24 mmol) was added to a stirred solution of the β-diketone of Preparation 24 (550 mg, 2.04 mmol) in glacial acetic acid (5 ml) and the resulting solution was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (60:40, by volume) to provide the title compound (350 mg) as a yellow solid, m.p. 142-144° C.

[0424]¹H-NMR (300 MHz, CDCl₃): δ=1.21 (d, 6H), 2.09 (s, 3H), 2.90 (sept, 1H), 7.40 (s, 2H), 7.60 (s, 1H).

[0425] LRMS (thermospray): m/z [MH⁺] 267.

Example 96

[0426] 5-{[1-(2-Hydroxyethyl)-3-isopropyl-5-methyl-1H-pyrazol-4-yl]oxy}isophthalonitrile

[0427] Tetrabutylammonium fluoride (0.28 ml of a 1.0M solution in tetrahydrofuran, 0.280 mmol) was added in one portion to a stirred solution of the pyrazole of Preparation 25 (60 mg, 0.140 mmol) in dichloromethane (5 ml) at room temperature. The reaction was stirred for 12 hours and concentrated under reduced pressure to leave a colourless oil. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (20:80, by volume) to provide the title compound (30 mg) as a white solid.

[0428]¹H-NMR (400 MHz, CDCl₃): δ=1.17 (d, 6H), 2.08 (s, 3H), 2.76 (sept, 1H), 3.52 (m, 2H), 4.10 (m, 2H), 7.40 (s, 2H), 7.59 (s, 1H).

[0429] LRMS (electrospray): m/z [MH⁺] 311.

[0430] Microanalysis: Found: C, 65.44; H, 5.87; N, 17.91. C₁₇H₁₈N₄O₂ requires C, 65.79; H, 5.85; N, 18.05%.

Example 97

[0431] 3-(3,5-Dichlorophenoxy)-2-ethyl-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one

[0432] Lithium diisopropylamide (18.0 ml of a 1.5M solution in cyclohexane, 27.0 mmol) was added dropwise to a stirred solution of the pyrazole of Preparation 26 (12.3 g, 24.6 mmol) in tetrahydrofuran (120 ml) at −78° C. under nitrogen. The reaction was stirred for 14 hours, slowly warming to room temperature, and cautiously quenched with saturated aqueous ammonium chloride solution (20 ml). The mixture was concentrated under reduced pressure and the residue was dissolved in dichloromethane (200 ml). The resulting solution was washed with saturated aqueous ammonium chloride solution (100 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a white solid. The solid was triturated with a mixture of dichloromethane and pentane (100 ml and 100 ml) to give the title compound (2.63 g) as a white solid, m.p. 220-223° C.

[0433]¹H-NMR (400 MHz, D₆DMSO): δ=1.08 (t, 3H), 2.44 (q, 2H), 3.60 (m, 2H), 4.24 (t, 2H), 7.00 (s, 2H), 7.26 (s, 1H), 8.15 (s, 1H).

[0434] LRMS (thermospray): m/z [MNH₄ ⁺] 343.

[0435] Microanalysis: Found: C, 51.52; H, 3.98; N, 12.74. C₁₄H₃₁Cl₂N₃O₂ requires C, 51.55; H, 4.02; N, 12.88%.

Example 98

[0436] 3-(3,5-Dichlorophenoxy)-2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine

[0437] Borane (2.00 ml of a 1.0M solution in tetrahydrofuran, 2.00 mmol) was added to a stirred solution of the pyrazole of Example 97 (326 mg, 1.00 mmol) in tetrahydrofuran (10 ml) at room temperature under nitrogen. The reaction was heated under reflux for 5 hours and further borane (3.00 ml of a 1.0M solution in tetrahydrofuran, 3.00 mmol) was added. The reaction was heated under reflux for 14 hours and further borane (2.00 ml of a 1.0M solution in tetrahydrofuran, 2.00 mmol) was added. The reaction was heated under reflux for 3 hours and further borane (2.00 ml of a 1.0M solution in tetrahydrofuran, 2.00 mmol) was added. The mixture was cooled to room temperature, 2M hydrochloric acid (10 ml) was added and the mixture was heated under reflux for 1 hour. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in dichloromethane (40 ml), washed with 1 M aqueous potassium carbonate solution (30 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol (98:2, by volume), then dichloromethane:methanol (95:5, by volume) and then dichloromethane:methanol:ammonia (90:9:1, by volume) to provide the title compound (219 mg) as a white solid, m.p. 76-77° C.

[0438]¹H-NMR (400 MHz, CDCl₃): δ=1.10 (t, 3H), 2.42 (q, 2H), 3.24 (t, 2H), 3.80 (s, 2H), 4.05 (t, 2H), 6.76 (s, 2H), 6.95 (s, 1H).

[0439] LRMS (thermospray): m/z [MH⁺] 312.

[0440] Microanalysis: Found: C, 53.79; H, 4.88; N, 13.14. C₁₄H₁₅Cl₂N₃O requires C, 53.86; H, 4.84; N, 13.46%.

Example 99

[0441] 3-(3,5-Dichlorophenoxy)-2-ethyl-5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine

[0442] Methyl iodide (11 μl, 0.176 mmol) was added to astirred solution of potassium carbonate (24 mg, 0.176 mmol) and the amine of Example 98 (50 mg, 0.160 mmol) in N,N-dimethylformamide (2 ml) at room temperature under nitrogen. The reaction was stirred for 3 hours and then concentrated under reduced pressure. The residue was dissolved in ethyl acetate (20 ml), washed with 1M aqueous potassium carbonate solution (20 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound (18 mg) as a colourless oil.

[0443]¹H-NMR (400 MHz, CDCl₃): δ=1.11 (t, 3H), 2.42 (m, 5H), 2.84 (t, 2H), 3.37 (s, 2H), 4.11 (t, 2H), 6.77 (s, 2H), 6.98 (s, 1H).

[0444] LRMS (thermospray): m/z [MH⁺] 326.

Example 100

[0445] 4-[(3-(3,5-Dichlorophenoxy)-2-ethyl-6,7-dihydropyrazolo[1,5-a]pyrazin-5 (4H)-yl)methyl]benzonitrile

[0446] 4-Cyanobenzylbromide (35 mg, 0.176 mmol) was added to a stirred solution of potassium carbonate (24 mg, 0.176 mmol) and the amine of Example 98 (50 mg, 0.160 mmol) in N₅N-dimethylformamide (2 ml) at room temperature under nitrogen. The reaction was stirred for 14 hours and then concentrated under reduced pressure. The residue was dissolved in ethyl acetate (20 ml) and the resulting solution was washed with 1M aqueous potassium carbonate solution (15 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound (66 mg) as a white solid, m.p. 149-150° C.

[0447]¹H-NMR (400 MHz, CDCl₃): δ=1.13 (t, 3H), 2.44 (q, 2H), 2.92 (t, 2H), 3.42 (s, 2H), 3.71 (s, 2H), 4.13 (t, 2H), 6.74 (s, 2H), 6.97 (s, 1H), 7.42 (d, 2H), 7.60 (d, 2H).

[0448] LRMS (thermospray): m/z [MH⁺] 427.

Example 101

[0449] 3-(3.5-Dichlorophenoxy)-2-ethyl-5-(4-methoxybenzyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine

[0450] 4-Methoxybenzylchloride (24 μl, 0.176 mmol) was added to a stirred solution of potassium carbonate (24 mg, 0.176 mmol) and the amine of Example 98 (50 mg, 0.160 mmol) in N,N-dimethylformamide (6 ml) at room temperature under nitrogen. The reaction was stirred for 14 hours and then potassium carbonate (12 mg, 0.088 mmol) and 4-methoxybenzylchloride (12 μl, 0.088 mmol) added. The reaction was stirred for 3 hours and then concentrated under reduced pressure. The residue was dissolved in ethyl acetate (20 ml) and the resulting solution was washed with 1M aqueous potassium carbonate solution (20 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol (99:1, by volume) to provide the title compound (50 mg) as a colourless oil.

[0451]¹H-NMR (400 MHz, CDCl₃): δ=1.13 (t, 3H), 2.45 (q, 2H), 2.92 (t, 2H), 3.44 (s, 2H), 3.60 (s, 2H), 3.80 (s, 3H), 4.10 (t, 2H), 6.77 (s, 2H), 6.85 (d, 2H), 7.00 (s, 1H), 7.23 (d, 2H).

[0452] LRMS (thermospray): m/z [MH⁺] 432.

Example 102

[0453] [1-(2-Aminoethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-5-yl]methanol

[0454] Hydrogen chloride (0.50 ml of a 4.0M solution in dioxane, 2.00 mmol) was added to a stirred solution of the pyrazole of Example 135 (86 mg, 0.200 mmol) in dioxane (0.5 ml) at room temperature under nitrogen. The reaction was stirred for 24 hours and concentrated under reduced pressure. The residue was dissolved in dichloromethane (20 ml) and the resulting solution was washed with 1M aqueous potassium carbonate solution (10 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (99:1, by volume) to provide the title compound (40 mg) as a white solid, m.p. 105-107° C.

[0455]¹H-NMR (400 MHz, CDCl₃): δ=1.10 (t, 3H), 2.42 (q, 2H), 2.55 (s, 2H), 3.13 (t, 2H), 4.13 (t, 2H), 4.37 (s, 2H), 6.79 (s, 2H), 6.98 (s, 1H).

[0456] LRMS (thermospray): m/z [MH⁺] 330.

[0457] Microanalysis: Found: C, 50.61; H, 5.23; N, 12.31. C₁₄H₁₇Cl₂N₃O₂ requires C, 50.92; H, 5.19; N, 12.73%.

Example 103

[0458] 2-[4-(3,5-Dichlorophenoxy)-5-(ethoxymethyl)-3-ethyl-1H-pyrazol-1-yl]ethylamine

[0459] Hydrogen chloride (0.50 ml of a 4.0M solution in dioxane, 2.00 mmol) was added to a stirred solution of the pyrazole of Example 136 (60 mg, 0.130 mmol) in dioxane (0.5 ml) at room temperature under nitrogen. The reaction was stirred for 2 days and concentrated under reduced pressure. The residue was dissolved in dichloromethane (20 ml) and the resulting solution was washed with 1M aqueous potassium carbonate solution (10 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:ammonia (99:9:1, by volume) to provide the title compound (32 mg) as a colourless oil.

[0460]¹H-NMR (400 MHz, CDCl₃): δ=1.10 (m, 6H), 2.42 (q, 2H), 3.15 (t, 2H), 3.40 (q, 2H), 4.11 (t, 2H), 4.29 (s, 2H), 6.79 (s, 2H), 6.98 (s, 1H).

[0461] LRMS (thermospray): m/z [MH⁺] 358.

Examples 104 to 106

[0462] The compounds of the following tabulated Examples of the general formula:

[0463] were prepared by a similar method to that of Example 103 using the appropriate starting material. Example No. LRMS (Starting material) R (thermospray) Analytical Data 104 (Example 140)

m/z [MH⁺] 380. ¹H-NMR (400MHz, # CDCl₃): δ = 1.10 (t, 3H), 2.40 (q, 2H), 2.97 (t, 2H), 4.15 (t, 2H), 5.20 (s, 2H), 6.16 (s, 1H), 6.71 (d, 2H), 6.97 (s, 1H), 7.15 (s, 1H), 7.42 (s, 1H). Microanalysis: Found: C, 52.78; H, 5.09; N, 17.86. C₁₇H₁₉Cl₂N₅O.0.12CH₂Cl₂requires C, 52.66; H, 4.97; N, 17.94%. 105 (Example 142)

m/z [MH⁺] 449. ¹H-NMR (400MHz, CDCl₃): CDCl₃): δ = 1.10 (t, # 3H), 2.42 (q, 2H), 3.11 (t, 2H), 3.55 (s, 2H), 3.60 (s, 2H), 3.75 (s, 3H), 4.07 (t, 2H), 6.73 (s, 2H), 6.79 (d, 2H), 6.97 (s, 1H), 7.10 (d, 2H). Microanalysis: Found: C, 56.88; H, 5.67; N, 11.88. C₂₂H₂₆Cl₂N₄O₂.0.23CH₂Cl₂requires C, 56.94; H, 5.69; N, 11.95%. 106 (Example 143)

m/z [MH⁺] 444. ¹H-NMR (400MHz, # CDCl₃): δ = 1.10 (t, 3H), 2.41 (q, 2H), 3.15 (t, 2H), 3.60 (s, 2H), 3.74 (s, 2H), 4.10 (d, 2H), 6.73 (s, 2H), 6.97 (s, 1H), 7.29 (d, 2H), 7.53 (d, 2H). Microanalysis: Found: C, 57.53; H, 5.09; N, 15.05. C₂₂H₂₃Cl₂N₅O.0.22CH₂Cl₂requires C, 57.64; H, 5.10; N, 15.12%.

Example 107

[0464] 2-[5-[(4-Acetyl-1-piperazinyl)methyl]-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-1-yl]ethylamine

[0465] Trifluoroacetic acid (1 ml) was added to a stirred solution of the pyrazole of Example 139 (150 mg, 0.28 mmol) in dichloromethane (2 ml) at room temperature under nitrogen. The reaction was stirred for 3 hours and the mixture was concentrated under reduced pressure. The residue was dissolved in dichloromethane (20 ml) and the resulting solution was washed with 1M aqueous potassium carbonate solution (30 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:ammonia (90:9:1, by volume) to provide the title compound (103 mg) as a colourless oil.

[0466]¹H-NMR (400 MHz, CDCl₃): δ=1.11 (t, 3H), 2.05 (s, 3H), 2.32 (m, 4H), 2.42 (q, 2H), 3.13 (m, 2H), 3.33 (s, 2H), 3.34 (m, 2H), 3.52 (m, 2H), 4.15 (t, 2H), 6.73 (s, 2H), 6.97 (s, 1H).

[0467] LRMS (thermospray): m/z [MH⁺] 440.

Example 108

[0468] N-[2-({[1-(2-Aminoethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-5-yl]methyl}amino)ethyl]acetamide

[0469] Trifluoroacetic acid (1 ml) was added to a stirred solution of the pyrazole of Example 141 (122 mg, 0.24 mmol) in dichloromethane (2 ml) at room temperature under nitrogen. The reaction was stirred for 3 hours and the mixture was concentrated under reduced pressure. The residue was dissolved in dichloromethane (50 ml) and the resulting solution was washed with 1M aqueous potassium carbonate solution (30 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:ammonia (90:9:1, by volume) to provide the title compound (64 mg) as a colourless oil.

[0470]¹H-NMR (400 MHz, CDCl₃): δ=1.15 (t, 3H), 1.95 (s, 3H), 2.45 (q, 2H), 2.69 (t, 2H), 3.20 (t, 2H), 3.27 (m, 2H), 3.65 (s, 2H), 4.15 (t, 2H), 6.31 (s, 1H), 6.81 (s, 2H), 7.02 (s, 1H).

[0471] LRMS (thermospray): m/z [MH⁺] 414.

Example 109

[0472] [4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methanamine hydrobromide

[0473] The bromide of Preparation 8 (500 mg, 1.30 mmol) was added portionwise to a saturated solution of ammonia in isopropanol (50 ml) at 0° C. The reaction was stirred for 2 hours and allowed to slowly warm to room temperature. The mixture was concentrated under reduced pressure and the resulting solid was triturated with diethyl ether to provide the title compound (340 mg) as a white solid.

[0474]¹H-NMR (400 MHz, CDCl₃): δ=2.38 (s, 3H), 4.78 (s, 2H), 6.88 (s, 2H), 7.19 (s, 1H).

[0475] LRMS (thermospray): m/z [MH⁺] 272.

Example 110

[0476] N-{[4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}-N-(4-fluorobenzyl)amine

[0477] Sodium triacetoxyborohydride (36 mg, 0.160 mmol) was added in one portion to a stirred solution of the pyrazole of Example 109 (150 mg, 0.400 mmol), 4-fluorobenzaldehyde (11 mg, 0.080 mmol) and acetic acid (3 drops) in dichloromethane (15 ml) at room temperature under nitrogen. The reaction was stirred for 3 hours and then concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:ammonia (90:9:1, by volume) to provide the title compound (6 mg) as a colourless oil.

[0478]¹H-NMR (300 MHz, CDCl₃): δ=2.17 (s, 3H), 3.67 (s, 2H), 3.73 (s, 2H), 6.81 (s, 2H), 6.99 (s, 2H), 7.02 (s, 1H), 7.22 (s, 2H).

[0479] LRMS (electrospray): m/z [M−H⁺] 378.

Example 111

[0480] 4-[({[4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}amino)methyl]benzonitrile

[0481] Sodium triacetoxyborohydride (216 mg, 1.09 mmol) was added in one portion to a stirred solution of the pyrazole of Example 109 (300 mg, 0.850 mmol), 4-cyanobenzaldehyde (111 mg, 0.850 mmol) and acetic acid (3 drops) in dichloromethane (25 ml) at room temperature under nitrogen. The reaction was stirred for 14 hours and then washed with 1M aqueous sodium carbonate solution (2×10 ml) and brine (10 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (10 mg) as a colourless oil.

[0482]¹H-NMR (300 MHz, CDCl₃): δ=2.16 (s, 3H), 3.70 (s, 2H), 3.85 (s, 2H), 6.78 (s, 2H), 7.01 (s, 2H), 7.35 (d, 2H), 7.58 (d, 2H).

[0483] LRMS (electrospray): m/z [MH⁺] 387.

Example 112

[0484] 3-Chloro-5-[(1,3,5-trimethyl-1H-pyrazol-4-yl)oxy]benzonitrile

[0485] Methyl hydrazine (250 mg, 5.17 mol) was added to a stirred solution of the β-diketone of Preparation 16 (1.00 g, 3.97 mmol) in glacial acetic acid (10 ml) and the resulting solution was stirred at room temperature for 2 days. The mixture was concentrated under reduced pressure and the resulting orange oil was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (50:50, by volume) to provide the title compound (500 mg) as a white solid, m.p. 114-116° C.

[0486]¹H-NMR (300 MHz, CDCl₃): δ=1.85 (s, 3H), 1.87 (s, 3H), 3.61 (s, 3H), 6.88 (s, 1H), 6.98 (s, 1H), 7.11 (s, 1H).

[0487] LRMS (thermospray): m/z [MH⁺] 262.

[0488] Microanalysis: Found: C, 59.48; H, 4.60; N, 15.88. C₁₃H₁₂N₃OCl requires C, 59.66; H, 4.62; N, 16.06%.

Example 113

[0489] 3-Chloro-5-[(5-{[(4-cyanobenzyl)amino]methyl-1,3-dimethyl-1H-pyrazol-4-yl)oxy]benzonitrile

[0490] 4-Cyanobenzylamine (155 mg, 1.17 mmol) was added in one portion to a stirred solution of the bromide of Example 144 (100 mg, 0.300 mmol) in isopropanol (10 ml) at room temperature. The mixture was heated at 50° C. for 1 hour, cooled to room temperature and concentrated under reduced pressure to leave a yellow oil. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (97 mg) as a colourless oil.

[0491]¹H-NMR (300 MHz, CDCl₃): δ=2.03 (s, 3H), 3.66 (s, 2H), 3.79 (s, 2H), 3.84 (s, 3H), 7.02 (s, 1H), 7.13 (s, 1H), 7.31 (s, 1H), 7.37 (d, 2H), 7.58 (d, 2H).

[0492] LRMS (thermospray): m/z [MH⁺] 392.

Example 114

[0493] 3-Chloro-5-{[1-(2-hydroxyethyl)-3,5-dimethyl-1H-pyrazol-4-yl]oxy}benzonitrile

[0494] 2-Hydroxyethyl hydrazine (1.80 g, 24.0 mol) was added to a stirred solution of the β-diketone of Preparation 16 (5.80 g, 23.0 mmol) in glacial acetic acid (30 ml) and the resulting solution was stirred at room temperature for 2 days. The mixture was concentrated under reduced pressure and the resulting brown oil was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (50:50, by volume) to provide the title compound (4.80 g) as a yellow solid, m.p. 114-116° C.

[0495]¹H-NMR (300 MHz, CDCl₃): δ=2.04 (s, 3H), 2.12 (s, 3H), 3.24 (s, 1H), 4.08 (m, 4H), 7.03 (s, 1H), 7.15 (s, 1H), 7.28 (s, 1H).

[0496] LRMS (thermospray): m/z [MH⁺] 292.

[0497] Microanalysis: Found: C, 57.40; H, 4.86; N, 14.14. C₁₄H₁₄N₃O₂Cl requires C, 57.69; H, 4.84; N, 14.40%.

Example 115

[0498] 3-Chloro-5-{[5-{[(4-cyanobenzyl)amino]methyl}-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy}benzonitrile

[0499] 4-Cyanobenzylamine (131 mg, 0.910 mmol) was added to a stirred solution of the pyrazole of Preparation 30 (120 mg, 0.240 mmol) in N-methylpyrrolidine (10 ml) and the resulting solution was heated at 60° C. for 3 hours. The mixture was concentrated under reduced pressure and the resulting brown oil was dissolved in acetic acid (10 ml) and heated at 40° C. for 6 hours. The mixture was concentrated under reduced pressure and the crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (5 mg) as a white solid.

[0500]¹H-NMR (300 MHz, CDCl₃): δ=2.05 (s, 3H), 3.04 (s, 2H), 3.91 (s, 2H), 3.99 (t, 2H), 4.32 (m, 2H), 7.06 (s, 1H), 7.11 (s, 1H), 7.33 (s, 1H), 7.46 (d, 2H), 7.62 (d, 2H).

[0501] LRMS (thermospray): m/z [MNa⁺] 444.

Example 116

[0502] 4-[({[4-(3-Chloro-5-cyanophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}amino)methyl]benzamide

[0503] The amine of Preparation 55 (150 mg, 0.800 mmol) was added to a stirred solution of the pyrazole of Preparation 18 (100 mg, 0.270 mmol) and triethylamine (81 mg, 0.800 mmol) in isopropanol (10 ml) and N,N-dimethylformamide (5 ml) and the resulting solution was heated at 60° C. for 3 hours. The mixture was concentrated under reduced pressure and the resulting brown oil was dissolved in ethyl acetate (20 ml). The solution was washed with 1M aqueous sodium carbonate solution (2×10 ml) and brine (10 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:ammonia (90:9:1, by volume) to provide the title compound (5 mg) as a colourless oil.

[0504]¹H-NMR (300 MHz, CDCl₃): δ=2.16 (s, 3H), 3.68 (s, 2H), 3.82 (s, 2H), 7.05 (s, 1H), 7.13 (s, 1H), 7.28 (s, 1H), 7.32 (d, 2H), 7.76 (d, 2H).

[0505] LRMS (electrospray): m/z [MH⁺] 396.

Examples 117 to 120

[0506] The compounds of the following tabulated Examples of the general formula:

[0507] were prepared by a similar method to that of Example 114 using the appropriate diketone starting material and 2-hydroxyethylhydrazine. Example No. (Diketone No.) R LRMS Analytical Data 117 F m/z [MH⁺] 303. ¹H-NMR(300 MHz, CDCl₃): (Preparation 43) (thermospray) δ = 1.10(m, 6H), 2.39(q, 2H), 2.49(q, 2H), 4.04(m, 4H), 6.85(dd, 1H), 6.99(s, 1H), 7.00(dd, 1H). Microanalysis: Found: C, 62.96; H, 5.94; N, 13.75. C₁₆H₁₈N₃O₂F requires C, 63.35; H, 5.98; N, 13.85%. 118 Me m/z [MH⁺] 300. ¹H-NMR(400 MHz, CDCl₃): (Preparation 44) (electrospray) δ = 1.09(t, 3H), 1.12(t, 3H), 2.34(s, 3H), 2.39(q, 2H), 2.50(q, 2H), 3.70(s, 1H), 4.60(m, 4H), 6.91(s, 1H), 6.97(s, 1H), 7.10(s, 1H). 119 CN m/z [MH⁺] 311. ¹H-NMR(400 MHz, CDCl₃): (Preparation 45) (electrospray) δ = 1.13(m, 6H), 2.40(q, 2H), 2.53(q, 2H), 3.53(m, 1H), 4.11(m, 4H), 7.40(s, 2H), 7.58(s, 1H). Microanalysis: Found: C, 65.64; H, 5.84; N, 18.05. C₁₇H₁₈N₄O₂ requires C, 65.79; H, 5.85; N, 18.05%. m.p. 120-121° C. 120 Cl m/z [MH⁺] 320. ¹H-NMR(400 MHz, CDCl₃): (Preparation 46) (thermospray) δ = 1.08(m, 6H), 2.39(q, 2H), 2.50(q, 2H), 4.01(m, 2H), 4.08(m, 2H), 7.03(s, 1H), 7.13(s, 1H), 7.24(s, 1H). Microanalysis: Found: C, 59.67; H, 5.71; N, 12.99. C₁₆H₁₈N₃O₂Cl requires C, 60.09; H, 5.67; N, 13.14%.

Examples 121 to 124

[0508] The compounds of the following tabulated Examples of the general formula:

[0509] were prepared by a similar method to that of Example 76 using the appropriate diketone starting material and hydrazine. Example No. (Diketone No.) R LRMS Analytical Data 121 F m/z [MH⁺] 260. ¹H-NMR(400 MHz, CDCl₃): (Preparation 43) (thermospray) δ = 1.18(t, 6H), 2.47(q, 4H), 6.85(dd, 1H), 6.98(s, 1H), 7.01(dd, 1H). 122 CN m/z [MH⁺] 267. ¹H-NMR(400 MHz, CDCl₃): (Preparation 45) (thermospray) δ = 1.20(6H, m), 2.47(q, 4H), 7.39(s, 2H), 7.59(s, 1H). 123 Me m/z [MH⁺] 256. ¹H-NMR(400 MHz, CDCl₃): (Preparation 44) (electrospray) δ = 1.17(t, 6H), 2.34(s, 3H), 2.48(q, 4H), 6.92(s, 1H), 6.96(s, 1H), 7.10(s, 1H). 124 Cl m/z [MH⁺] 276. ¹H-NMR(400 MHz, CDCl₃): (Preparation 46) (thermospray) δ = 1.18(t, 6H), 2.49(q, 4H), 7.07(s, 1H), 7.13(s, 1H), 7.27(s, 1H).

Examples 125 to 128

[0510] The compounds of the following tabulated Examples of the general formula:

[0511] were prepared by a similar method to that of Example 13 using the appropriate pyrazole starting material and chloroethylamine hydrochloride. Example No. (Starting pyrazole No.) R LRMS Analytical Data 125 Me m/z [MH⁺] 299. ¹H-NMR(400 MHz, CDCl₃): (Example 123) (electrospray) δ = 1.10(m, 6H), 2.34(s, 3H), 2.39(q, 2H), 2.43(q, 2H), 3.17(t, 2H), 4.04(t, 2H), 6.91(s, 1H), 6.96(s, 1H), 7.09(s, 1H). 126 Cl m/z [MH⁺] 319. ¹H-NMR(400 MHz, CDCl₃): (Example 124) (thermospray) δ = 1.09(m, 6H), 2.40(q, 2H), 2.51(q, 2H), 3.15(m, 2H), 4.02(m, 2H), 7.04(s, 1H), 7.12(s, 1H), 7.28(s, 1H). 127 CN m/z [MH⁺] 310. ¹H-NMR(400 MHz, CDCl₃): (Example 122) (thermospray) δ = 1.09(m, 6H), 2.38(q, 2H), 2.50(q, 2H), 3.15(m, 2H), 4.03(m, 2H), 7.39(s, 2H), 7.57(s, 1H). 128 F m/z [MH⁺] 303. ¹H-NMR(400 MHz, CDCl₃): (Example 121) (thermospray) δ = 1.06(m, 6H), 2.37(q, 2H), 2.48(q, 2H), 3.13(t, 2H), 4.03(t, 2H), 6.84(d, 1H), 6.94(s, 1H), 6.97(d, 1H).

Examples 129 to 131

[0512] The compounds of the following tabulated Examples of the general formula:

[0513] were prepared by a similar method to that of Example 76 using the appropriate diketone starting material and hydrazine. Example No. (Diketone No.) R R′ LRMS Analytical Data 129 cycloPr Et m/z [MH⁺] 279. ¹H-NMR(400 MHz, CDCl₃): (Preparation 52) (electrospray) 0.73(m, 2H), 0.81(m, 2H), 1.16(t, 3H), 1.58(m, 1H), 2.46(q, 2H), 7.42(s, 2H), 7.58(s, 1H). m.p. 136-141° C. 130 tBu Me m/z [MH⁺] 281. ¹H-NMR(300 MHz, CDCl₃): (Preparation 53) (electrospray) 1.21(s, 9H), 1.94(s, 3H), 7.34(s, 2H), 7.56(s, 1H). Microanalysis: Found: C, 68.18; H, 5.74; N, 19.72. C₁₆H₁₆N₄O requires C, 68.55; H, 5.75; N, 19.99%. m.p. 61-63° C. 131 iPr Et m/z [MH⁺] 281. ¹H-NMR(400 MHz, CDCl₃): (Preparation 54) (electrospray) 1.15(m, 9H), 2.41(q, 2H), 2.82 (m, 1H), 7.36(s, 2H), 7.58(s, 1H). m.p. 136-141° C.

Example 132

[0514] 4-(3,5-Dichlorophenoxy)-3,5-diethyl-1-(1-methyl-3-azetidinyl)-1H-pyrazole

[0515] Paraformaldehyde (30 mg, 0.330 mmol) was added in one portion to a stirred solution of the pyrazole of Example 51 (120 mg, 0.330 mmol) in formic acid (2 ml) at room temperature. The mixture was heated at 100° C. for 5 hours, cooled to room temperature and concentrated under reduced pressure to leave a colourless oil. The oil was dissolved in ethyl acetate (50 ml) and the resulting solution was washed with saturated aqueous sodium hydrogencarbonate (20 ml), water (20 ml) and brine (20 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (85 mg) as a colourless oil.

[0516]¹H-NMR (300 MHz, CDCl₃): δ=1.08 (t, 3H), 1.16 (t, 3H), 2.49 (m, 7H), 3.63 (m, 2H), 3.81 (m, 2H), 4.79 (m, 1H), 6.79 (s, 2H), 7.00 (s, 1H).

[0517] LRMS (thermospray): m/z [MH⁺] 354.

Examples 133-134

[0518] 2-[4-(3,5-Dichlorophenoxy)-3-ethyl-1H-pyrazol-1-yl]ethylamine (Example 133) and

[0519] 2-[4-(3,5-Dichlorophenoxy)-5-ethyl-1H-pyrazol-1-yl]ethylamine (Example 134)

[0520] A mixture of the pyrazole (1.03 g, 4.00 mmol) of Example 42 and chloroethylamine hydrochloride (510 mg, 4.40 mmol) was stirred and heated at 150° C. for 24 hours. After cooling the mixture was partitioned between 1M aqueous potassium carbonate solution (30 ml) and dichloromethane (30 ml). The organic layer was washed with brine (30 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The resulting brown oil was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:ammonia (93:6:1, by volume) to afford the title compounds (768 mg) in a 85:15 ratio of regioisomers as a colourless oil.

[0521]¹H-NMR (400 MHz, CDCl₃): δ=1.16 (major, t, 3H), 1.16 (minor, t, 3H), 2.48 (major, q, 2H), 2.60 (minor, q, 2H), 3.13 (major, t, 2H), 3.19 (minor, t, 2H), 4.10 (major, t, 2H), 4.10 (minor, t, 2H), 6.85 (major, s, 2H), 6.85 (minor, s, 2H), 7.02 (major, s, 1H), 7.02 (minor, s, 1H), 7.27 (major, s, 1H), 7.31 (minor, s, 1H).

[0522] LRMS (thermospray): m/z [MH⁺] 300.

Example 135

[0523] tert-Butyl 2-[4-(3,5-dichlorophenoxy)-3-ethyl-5-(hydroxymethyl)-1H-pyrazol-1-yl]ethylcarbamate

[0524] A solution of the pyrazole of Example 97 (1.96 g, 6.00 mmol) in concentrated hydrochloric acid (50 ml) was heated under reflux for 20 hours. The reaction was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in dioxane (80 ml) and water (60 ml), di-t-butyldicarbonate (1.44 g, 6.60 mmol) and sodium hydrogencarbonate (1.26 g, 15.0 mmol) were added and the reaction was stirred at room temperature for 3 days. The reaction was concentrated under reduced pressure. A solution of the residue in dichloromethane (300 ml) was washed with 2M aqueous hydrochloric acid (100 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. A solution of the crude product in tetrahydrofuran (50 ml) was cooled to −40° C. under nitrogen and triethylamine (0.79 ml, 5.68 mmol) and isopropylchloroformate (5.68 ml of a 1.0M solution in toluene, 5.68 mmol) were added dropwise. The reaction was stirred at −40° C. for 40 minutes and then warmed to 0° C. Sodium borohydride (537 mg, 14.2 mmol) was added in one portion and then water (3 drops) was added and the reaction was stirred at 0° C. for 1 hour and at room temperature for 14 hours. The mixture was concentrated under reduced pressure and a solution of the residue in dichloromethane (100 ml) was washed with water (100 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (97:3, by volume) to provide the title compound (1.37 g) as a white foam.

[0525]¹H-NMR (400 MHz, CDCl₃): δ=1.10 (t, 3H), 1.37 (s, 9H), 2.40 (q, 2H), 3.00 (s, 1H), 3.56 (m, 2H), 4.20 (t, 2H), 4.48 (d, 2H), 5.00 (m, 1H), 6.80 (s, 2H), 6.97 (s, 1H).

[0526] LRMS (thermospray): m/z [MH⁺] 430.

Example 136

[0527] tert-Butyl 2-[4-(3,5-dichlorophenoxy)-5-(ethoxymethyl)-3-ethyl-1H-pyrazol-1-yl]ethylcarbamate

[0528] Silver(I)oxide (210 mg, 0.900 mmol) was added in one portion to a stirred solution of the alcohol of Example 135 (129 mg, 0.300 mmol) in ethyl iodide (1.75 ml) at room temperature under nitrogen. The reaction was heated at 40° C. for 1 day and then cooled to room temperature. The mixture was filtered and the residual solid was washed with dichloromethane (10 ml). The filtrate was concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (99:1, by volume) to provide the title compound (60 mg) as a colourless oil.

[0529]¹H-NMR (400 MHz, CDCl₃): δ=1.15 (m, 6H), 1.44 (s, 9H), 2.45 (q, 2H), 3.45 (q, 2H), 3.58 (m, 2H), 4.18 (m, 2H), 4.29 (s, 2H), 5.26 (m, 1H), 6.92 (s, 2H), 7.00 (s, 1H).

[0530] LRMS (electrospray): m/z [MNa⁺] 480.

Example 137

[0531] tert-Butyl 2-[5-(bromomethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-1-yl]ethylcarbamate

[0532] Bromine (16011,3.12 mmol) was added dropwise to a stirred solution of triphenylphosphine (820 mg, 3.12 mmol) and imidazole (213 mg, 3.12 mmol) in dichloromethane (15 ml) at room temperature under nitrogen. A solution of the alcohol of Example 135 (1.12 g, 2.60 mmol) in dichloromethane (5 ml) was then added to the reaction. The reaction was stirred at room temperature for 2 hours, diluted with dichloromethane (50 ml), washed with brine (20 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound (969 mg) as a white foam.

[0533]¹H-NMR (400 MHz, CDCl₃): δ=1.10 (t, 3H), 1.40 (s, 9H), 2.40 (q, 2H), 3.60 (m, 2H), 4.18 (t, 2H), 4.27 (s, 2H), 4.95 (s, 1H), 6.82 (s, 2H), 7.00 (s, 1H).

[0534] LRMS (electrospray): m/z [MH⁺] 494.

[0535] Microanalysis: Found: C, 46.22; H, 4.89; N, 8.44. C₁₉H₂₄BrCl₂N₃O₃ requires C, 46.27; H, 4.90; N, 8.52%.

Example 138

[0536] tert-Butyl 2-[5-(aminomethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-1-yl]ethylcarbamate

[0537] The bromide of Example 137 (444 mg, 0.900 mmol) was added to a saturated solution of ammonia in isopropanol (25 ml) and diisopropylethylamine (173μ, 1.00 mmol) at room temperature. The reaction was stirred for 5 hours and then concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (95:5, by volume) to provide the title compound (359 mg) as a white solid, m.p. 112-114° C.

[0538]¹H-NMR (400 MHz, CDCl₃): δ=1.11 (t, 3H), 1.40 (s, 9H), 2.40 (q, 2H), 3.55 (m, 2H), 3.73 (s, 2H), 4.18 (t, 2H), 5.60 (s, 1H), 6.77 (s, 2H), 6.98 (s, 1H).

[0539] LRMS (thermospray): m/z [MH⁺] 429.

Example 139

[0540] tert-Butyl 2-[5-[(4-acetyl-1-piperazinyl)methyl]-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-1-yl]ethylcarbamate

[0541] N-Acetylpiperazine (42 mg, 0.330 mmol) in N,N-dimethylformamide (1 ml) was added to a stirred solution of the bromide of Example 137 (148 mg, 0.300 mmol) and diisopropylethylamine (57 μL, 0.330 mmol) in N,N-dimethylformamide (2 ml) at room temperature. The reaction was stirred for 5 hours and the mixture was concentrated under reduced pressure. A solution of the residue in dichloromethane (30 ml) was washed with 1M aqueous potassium carbonate solution (10 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound (150 mg) as a colourless oil.

[0542]¹H-NMR (400 MHz, CDCl₃): δ=1.15 (t, 3H), 1.42 (s, 9H), 2.06 (s, 3H), 2.44 (m, 6H), 3.32 (s, 2H), 3.47 (m, 2H), 3.60 (m, 2H), 3.65 (m, 2H), 4.23 (m, 2H), 5.89 (s, 1H), 6.76 (s, 2H), 7.02 (s, 1H).

[0543] LRMS (thermospray): m/z [MH⁺] 540.

Example 140

[0544] tert-Butyl 2-[4-(3,5-dichlorophenoxy)-3-ethyl-5-(1H-pyrazol-1-ylmethyl)-1H-pyrazol-1-yl]ethylcarbamate

[0545] Pyrazole (23 mg, 0.330 mmol) was added in one portion to a stirred solution of the bromide of Example 137 (148 mg, 0.300 mmol) and sodium hydride (60% dispersion in oil, 13.2 mg, 0.330 mmol) in N,N-dimethylformamide (2 ml) at room temperature under nitrogen. The reaction was stirred for 5 hours, quenched with water (1.00 ml) and concentrated under reduced pressure. The residue was dissolved in dichloromethane (30 ml) and the resulting solution was washed with 1M aqueous potassium carbonate solution (10 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound (125 mg) as a colourless oil.

[0546]¹H-NMR (400 MHz, CDCl₃): δ=1.13 (t, 3H), 1.44 (s, 9H), 2.42 (q, 2H), 3.52 (m, 2H), 4.26 (t, 2H), 5.18 (s, 2H), 5.48 (s, 1H), 6.16 (s, 1H), 6.73 (s, 2H), 7.00 (s, 1H), 7.18 (s, 1H), 7.45 (s, 1H).

[0547] LRMS (thermospray): m/z [MH⁺] 480.

Example 141

[0548] tert-Butyl 2-[5-({[2-(acetylamino)ethyl]amino}methyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-1-yl]ethylcarbamate

[0549] N-Acetylethylenediamine (153 mg, 1.50 mmol) in isopropanol (1 ml) was added to a stirred solution of the bromide of Example 137 (148 mg, 0.300 mmol) and diisopropylethylamine (57 μl, 0.330 mmol) in isopropanol (2 ml) at room temperature. The reaction was stirred for 5 hours and the mixture was concentrated under reduced pressure. A solution of the residue in dichloromethane (50 ml) was washed with 1 M aqueous potassium carbonate solution (20 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (90:10, by volume) then dichloromethane:methanol:ammonia (90:9:1, by volume) to provide the title compound (122 mg) as a colourless oil.

[0550]¹H-NMR (400 MHz, CDCl₃): δ=1.13 (t, 3H), 1.42 (s, 9H), 1.94 (d, 3H), 2.44 (q, 2H), 2.74 (m, 2H), 3.35 (m, 2H), 3.58 (m, 4H), 4.19 (m, 2H), 5.68 (s, 1H), 6.77 (s, 2H), 7.00 (s, 1H), 7.65 (s, 1H).

[0551] LRMS (thermospray): m/z [MH⁺] 514.

Example 142

[0552] tert-Butyl 2-(4-(3,5-dichlorophenoxy)-3-ethyl-5-{[(4-methoxybenzyl)amino]methyl}-1H-pyrazol-1-yl)ethylcarbamate

[0553] 4-Methoxybenzaldehyde (46 μl, 0.380 mmol), the amine of Example 138 (172 mg, 0.400 mmol) and magnesium sulphate (200 mg) were stirred in dichloromethane (4 ml) at room temperature for 4 days. The mixture was filtered and the filtrate was concentrated under reduced pressure to leave a yellow oil. The oil was dissolved in methanol (4 ml) and sodium borohydride (18 mg, 0.480 mmol) was added with vigorous stirring. Once the addition was complete the reaction was stirred for 4 hours and then water (2 ml) was added. The mixture was concentrated under reduced pressure and the residue was dissolved in dichloromethane (50 ml). The resulting solution was washed with 1M aqueous potassium carbonate solution (20 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (99:1, by volume) and then dichloromethane:methanol (95:5, by volume) to provide the title compound (142 mg) as a colourless oil.

[0554]¹H-NMR (400 MHz, CDCl₃): δ=1.10 (t, 3H), 1.40 (s, 9H), 2.42 (m, 2H), 3.55 (m, 5H), 3.66 (s, 2H), 3.77 (s, 2H), 4.15 (m, 2H), 6.11 (s, 1H), 6.74 (s, 2H), 6.80 (d, 2H), 7.00 (s, 1H), 7.11 (d, 2H).

[0555] LRMS (thermospray): m/z [MH⁺] 549.

Example 143

[0556] tert-Butyl 2-[5-{[(4-cyanobenzyl)amino]methyl}-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-1-yl]ethylcarbamate

[0557] A mixture of 4-cyanobenzaldehyde (50 mg, 0.380 mmol), the amine of Example 138 (172 mg, 0.400 mmol), magnesium sulphate (200 mg) and dichloromethane (4 ml) was stirred at room temperature for 4 days. The mixture was filtered and the filtrate was concentrated under reduced pressure to leave a yellow oil. The oil was dissolved in methanol (4 ml) and sodium borohydride (18 mg, 0.480 mmol) was added with vigorous stirring. Once the addition was complete the reaction was stirred for 4 hours and then water (2 ml) was added. The mixture was concentrated under reduced pressure and the residue was dissolved in dichloromethane (50 ml). The resulting solution was washed with 1M aqueous potassium carbonate solution (20 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (99:1, by volume) then dichloromethane:methanol (95:5, by volume) to provide the title compound (120 mg) as a colourless oil.

[0558]¹H-NMR (400 MHz, CDCl₃): δ=1.10 (t, 3H), 1.35 (s, 9H), 2.40 (q, 2H), 3.55 (m, 2H), 3.58 (s, 2H), 3.76 (s, 2H), 4.16 (m, 2H), 5.45 (s, 1H), 6.73 (s, 2H), 6.98 (s, 1H), 7.32 (d, 2H), 7.55 (d, 2H).

[0559] LRMS (thermospray): m/z [MH⁺] 544.

Example 144

[0560] 3-{[5-(Bromomethyl)-1,3-dimethyl-1H-pyrazol-4-yl]oxy}-5-chlorobenzonitrile

[0561] N-Bromosuccinimide (340 mg, 1.90 mmol) was added to a stirred solution of the pyrazole of Example 112 (500 mg, 1.90 mmol) in carbon tetrachloride (10 ml) and azobisisobutyronitrile (20 mg) at room temperature under nitrogen. The reaction was heated under reflux for 1 hour, cooled to room temperature and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (80:20, by volume) to provide the title compound (340 mg) as a white solid, m.p. 76-78° C.

[0562]¹H-NMR (300 MHz, CDCl₃): δ=2.03 (s, 3H), 3.45 (s, 3H), 4.32 (s, 2H), 7.12 (s, 1H), 7.19 (s, 1H), 7.34 (s, 1H).

[0563] LRMS (thermospray): m/z [MH⁺] 342.

Example 145

[0564] 3-[(3,5-Diethyl-1-methyl-1H-pyrazol-4-yl)oxy]benzonitrile

[0565] Sodium hydride (60% dispersion in oil, 22 mg, 0.53 mmol) was added to a solution of the pyrazole from Example 60 (100 mg, 0.41 mmol) and methyl iodide (34 μl, 0.53 mmol) in dimethylformamide (1.5 ml) at 0° C. under nitrogen. The reaction was allowed to warm to room temperature and was stirred for 4 hours. The reaction was quenched with water and the solvent was removed under reduced pressure. The residue was partitioned between ethyl acetate (20 ml) and water (10 ml) and the organic phase was washed with water (2×10 ml), dried over magnesium sulphate and concentrated under reduced pressure. The residual oil was purified by flash chromatography on silica gel eluting with a solvent gradient of 100% pentane changing to 100% ethyl acetate and finally ethyl acetate:methanol (10:1, by volume) to provide the title compound (65 mg) as a colourless oil.

[0566]¹H NMR (400 MHz, CDCl₃): δ=1.09 (t, 3H), 1.12 (t, 3H), 2.41 (q, 2H), 2.50 (q, 2H), 3.77 (s, 3H), 7.12-7.38 (m, 4H).

[0567] LRMS (electrospray): m/z [MH⁺] 256, [MNa⁺] 278.

[0568] Microanalysis: Found C, 70.15; H, 6.78; N, 16.42. C₁₅H₁₅N₃O.0.08H₂O requires C, 70.17; H, 6.74; N, 16.37%.

Example 146

[0569] 3-{[35-Diethyl-1-(2-methoxyethyl)-1H-pyrazol-4-yl]oxy}benzonitrile

[0570] Sodium hydride (60% dispersion in oil, 22 mg, 0.54 mmol) was added to a solution of the pyrazole from Example 60 (100 mg, 0.41 mmol) and 1-bromo-2-methoxy-ethane (51 μl, 0.54 mmol) in dimethylformamide (1.5 ml) at 0° C. under nitrogen. The reaction was allowed to warm to room temperature and was stirred for 4 hours. The reaction was quenched with water and the solvent was removed under reduced pressure. The residue was partitioned between ethyl acetate (20 ml) and water (10 ml) and the organic phase was washed with water (2×10 ml), dried over magnesium sulphate and concentrated under reduced pressure. The residual oil was purified by flash chromatography on silica gel eluting with a solvent gradient of 100% pentane changing to 100% ethyl acetate and finally ethyl acetate:methanol (90:10, by volume) to provide the title compound (66 mg) as a colourless oil.

[0571]¹H NMR (400 MHz, CDCl₃): δ=1.09 (t, 3H), 1.12 (t, 3H), 2.42 (q, 2H), 2.54 (q, 2H), 3.34 (s, 3H), 3.75 (t, 2H), 4.16 (t, 2H), 7.11-7.38 (m, 4H).

[0572] LRMS (electrospray): m/z [MH⁺] 300, [MNa⁺] 322.

[0573] Microanalysis: Found C, 68.21; H, 7.07; N, 14.04. C₁₇H₂₁N₃O₂ requires C, 67.85; H, 7.12; N, 14.09%.

Example 147

[0574] 3-({5-[2-(Benzyloxy)ethyl]-3-ethyl-1H-pyrazol-4-yl}oxy)-5-fluorobenzonitrile

[0575] Hydrazine hydrate (390%, 8.00 mmol) was added to a solution of the enol from Preparation 60 (2.47 g, 6.69 mmol) in acetic acid (5 ml) under nitrogen at room temperature. After stirring for 18 hours, the mixture was concentrated under reduced pressure and purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (70:30 changing to 50:50, by volume) to provide the title compound (5.8 g) as a yellow oil.

[0576]¹H NMR (400 MHz, CDCl₃): δ=1.13 (t, 3H), 2.41 (q, 2H), 2.67 (t, 2H), 3.62 (t, 2H), 4.48 (s, 2H), 6.79 (m, 1H), 6.98 (m, 2H), 7.24 (m, 5H).

[0577] LRMS (electrospray): m/z [M−H⁺] 364.

[0578] Microanalysis: Found C, 66.96; H, 5.62; N, 11.25. C₂₁H₂₀N₃O₂F.0.60H₂O requires C, 67.04; H, 5.68; N, 11.17%.

Example 148

[0579] 3-{[3-Ethyl-5-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-fluorobenzonitrile

[0580] Iron(III)chloride (9.30 g, 57.5 mmol) was added to a solution of the pyrazole from Example 147 (2.10 g, 5.75 mmol) in dichloromethane (90 ml) under nitrogen at room temperature. After stirring for 20 minutes the mixture was diluted with dichloromethane (50 ml), washed with water (100 ml) then saturated aqueous sodium ethylenediaminetetraacetate solution (70 ml), dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (98:2 changing to 95:5, by volume) to provide the title compound (1.2 g) as a brown oil which solidified on standing.

[0581]¹H NMR (400 MHz, CDCl₃): δ=1.16 (t, 3H), 2.44 (q, 2H), 2.63 (t, 2H), 3.82 (t, 2H), 6.82 (m, 1H), 6.98 (m, 2H).

[0582] LRMS (electrospray): m/z [MH⁺] 276.

[0583] Microanalysis: Found C, 60.69; H, 5.12; N, 15.08. C₁₄H₁₄N₃O₂F requires C, 61.08; H, 5.13; N, 15.26%.

Example 149

[0584] 3-({5-[2-(4-Cyanophenoxy)ethyl]-3-ethyl-1H-pyrazol-4-yl}oxy)-5-fluorobenzonitrile

[0585] 4-Hydroxy-benzonitrile (49 mg, 0.41 mmol), triphenylphosphine (106 mg, 0.41 mmol) and diethylazodicarboxylate (65 μl, 0.41 mmol) were added sequentially to a solution of the alcohol from Example 148 (74 mg, 0.27 mmol) in tetrahydrofuran (2 ml) under nitrogen at 0° C. The reaction was allowed to warm to room temperature and was stirred for 18 hours. The mixture was concentrated under reduced pressure and purified by flash chromatography on silica gel eluting with toluene:ethyl acetate (75:25, by volume) to provide the title compound (50 mg) as a yellow oil.

[0586]¹H NMR (400 MHz, CDCl₃): δ=1.18 (t, 3H), 2.49 (q, 2H), 2.98 (t, 2H), 4.21 (t, 2H), 6.82 (m, 3H), 6.99 (m, 2H), 7.56 (m, 2H).

[0587] LRMS (electrospray): m/z [MH⁺] 377.

Examples 150-152

[0588] The preparations of the following tabulated Examples of the general formula

[0589] were performed by a similar method to that of Example 149 using the appropriate aryl alcohol as the starting material. Example Starting Material No. Example No. R Analytical Data 150¹ 148

¹H NMR (400MHz, CDCl₃): δ = 1.18 (t, 3H), 2.42 (s, 3H), 2.52 (q, 2H), 2.99 (t, 2H), 4.18 (t, 2H), 6.83 (m, 1H), 6.99 (m, 4H), 8.04 (m, 1H). LRMS (thermospray): m/z [MH⁺] 367. 151¹ 148

¹H NMR (400MHz, CDCl₃): δ = 1.19 (t, 3H), 2.50 (q, 2H), 2.98 (t, 2H), 4.22 (t, 2H), 6.85 (m, 1H), 6.99 (m, 2H), 7.12 (m, 1H), 7.18 (m, 1H), 8.22 (m, 2H). LRMS (thermospray): m/z [MH⁺] 353. 152¹ 148

¹H NMR (400MHz, CDCl₃): δ = 1.20 (t, 3H), 2.53 (q, 2H), 2.98 (t, 2H), 4.19 (t, 2H), 4.85 (brs, 2H), 6.58 (m, 1H), 6.83 (m, 2H), 6.99 (m, 2H), 7.63 (d, 1H). LRMS (thermospray): m/z [MH⁺] 368.

[0590]¹ These compounds were purified on silica gel eluting with a solvent gradient of cyclohexane:ethyl acetate (75:25 then 66:34 then 50:50, by volume) changing to ethyl acetate and finally ethyl acetate:methanol (90:10, by volume).

Example 153

[0591] 5-({5-[2-(benzyloxy)ethyl]-3-ethyl-1H-pyrazol-4-yl}oxy)isophthalonitrile

[0592] Hydrazine hydrate (177 μl, 3.66 mmol) was added to a solution of the crude enol from Preparation 61 (917 mg, 2.40 mmol) in acetic acid (10 ml) under nitrogen at room temperature. After stirring for 18 hours, the mixture was concentrated under reduced pressure and purified by flash chromatography on silica gel eluting with pentane:cyclohexane (75:25, by volume) changing to toluene:ethyl acetate (50:50, by volume) to give the product which was further purified by preparative HPLC using a Develosil combi-rp C30 50×4.6 mm 3 μm column eluting with a solvent gradient of 5:95 0.1% aqueous trifluoroacetic acid in water:acetonitrile to provide the title compound (5 mg) as a colourless oil.

[0593]¹H NMR (400 MHz, CDCl₃): δ=1.18 (t, 3H), 2.44 (q, 2H), 2.77 (t, 2H), 3.63 (t, 2H), 4.52 (s, 2H), 7.30 (m, 7H), 7.55 (s, 1H).

[0594] LRMS (electrospray): m/z [MH⁺] 231, [MNa⁺] 253.

Example 154

[0595] 5-{[3-Ethyl-5-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile

[0596] Iron(III)Chloride (217 mg, 1.30 mmol) was added to a solution of the pyrazole from Example 153 (50 mg, 0.13 mmol) in dichloromethane (5 ml) under nitrogen at room temperature. After stirring for 30 minutes the mixture was diluted with dichloromethane (20 ml), washed with water (100 ml) then saturated aqueous sodium ethylenediaminetetraacetate solution (20 ml), dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (98:2 changing to 95:5, by volume) to provide the title compound (20 mg) as a white solid.

[0597]¹H NMR (400 MHz, CDCl₃): δ=1.19 (t, 3H), 2.51 (q, 2H), 2.69 (t, 2H), 3.88 (t, 2H), 7.40 (s, 2H), 7.59 (s, 1H).

[0598] LRMS (electrospray): m/z [MH⁺] 283.

Example 155

[0599] 3-{[5-(Aminomethyl)-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy}-5-chlorobenzonitrile

[0600] The protected alcohol from Preparation 31 (100 mg, 0.23 mmol) and tert-butyl-ammonium fluoride (360 μl of a 1 M solution in tetrahydrofuran, 0.36 mmol) were stirred in dichloromethane (5 ml) at room temperature under nitrogen for 3 hours. The reaction mixture was concentrated under reduced pressure and the residue was dissolved in methanol (2 ml) and purified on a BondElut® SCX polymer supported sulphonic acid column washing with methanol (2×3 ml) to remove impurities and 2N aqueous ammonia to remove the product. This procedure was repeated twice to provide the title compound (40 mg) as a colourless oil.

[0601]¹H NMR (400 MHz, CD₃OD): δ=1.99 (s, 3H), 3.85 (t, 2H), 4.02 (s, 2H), 4.32 (t, 2H), 7.22 (s, 1H), 7.28 (s, 1H), 7.47 (s, 1H).

[0602] LRMS (thermospray): m/z [MH⁺] 309.

[0603] Microanalysis: Found C, 53.32; H, 5.17; N, 16.38. C₁₄H₁₅ClN₄O₂.0.85CH₃OH requires C, 53.40; H, 5.55; N, 16.77%.

Example 156

[0604] 5-[(1-Allyl-3-tert-butyl-5-methyl-1H-pyrazol-4-yl)oxy]isophthalonitrile

[0605] Sodium hydride (60% dispersion in oil, 120 mg, 3.15 mmol) was added to a solution of the pyrazole from Example 130 (800 mg, 2.80 mmol) and allyl bromide (345 mg, 2.80 mmol) in dimethylformamide (30 ml) at room temperature under nitrogen and the reaction was stirred for 3 hours. The reaction was diluted with ethyl acetate (50 ml), washed with water (2×50 ml) then brine (50 ml) and the organic phase was concentrated under reduced pressure. The residual oil was purified by flash chromatography on silica gel eluting with a solvent gradient of pentane changing to ethyl acetate:pentane (20:80, by volume) to provide the title compound (600 mg) as a colourless oil.

[0606]¹H NMR (400 MHz, CDCl₃): δ=1.21 (s, 9H), 1.96 (s, 3H), 4.66 (s, 2H), 5.04 (d, 1H), 5.24 (d, 1H), 5.98 (m, 1H), 7.37 (s, 2H), 7.57 (s, 1H).

[0607] LRMS (thermospray): m/z [MH⁺] 322.

[0608] Microanalysis: Found C, 70.79; H, 6.29; N, 17.11. C₁₉H₂₀N₄O.0.05CH₂Cl₂ requires C, 70.48; H, 6.24; N, 17.26%.

Example 157

[0609] 5-{[3-tert-Butyl-1- (2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy}isophthalonitrile

[0610] Sodium periodate (1.00 g, 4.60 mmol), osmium tetroxide (1.5% solution in tert-butanol, 190 mg, 0.02 mmol) and the pyrazole from Example 156 (600 mg, 1.86 mmol) were dissolved in acetone (9 ml) and water (3 ml) under nitrogen at room temperature, and the reaction was stirred for 5 hours. The acetone was removed under reduced pressure and the residue was extracted with ethyl acetate (30 ml). The organic phase was washed with water (2×30 ml) then brine (30 ml), dried over magnesium sulphate and concentrated under reduced pressure. The crude aldehyde was then dissolved in methanol (15 ml) and sodium borohydride (84 mg, 2.22 mmol) was added portionwise at room temperature under nitrogen. The reaction was stirred for 3 hours and the solvent was removed under reduced pressure. The residue was partitioned between ethyl acetate (10 ml) and water (10 ml) and the organic phase was washed with water (2×10 ml) then brine (10 ml), dried over magnesium sulphate and concentrated under reduced pressure. The residual oil was purified by flash chromatography on silica gel eluting with a solvent gradient of pentane changing to ethyl acetate:pentane (50:50, by volume) to provide the title compound (250 mg) as a colourless oil.

[0611]¹H NMR (400 MHz, CDCl₃): δ=1.17 (s, 9H), 1.98 (s, 3H), 3.67 (s, 1H), 4.04 (m, 4H), 7.35 (s, 2H), 7.54 (s, 1H).

[0612] LRMS (thermospray): m/z [MH⁺] 325.

[0613] Microanalysis: Found C, 64.30; H, 6.10; N, 16.35. C₁₈H₂₀N₄O₂.0.20CH₂Cl₂ requires C, 64.04; H, 6.02; N, 16.41%.

Example 158

[0614] 5-{[1-(2-Aminoethyl)-3-tert-butyl-5-methyl-1H-pyrazol-4-yl]oxy}isophthalonitrile

[0615] Diphenylphosphorylazide (305 mg, 1.10 mmol) was dissolved in tetrahydrofuran (5 ml) and added to a solution of the pyrazole from Example 157 (180 mg, 0.55 mmol), triphenylphosphine (291 mg, 1.10 mmol) and diethylazodicarboxylate (193 mg, 1.10 mmol) in tetrahydrofuran (20 ml) under nitrogen at room temperature. The reaction was stirred for 18 hours then triphenylphosphine (291 mg, 1.10 mmol) was added, and the reaction was stirred for a further 18 hours. Water (180 μl, 10.0 mmol) was then added and the reaction was stirred for 64 hours. The solvent was removed under reduced pressure and the residual white paste was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (95:4.5:0.5, by volume) to provide the title compound (55 mg) as a colourless oil.

[0616]¹H NMR (300 MHz, CDCl₃): δ=1.22 (s, 9H), 1.78 (s, 2H), 2.03 (s, 3H), 3.18 (t, 2H), 4.05 (m, 2H), 7.38 (s, 2H), 7.58 (s, 1H).

[0617] LRMS (thermospray): m/z [MH⁺] 324.

[0618] Microanalysis: Found C, 64.46; H, 6.48; N, 20.47. C₁₈H₂₁N₅O.0.20CH₂Cl₂ requires C, 64.22; H, 6.34; N, 20.57%.

Example 159

[0619] 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(1H-1,2,4-triazol-1-yl)benzonitrile

[0620] Cesium carbonate (179 mg, 0.55 mmol) was added to a solution of 1H[1,2,4]triazole (38 mg, 0.55 mmol) in dimethylsulfoxide (1 ml) under nitrogen at room temperature and the reaction was stirred for 10 minutes. The aryl fluoride from Preparation 62 (210 mg, 0.5 mmol) dissolved in dimethylsulfoxide (1 ml) was then added and the reaction was heated to 100° C. for 18 hours. After cooling to room temperature the reaction was diluted with water (15 ml) and extracted with ethyl acetate (25 ml). The organic phase was washed with brine (15 ml), dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with a solvent gradient of dichloromethane:methanol (98:2 changing to 90:10, by volume) to provide the title compound (67.5 mg) as a white solid, m.p. 122-124° C.

[0621]¹H NMR (400 MHz, CDCl₃): δ=1.10 (m, 6H), 2.39 (q, 2H), 2.51 (q, 2H), 3.61 (brs, 1H), 4.04 (m, 2H), 4.07 (m, 2H), 7.10 (s, 1H), 7.52 (s, 1H), 7.60 (s, 1H), 8.07 (s, 1H), 8.54 (s, 1H).

[0622] LRMS (thermospray): m/z [MH⁺] 353.

[0623] Microanalysis: Found C, 60.69; H, 5.83; N, 22.98. C₁₈H₂₀N₆O₂.0.08CH₂Cl₂ requires C, 60.46; H, 5.66; N, 23.40%.

Examples 160-162

[0624] The preparation of the following tabulated Examples of the general formula

[0625] were performed by a similar method to that of Example 159 using the appropriate heterocycle as the starting material. Example No. (Starting Material Preparation No) R Analytical Data 160 (62)

¹H NMR (400MHz, CDCl₃): δ =1.10 (m, 6H), 2.39 (q, 2H), 2.52 (q, 2H), 3.62 (brs, 1H), 4.02 (t, 2H), 4.08 (t, 2H), 6.44 (d, 2H), 7.14 (s, 1H), 7.16 (s, 1H), 7.25 (s, 1H), 7.49 (d, 2H). m.p. 169-170° C. LRMS (thermospray): m/z [MH⁺] 379. Microanalysis: Found C, # 65.68; H, 5.98; N, 14.31. C₂₁H₂₂N₄O₃.0.09CH₂Cl₂ requires C, 65.61; H, 5.79; N, 14.51%. 161¹ (62)

¹H NMR (400MHz, CDCl₃): δ =1.10 (m, 6H), 2.40 (q, 2H), 2.51 (q, 2H), 3.56 (t, 1H), 4.04 (m, 2H), 4.07 (m, 2H), 7.20 (s, 1H), 7.65 (s, 2H), 7.85 (s, 1H), 7.98 (s, 1H). LRMS (thermospray): m/z [MH⁺] 353. HRMS: [MH⁺] 353.1722. C₁₈H₂₀N₆O₂ requires 353.1720. 162¹ (62)

¹H NMR (400MHz, CDCl₃): δ =1.10 (m, 6H), 2.41 (q, 2H), 2.51 (q, 2H), 3.62 (t, 1H), 4.04 (m, 2H), 4.07 (m, 2H), 7.08 (s, 1H), 7.80 (s, 2H), 7.87 (s, 1H), 8.02 (s, 1H). LRMS (thermospray): m/z [MH⁺] 353. HRMS: [MH⁺] 353.1719. C₁₈H₂₀N₆O₂ requires 353.1720.

Example 163

[0626] 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-fluorobenzamide

[0627] The protected alcohol from Preparation 64 (432 mg, 1.07 mmol) and p-toluene-sulphonic acid (30.3 mg, 0.11 mmol) were dissolved in methanol (4 ml) and stirred under nitrogen at room temperature for 18 hours. The solvent was removed under reduced pressure and the residue was partitioned between saturated aqueous sodium bicarbonate solution (20 ml) and dichloromethane (20 ml). The aqueous phase was extracted with dichloromethane (10 ml) and the combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with a solvent gradient of dichloromethane:methanol (100:0 changing to 93:7, by volume) to provide the title compound (241 mg) as a white foam.

[0628]¹H NMR (400 MHz, CDCl₃): δ=1.10 (m, 6H), 2.39 (q, 2H), 2.49 (q, 2H), 3.68 (brs, 1H), 4.04 (m, 4H), 5.59 (brs, 1H), 5.88 (brs, 1H), 6.71 (d, 1H), 7.11 (m, 2H).

[0629] LRMS (thermospray): m/z [MH⁺] 322.

[0630] Microanalysis: Found C, 57.91; H, 6.32; N, 12.56. C₁₆H₂₀FN₃O₃.0.13CH₂Cl₂.0.12H₂O requires C, 57.91; H, 6.18; N, 12.56%.

Examples 164-167

[0631] The preparation of the following tabulated Examples of the general formula

[0632] were performed by a similar method to that of Example 163 using the appropriate protected alcohol as the starting material. Example No. (Starting Material Preparation No.) R Analytical Data 164¹ (65)

¹H NMR (400MHz, CDCl₃): δ =1.13 (m, 6H), 2.44 (q, 2H), 2.54 (q, 2H), 3.65 (brs, 1H), 4.07 (t, 2H), 4.11 (t, 2H), 6.51 (s, 1H), 7.00 (s, 1H), 7.56 (s, 1H), 7.63 (s, 1H), 7.74 (s, 1H), 7.90 (s, 1H). LRMS (electrospray): m/z [MH⁺]352, [MNa⁺] 374. HRMS: [MH⁺] Found 352.1770. C₁₉H₂₂N₅O₂ requires 352.1768. 165¹ (66)

¹H NMR (400MHz, CDCl₃): δ =1.10 (m, # 6H), 2.40 (q, 2H), 2.50 (q, 2H), , 4.00 (t, 2H), 4.06 (t, 2H), 6.24 (t, 1H), 6.60 (d, 1H), 7.18 (d, 2H), 7.24 (d, 1H), 7.30 (s, 1H), 7.38 (t, 1H). LRMS (electrospray): m/z [MH⁺] 379, [MNa⁺] 401. HRMS: [MH⁺] Found 379.1766. C₂₁H₂₃N₄O₃ requires 379.1765 [MNa⁺] Found 401.1585. C₂₁H₂₂N₄O₃Na requires 401.1584. 166¹ (67)

¹H NMR (400MHz, CDCl₃): δ =1.10 (m, 6H), 2.41 (q, 2H), 2.51 (q, 2H), 4.01 (t, 2H), 4.06 (t, 2H), 7.07 (d, 1H), 7.13 (s, 1H), 7.22 (m, 1H), 7.52 (s, 1H), 7.65 (s, 1H), 7.88 (s, 1H). LRMS (electrospray): m/z [MH⁺]380, [MNa⁺] 402. HRMS: [MH⁺] Found 380.1722. C₂₀H₂₂N₅O₃ requires 380.1717. 167² (68)

¹H NMR (400MHz, CDCl₃): δ =1.11 (m, 6H), 2.27 (s, 3H), 2.41 (q, 2H), 2.50 (q, 2H), 3.70 (s, 3H), 4.04 (t, 1H), # 4.08 (t, 2H), 5.64 (s, 1H), 6.81 (s, 1H), 6.91 (s, 1H), 6.99 (s, 1H). LRMS (electrospray): m/z [MH⁺]396, [MNa⁺] 418. HRMS: [MH⁺] Found 396.2027. C₂₁H₂₆N₅O₃ requires 396.2030.

Example 168

[0633] 5-{[3-Cyclopropyl-5-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile

[0634] and

Example 169

[0635] 5-{[5-Cyclopropyl-3-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile

[0636] Potassium carbonate (91 mg, 0.66 mmol) and 2-(2-bromoethoxy)-tetrahydropyran (91 μl, 0.61 mmol) were sequentially added to a solution of the pyrazole from Example 129 (152 mg, 0.55 mmol) dissolved in dimethylformamide (4 ml) and the reaction was heated to 35° C. under nitrogen for 5 hours. Starting material still remained, so the temperature was increased to 80° C. and the reaction was stirred for a further 18 hours. The reaction was cooled to room temperature, sodium hydride (60% dispersion in oil, 24 mg, 0.60 mmol) was added and the reaction was stirred at room temperature for 1 hour. The mixture was diluted with water (50 ml) and extracted with ethyl acetate (2×50 ml). The combined organic extracts were washed with brine (30 ml), dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with pentane:cyclohexane (75:25, by volume) to provide a mixture of regioisomers (239 mg). The regioisomers (239 mg, 0.55 mmol) and p-toluenesulphonic acid (10 mg, 0.05 mmol) were dissolved in methanol (5 ml) and stirred under nitrogen at room temperature for 18 hours. The solvent was removed under reduced pressure and the residue was partitioned between saturated aqueous sodium bicarbonate solution (20 ml) and dichloromethane (30 ml). The organic phase was dried over magnesium sulphate, concentrated under reduced pressure and the residual oil was purified by flash chromatography on silica gel eluting with toluene:ethyl acetate (50:50, by volume) to yield two products as colourless oils.

[0637] Least Polar Fraction (Example 168)—34 mg

[0638]¹H NMR (400 MHz, CDCl₃): δ=0.76 (m, 4H), 1.05 (t, 3H), 1.45 (m, 1H), 2.48 (q, 2H), 3.39 (brs, 1H), 4.02 (m, 4H), 7.39 (s, 2H), 7.56 (s, 1H).

[0639] LRMS (electrospray): m/z [M−H⁺] 321.

[0640] Most Polar Fraction (Example 169)—9 mg

[0641]¹H NMR (400 MHz, CDCl₃): δ=0.62 (m, 2H), 0.78 (m, 2H), 1.18 (t, 3H), 1.46 (m, 1H), 2.38 (q, 2H), 3.42 (brs, 1H), 4.02 (m, 2H), 4.21 (t, 2H), 7.38 (s, 2H), 7.57 (s, 1H).

[0642] LRMS (electrospray): m/z [MH⁺] 323, [MH⁻] 321.

Example 170

[0643] 5-{[5-Ethyl-1-(2-hydroxyethyl)-3-isopropyl-1H-pyrazol-4-yl]oxy}isophthalonitrile

[0644] 2-(2-Bromoethoxy)-tetrahydropyran (91 μl, 0.60 mmol) was added to a solution of the pyrazole from Example 131 (153 mg, 0.55 mmol) dissolved in dimethylformamide (4 ml) at room temperature under nitrogen, then sodium hydride (60% dispersion in oil, 24 mg, 0.60 mmol) was added and the reaction was stirred at room temperature for 3 hours. The mixture was diluted with water (50 ml) and extracted with ethyl acetate (2×50 ml). The combined organic extracts were washed with brine (30 ml), dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with toluene:ethyl acetate (85:15, by volume) to provide the separated isomers as colourless oils (83 mg of Isomer 1, 55 mg of Isomer 2).

[0645] The least polar isomer (isomer 1) (83 mg, 0.20 mmol) and p-toluene-sulphonic acid (4 mg, 0.02 mmol) were dissolved in methanol (5 ml) and stirred under nitrogen at room temperature for 18 hours. The solvent was removed under reduced pressure and the residue was partitioned between water (30 ml) and dichloromethane (30 ml). The aqueous phase was extracted with dichloromethane (20 ml) and the combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and the residual oil was purified by flash chromatography on silica gel eluting with toluene:ethyl acetate (66:34, by volume) to provide the title compound (39 mg) as an oil.

[0646]¹H NMR (400 MHz, CDCl₃): δ=1.05 (t, 3H), 1.14 (d, 6H), 2.44 (q, 2H), 2.68 (sept, 1H), 3.77 (brs, 1H), 4.06 (m, 4H), 7.38 (s, 2H), 7.58 (s, 1H).

[0647] LRMS (electrospray): m/z [MH⁺] 325.

Example 171

[0648] 5-{[3-Ethyl-1-(2-hydroxyethyl)-5-isopropyl-1H-pyrazol-4-yl]oxy}isophthalonitrile

[0649] The most polar isomer (isomer 2) from Example 170 (55 mg, 0.13 mmol) and p-toluene-sulphonic acid (3 mg, 0.01 mmol) were dissolved in methanol (5 ml) and stirred under nitrogen at room temperature for 18 hours. The solvent was removed under reduced pressure and the residue was partitioned between water (30 ml) and dichloromethane (30 ml). The aqueous phase was extracted with dichloromethane (20 ml) and the combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and the residual oil was purified by flash chromatography on silica gel eluting with toluene:ethyl acetate 66:33, by volume) to provide the title compound (39 mg) as a white solid.

[0650]¹H NMR (400 MHz, CDCl₃): δ=1.08 (t, 3H), 1.13 (d, 6H), 2.49 (q, 2H), 2.97 (sept, 1H), 3.59 (t, 1H), 4.06 (m, 4H), 7.37 (s, 2H), 7.57 (s, 1H).

[0651] LRMS (electrospray): m/z [MH⁺] 325.

Example 172

[0652] 2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl carbamate

[0653] Trichloroacetyl-isocyanate (46 μl, 0.38 mmol) was added to a solution of the alcohol from Example 119 (100 mg, 0.32 mmol) dissolved in dichloromethane (3.2 ml) under nitrogen at 0° C. After stirring for 2 hours the dichloromethane was removed under reduced pressure and methanol (1.6 ml), water (1.6 ml) and potassium carbonate (134 mg, 0.96 mmol) were added and the reaction was stirred for a further 2 hours. The methanol was removed under reduced pressure and the residue was extracted with dichloromethane (3×10 ml). The combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and the residual solid was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound (60 mg) as a white solid.

[0654]¹H NMR (400 MHz, CDCl₃): δ=1.10 (m, 6H), 2.39 (q, 2H), 2.48 (q, 2H), 4.26 (m, 2H), 4.44 (m, 2H), 4.62 (brs, 2H), 7.41 (s, 2H), 7.58 (s, 1H).

[0655] LRMS (thermospray): m/z [MH⁺] 354.

[0656] Microanalysis: Found C, 60.00; H, 5.55; N, 19.82. C₁₈H₁₉N₅O₃.0.23EtOAc requires C, 60.30; H, 5.67; N, 18.58%.

Example 173

[0657] N-{2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl}sulfamide

[0658] Sulfamide (31 mg, 0.32 mmol) was added to a solution of the amine from Example 127 (100 mg, 0.32 mmol) dissolved in dioxan (0.5 ml) under nitrogen at room temperature. The reaction was heated to 100° C. for 18 hours, cooled to room temperature and partitioned between ethyl acetate (15 ml) and water (15 ml). The organic phase was dried over magnesium sulphate, concentrated under reduced pressure and the residual brown oil was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (95:5:0.5, by volume) to provide the title compound (25 mg) as a white solid.

[0659]¹H NMR (400 MHz, CDCl₃): δ=1.12 (m, 6H), 2.39 (q, 2H), 2.51 (q, 2H), 3.61 (m, 2H), 4.20 (m, 2H), 4.78 (s, 2H), 5.42 (s, 1H), 7.40 (s, 2H), 7.59 (s, 1H).

[0660] Microanalysis: Found C, 50.33; H, 5.07; N, 20.60. C₁₇H₂₀N₆O₃S.0.95H₂O requires C, 50.35; H, 5.44; N, 20.72%.

Example 174

[0661] N-{2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl}-2-methoxyacetamide

[0662] The amine from Example 127 (100 mg, 0.32 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (68 mg, 0.35 mmol) and N,N-dimethylaminopyridine (43 mg, 0.35 mmol) were added to a solution of 1-methoxyacetic acid (27 μl, 0.35 mmol) dissolved in dichloromethane (10 ml) under nitrogen at room temperature. The reaction was stirred for 18 hours, concentrated under reduced pressure and the residual yellow oil was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (95:5:0.5, by volume) to provide the title compound (32 mg) as a colourless oil.

[0663]¹H NMR (400 MHz, CDCl₃): δ=1.11 (t, 3H), 1.16 (t, 3H), 2.38 (q, 2H), 2.47 (q, 2H), 3.41 (s, 3H), 3.77 (dd, 2H), 3.89 (s, 2H), 4.15 (m, 2H), 7.19 (brs, 1H), 7.40 (s, 2H), 7.59 (s, 1H).

[0664] LRMS (thermospray): m/z [MH⁺] 382.

[0665] Microanalysis: Found C, 61.26; H, 6.18; N, 17.59. C₂₀H₂₃N₅O₃.0.60H₂O requires C, 61.24; H, 6.22; N, 17.85%.

Example 175

[0666] 5-{[1-(3-Azetidinyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}isophthalonitrile

[0667] The protected amine from Preparation 69 (178 mg, 0.42 mmol) was dissolved in 4M hydrochloric acid in dioxan solution (1 ml) and dioxan (1 ml) and the reaction was stirred at room temperature for 18 hours. The solvent was removed under reduced pressure and the residue was partitioned between dichloromethane (20 ml) and saturated aqueous sodium bicarbonate solution (20 ml). The organic phase was dried over magnesium sulphate, concentrated under reduced pressure and purified by flash chromatography on silica gel eluting with a solvent gradient of dichloromethane:methanol:0.88 ammonia (100:0:0 then 98:2:0 then 95:5:0 then 95:5:0.5 then 90:10:1 then 80:20:1, by volume) to provide the title compound (33 mg) as a white solid.

[0668]¹H NMR (400 MHz, CDCl₃): δ=1.05 (t, 3H), 1.11 (t, 3H), 2.44 (m, 4H), 3.85 (m, 2H), 4.38 (m, 2H), 5.05 (m, 1H), 7.37 (s, 2H), 7.56 (s, 1H).

[0669] LRMS (electrospray): m/z [MH⁺] 322.

[0670] Microanalysis: Found C, 65.87; H, 5.94; N, 20.98. C₁₈H₁₉N₅O.0.38H₂O requires C, 65.87; H, 6.07; N, 21.04%.

Example 176

[0671] 5-{[3,5-Diethyl-1-(3-hydroxypropyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile

[0672] The protected alcohol from Preparation 70 (215 mg, 0.53 mmol) and p-toluene-sulphonic acid (10 mg, 0.05 mmol) were dissolved in methanol (2 ml) and stirred under nitrogen at room temperature for 18 hours. The solvent was removed under reduced pressure and the residue was partitioned between water (10 ml) and dichloromethane (10 ml). The organic phase was dried over magnesium sulphate and concentrated under reduced pressure to provide the title compound (148 mg) as a pale yellow solid, m.p. 93-95° C.

[0673]¹H NMR (400 MHz, CDCl₃): δ=1.11 (m, 6H), 2.04 (tt, 2H), 2.37 (q, 2H), 2.53 (q, 2H), 3.06 (t, 1H), 3.69 (dt, 2H), 4.18 (t, 2H), 7.38 (s, 2H), 7.58 (s, 1H).

[0674] LRMS (electrospray): m/z [MH⁺] 325, [MNa⁺] 347.

[0675] Microanalysis: Found C, 66.27; H, 6.27; N, 17.00. C₁₈H₂₀N₄O₂ requires C, 66.28; H, 6.24; N, 17.18%.

Example 177

[0676] 5-[(3,5-Diethyl-1-methyl-1H-pyrazol-4-yl)oxy]isophthalonitrile

[0677] Sodium hydride (60% dispersion in oil, 33 mg, 0.82 mmol) was added to a solution of the pyrazole from Example 122 (200 mg, 0.75 mmol) in dimethylformamide (3 ml) at 0° C. under nitrogen and the reaction was stirred for 10 minutes. Methyl iodide (117 mg, 0.82 mmol) was added and the reaction was stirred at room temperature for 18 hours. The reaction was quenched with water (0.2 ml) and concentrated under reduced pressure. The residue was partitioned between dichloromethane (5 ml) and water (5 ml) and the organic phase was isolated using a 5 μM Whatman PTFE fritted cartridge, then concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with a solvent gradient of ethyl acetate:pentane (20:80, by volume) changing to ethyl acetate:methanol (90:10, by volume) then dichloromethane:methanol:0.88 ammonia (90:10:1 then 80:20:1, by volume) to provide the title compound (170 mg) as a yellow solid.

[0678]¹H NMR (400 MHz, CDCl₃): δ=1.10 (m, 6H), 2.39 (q, 2H), 2.49 (q, 2H), 3.80 (s, 3H), 7.40 (s, 2H), 7.56 (s, 1H).

[0679] LRMS (electrospray): m/z [MH⁺] 281.

[0680] Microanalysis: Found C, 68.41; H, 5.71; N, 19.93. C₁₆H₁₆N₄O requires C, 68.55; H, 5.75; N, 19.99%.

Examples 178-180

[0681] The preparation of the following tabulated Examples of the general formula

[0682] were performed by a similar method to that of Example 177 using the appropriate alkyl halide as the starting material. Example No. (Starting Material Example No.) R Analytical Data 178 (122)

¹H NMR (400MHz, CDCl₃): δ = 1.08 (t, 3H), 1.12 (t, 3H), 2.40 (q, 2H), 2.54 (q, 2H), 3.34 # (s, 3H), 3.75 (t, 2H), 4.17 (t, 2H), 7.38 (s, 2H), 7.56 (s, 1H). LRMS (electrospray): m/z [MH⁺]325, [MNa⁺] 347. Microanalysis: Found C, 65.73; H, 6.17; N, 17.08. C₁₈H₂₀N₄O₃.0.25H₂O requires C, 65.74; H, 6.28; N, 17.04%. 179^(1,2) (122)

¹H NMR (400MHz, CDCl₃): δ = 1.10 (m, 6H), 1.98 (tt, 2H), 2.38 (q, 2H), 2.51 (q, 2H), 2.76 # (t, 2H), 4.09 (t, 2H), 7.38 (s, 2H), 7.57 (s, 1H). LRMS (electrospray): m/z [MH⁺] 324. Microanalysis: Found C, 64.86; H, 6.51; N, 20.79. C₁₈H₂₁N₅O.0.57H₂O requires C, 64.79; H, 6.69; N, 20.99%. 180³ (122)

¹H NMR (400MHz, CDCl₃): δ = 1.09 (t, 3H), 1.14 (t, 3H), 2.41 (q, 2H), 2.47 (q, 2H), 3.79 (s, # 3H), 4.82 (s, 2H), 7.40 (s, 2H), 7.57 (s, 1H). LRMS (electrospray): m/z [MH⁺] 339. Microanalysis: Found C, 63.58; H, 5.35; N, 16.35. C₁₈H₁₈N₄O₃.0.10H₂O requires C, 63.56; H, 5.39; N, 16.47%.

Example 181

[0683] 2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetamide

[0684] The ester from Example 180 (200 mg, 0.59 mmol) was dissolved in 2M methanolic ammonia solution (5 ml) and the reaction was stirred under nitrogen at 75° C. for 18 hours. The mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with a solvent gradient of dichloromethane:methanol:0.88 ammonia (95:5:0.5, by volume) to provide the title compound (6 mg).

[0685]¹H NMR (400 MHz, CDCl₃): δ=1.10 (t, 3H), 1.15 (t, 3H), 2.44 (q, 2H), 2.54 (q, 2H), 4.69 (s, 2H), 5.55 (brs, 1H), 6.22 (brs, 1H), 7.38 (s, 2H), 7.59 (s, 1H).

[0686] LRMS (electrospray): m/z [M−H⁺] 322.

[0687] Microanalysis: Found C, 68.41; H, 5.71; N, 19.93. C₁₆H₁₆N₄O requires C, 68.55; H, 5.75; N, 19.99%.

Example 182

[0688] 5-{[3,5-Diethyl-1-(hydroxymethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile

[0689] Formaldehyde (37% solution in water, 253 μl, 3.14 mmol) was added to a solution of the pyrazole from Example 122 (440 mg, 1.65 mmol) in ethanol (5 ml) and the reaction was stirred at 80° C. for 18 hours. After cooling to room temperature the solvent was removed under reduced pressure and the residual yellow solid was partitioned between ethyl acetate (15 ml) and water (10 ml) and the organic phase was removed. The aqueous phase was washed with ethyl acetate (2×15 ml) and the combined organic extracts were dried over magnesium sulphate and concentrated under reduced pressure to provide the title compound (490 mg) as a white solid.

[0690]¹H NMR (400 MHz, CDCl₃): δ=1.13 (t, 3H), 1.14 (t, 3H), 2.39 (q, 2H), 2.61 (q, 2H), 5.49 (s, 2H), 5.68 (brs, 1H), 7.40 (s, 2H), 7.56 (s, 1H).

[0691] LRMS (thermospray): m/z [MH⁺] 267.

[0692] Microanalysis: Found C, 64.28; H, 5.52; N, 18.47. C₁₆H₁₆N₄O₂.0.15H₂O requires C, 64.27; H, 5.49; N, 18.24%.

Example 183

[0693] 3-[({[4-(3-cyano-5-fluorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}amino)methyl]benzamide

[0694] The pyrazole from Preparation 75 (320 mg, 0.91 mmol) and the amine from Preparation 80 (680 mg, 4.61 mmol) were refluxed in isopropanol (5 ml) for 1.5 hours. The solvent was removed under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (95:5:0.5, by volume) to give the product which was further purified by preparative HPLC using a Develosil combi-rp C30 50×4.6 mm 3 μm column eluting with a solvent gradient of 5:95 0.1% aqueous trifluoroacetic acid in acetonitrile:acetonitrile (0-6 min 95:5 changing to 50:50; 6-7 min 50:50; 7-7.1 min 50:50 changing to 5:95; 7.1-8 min 5:95) to provide the title compound (38 mg).

[0695]¹H NMR (400 MHz, CD₃OD): δ=2.14 (s, 3H), 4.10 (s, 2H), 4.34 (s, 2H), 7.03 (m, 1H), 7.10 (s, 1H), 7.25 (m, 1H), 7.54 (t, 1H), 7.64 (d, 1H), 7.92 (d, 1H), 7.97 (s, 1H).

[0696] LRMS (electrospray): m/z [MH⁺] 380.

[0697] Microanalysis: Found C, 51.32; H, 3.91; N, 13.69. C₂₀H₁₈N₅O₂F.1.00CF₃CO₂H1.10H₂O requires C, 51.49; H, 4.16; N, 13.65%.

Examples 184-188

[0698] The preparation of the following tabulated Examples of the general formula

[0699] were performed by a similar method to that of Example 183 using as the starting materials the appropriate pyrazole (P) and amine (A). P prep. A prep. Ex. no no. no. X R Analytical Data 184¹ 75 55 F

¹H NMR (400 MHz, CDCl₃): δ = 2.09(s, 3H), 3.65(s, 2H), 3.79(s, 2H), 6.80(d, 1H), 6.93(s, 1H), 6.97(d, 1H), 7.31(d, 2H), 7.72(d, 2H). LRMS (thermospray): m/z [MH⁺] 380. 185¹ 76 55 CN

m.p. 114-116° C. ¹H NMR (400 MHz, CDCl₃): δ = 2.08(s, 3H), 3.62(s, 2H), 3.77(s, 2H), 7.34(d, 2H), 7.55(s, 1H), 7.77(d, 2H), 7.79(s, 1H). LRMS (thermospray) m/z [MH⁺] 387. 186¹ 18 80 Cl

m.p. 98-101° C. ¹H NMR (400 MHz, CDCl₃): δ = 2.04(s, 3H), 3.62(s, 2H), 3.74(s, 2H), 6.97(s, 1H), 7.07(s, 1H), 7.20(s, 1H), 7.22(d, 1H), 7.29(t, 1H), 7.62(s, 1H), 7.81(s, 1H). # LRMS (thermospray): m/z [MH⁺] 396. Microanalysis: Found C, 56.98; H, 4.58; N, 17.69. C₂₀H₁₈ClN₅O₂.0.40CH₂Cl₂requires C, 57.01; H, 4.41; N, 16.29%. 187^(1,2,3) 77 55 Me

¹H NMR (400 MHz, CDCl₃): δ = 2.10(s, 3H), 2.30(s, 3H), 3.65(s, 2H), 3.80(s, 2H), 6.85(s, 1H), 6.95(s, 1H), 7.10(s, 1H), 7.30(d, 2H), 7.70(d, 2H). LRMS (electrospray): m/z [MH⁺] 376, # [M − H⁺] 374. Microanalysis: Found C, 65.59; H, 5.65; N, 18.19. C₂₁H₂₁N₅O₂.0.50H₂O requires C, 65.51; H, 5.77; N, 18.22%. 188⁴ 78 55 H

¹H NMR (400 MHz, CD₃OD): δ = 2.15(s, 3H), 4.10(s, 2H), 7.20(m, 2H), 7.40(m, 1H), 7.50(m, 1H), 7.55(d, 2H), 7.90(d, 2H). Microanalysis: Found C, 53.51; H, 4.13; N, 13.59. C₂₀H₁₉N₅O₂. # 1.25 TFA requires C, 53.63; H, 4.05; N, 13.90%.

Example 189

[0700] 5-[(3,5-Dicyclopropyl-1H-pyrazol-4-yl)oxy]isophthalonitrile

[0701] Hydrazine hydrate (133 μl, 2.75 mmol) was added to a solution of the diketone from Preparation 82 (735 mg, 2.50 mmol) in acetic acid (25 ml) under nitrogen at room temperature. After stirring for 64 hours, the mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane (25 ml) and saturated aqueous sodium bicarbonate solution (25 ml). The organic phase was dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (98:2 changing to 96:4, by volume) to provide the title compound (473 mg) as a white solid, m.p. 168-170° C.

[0702]¹H NMR (400 MHz, CDCl₃): δ=0.77 (m, 4H), 0.85 (m, 4H), 1.59 (m, 2H), 7.44 (s, 2H), 7.59 (s, 1H).

[0703] LRMS (thermospray): m/z [MH⁺] 291.

[0704] Microanalysis: Found C, 69.90; H, 4.85; N, 19.18. C₁₇H₁₄N₄O.0.10H₂O requires C, 69.90; H, 4.90; N, 19.18%.

Example 190

[0705] 5-{[3,5-Dicyclopropyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile

[0706] 2-Hydroxyethylhydrazine (84 mg, 1.10 mmol) was added to a solution of the diketone from Preparation 82 (294 mg, 1.00 mmol) in acetic acid (10 ml) under nitrogen at room temperature. After stirring for 64 hours, the mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane (25 ml) and saturated aqueous sodium bicarbonate solution (25 ml). The organic phase was dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (99:1 changing to 95:5, by volume) to provide the title compound (137 mg) as a white solid, m.p. 115-117° C.

[0707]¹H NMR (400 MHz, CDCl₃): δ=0.67 (m, 2H), 0.80 (m, 4H), 0.85 (m, 2H), 1.52 (m, 2H), 3.39 (brs, 1H), 4.05 (m, 2H), 4.22 (t, 2H), 7.42 (s, 2H), 7.58 (s, 1H).

[0708] LRMS (thermospray): m/z [MH⁺] 355.

[0709] Microanalysis: Found C, 67.63; H, 5.55; N, 16.35. C₁₉H₁₈N₄O₂.0.17H₂O requires C, 67.63; H, 5.48; N, 16.60%.

Example 191

[0710] 5-{[1-(2-Aminoethyl)-3,5-dicyclopropyl-1H-pyrazol-4-yl]oxy}isophthalonitrile

[0711] 2-Chloroethylamine hydrochloride (192 mg, 1.65 mmol) and the pyrazole from Example 189 (440 mg, 1.50 mmol) were heated as a melt at 160° C. for 18 hours and the residue was partitioned between dichloromethane (25 ml) and 10% aqueous potassium carbonate solution (25 ml). The organic phase was dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (95:5:0 changing to 95:5:0.5, by volume) to provide the title compound (9.2 mg) as a white solid, m.p. 175-177° C.

[0712]¹H NMR (400 MHz, CDCl₃): δ=0.70 (m, 2H), 0.79 (m, 4H), 0.88 (m, 2H), 1.57 (m, 1H), 1.66 (m, 1H), 3.46 (t, 2H), 4.41 (t, 2H), 7.62 (s, 2H), 7.58 (s, 1H).

Example 192

[0713] 3-{[3-cyclopropyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile

[0714] and

Example 193

[0715] 3-{[5-cyclopropyl-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile

[0716] 2-Hydroxy-ethyl-hydrazine (3261,4.80 mmol) was added to a solution of the diketone from Preparation 86 (1.00 g, 4.37 mmol) in acetic acid (10 ml) under nitrogen at room temperature. After stirring for 18 hours, the mixture was concentrated under reduced pressure and the residual orange oil was purified by flash chromatography on silica gel eluting with ethyl acetate:pentane (50:50 changing to 100:0, by volume) to provide two pale yellow oils.

[0717] Least Polar Fraction (Example 192)—419 mg

[0718]¹H NMR (400 MHz, CDCl₃): δ=0.69 (m, 2H), 0.82 (m, 2H), 1.54 (m, 1H), 2.00 (s, 3H), 2.35 (s, 3H), 3.46 (brs, 1H), 4.05 (t, 2H), 4.22 (t, 2H), 6.88 (s, 1H), 6.94 (s, 1H), 7.08 (s, 1H).

[0719] LRMS (thermospray): m/z [MH⁺] 298.

[0720] Microanalysis: Found C, 68.29; H, 6.51; N, 13.92. C₁₇H₁₉N₃O₂ requires C, 68.67; H, 6.44; N, 14.13%.

[0721] Most Polar Fraction (Example 193)—201 mg

[0722]¹H NMR (400 MHz, CDCl₃): δ=0.75 (m, 4H), 1.58 (m, 1H), 2.07 (s, 3H), 2.35 (s, 3H), 3.45 (brs, 1H), 4.00 (m, 4H), 6.92 (s, 1H), 7.00 (s, 1H), 7.10 (s, 1H).

[0723] LRMS (thermospray): m/z [MH⁺] 298.

[0724] Microanalysis: Found C, 68.44; H, 6.49; N, 13.95. C₁₇H₁₉N₃O₂ requires C, 68.67; H, 6.44; N, 14.13%.

Example 194

[0725] 3-[3-Cyclopropyl-1- (2-amino-ethyl)-5-methyl-1H-pyrazol-4-yloxy]-5-methyl-benzonitrile

[0726] The alcohol from Example 192 (140 mg, 0.47 mmol), triphenylphosphine (309 mg, 1.18 mmol) and phthalimide (174 mg, 1.18 mmol) were dissolved in tetrahydrofuran (9 ml) at 0° C. under nitrogen and diisopropylazodicarboxylate (232 μl, 1.18 mmol) dissolved in tetrahydrofuran (2 ml) was added over 10 minutes. The reaction was allowed to warm to room temperature and was stirred for 18 hours. The solvent was removed under reduced pressure, the residue was dissolved in ethanol (11 ml) and hydrazine hydrate (114 μl, 2.35 mmol) was added. The thick white slurry was stirred for 18 h at room temperature under nitrogen, methanol (10 ml) was added and the mixture was filtered. The filtrate was concentrated under reduced pressure and the residue was dissolved in dichloromethane (20 ml). The organic phase was extracted with 2M aqueous hydrochloric acid (20 ml) and the aqueous phase was washed with dichloromethane (5×10 ml), basified with 1M aqueous sodium hydroxide and extracted with dichloromethane (50 ml). The organic phase was dried over magnesium sulphate and concentrated under reduced pressure to provide the title compound (135 mg) as a yellow oil.

[0727]¹H NMR (400 MHz, CDCl₃): δ=0.70 (m, 4H), 1.56 (m, 1H), 2.06 (s, 3H), 2.30 (s, 3H), 3.10 (t, 2H), 3.97 (t, 2H), 6.87 (s, 1H), 6.92 (s, 1H), 7.05 (s, 1H).

[0728] LRMS (electrospray): m/z [MH⁺] 297.

[0729] Microanalysis: Found C, 63.81; H, 6.51; N, 17.30. C₁₇H₂₀N₄O.0.36CH₂Cl₂ requires C, 63.78; H, 6.39; N, 17.14%.

Example 195

[0730] 3-[(3-Cyclopropyl-5-methyl-1H-pyrazol-4-yl)oxy]-5-methylbenzonitrile

[0731] Hydrazine hydrate (31 μl, 0.64 mmol) was added to a solution of the diketone from Preparation 86 (150 mg, 0.58 mmol) in acetic acid (1.3 ml) under nitrogen at room temperature. After stirring for 24 hours, the mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (60:40 changing to 40:60, by volume) to provide the title compound (140 mg).

[0732]¹H NMR (400 MHz, CDCl₃): δ=0.60 (m, 4H), 1.69 (m, 1H), 2.09 (s, 3H), 2.34 (s, 3H), 6.95 (s, 1H), 6.99 (s, 1H), 7.10 (s, 1H).

[0733] LRMS (thermospray): m/z [MH⁺] 254.

[0734] Microanalysis: Found C, 68.35; H, 6.13; N, 15.10. C₁₅H₁₅N₃O.0.29EtOAc requires C, 68.72; H, 6.32; N, 14.88%.

Example 196

[0735] 3-{[1-(3-Aminopropyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile

[0736] 3-Chloropropylamine hydrochloride (62 mg, 0.48 mmol) and the pyrazole from Example 123 (113 mg, 0.44 mmol) were heated as a melt at 150° C. for 18 hours. After cooling the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (98:2:0 changing to 95:5:0.5, by volume). An impurity remained so the oil was dissolved in acetone (3 ml) and (L)-tartaric acid (54 mg, 0.44 mmol) was added, the mixture was heated to effect dissolution and cooled. The resultant precipitate was isolated by filtration washing with acetone (10 ml) to provide the title compound (127 mg) as a white solid which was the tartrate salt.

[0737]¹H NMR (400 MHz, CD₃OD): δ=1.05 (m, 6H), 2.07 (m, 2H), 2.37 (q, 2H), 2.53 (s, 3H), 2.57 (q, 2H), 2.99 (t, 2H), 4.15 (t, 2H), 4.38 (s, 2H), 6.89 (s, 1H), 7.01 (s, 1H), 7.19 (s, 1H).

[0738] LRMS (thermospray): m/z [MH⁺] 313.

[0739] Microanalysis: Found C, 56.81; H, 6.57; N, 12.06. C₂₂H₃₀N₄O₇ requires C, 57.13; H, 6.54; N, 12.11%.

Example 197

[0740] 3-{[3,5-Diethyl-1- (2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-4-methoxybenzonitrile

[0741] Cesium carbonate (700 mg, 2.14 mmol) was added to a stirred solution of 2-methoxy-5-cyanophenol (285 mg, 2.15 mmol) and the dione of Preparation 2 (348 mg, 2.15 mmol) in acetone (20 ml) at room temperature. The reaction was heated at 50° C. for 3 hours and then cooled to room temperature. The mixture was concentrated under reduced pressure, dissolved in dichloromethane (5 ml) and washed with water (5 ml). The organic phase was isolated using a 5 μM Whatman PTFE fritted cartridge, then concentrated under reduced pressure. The residue was dissolved in acetic acid (5.4 ml) and 2-hydroxy-ethyl-hydrazine (160 μl, 2.15 mmol) added under nitrogen at room temperature. After stirring for 18 hours, the mixture was concentrated under reduced pressure and the residual orange oil was purified by flash chromatography on silica gel eluting with a solvent gradient of ethyl acetate:pentane (25:75 changing to 50:50, by volume) to provide the title compound (182 mg).

[0742]¹H NMR (400 MHz, CDCl₃): δ=1.10 (m, 6H), 2.39 (q, 2H), 2.51 (q, 2H), 3.71 (brs, 1H), 4.00 (s, 3H), 4.08 (m, 2H), 4.09 (m, 2H), 6.89 (s, 1H), 6.99 (d, 1H), 7.32 (d, 1H).

[0743] LRMS (thermospray): m/z [MH⁺] 316.

[0744] Microanalysis: Found C, 64.57; H, 6.73; N, 13.15. C₁₇H₂₁N₃O₃ requires C, 64.74; H, 6.71; N, 13.32%.

Examples 198-199

[0745] The preparation of the following tabulated Examples of the general formula

[0746] were performed by a similar method to that of Example 197 using the β-diketone of Preparation 2 and the appropriate aryl alcohol as the starting materials. Example No. R Analytical Data 198

¹H NMR (400 MHz, CDCl₃): δ = 1.04(m, 6H), 2.42(q, 2H), 2.51 (q, 2H), 4.07(m, 2H), 4.12(m, 2H), 6.60(d, 1H), 7.25(t, 1H), 7.49(d, 1H), 7.53(m, 2H), 7.82(m, 1H), 8.41(m, 1H). LRMS (thermospray): m/z [MH⁺] 311. 199

¹H NMR (400 MHz, CDCl₃): δ = 1.19(m, 6H), 2.48(q, 2H), 2.51 (q, 2H), 4.03(m, 2H), 4.10(m, 2H), 7.06(s, 1H), 7.22(m, 1H), 7.38(t, 1H), 7.42(m, 1H), 7.69(d, 1H), 7.79(s, 1H), 7.80(s, 1H). LRMS (thermospray): m/z [MH⁺] 311. Microanalysis: Found C, 72.16; H, 7.20; N, 8.95. # C₁₉H₂₂N₂O₂.0.10EtOAc requires C, 72.45; H, 7.19; N, 8.63%.

Example 200

[0747] 2-[4-[3,5-Di(1H-pyrazol-1-yl)phenoxy]-3,5-diethyl-1H-pyrazol-1-yl]ethanol

[0748] The protected alcohol from Preparation 88 (254 mg, 0.53 mmol) and p-toluene-sulphonic acid (10 mg, 0.05 mmol) were dissolved in methanol (4 ml) and stirred under nitrogen at room temperature for 18 hours. The solvent was removed under reduced pressure and the residue was partitioned between saturated aqueous sodium bicarbonate solution (20 ml) and dichloromethane (20 ml). The aqueous phase was extracted with dichloromethane (10 ml) and the combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and purified by flash chromatography on silica gel eluting with a solvent gradient of dichloromethane:methanol (100:0 changing to 93:7, by volume) to provide the title compound (56 mg) as a white solid, m.p. 108-110° C.

[0749]¹H NMR (400 MHz, CDCl₃): δ=1.11 (m, 6H), 2.46 (q, 2H), 2.53 (q, 2H), 4.01 (t, 2H), 4.07 (t, 2H), 6.44 (s, 2H), 7.16 (s, 2H), 7.68 (s, 3H), 7.92 (s, 2H).

[0750] LRMS (electrospray): m/z [MH⁺] 393, [MNa⁺] 415.

[0751] Microanalysis: Found C, 63.62; H, 6.11; N, 21.11. C₂₁H₂₄N₆O₂.0.06CH₂Cl₂ requires C, 63.63; H, 6.12; N, 21.14%.

Example 201

[0752] 2-{3,5-Diethyl-4-[3-fluoro-5-(1H-pyrazol-1-yl)phenoxy]-1H-pyrazol-1-yl}ethanol

[0753] The protected alcohol from Preparation 89 (38.6 mg, 0.09 mmol) and p-toluene-sulphonic acid (3.5 mg, 0.01 mmol) were dissolved in methanol (1 ml) and stirred under nitrogen at room temperature for 18 hours. The solvent was removed under reduced pressure and the residue was partitioned between 10% aqueous potassium carbonate solution (4 ml) and dichloromethane (4 ml). The aqueous phase was extracted with dichloromethane (10 ml) and the combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and purified by flash chromatography on silica gel eluting with a solvent gradient of dichloromethane:methanol (99:1 changing to 98:2, by volume) to provide the title compound (23 mg) as a white solid, m.p. 120-122° C.

[0754]¹H NMR (400 MHz, CDCl₃): δ=1.14 (m, 6H), 2.46 (q, 2H), 2.55 (q, 2H), 4.06 (m, 2H), 4.09 (m, 2H), 6.47 (s, 1H), 6.49 (s, 1H), 7.09 (s, 1H), 7.12 (s, 1H), 7.71 (s, 1H), 7.86 (s, 1H).

[0755] LRMS (electrospray): m/z [MNa⁺] 367.

[0756] HRMS: [MH⁺] Found 345.1717. C₁₈H₂₂FN₄O₂ requires 345.1722.

Example 202

[0757] 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-methoxybenzonitrile

[0758] The protected alcohol from Preparation 90 (400 mg, 1.00 mmol) and p-toluene-sulphonic acid (19 mg, 0.10 mmol) were dissolved in methanol (10 ml) and stirred under nitrogen at room temperature for 18 hours. The solvent was removed under reduced pressure and the residue was partitioned between saturated aqueous sodium bicarbonate solution (20 ml) and dichloromethane (20 ml). The aqueous phase was extracted with dichloromethane (40 ml) and the combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and purified by flash chromatography on a silica gel eluting with dichloromethane:methanol (97:3, by volume) to provide the title compound (174 mg) as an oil.

[0759]¹H NMR (400 MHz, CDCl₃): δ=1.09 (m, 6H), 2.40 (q, 2H), 2.49 (q, 2H), 3.78 (s, 3H), 4.04 (m, 2H), 4.08 (m, 2H), 6.66 (s, 1H), 6.71 (s, 1H), 6.79 (s, 1H).

[0760] LRMS (electrospray): m/z [MH⁺] 316.

[0761] Microanalysis: Found C, 63.63; H, 6.76; N, 13.06. C₁₇H₂₁N₃O₃.0.08CH₂Cl₂ requires C, 63.68; H, 6.68; N, 13.04%.

Example 203

[0762] 2-[4-(3,5-Difluorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethylamine

[0763] The alcohol from Example 38 (371 mg, 1.25 mmol), triphenylphosphine (984 mg, 3.75 mmol) and phthalimide (552 mg, 3.75 mmol) were dissolved in tetrahydrofuran (20 ml) at 0° C. under nitrogen and diisopropylazodicarboxylate (738 μl, 3.75 mmol) dissolved in tetrahydrofuran (2 ml) was added over 10 minutes. The reaction was allowed to warm to room temperature and was stirred for 18 hours. The solvent was removed under reduced pressure, the residue was dissolved in ethanol (25 ml) and hydrazine hydrate (303 μl, 6.25 mmol) was added. The slurry was stirred for 4 hours at 45° C. under nitrogen, concentrated under reduced pressure and the residue was dissolved in methanol. The solution was then passed through an SCX column eluting with methanol to remove impurities, then 2M methanolic ammonia solution to elute the product. The product was then purified by flash chromatography on alumina eluting with dichloromethane:methanol:0.88 ammonia (90:10:1, by volume) to provide the title compound (212 mg) as an oil.

[0764]¹H NMR (400 MHz, CDCl₃): δ=1.12 (m, 6H), 2.43 (q, 2H), 2.54 (q, 2H), 3.21 (t, 2H), 4.07 (t, 2H), 6.43 (m, 3H).

[0765] Microanalysis: Found C, 59.78; H, 6.50; N, 14.35. C₁₅H₁₉F₂N₃O.0.26H₂O requires C, 60.05; H, 6.56; N, 14.01%.

Example 204

[0766] 3-{[1-(2-Aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-fluorobenzamide

[0767] The alcohol from Example 163 (142 mg, 0.44 mmol), triphenylphosphine (346 mg, 1.32 mmol) and phthalimide (194 mg, 1.32 mmol) were dissolved in tetrahydrofuran (8 ml) at 0° C. under nitrogen and diisopropylazodicarboxylate (260 μl, 1.32 mmol) dissolved in tetrahydrofuran (1 ml) was added over 10 minutes. The reaction was allowed to warm to room temperature and was stirred for 18 hours. The solvent was removed under reduced pressure, the residue was dissolved in ethanol (9 ml) and hydrazine hydrate (107 μl, 2.2 mmol) was added. The slurry was stirred for 4 hours at 45° C. under nitrogen, concentrated under reduced pressure and the residue was dissolved in methanol. The solution was then passed through a polymer supported sulphonic acid column eluting with methanol to remove impurities, then 2M methanolic ammonia solution to elute the product. The product was then purified by flash chromatography on alumina eluting with dichloromethane:methanol:0.88 ammonia (90:10:1, by volume) to provide the title compound (60 mg) as an oil.

[0768]¹H NMR (400 MHz, CDCl₃): δ=1.11 (m, 6H), 2.43 (q, 2H), 2.53 (q, 2H), 3.17 (t, 2H), 4.05 (t, 2H), 6.01 (brs, 1H), 6.25 (brs, 1H), 6.75 (d, 1H), 7.16 (m, 2H).

[0769] HRMS: [MH⁺] Found 321.1718. C₁₆H₂₁FN₄O₂ requires 321.1722.

Example 205

[0770] 3-[(3-Isopropyl-5-methyl-1H-pyrazol-4-yl)oxy]-5-methylbenzonitrile

[0771] Hydrazine hydrate (100 μl, 2.10 mmol) was added to a solution of the diketone from Preparation 91 (544 mg, 2.10 mmol) in acetic acid (10 ml) under nitrogen at room temperature. After stirring for 64 hours, the mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (66:34, by volume) to provide the title compound (308 mg) as a pale yellow oil.

[0772]¹H NMR (400 MHz, CDCl₃): δ=1.22 (d, 6H), 2.09 (s, 3H), 2.56 (s, 3H), 2.84 (m, 1H), 6.91 (s, 1H), 6.94 (s, 1H), 7.11 (s, 1H).

[0773] LRMS (thermospray): m/z [MH⁺] 256.

Example 206

[0774] 3-{[1-(2-Aminoethyl)-3-isopropyl-5-methyl-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile

[0775] The pyrazole from Example 205 (70 mg, 0.27 mmol) and 2-chloroethylamine hydrochloride (38 mg, 0.33 mmol) were heated as a melt at 150° C. for 18 hours. The residue was cooled and purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (95:5:0.5, by volume) to give the title compound (25 mg).

[0776]¹H NMR (400 MHz, CDCl₃): δ=1.18 (m, 6H), 2.06 (s, 3H), 2.35 (s, 3H), 2.79 (m, 1H), 3.19 (m, 2H), 4.04 (m, 2H), 6.89 (s, 1H), 6.97 (s, 1H), 7.12 (s, 1H).

[0777] LRMS (electrospray): m/z [MH⁺] 300.

Example 207

[0778] 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]-N-(2-pyridinylmethyl)acetamide

[0779] Standard solutions: The acid of Preparation 4 (800 mg, 2.33 mmol), 1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (822 mg, 3.50 mmol) and diisopropylethylamine (603 mg, 4.66 mmol) were separately dissolved in N,N-dimethylformamide (3×13 ml). 2-(Methylamino)pyridine (3 mg, 0.029 mmol) was treated with the standard solutions of the acid and coupling reagents (3×170 μl) in a 96 well plate and the mixture was shaken for 14 hours at room temperature. The solvent was removed under reduced pressure and the mixture dissolved in dimethylsulphoxide (500 μl) and purified by HPLC (Magellen C₈(2) 150×10 mm column; a gradient mobile phase was used, 5:95 (by volume) to 95:5 (by volume) acetonitrile:(0.1% trifluoroacetic acid in water).

[0780] Retention time: 5.69 minutes.

[0781] LRMS (electrospray): m/z [MH⁺] 434.

Example 208

[0782] [4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]acetonitrile

[0783] The pyrazole of Preparation 8 (1.00 g, 2.60 mmol) in tetrahydrofuran (10 ml) was added in one portion to a solution of sodium cyanide (284 mg, 5.20 mmol) in water (10 ml) at room temperature. The reaction was heated at 80° C. for 14 hours and cooled to room temperature. The solvent was removed under reduced pressure and the resulting brown solid was dissolved in dichloromethane (50 ml) and water (50 ml). The organic layer was separated, washed with water (50 ml), brine (30 ml), dried over magnesium sulphate, filtered and the solvent removed under reduced pressure to give a brown solid. The product was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (50:50, by volume) to give the title compound as a yellow solid (500 mg), m.p. 150-152° C.

[0784]¹H NMR (400 MHz, CDCl₃): δ=2.17 (s, 3H), 3.56 (s, 2H), 6.77 (s, 2H), 7.02 (s, 1H).

[0785] LRMS (thermospray): m/z [MH⁺] 282.

Example 209

[0786] 1-{[4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]acetyl}piperidine

[0787] Standard solutions: The acid of Preparation 92 (680 mg, 2.16 mmol) and 1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (761 mg, 3.23 mmol) were separately dissolved in N,N-dimethylacetamide:triethylamine (96:4) (2×17 ml).

[0788] Piperidine (3 mg, 0.031 mmol) was treated with the standard solutions of the acid and coupling reagents (250 μl of each) in a 96 well plate and the mixture was shaken for 14 hours at 80° C. The solvent was removed under reduced pressure and the mixture dissolved in dimethylsulphoxide (500 μl) and purified by HPLC (Magellen C₁₈(2) 150×10 mm column; a gradient mobile phase was used, 5:95 (by volume) to 95:5 (by volume) acetonitrile:(0.1% trifluoroacetic acid in water).

[0789] Retention time: 4.7 minutes.

[0790] LRMS (electrospray): m/z [MH⁺] 368.

Examples 210-217

[0791] The compounds of the following tabulated Examples of the general formula:

[0792] were performed by a similar method to that of Example 209 using the appropriate amine. HPLC retention times/ LRMS (electrospray) m/z Example No. X min [MH⁺] 210

3.9 384 211

5.5 459 212

5.4 476 213

5.3 458 214

5.1 424 215

5.3 458 216

4.9 408 217

5.2 404

Example 218

[0793] 3-chloro-5-[(5-{[(2-chlorobenzyl)amino]methyl}-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile

[0794] Standard solutions: The bromide of Preparation 18 (850 mg, 2.30 mmol) was dissolved in N-methylpyrolidinone (43 ml).

[0795] 2-Chlorobenzylamine (19 mg, 0.13 mmol) in a 96 well plate was treated with the solution of the bromide of Preparation 18 (5001 μl) and the mixture was shaken for 14 hours at 80° C. The solvent was removed under reduced pressure and the mixture dissolved in dimethylsulphoxide (500 μl) and purified by HPLC (Magellen C₈(2) 150×10 mm column; a gradient mobile phase was used, 5:95 (by volume) to 95:5 (by volume) acetonitrile:(0.1% trifluoroacetic acid in water).

[0796] Retention time: 5.3 minutes.

[0797] LRMS (electrospray): m/z [MH⁺] 386.

Examples 219-249

[0798] The compounds of the following tabulated Examples of the general formula:

[0799] were performed by a similar method to that of Example 218 using the appropriate amine. LRMS (electrospray) HPLC retention times/ m/z Example No. X min [MH⁺] 219

4.2 367 220

4.1 366 221

3.8 374 222

3.2 353 223

4.2 366 224

3.7 334 225

3.7 445 226

4.1 366 227

4.3 387 228

4.2 380 229

3.6 328 230

3.5 347 231

4.3 387 232

4.5 438 233

3.8 353 234

3.7 370 235

4.1 370 236

4.1 396 237

4.1 352 238

4.1 382 239

4.4 420 240

4.0 362 241

4.1 382 242

4.2 372 243

3.2 353 244

4.2 420 245

4.4 421 246

3.7 353 247

4.4 421 248

4.1 382 249

4.1 382

Example 250

[0800] 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(methylsulfanyl)benzonitrile

[0801] The protected alcohol from Preparation 93 (687 mg, 1.65 mmol) and p-toluene-sulphonic acid (32 mg, 0.17 mmol) were dissolved in methanol (16 ml) and stirred under nitrogen at room temperature. After 4 hours a second portion of p-toluene-sulphonic acid (32 mg, 0.17 mmol) was added. After 18 hours the solvent was removed under reduced pressure and the residue was partitioned between saturated aqueous sodium bicarbonate solution (20 ml) and dichloromethane (20 ml). The aqueous phase was extracted with dichloromethane (40 ml) and the combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and purified by flash chromatography on silica gel eluting with dichloromethane:methanol (97:3, by volume) to provide the title compound (487 mg) as a white solid. m.p. 72° C.

[0802]¹H NMR (400 MHz, CDCl₃): δ=1.14 (m, 6H), 2.44 (q, 2H), 2.49 (s, 3H), 2.53 (q, 3H), 4.08 (m, 2H), 4.14 (m, 2H), 6.84 (s, 1H), 7.00 (s, 1H), 7.10 (s, 1H).

[0803] LRMS (electrospray): m/z [MH⁺] 332.

[0804] Microanalysis: Found C, 61.36; H, 6.43; N, 12.55. C₁₇H₂₁N₃O₂S requires C, 61.61; H, 6.39; N, 12.68%.

Example 251

[0805] 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(methylsulfinyl)benzonitrile

[0806] Wet alumina was prepared by adding water (1 ml) to Brockman grade I alumina (5 g). To a stirred solution of the sulphide from Example 250 (134 mg, 0.40 mmol) in dichloromethane (2 ml) was added of wet alumina (400 mg) followed by Oxone® (123 mg, 0.4 mmol) and the mixture was heated at reflux. After 1 hour a second portion of oxone (123 mg, 0.40 mmol) was added and the mixture was heated for a further 2 hours. After cooling to room temperature the reaction mixture was filtered and the resulting solids were washed with dichloromethane (20 ml). The filtrate was concentrated and was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (a gradient from 99:1 to 90:10, by volume) to provide the title compound (92 mg) as an oil.

[0807]¹H NMR (400 MHz, CDCl₃): δ=1.12 (m, 6H), 2.44 (q, 2H), 2.53 (q, 2H), 2.73 (s, 3H), 4.06 (m, 2H), 4.18 (m, 2H), 7.24 (s, 1H), 7.45 (s, 1H), 7.49 (s, 1H).

[0808] LRMS (electrospray): m/z [M+Na⁺] 370.

Example 252

[0809] 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(methylsulfonyl)benzonitrile

[0810] To a stirred solution of the sulphide from Example 250 (133 mg, 0.4 mmol) in dichloromethane (2 ml) at −78° C. was added a solution of meta-chloroperoxybenzoic acid (138 mg of 50% by weight mixture, 0.4 mmol) in dichloromethane (2 ml). The cooling bath was removed and the solution was stirred at room temperature for 4 hours. The mixture was quenched by addition of saturated aqueous sodium bicarbonate solution (6 ml) and extracted with dichloromethane (3×5 ml). The combined organic components were dried over magnesium sulphate and concentrated. Analysis of the ¹H NMR (400 MHz, CDCl₃) suggested a mixture of the desired product and the sulphoxide from Example 251. The crude product mixture was dissolved in dichloromethane (2 ml), cooled to −78° C. and to this was added meta-chloroperoxybenzoic acid (138 mg of 50% by weight mixture, 0.4 mmol) in dichloromethane (2 ml). The cooling bath was removed and the mixture was stirred at room temperature for 1 hour. The mixture was quenched by addition of saturated aqueous sodium bicarbonate solution (6 ml) and extracted with dichloromethane (3×5 ml). The combined organic components were dried over magnesium sulphate and concentrated. The crude product mixture was purified by flash chromatography on a silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound contaminated with meta-chloroperxoybenzoic acid. To a solution of this crude product in dichloromethane at −78° C. was added dimethylsulphoxide (30 μl, 0.4 mmol). The cooling bath was removed and the mixture was stirred at room temperature for 15 minutes. The mixture was quenched by addition of 10% aqueous potassium carbonate solution (10 ml) and the dichloromethane was evaporated. The remaining aqueous mixture was then extracted with diethyl ether (2×10 ml) and ethyl acetate (10 ml). The organic components were combined, dried over magnesium sulphate and concentrated to give the crude product mixture which was purified by flash chromatography on a silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound (26 mg) as a white solid. m.p. 133° C.

[0811]¹H NMR (400 MHz, CDCl₃): δ=1.10 (m, 6H), 2.39 (q, 2H), 2.51 (q, 2H), 3.06 (s, 3H), 4.05 (m, 2H), 4.10 (m, 2H), 7.39 (s, 1H), 7.67 (s, 1H), 7.84 (s, 1H).

[0812] LRMS (electrospray): m/z [M+Na⁺] 385.

[0813] HRMS: [MH⁺] 364.1329. C₁₈H₂₀N₆O₂ requires 364.1326.

Example 253

[0814] 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-[2-(dimethylamino)ethoxy]benzonitrile

[0815] To a stirred solution of the protected alcohol from Preparation 94 (180 mg, 0.39 mmol) in methanol (4 ml) was added para-toluenesulphonic acid (89 mg, 0.47 mmol). After 18 hours at room temperature the solvent was evaporated under reduced pressure and the residue was partitioned between dichloromethane (5 ml) and 10% aqueous potassium carbonate solution (5 ml). The aqueous phase was separated and extracted with a dichloromethane (3 ml). The organic components were combined, dried over magnesium sulphate and concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (95:5, by volume) followed by dichloromethane:methanol:ammonia (80:20:1, by volume) to provide the title compound (63 mg) as an oil.

[0816]¹H NMR (400 MHz, CDCl₃): δ=1.13 (m, 6H), 2.43 (m, 8H), 2.52 (q, 2H), 2.85 (m, 2H), 3.81 (broad s, 1H), 4.08 (m, 6H), 6.70 (s, 1H), 6.78 (s, 1H), 6.81 (s, 1H).

[0817] LRMS (APCI): m/z [MH⁺] 373.

[0818] HRMS: [MH⁺] 373.2234. C₂₀H₂₉N₄O₃ requires 373.2234.

Examples 254-256

[0819] The compounds of the following tabulated Examples of the general formula:

[0820] were performed by a similar method to that of Example 253 using as starting material the appropriate protected alcohol (PA) from Preparations 95-97. Example PA prep No. No. R Analytical Data 254 95 CH₂CH₂NHMe ¹H NMR(400 MHz, CDCl₃): δ = 1.13(m, 6H), 2.42(q, 2H), 2.53(q, 2H), 2.59(s, 3H), 3.12(t, 2H), 4.05(m, 2H), 4.09(m, 2H), 4.16(t, 2H), 6.75(s, 1H), 6.81(s, 1H), 6.82(s, 1H). LRMS (APCI): m/z [MH⁺] 359 HRMS: [MH⁺] 359.2083. C₁₉H₂₇N₄O₃ requires 359.2078. 255 96 CH₂CONH₂ ¹H NMR(400 MHz, CDCl₃): δ = 1.11(m, 6H), 2.41(q, 2H), 2.52(q, 2H), 4.05(t, 2H), 4.09(t, 2H), 4.46 (s, 2H), 5.74(broad s, 1H), 6.42 (broad s, 1H), 6.69(s, 1H), 6.85(s, 2H). LRMS (APCI): m/z 359 (MH⁺) 256 97 CH₂CH₂OCH₃ ¹H NMR(400 MHz, CDCl₃): δ = 1.12(m, 6H), 2.42(q, 2H), 2.51(q, 2H), 3.44(s, 3H), 3.73(t, 2H), 4.09 (m, 6H), 6.71(s, 1H), 6.77(s, 1H), 6.83(s, 1H). LRMS (electrospray): m/z 360 (MH⁺) HRMS: [MH⁺] 360.1920. C₁₉H₂₆N₃O₄ requires 360.1918.

Example 257

[0821] 3-{[1-(2-Aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-methoxybenzonitrile

[0822] The alcohol from Example 202 (87 mg, 0.28 mmol), triphenylphosphine (220 mg, 0.84 mmol) and phthalimide (124 mg, 0.84 mmol) were dissolved in tetrahydrofuran (5 ml) at 0° C. under nitrogen and diisopropylazodicarboxylate (165 μl, 0.84 mmol) dissolved in tetrahydrofuran (1 ml) was added dropwise. The reaction was allowed to warm to room temperature and was stirred for 18 hours. The solvent was removed under reduced pressure, the residue was dissolved in ethanol (6 ml) and hydrazine hydrate (68 μl, 1.40 mmol) was added. The slurry was stirred for 48 hours at room temperature under nitrogen, concentrated under reduced pressure and the residue was dissolved in methanol. The solution was then passed through an SCX column eluting with methanol to remove impurities, then 2M ammonia in methanol solution to elute the product. The product was then purified by flash chromatography on silica gel eluting with dichloromethane:methanol (95:5) then dichloromethane:methanol:0.88 ammonia (90:10:1, by volume) to provide the title compound (67 mg) as an oil.

[0823]¹H NMR (400 MHz, CDCl₃): δ=1.13 (m, 6H), 2.19 (broad s, 2H), 2.43 (q, 2H), 2.54 (q, 2H), 3.19 (t, 2H), 3.60 (s, 3H), 4.06 (t, 2H), 6.68 (s, 1H), 6.73 (s, 1H), 6.80 (s, 1H).

[0824] LRMS (electrospray): m/z 315 (MH⁺)

[0825] HRMS: [MH⁺] 315.1819. C₁₇H₂₃N₄O₂ requires 315.1816.

Example 258

[0826] 3-{[1-(2-Aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-(1H-pyrazol-1-yl)benzonitrile

[0827] The alcohol from Example 164 (162 mg, 0.46 mmol), triphenylphosphine (362 mg, 1.38 mmol) and phthalimide (203 mg, 1.38 mmol) were dissolved in tetrahydrofuran (8 ml) at 0° C. under nitrogen and diisopropylazodicarboxylate (272 μl, 1.38 mmol) dissolved in tetrahydrofuran (1 ml) was added dropwise. The reaction was allowed to warm to room temperature and was stirred for 18 hours. The solvent was removed under reduced pressure, the residue was dissolved in ethanol (9 ml) and hydrazine hydrate (112 μl, 2.3 mmol) was added. The slurry was stirred for 48 hours at room temperature under nitrogen, concentrated under reduced pressure and the residue was dissolved in methanol. The solution was then passed through an SCX column eluting with methanol to remove impurities, then 2M ammonia in methanol solution to elute the product. The product was then purified by flash chromatography on silica gel eluting with dichloromethane:methanol (95:5) then dichloromethane:methanol:0.880 ammonia (90:10:1, by volume) to provide the title compound (62 mg) as an oil.

[0828]¹H NMR (400 MHz, CD₃OD): δ=1.15 (m, 6H), 2.46 (q, 2H), 2.63 (q, 2H), 3.13 (t, 2H), 4.13 (t, 2H), 6.54 (s, 1H), 7.17 (s, 1H), 7.69 (s, 1H), 7.72 (s, 1H), 7.82 (s, 1H), 8.32 (s, 1H).

[0829] LRMS (APCI): m/z 351 (MH⁺)

[0830] HRMS: [MH⁺] 351.1929. C₁₉H₂₂N₄O₂ requires 351.1928.

Example 259

[0831] 3,5-Dichlorophenyl-3-methyl-5-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-1H-pyrazol-4-yl ether

[0832] To a stirred solution of the acid (100 mg, 0.33 mmol) from Preparation 92 in dimethylformamide (2 ml) was added carbonyldiimidazole (59 mg, 0.36 mmol) in one portion. After 30 minutes at room temperature (1Z)-N′-hydroxyethanimidamide (27 mg, 0.36 mmol) was added and the reaction mixture was stirred at room temperature for 3 hours. A second portion of carbonyldiimidazole (59 mg, 0.36 mmol) was added and the mixture was heated at 100° C. for 12 hours. After cooling to room temperature water (30 ml) was added and the mixture was extracted with ethyl acetate (3×20 ml). The combined organic components were dried over magnesium sulphate and concentrated under reduced pressure to give a brown oil. The crude product mixture was purified by flash chromatography on silica gel eluting with ethyl acetate:pentane (30:70, by volume) to provide the title compound (40 mg) as a pale yellow oil.

[0833]¹H NMR (400 MHz, CDCl₃): δ=2.12 (s, 3H), 2.29 (s, 3H), 4.08 (s, 2H), 6.74 (s, 2H), 6.98 (s, 1H).

[0834] LRMS (electrospray): m/z 339 (MH⁺)

Example 260

[0835] 3-Fluoro-5-{[1-(2-hydroxyethyl)-5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]oxy}benzonitrile

[0836] To a stirred solution of the protected alcohol (85 mg, 0.21 mmol) from Preparation 99 in methanol (0.5 ml) was added para-toluenesulphonic acid (4 mg, 0.02 mmol). After 5 hours the reaction mixture was concentrated under reduced pressure, dissolved in dichloromethane (20 ml), washed with saturated sodium bicarbonate solution (20 ml), dried over magnesium sulphate and concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (60:40 followed by 40:60, by volume) to provide the title compound (54 mg) as a white solid.

[0837]¹H NMR (400 MHz, CDCl₃): δ=2.19 (s, 3H), 2.45 (t, 1H), 4.10 (m, 2H), 4.20 (m, 2H), 6.87 (d, 1H), 6.96 (s, 1H), 7.05 (d, 1H).

[0838] LRMS (APCI): m/z 330 (MH⁺)

[0839] Microanalysis: Found C, 51.38; H, 3.52; N, 12.37. C₁₄H₁₁F₄N₃O₂ requires C, 51.07; H, 3.37; N, 12.76%.

Example 261

[0840] 5-[(3,5-Diethyl-1-{2-[(2-methoxyethoxy)methoxy]ethyl}-1H-pyrazol-4-yl)oxy}isophthalonitrile

[0841] To a stirred solution of the alcohol (5.0 g, 16.11 mmol) from Example 119 in tetrahydrofuran (65 ml) at 0° C. was added 2-methoxyethoxymethylchloride (2.39 ml, 20.94 mmol) followed by sodium hydride (838 mg of a 60% by weight dispersion in oil, 20.94 mmol). After 10 minutes the reaction mixture was heated at 50° C. for 18 hours. After cooling to room temperature, the mixture was diluted with saturated aqueous ammonium chloride solution dropwise (3 ml). The mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane (250 ml) and water (200 ml). The aqueous phase was separated and extracted with dichloromethane (150 ml). The organic components were combined, dried over magnesium sulphate and concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane, followed by dichloromethane:methanol (99:1, by volume) to provide the title compound (5.38 g) as a colourless oil.

[0842]¹H NMR (400 MHz, CDCl₃): δ=1.10 (m, 6H), 2.39 (q, 2H), 2.55 (q, 2H), 3.38 (s, 3H), 3.51 (m, 2H), 3.56 (m, 2H), 3.93 (t, 2H), 4.20 (t, 2H), 4.66 (s, 2H), 7.38 (s, 2H), 7.56 (s, 1H).

[0843] LRMS (APCI): m/z 399 (MH⁺)

[0844] Microanalysis: Found C, 62.11; H, 6.67; N, 13.51. C₂₁H₂₆N₄O₄+0.43H₂O requires C, 62.09; H, 6.67; N, 13.79%.

Example 262

[0845] 3-Cyano-5-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4- yl]oxy}benzamide

[0846] To a stirred solution of the pyrazole (60 mg) from Preparation 100 in dichloromethane (4 ml) was added aluminium trichloride (134 mg, 1 mmol). After 18 hours, ice was added, the mixture was neutralised using saturated aqueous sodium bicarbonate solution, diluted with water (30 ml) and extracted with dichloromethane (2×40 ml). The organic components were combined, dried over magnesium sulphate and concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (95:5, by volume) to provide the title compound (27 mg) as a colourless glass.

[0847]¹H NMR (400 MHz, CDCl₃): δ=1.10 (m, 6H), 2.40 (q, 2H), 2.52 (q, 2H), 4.07 (m, 4H), 7.25 (s, 1H), 7.60 (s, 1H), 7.65 (s, 1H).

[0848] LRMS (APCI): m/z 329 (MH⁺)

Example 263

[0849] 5-{[5-Ethyl-3-(1-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile

[0850] To a stirred solution of the pyrazole from Preparation 102 (219 mg, 0.57 mmol) in tetrahydrofuran (2.5 ml) was added saturated aqueous sodium carbonate solution (0.5 ml). The reaction mixture was stirred at room temperature for 4 hours and then heated at reflux for 18 hours. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane (20 ml) and water (20 ml). The organic phase was dried over magnesium sulphate and concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (a gradient from 100:0 to 90:10, by volume) to provide the title compound (68 mg) as a white solid.

[0851]¹H NMR (400 MHz, CDCl₃): δ=1.21 (t, 3H), 1.51 (d, 3H), 2.54 (q, 2H), 4.89 (q, 1H), 7.25 (s, 2H), 7.43 (s, 1H).

[0852] LRMS (APCI): m/z 283 (MH⁺)

Example 264

[0853] 5-{[5-Ethyl-3-(1-hydroxyethyl)-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile

[0854] To a stirred solution of the pyrazole from Preparation 103 (80 mg, 0.19 mmol) in methanol (1 ml) was added para-toluenesulphonic acid (4 mg, 0.02 mmol). After 5 hours at room temperature the reaction mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane (20 ml) and water (20 ml). The organic component was dried over magnesium sulphate and concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (a gradient from 100:0 to 95:5, by volume) to provide the title compound (44 mg) white solid.

[0855]¹H NMR (400 MHz, CDCl₃): δ=1.11 (t, 3H), 1.46 (d, 3H), 2.54 (q, 2H), 4.10 (q, 2H), 4.17 (q, 2H), 4.79 (q, 1H), 7.44 (s, 2H), 7.57 (s, 1H).

[0856] LRMS (APCI): m/z 327 (MH⁺)

Example 265

[0857] 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(5-trifluoromethyl-1,2,4-oxadiazol-3-yl)benzonitrile

[0858] To a stirred solution of the pyrazole from Preparation 105 (235 mg, 0.46 mmol) in dichloromethane (2 ml) was added aluminium trichloride (373 mg, 2.8 mmol). The reaction mixture was stirred at room temperature for 48 hours, diluted with water (6 ml) and extracted with dichloromethane (6 ml). The organic component was concentrated under reduced pressure and purified by flash chromatography on silica gel eluting with dichloromethane:methanol (a gradient from 99:1 to 80:20, by volume) followed by dichloromethane:methanol:0.88 ammonia (80:20:1, by volume) to provide an impure sample of the title compound (44 mg) as a white solid. The product was further purified by HPLC using a Phenomenex Luna C₁₈ 150×21.2 mm column eluting with a solvent gradient of 5:95 0.1% aqueous trifluoroacetic acid in acetonitrile:acetonitrile (0-1 min 80:20; 1-7 min 80:20 changing to 0:100; 7-12 min 0:100; 12-12.1 min 0:100 changing to 80:20; 12.1-15 min 80:20) to provide the title compound (38 mg) as a white solid.

[0859] Retention time 5.7 minutes.

[0860] LRMS (electrospray): m/z 422 (MH⁺)

Examples 266-268

[0861] The compounds of the following tabulated Examples of the general formula:

[0862] were prepared by a similar method to that of Example 265 using the appropriate profected alcohol (PA) from Preparation 106-108. Example No. PA prep No. R Analytical Data 266 106 Me Retention time 4.8 minutes LRMS (electrospray): m/z [MH⁺] 368 267 107 Et Retention time 5.3 minutes LRMS (electrospray): m/z [MH⁺] 382 268 108 ^(i)Pr Retention time 5.7 minutes LRMS (electrospray): m/z 396 (MH⁺)

Example 269

[0863] 5-[({[4-(3-Chloro-5-cyanophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}amino)methyl]nicotinamide

[0864] To a stirred solution of the amine from Preparation 111 (650 mg, 1.70 mmol) in iso-propyl alcohol (6 ml) was added the pyrazole from Preparation 18 (210 mg, 0.57 mmol) followed by potassium carbonate (240 mg, 1.70 mmol). The reaction mixture was heated at reflux for 1.5 hours. After cooling to room temperature the mixture was concentrated under reduced pressure and the crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (95:5:0.5 then 90:10:1 then 80:20:1, by volume) which gave an impure sample of the desired product. Flash chromatography was repeated eluting with dichloromethane:methanol:0.88 ammonia (100:0:0 then 95:5:0.5 then 90:10:1, by volume) to provide the title compound (10 mg) as a pale yellow solid.

[0865]¹H NMR (400 MHz, CD₃OD): =2.05 (s, 3H), 3.62 (s, 2H), 3.79 (s, 2H), 7.16 (m, 1H), 7.18 (m, 1H), 7.38 (s, 1H), 8.15 (s, 1H), 8.54 (s, 1H), 8.84 (s, 1H).

[0866] LRMS (APCI): m/z 419 (M+Na⁺)

[0867] HRMS: [MH⁺] 397.1173. C₁₉H₁₈N₆O₂Cl requires 397.1175.

Example 270

[0868] 2-[({[4-(3-Chloro-5-cyanophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}amino)methyl]isonicotinamide

[0869] To a stirred suspension of the amine from Preparation 115 (250 mg, 1.66 mmol) and the pyrazole from Preparation 18 (155 mg, 0.42 mmol) in isopropanol (6 ml) was added tetrahydofuran (2 ml). The mixture was heated at reflux for 2 hours after which the reaction mixture was concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (85:15:1, by volume) to provide an impure sample of the title compound. The product was further purified by HPLC using a Phenomenex Luna C₈(II) 10 μM 150×21.2 mm column eluting with a solvent gradient of 5:95 0.1% aqueous trifluoroacetic acid in acetonitrile:acetonitrile (0-6 min 95:5 changing to 0:100; 6-10 min 0:100) to provide the title compound (65 mg) as an off-white solid.

[0870] Retention time: 3.40 minutes

[0871]¹H NMR (400 MHz, CD₃OD): δ=2.14 (s, 3H), 4.21 (s, 2H), 4.50 (s, 2H), 7.19 (s, 1H), 7.27 (m, 1H), 7.43 (m, 1H), 7.48 (m, 1H), 7.78 (m, 1H), 8.68 (d, 1H)

[0872] LRMS (electrospray): m/z 397 (MH⁼)

[0873] Microanalysis: Found C, 44.56; H, 3.41; N, 14.07. C₁₉H₁₇N₆O₂Cl+1.9.CF₃CO₂H requires C, 44.64; H, 3.11; N, 13.70%.

Example 271

[0874] Di(tert-butyl) 2-[4-(3,5-dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl phosphate

[0875] To a stirred solution of the alcohol from Example 119 (500 mg, 1.60 mmol) in dichloromethane (5 ml) was added tetrazole (226 mg, 3.20 mmol) followed by di-tert-butyl-N,N-diisopropylphosphoramidite (1.02 ml, 3.20 mmol). After stirring for 4 hours at room temperature the reaction mixture was cooled to 0° C. and meta-chloroperoxybenzoic acid (1.0 g of 50% by weight mixture, 3 mmol) was added portionwise (CARE, EXOTHERM). After 10 minutes the mixture was warmed to room temperature and was diluted with dichloromethane (50 ml). The solution was washed with saturated aqueous sodium carbonate solution (20 ml) and the aqueous component was separated and extracted with dichloromethane (20 ml). The combined organic components were washed with brine (20 ml), dried over magnesium sulphate and concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (100:0:0 then 99:1:0.1 then 98:2:0.2, by volume) to provide a sample of the title compound (660 mg)

[0876]¹H NMR (400 MHz, CDCl₃): δ=1.10 (m, 6H), 1.43 (s, 18H), 2.38 (q, 2H), 2.55 (q, 2H), 4.26 (m, 4H), 7.38 (s, 2H), 7.54 (s, 1H).

[0877] LRMS (electrospray): m/z 525 (MH⁺)

[0878] Microanalysis: Found C, 57.77; H, 7.38; N, 10.33. C₂₅H₃₅N₄O₅P+H₂O requires C, 57.68; H, 7.16; N, 10.76%.

Example 272

[0879] 2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl dihydrogen phosphate

[0880] To a stirred solution of the phosphate ester from Example 271 (250 mg, 0.48 mmol) in dichloromethane (10 ml) at 0° C. was added trifluoroacetic acid (0.5 ml). The reaction mixture was allowed to warm to room temperature and after 4 hours it was concentrated under reduced pressure. The residue was purified by HPLC using a Phenomenex Luna C₈(II) 10 μM 150×21.2 mm column eluting with a solvent gradient of 5:95 0.1% aqueous trifluoroacetic acid in acetonitrile:acetonitrile (0-1.9 m in 95:5; 2-10 min 90:10 changing to 30:70; 10.0-13.8 min 30:70; 13.8-13.9 min 30:70 changing to 95:5; 13.9-15 min 95:5) to give a sample of the desired product. This sample was further purified by recrystallisation using acetonitrile/water which gave the title compound as a white solid, m.p. 198-199° C.

[0881] Retention time: 2.31 minutes.

[0882]¹H NMR (400 MHz, CD₃OD): δ=1.09 (m, 6H), 2.35 (q, 2H), 2.61 (q, 2H), 4.28 (m, 4H), 7.55 (s, 2H), 7.79 (s, 1H).

[0883] LRMS (APCI): m/z 391 (MH⁺)

[0884] Microanalysis: Found C, 50.99; H, 4.92; N, 14.06. C₁₇H₁₉N₄O₅P+0.5H₂O requires C, 51.13; H, 5.05; N, 14.03%.

Example 273

[0885] 5-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile Sulfate Salt

[0886] To a stirred solution of the pyrazole from Example 119 (200 mg, 0.65 mmol) in acetone (5 ml) was added sulfuric acid (0.32 ml of a 2M aqueous solution, 0.64 mmol) and the mixture was stirred at room temperature and the solvent allowed to evaporate. The residue was recrystallised (toluene/acetone) to give the title compound (160 mg) as a white powder, m.p. 105-110° C.

[0887]¹H NMR (400 MHz, CDCl₃): δ=1.22 (m, 6H), 2.70 (m, 4H), 4.12 (bs, 1H), 4.59 (m, 2H), 4.75 (bs, 1H), 7.66 (s, 1H), 7.69 (m, 1H), 2 (s, 1H).

[0888] Microanalysis: Found C, 50.29; H, 4.90; N, 13.48. C₁₇H₁₈N₄O₂.H₂SO₄ requires C, 49.99; H, 4.93; N, 13.72%.

Example 274

[0889] 5-{13,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile Benzenesulfonic Acid Salt

[0890] To a stirred solution of the pyrazole from Example 119 (20 g, 65 mmol) in acetone (200 ml) was added benzenesulfonic acid (10.7 g, 68 mmol) and the mixture was stirred at room temperature for 10 minutes. The reaction mixture was concentrated under reduced pressure and the residue was recrystallised twice (acetone) to give the title compound (16.2 g) as a white powder, m.p. 142-144° C.

[0891]¹H NMR (400 MHz, CDCl₃): δ=1.05-1.08 (m, 6H), 2.59 (q, 2H), 2.68 (q, 2H), 4.04 (t, 2H), 4.54 (t, 2H), 7.35-7.42 (m, 3H), 7.55 (s, 1H), 7.64 (s, 1H), 7.86 (d, 2H).

[0892] Microanalysis: Found C, 58.86; H, 5.13; N, 11.88. C₂₃H₂₄N₄O₅S requires C, 58.96; H, 5.16; N, 11.96%.

Example 275

[0893] 5-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile Tosylate Salt

[0894] To a stirred suspension of the pyrazole from Example 119 (300 mg, 1.00 mmol) in ethanol (2 ml) was added p-toluenesulfonic acid (202 mg, 1.10 mmol) and the mixture was heated on an oil bath until the solids dissolved. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was crystallised (diethyl ether), filtered and recrystallised (isopropyl alcohol) to give the title compound (200 mg) as a white solid, m.p. 120° C.

[0895]¹H NMR (400 MHz, DMSO-d₆): δ=1.00 (m, 6H), 2.24 (m, 5H), 2.49 (m, 2H), 4.00 (m, 2H), 7.11 (d, 2H), 7.45 (d, 2H), 7.73 (s, 2H), 8.09 (s, 1H).

[0896] Microanalysis: Found C, 59.64; H, 5.46; N, 11.60. C₂₄H₂₆N₄O₅S requires C, 59.74; H, 5.43; N, 11.61%.

Example 276

[0897] 5-{f[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile Mesylate Salt

[0898] To a stirred suspension of the pyrazole from Example 119 (250 mg, 0.83 mmol) in isopropyl alcohol (3 ml) was added methanesulfonic acid (52 μl, 0.91 mmol) and the mixture was heated on an oil bath until the solids dissolved. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to a volume of 1 ml. A white solid precipitated out which was washed with cold isopropyl alcohol to give the title compound (239 mg) as a white solid, m.p. 144-146° C.

[0899]¹H NMR (400 MHz, DMSO-d₆): δ=1.02 (m, 6H), 2.32 (q, 2H), 2.43 (s, 3H), 2.52 (m, 2H), 3.73 (m, 2H), 4.02 (m, 2H), 7.75 (s, 2H), 8.11 (s, 1H).

[0900] Microanalysis: Found C, 53.20; H, 5.52; N, 13.68. C₁₈H₂₂N₄O₅S requires C, 53.19; H, 5.46; N, 13.78%.

Example 277

[0901] 3-{[1-(2-Aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile bis-mesylate Salt

[0902] To a stirred solution of the amine from Example 125 (119 mg, 0.40 mmol) in ethanol (2 ml) was added methanesulfonic acid (1.00 ml of a 0.84M solution in ethanol, 0.84 mmol). The reaction mixture was concentrated under reduced pressure to remove some of the ethanol. A mixture of diethyl ether and acetone were added and a white solid precipitated out which was filtered and washed (diethyl ether/acetone) to give the title compound (153 mg) as a white solid, m.p. 146-148° C.

[0903]¹H NMR (400 MHz, CD₃OD): δ=1.09 (m, 6H), 2.33 (s, 3H), 2.39 (q, 2H), 2.55 (q, 2H), 2.68 (s, 6H), 3.42 (t, 2H), 4.29 (t, 2H), 6.93 (s, 1H), 7.06 (s, 1H), 7.19 (s, 1H).

[0904] LRMS (thermospray): m/z [free base+H⁺] 299

[0905] Microanalysis: Found C, 45.83; H, 6.12; N, 11.27. C₁₉H₃₀N₄O₇S₂.0.50H₂O requires C, 45.68; H, 6.25; N, 11.21%.

Example 278

[0906] 3-{[1-(2-Aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile phosphate salt

[0907] To a stirred solution of the amine from Example 125 (251 mg, 0.84 mmol) in ethanol (5 ml) was added phosphoric acid (63 μl, 0.93 mmol). The resulting precipitate was filtered, washed (ethanol then diethyl ether) and dried to give the title compound (265 mg) as a white solid, m.p. 210-211° C.

[0908]¹H NMR (400 MHz, CD₃OD): δ=1.08 (m, 6H), 2.32 (s, 3H), 2.39 (q, 2H), 2.56 (q, 2H), 3.39 (m, 2H), 4.29 (m, 2H), 6.93 (s, 1H), 7.05 (s, 1H), 7.18 (s, 1H).

[0909] LRMS (thermospray): m/z [free base+H⁺] 299

[0910] Microanalysis: Found C, 51.26; H, 6.36; N, 14.08. C₁₇H₂₅N₄O₅P requires C, 51.51; H, 6.36; N, 14.14%.

Example 279

[0911] 3-{[1-(2-Aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile (L) Tartrate Salt

[0912] To a stirred solution of the amine from Example 125 (500 mg, 1.68 mmol) in acetone (15 ml) was added (L)-tartaric acid (252 mg, 1.68 mmol) and the mixture was heated on an oil bath until complete dissolution had occurred. The mixture was cooled to room temperature and a white precipitate formed which was filtered and washed (acetone) to give the title compound (515 mg) as a white powder, m.p. 159-161° C.

[0913]¹H NMR (400 MHz, CD₃OD): δ=1.05-1.10 (m, 6H), 2.32 (s, 3H), 2.34-2.41 (m, 2H), 2.53-2.57 (m, 2H), 3.40 (m, 2H), 4.27 (m, 2H), 4.35 (s, 2H), 6.93 (s, 1H), 7.05 (s, 1H), 7.17 (s, 1H).

[0914] LRMS (electrospray): m/z [free base+H⁺] 299

[0915] Microanalysis: Found C, 54.80; H, 6.38; N, 12.11. C₂₁H₂₈N₄O₇.0.65H₂O requires C, 54.81; H, 6.42; N, 12.10%.

Example 280

[0916] 3-{[1-(2-Aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile succinate salt

[0917] To a stirred solution of the amine from Example 125 (235 mg, 0.79 mmol) in acetone (7 ml) was added succinic acid (93 mg, 0.79 mmol). After two minutes the mixture was concentrated to ˜3 ml using a stream of nitrogen gas which resulted in the formation of white crystals. The precipitate was filtered and washed (acetone) to give the title compound (172 mg) as white crystals, m.p. 155° C.

[0918]¹H NMR (400 MHz, CD₃OD): δ=1.03-1.07 (m, 6H), 2.34 (s, 3H), 2.40 (q, 2H), 2.50 (s, 4H), 2.59 (q, 2H), 3.34 (t, 2H), 4.23 (t, 2H), 6.95 (s, 1H), 7.06 (s, 1H), 7.22 (s, 1H).

[0919] LRMS (electrospray): m/z [free base+H⁺] 299

[0920] Microanalysis: Found C, 60.47; H, 6.77; N, 13.39. C₂₁H₂₈N₄O₅ requires C, 60.56; H, 6.78; N, 13.45%.

Example 281

[0921] 3-{[1-(2-Aminoethyl)-3,5-diethyl-1H-Pyrazol-4-yl]oxy}-5-methylbenzonitrile (L) Citrate Salt

[0922] To a stirred solution of the amine from Example 125 (140 mg, 0.47 mmol) in acetone (3 ml) was added citric acid (90 mg, 0.47 mmol). The mixture was stirred until complete dissolution had occurred. The mixture was concentrated to ˜1 ml using a stream of nitrogen gas and cooled in a freezer for 1.5 hours. A precipitate collected which was filtered to give the title compound (149 mg) as a white powder, m.p. 180-182° C.

[0923]¹H NMR (400 MHz, CD₃OD): δ=1.04-1.07 (m, 6H), 2.35 (s, 3H), 2.40 (q, 2H), 2.58 (q, 2H), 2.73 (d, 2H), 2.80 (d, 2H), 3.42 (t, 2H), 4.30 (t, 2H), 6.95 (s, 1H), 7.08 (s, 1H), 7.21 (s, 1H).

[0924] LRMS (electrospray): m/z [free base+H⁺] 299

[0925] Microanalysis: Found C, 56.19; H, 6.20; N, 11.31. C₂₃H₃₀N₄O₈ requires C, 56.32; H, 6.16; N, 11.42%.

Example 282

[0926] 5-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile

[0927] 2-Hydroxyethylhydrazine (8.43 ml, 124 mmol) was added dropwise to a solution of the diketone of Preparation 45 (30.5 g, 113 mmol) in acetic acid (300 ml) at room temperature under nitrogen. The reaction was stirred at room temperature for 90 minutes and the solvent removed under reduced pressure to give an orange solid. This was combined with an orange solid from another reaction carried out in an identical manner to this. The combined crude product was purified by flash column chromatography on silica gel eluting with ethyl acetate:pentane (75:25 by volume) to provide the title compound as a white solid. Analysis of the proton nmr showed minor impurities were present so the product was purified by flash column chromatography on silica gel eluting with ethyl acetate:pentane (50:50 by volume) to provide the title compound (50 g) as a white solid, m.p. 125° C.

[0928]¹H-NMR (400 MHz, CDCl₃): δ=1.13 (6H, m), 2.40 (2H, q), 2.53 (2H, q), 3.53 (1H, m), 4.11 (4H, m), 7.40 (2H, s), 7.58 (1H, s).

[0929] LRMS (electrospray): m/z [MH⁺] 311.

[0930] Microanalysis: Found: C, 65.62; H, 5.85; N, 18.04. C₁₇H₁₈N₄O₂ requires C, 65.64; H, 5.84; N, 18.05%.

Example 283

[0931] 2-[4-(3,5-Dichlorophenoxy)-3-ethyl-1H-pyrazol-1-yl]ethylamine and 2-[4-(3,5-Dichlorophenoxy)-5-ethyl-1H-pyrazol-1-yl]ethylamine

[0932] The pyrazole from Example 42 (1.03 g, 4.00 mmol) and 2-chloroethylamine hydrochloride (510 mg, 4.40 mmol) were heated as a melt at 150° C. for 24 hours. The reaction was cooled and a solution of the residue in dichloromethane (100 ml) was washed with an aqueous solution of 1 M potassium carbonate (50 ml), brine (50 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:ammonia (93:7:1, by volume) to afford the title compounds (768 mg) in a 85:15 ratio of regioisomers as a colourless oil.

[0933]¹H-NMR (400 MHz, CDCl₃): δ=1.16 (major, t, 3H), 1.16 (minor, t, 3H), 2.47 (major, q, 2H), 2.60 (minor, q, 2H), 3.13 (major, m, 2H), 3.13 (minor, m, 2H), 4.10 (major, m, 2H), 4.10 (minor, m, 2H), 4.24 (major, t, 2H), 4.24 (minor, t, 2H), 6.85 (major, s, 2H), 6.85 (minor, s, 2H), 7.02 (major, s, 1H), 7.02 (minor, s, 1H), 7.27 (major, s, 1H), 7.31 (minor, s, 1H).

[0934] LRMS (thermospray): m/z [MH⁺] 300.

[0935] The following Preparations describe the preparation of certain intermediates used in the preceding Examples.

[0936] Preparation 1

[0937] 3-(3,5-Dichlorophenoxy)-2,4-pentanedione

[0938] 3-Chloro-2,4-pentanedione (183 μL, 1.53 mmol)) was added to a stirred suspension of 3,5-dichlorophenol (250 mg, 1.53 mmol) and potassium carbonate (233 mg, 1.69 mmol) in acetone (7.7 ml) at room temperature under nitrogen. The mixture was stirred for 30 minutes and then heated under reflux for 3½ hours. After cooling, sodium iodide (230 mg, 1.53 mmol) was added and refluxing continued for a further 3½ hours. After cooling again the mixture was diluted with water (5 ml) and concentrated under reduced pressure in a fumehood (Caution: possible residual lachrymator) to remove acetone. The resulting red aqueous solution was diluted with 2M hydrochloric acid (5 ml) and extracted with dichloromethane (3×10 ml). The combined organic layers were washed with saturated aqueous sodium sulphite solution (10 ml) and brine (10 ml), dried over magnesium sulphate, filtered and evaporated under reduced pressure to leave a red oil (344 mg). The crude product was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (20:1, by volume) to give the title compound (118 mg) as a cream solid m.p. 91-92° C.

[0939]¹H-NMR (400 MHz, CDCl₃): δ=2.04 (s, 6H), 6.84 (s, 2H), 7.06 (s, 1H), 14.38 (br.s, 1H)

[0940] LRMS (thermospray): m/z [MNH₄ ⁺] 278.

[0941] Microanalysis: Found: C, 50.43; H, 3.84. C₁₁H₁₀Cl₂O₃ requires C, 50.60; H, 3.86%.

[0942] Preparation 2

[0943] 4-Chloro-3,5-heptanedione

[0944] Chlorotrimethylsilane (29.7 ml, 0.234 mol) was added dropwise to a stirred pale yellow solution of tetrabutylammonium bromide (1.26 g, 3.9 mmol) in dry acetonitrile (116 ml) at room temperature under nitrogen. The resulting solution was cooled in ice and 3,5-heptanedione (10.6 ml, 78.0 mmol) and then dry dimethylsulphoxide (16.6 ml, 0.234 mol) were added dropwise over 5 minutes producing a yellow solution which was allowed to warm slowly to room temperature, with stirring, over 4 hours. The mixture was diluted with water (1 liter), stirred for 10 min and then extracted with ether (1×500 ml, 2×250 ml). The combined ether layers were dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a yellow oil. The crude product was purified by distillation under reduced pressure to afford the title compound (5.5 g) as a pale yellow oil, b.p. 102-105° C./54 mmHg containing ca. 10% 4,4-dichloro-3,5-heptanedione as estimated by microanalysis.

[0945]¹H-NMR (400 MHz, CDCl₃): δ=1.12 (t, 6H), 2.59 (q, 4H), 4.77 (s, 0.2H, diketone), 15.50 (s, 0.8H, enol).

[0946] LRMS (thermospray): m/z [MNH₄ ⁺] 180 for title compound and 214 for dichlorinated impurity.

[0947] Preparation 3

[0948] Ethyl 4-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]-3-oxobutanoate

[0949] Sodium hydride (60% dispersion in oil, 250 mg, 6.17 mmol) was added to a stirred solution of 4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazole (800 mg, 2.81 mmol, Example 3) in dry N,N-dimethylformamide (5 ml) at 0° C. under nitrogen. The mixture was stirred for 5 minutes during which time hydrogen was evolved and then ethyl 4-chloroacetoacetate (0.42 ml, 3.09 mmol) was added. After 30 minutes the reaction mixture was quenched by the addition of water (0.5 ml) and concentrated under reduced pressure. A solution of the residue in ethyl acetate (50 ml) was washed with saturated aqueous ammonium chloride solution (20 ml) and water (20 ml), dried over magnesium sulphate and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with ethyl acetate:pentane (30:70, by volume) to provide the title compound (1.1 g) as a white solid, m.p. 82-84° C.

[0950]¹H-NMR (300 MHz, CDCl₃): δ=1.40 (6H, m), 1.26 (3H, t), 2.44 (4H, q), 3.47 (2H, s), 4.22 (2H, q), 4.96 (2H, s), 6.82 (2H, s), 7.02 (1H, s).

[0951] LRMS (thermospray): m/z [MH⁺] 413.

[0952] Microanalysis: Found: C, 55.13; H, 5.34; N, 6.98. C₁₅H₁₅Cl₂N₃O requires C, 55.22; H, 5.37; N, 6.78%.

[0953] Preparation 4

[0954] [4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetic Acid

[0955] Aqueous sodium hydroxide solution (1 N, 6.2 ml, 6.2 mmol) was added dropwise to a stirred solution of the ester (2 g, 5.6 mmol) of Example 9 in tetrahydrofuran (20 ml) at 0° C. After 1 hour the solvent was removed under reduced pressure and aqueous hydrochloric acid (20 ml) was added with vigorous stirring. The resulting white precipitate was collected by filtration, washed with ether (3×30 ml) and dried in a vacuum pistol at 6° C./10 mmHg to afford the title compound as a white solid (1.5 g), m.p. 157-158° C.

[0956]¹H-NMR (300 MHz, CDCl₃): δ=1.13 (6H, m), 2.52 (2H, q), 2.60 (2H, q), 5.03 (2H, s), 6.95 (2H, s), 7.14 (1H, s).

[0957] LRMS (electrospray): m/z [M−H⁺] 341.

[0958] Preparation 5

[0959] 1-(3,5-Dichlorophenoxy)-2-butanone

[0960] Cesium carbonate (108 g, 0.33 mol) was added in one portion to a stirred solution of 3,5-dichlorophenol (49 g, 0.30 mol) in acetone (900 ml) at room temperature under nitrogen. To this suspension a solution of 1-bromo-2-butanone (30.6 ml, 0.30 mol) in acetone (300 ml) was added dropwise and the resultant suspension was heated under reflux for 2 hours. The suspension was cooled to room temperature, water (200 ml) was added and the acetone was removed under reduced pressure. The mixture was extracted with dichloromethane (2×300 ml) and the combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a clear oil. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:cyclohexane (50:50, by volume) to provide the title compound (65 g) as a yellow oil.

[0961]¹H-NMR (400 MHz, CDCl₃): δ=1.13 (t, 3H), 2.60 (q, 2H), 4.58 (s, 2H), 6.78 (s, 2H), 7.01 (s, 1H).

[0962] LRMS (thermospray): m/z [MNH₄ ⁺] 250.

[0963] Preparation 6

[0964] 2-(3,5-Dichlorophenoxy)-1-(dimethylamino)-1-penten-3-one

[0965] A solution of the ketone of Preparation 5 (65 g, 0.28 mol) in N,N-dimethylformamide dimethylacetal (75 ml, 0.56 mol) was heated at 100° C. using a Dean-Stark apparatus for 10 hours. The reaction was cooled and concentrated under reduced pressure to leave a brown oil. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (90:10, by volume) and then pentane:ethyl acetate (60:40, by volume) to provide the title compound (55 g) as a yellow oil that solidified upon standing. The resultant yellow solid was washed with pentane (100 ml) and dried to provide the title compound (28 g) as a yellow solid, m.p. 96-97° C.

[0966]¹H-NMR (400 MHz, CDCl₃): δ=0.98 (t, 3H), 2.30 (br s, 2H), 2.94 (s, 6H), 6.77 (s, 2H), 6.95 (s, 1H), 7.24 (s, 1H).

[0967] LRMS (thermospray): m/z [MNH₄ ⁺] 288.

[0968] Preparation 7

[0969] 1-Acetyl-4-(3,5-dichlorophenoxy)-3,5-dimethyl-1H-pyrazole

[0970] Sodium hydride (60% dispersion in oil, 684 mg, 17.1 mmol) was added to a stirred solution of acetyl chloride (1.21 ml, 17.1 mmol) and the pyrazole of Example 53 (4.00 g, 15.6 mmol) in N,N-dimethylformamide (20 ml) at 0° C. under nitrogen. The reaction was stirred at 0° C. for 1 hour and then quenched by the addition of water (100 ml). The aqueous extracted was with ether (2×50 ml). The combined organic phases were washed with water (30 ml) and brine (30 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a yellow solid. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ether (90:10, by volume) to provide the title compound (3.0 g) as a white solid, m.p. <60° C.

[0971]¹H-NMR (300 MHz, CDCl₃): δ=2.11 (s, 3H), 2.43 (s, 3H), 2.70 (s, 3H), 6.78 (s, 2H), 7.03 (s, 1H).

[0972] LRMS (thermospray): m/z [MH⁺] 299.

[0973] Preparation 8

[0974] 1-Acetyl-3-(bromomethyl)-4-(3,5-dichlorophenoxy)-5-methyl-1H-pyrazole

[0975] N-Bromosuccinimide (2.70 g, 15.0 mmol) was added to a stirred solution of the pyrazole of Preparation 7 (3.00 g, 10.0 mmol) in 1,1,1-trichloroethane (40 ml) at room temperature under nitrogen. The reaction was heated at 80° C. for 1 hour and then azobisisobutyronitrile (2 mg) was added and the reaction mixture was heated for a further 3 hours. The reaction was cooled to room temperature and a solid removed by filtration. The filtrate was concentrated under reduced pressure and the resulting yellow oil was dissolved in ethyl acetate (100 ml). The ethyl acetate was washed with 1 M aqueous sodium carbonate solution (30 ml), water (30 ml) and brine (30 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a yellow solid. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (90:10, by volume) to provide a yellow solid that was washed with ice cold ether (20 ml) to provide the title compound (2.3 g) as a white solid, m.p. 111-113° C.

[0976]¹H-NMR (300 MHz, CDCl₃): δ=2.10 (s, 3H), 2.73 (s, 3H), 4.73 (s, 2H), 6.86 (s, 2H), 7.11 (s, 1H).

[0977] LRMS (thermospray): m/z [MH⁺] 379.

[0978] Preparation 9

[0979] 4-(3-Cyanophenoxy)-3,5-heptanedione

[0980] A mixture of the β-diketone of Preparation 2 (1.79 g, 11.0 mmol), 3-cyanophenol (1.31 g, 11.0 mmol), cesium carbonate (3.58 g, 11.0 mmol) and acetone (44 ml) was heated under reflux for 2 hours. After cooling, the mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane (50 ml) and water (25 ml). The organic layer was separated, washed with brine (25 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a yellow oil. The crude product was purified by flash column chromatography on silica gel eluting with ethyl acetate:pentane (10:90, by volume) to provide the title compound (1.10 g) as a yellow oil.

[0981]¹H-NMR (400 MHz, CDCl₃): δ=1.04 (t, 6H), 2.49 (q, 4H), 7.16 (m, 2H), 7.30 (d, 1H), 7.39 (t, 2H), 14.51 (s, 1H).

[0982] LRMS (thermospray): m/z [MNH₄ ⁺] 263.

[0983] Preparation 10

[0984] tert-Butyl 3-(hydroxymethyl)-4-morpholinecarboxylate

[0985] Borane (38.1 ml of a 1.0M solution in tetrahydrofuran, 38.1 mmol) was added dropwise to a stirred suspension of 3-morpholinecarboxylic acid (1.00 g, 7.63 mmol) in tetrahydrofuran (50 ml) at room temperature under nitrogen. The reaction was heated under reflux and the reaction became homogeneous and heating was continued for 12 hours. The reaction was cooled to room temperature and concentrated under reduced pressure to leave a brown oil. The residue was dissolved in 1M aqueous sodium hydroxide solution and stirred at room temperature for 5 days. After this time di-tert-butyl dicarbonate (1.66 g, 7.63 mmol) was added and the reaction was stirred for 12 hours. The reaction was diluted with ether (100 ml). The organic layer was separated, washed with brine (10 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (50:50, by volume) and then ethyl acetate to provide the title compound (1.30 g) as a colourless oil.

[0986]¹H-NMR (400 MHz, CDCl₃): δ=1.48 (s, 9H), 2.05 (s, 1H), 3.19 (brt, 1H), 3.47 (td, 1H), 3.60 (dd, 1H), 3.87 (m, 6H).

[0987] LRMS (thermospray): m/z [MH⁺] 218.

[0988] Preparation 11

[0989] tert-Butyl 3-{[(methylsulfonyl)oxy]methyl}-4-morpholinecarboxylate

[0990] Triethylamine (1.15 ml, 8.29 mmol) was added dropwise to a stirred solution of the alcohol of Preparation 10 (1.20 g, 5.52 mmol) and methanesulfonic anhydride (1.44 g, 5.52 mmol) in dichloromethane (50 ml) at room temperature under nitrogen. The reaction was stirred for 1 hour and then poured onto water (50 ml). The organic layer was separated, dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (50:50, by volume) to provide the title compound (1.20 g) as a colourless oil.

[0991]¹H-NMR (400 MHz, CDCl₃): δ=1.49 (s, 9H), 3.06 (s, 3H), 3.50 (td, 1H), 3.60 (dd, 1H), 3.80 (m, 4H), 4.26 (br s, 1H), 4.39 (m, 2H).

[0992] LRMS (thermospray): m/z [MNH₄ ⁺] 313.

[0993] Preparation 12

[0994] Methyl-2-(3,5-dichlorophenoxy)-3-oxopentanoate

[0995] A mixture of methyl-2-chloro-3-pentanoate (25.0 g, 152 mmol), 3,5-dichlorophenol (24.6 g, 152 mmol), cesium carbonate (54.4 g, 167 mmol) and acetone (500 ml) was heated under reflux for 2 hours. After cooling the mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane (100 ml) and water (50 ml). The organic layer was separated, washed with brine (25 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave an orange oil. The crude product was purified by flash column chromatography on silica gel eluting with pentane:toluene (90:10, by volume) to provide the title compound (40.0 g) as a pink oil.

[0996]¹H-NMR (300 MHz, CDCl₃): δ=1.16 (t, 3H), 2.60 (m, 2H), 3.77 (s, 3H), 5.13 (s, 1H), 6.84 (s, 2H), 7.10 (s, 1H).

[0997] LRMS (thermospray): m/z [MNH₄ ⁺] 308.

[0998] Preparation 13

[0999] 4-(3,5-Dichlorophenoxy)-5-ethyl-2-(2-hydroxyethyl)-2,4-dihydro-3H-pyrazol-3-one

[1000] A solution of 2-hydroxyethylhydrazine (4.30 g, 56.7 mmol) in glacial acetic acid (2.0 ml) was added to a stirred solution of the ketoester of Preparation 12 (15.0 g, 51.5 mol) in glacial acetic acid (100 ml) and the resulting solution was stirred at room temperature for 48 hours. The mixture was concentrated under reduced pressure and the crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol (95:5, by volume) to provide the title compound (10.1 g) as a colourless oil.

[1001]¹H-NMR (400 MHz, CDCl₃): δ=1.02 (t, 3H), 2.29 (m, 2H), 3.63 (m, 2H), 3.80 (m, 2H), 6.92 (s, 2H), 7.21 (s, 1H).

[1002] LRMS (thermospray): m/z [MH⁺] 317.

[1003] Microanalysis: Found: C, 48.86; H, 4.44; N, 9.01. C₁₃H₁₄N₂O₃CO₂ requires C, 49.23; H, 4.45; N, 8.83%.

[1004] Preparation 14

[1005] 2-(2-{[tert-Butyl(dimethyl)silyl]oxy}ethyl)-4-(3,5-dichlorophenoxy)-5-ethyl-2,4-dihydro-3H-pyrazol-3-one

[1006] tert-Butyidimethylsilyl chloride (8.14 g, 54.0 mmol) was added in one portion to a stirred solution of the pyrazole of Preparation 13 (14.3 g, 45.0 mmol) and imidazole (3.98 g, 58.5 mmol) in N,N-dimethylformamide (90 ml) and the resulting solution was stirred at room temperature for 48 hours. The mixture was partitioned between ethyl acetate (100 ml) and water (300 ml). The organic layer was separated, dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol (95:5, by volume) to provide the title compound (9.56 g) as a colourless oil.

[1007]¹H-NMR (400 MHz, CDCl₃): δ=0.15 (s, 6H), 0.94 (s, 9H), 1.16 (t, 3H), 2.45 (m, 2H), 3.94 (m, 4H), 6.85 (s, 2H), 6.97 (s, 1H).

[1008] LRMS (thermospray): m/z [MH⁺] 431.

[1009] Microanalysis: Found: C, 52.87; H, 6.52; N, 6.46. C₁₉H₂₈N₂O₃Cl₂Si requires C, 52.90; H, 6.54; N, 6.49%.

[1010] Preparation 15

[1011] 1-(2-{[tert-Butyl(dimethyl)silyl]oxy}ethyl)-4-(3,5-dichlorophenoxy-3-ethyl-1H-pyrazol-5-yl trifluoromethanesulfonate

[1012] Phenyltriflamide (3.70 g, 10.5 mmol) was added in one portion to a stirred solution of the pyrazole of Preparation 14 (4.10 g, 9.50 mmol) and triethylamine (1.60 ml, 11.4 mmol) in dichloromethane (20 ml) at room temperature under nitrogen. The reaction was stirred for 2 hours and then poured onto water (50 ml). The organic layer was separated, dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane to provide the title compound (5.10 g) as a purple oil.

[1013]¹H-NMR (300 MHz, CDCl₃): δ=0.01 (s, 6H), 0.86 (s, 9H), 1.17 (t, 3H), 2.45 (q, 2H), 4.01 (m, 2H), 4.14 (m, 2H), 6.84 (s, 2H), 7.08 (s, 1H).

[1014] LRMS (thermospray): m/z [MH⁺] 563.

[1015] Preparation 16

[1016] 3-(1-Acetyl-2-oxopropoxy)-5-chlorobenzonitrile

[1017] A mixture of 3-chloro-2,4-pentanedione (6.73 g, 50.0 mmol), the phenol of Preparation 36 (7.67 g, 50.0 mmol), cesium carbonate (18.0 g, 55.4 mmol) and acetone (40 ml) was heated under reflux for 2 hours. The reaction was cooled to room temperature, N,N-dimethylformamide (6 ml) and acetone (30 ml) were added and the reaction was heated at 70° C. for a further 12 hours. After cooling, the solid was removed by filtration and dissolved in 1M aqueous hydrochloric acid (150 ml). The resulting solution was extracted with dichloromethane (3×100 ml) and the combined organic phases were washed with brine (30 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to provide the title compound (5.50 g) as a brown solid, m.p. 105-108° C.

[1018]¹H-NMR (300 MHz, CDCl₃): δ=2.04 (s, 6H), 7.13 (s, 1H), 7.19 (s, 1H), 7.35 (s, 1H), 14.40 (s, 1H).

[1019] Preparation 17

[1020] 3-[(1-Acetyl-3,5-dimethyl-1H-pyrazol-4-yl)oxy]-5-chlorobenzonitrile

[1021] Sodium hydride (60% dispersion in oil, 840 mg, 21.0 mmol) was added to a stirred solution of acetyl chloride (1.50 ml, 21.0 mmol) and the pyrazole of Example 76 (4.80 g, 19.4 mmol) in N,N-dimethylformamide (20 ml) at 0° C. under nitrogen. The reaction was stirred at 0° C. for 15 minutes and then quenched by the addition of water (200 ml). The reaction mixture was extracted with ethyl acetate (3×120 ml). The combined organic phases were washed with water (50 ml) and brine (50 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a yellow solid. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane to provide the title compound (5.00 g) as a white solid, m.p. <60° C.

[1022]¹H-NMR (400 MHz, CDCl₃): δ=2.06 (s, 3H), 2.38 (s, 3H), 2.65 (s, 3H), 6.99 (m, 1H), 7.08 (m, 1H), 7.29 (m, 1H).

[1023] LRMS (thermospray): m/z [MH⁺] 290.

[1024] Preparation 18

[1025] 3-{[1-Acetyl-3-(bromomethyl)-5-methyl-1H-pyrazol-4-yl]oxy}-5-chlorobenzonitrile

[1026] N-Bromosuccinimide (4.60 g, 25.6 mmol) was added to a stirred solution of the pyrazole of Preparation 17 (5.00 g, 17.3 mmol) in 1,1,1-trichloroethane (70 ml) and azobisisobutyronitrile (20 mg) at room temperature under nitrogen. The reaction was heated at 80° C. for 3 hours and then cooled to room temperature. A second portion of N-bromosuccinimide (2.00 g, 11.2 mmol) was added and the reaction mixture was heated at 80° C. for a further 4 hours. The reaction was cooled to room temperature and concentrated under reduced pressure and the resulting yellow oil was purified by flash column chromatography on silica gel eluting with pentane:dichloromethane (25:75, by volume) to provide the title compound (2.30 g) as a white solid, m.p. 122-123° C.

[1027]¹H-NMR (300 MHz, CDCl₃): δ=2.10 (s, 3H), 2.74 (s, 3H), 4.73 (s, 2H), 7.12 (s, 1H), 7.22 (s, 1H), 7.39 (s, 1H).

[1028] Preparation 19

[1029] 3-Chloro-5,5-dimethyl-2,4-hexanedione

[1030] Chlorotrimethylsilane (26.8 ml, 0.21 mol) was added dropwise to a stirred pale yellow solution of tetrabutylammonium bromide (1.13 g, 3.50 mmol) in dry acetonitrile (100 ml) at room temperature under nitrogen. The resulting solution was cooled in ice and 5,5-dimethylhexane-2,4-dione (10.0 g, 70.4 mmol) and then dry dimethylsulphoxide (14.7 ml, 0.21 mol) were added dropwise over 5 minutes producing a yellow solution which was allowed to warm slowly to room temperature with stirring over 3 hours. The mixture was diluted with water (1000 ml) and stirred for 10 min and then extracted with ether (1×500 ml, 2×250 ml). The combined ether layers were dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a yellow oil. The crude product was purified by distillation under reduced pressure to provide the title compound (10.0 g) as a pale yellow oil, b.p. 220-225° C./60 mmHg.

[1031]¹H-NMR (400 MHz, CDCl₃): δ=1.25 (s, 9H), 2.39 (s, 3H), 5.10 (s, 1H).

[1032] LRMS (thermospray): m/z [MNH₄ ⁺] 194.

[1033] Preparation 20

[1034] 4-[(Methylamino)methyl]benzonitrile

[1035] 4-Cyanobenzaldehyde (12.0 g, 92.0 mmol), methylamine (69 ml of a 2.0M solution in tetrahydrofuran, 137 mmol) and magnesium sulphate (45 g) were stirred in dichloromethane (300 ml) at room temperature for 5 days. The mixture was filtered and the filtrate was concentrated under reduced pressure to leave a yellow oil. The oil was dissolved in methanol (200 ml) and sodium borohydride (4.10 g, 109 mmol) was added cautiously with vigorous stirring. Once the addition was complete the reaction was stirred for 1 hour and the mixture was concentrated under reduced pressure. The residue was dissolved in 1M aqueous sodium hydroxide solution (200 ml) and the mixture was stirred at room temperature for 1 hour. The resulting solution was extracted with dichloromethane (2×200 ml) and the combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure to provide the title compound (13.4 g) as a pale yellow oil.

[1036]¹H-NMR (300 MHz, CDCl₃): δ=1.46 (s, 1H), 2.46 (s, 3H), 3.82 (s, 2H), 7.47 (d, 2H), 7.64 (d, 2H).

[1037] LRMS (electrospray): m/z [MH⁺] 147.

[1038] Preparation 21

[1039] 4-{[(2-Hydroxyethyl)amino]methyl}benzonitrile

[1040] A mixture of 4-Cyanobenzaldehyde (14.1 g, 107 mmol), ethanolamine (6.56 g, 107 mmol) and toluene (100 ml) was heated under reflux for 14 hours using a Dean-Stark apparatus to remove water. The reaction was cooled to room temperature and concentrated under reduced pressure to leave a yellow oil. The oil was dissolved in dichloromethane (200 ml), cooled to 0° C. and triethylamine (16.3 ml, 117 mmol) and chlorotrimethylsilane (14.9 ml, 117 mmol) were added dropwise. A white precipitate formed and after stirring for 1 hour the mixture was filtered. The filtrate was concentrated under reduced pressure to leave an orange solid (25.0 g). The orange solid was dissolved in methanol (200 ml) and sodium borohydride (4.50 g, 122 mmol) was added cautiously with vigorous stirring. Once the addition was complete the reaction was stirred for 1 hour and the mixture was then concentrated under reduced pressure. The residue was dissolved in 1M aqueous sodium hydroxide solution (200 ml) and the mixture was stirred at room temperature for 1 hour. The resulting solution was extracted with dichloromethane (3×200 ml) and the combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (12.0 g) as a pale yellow oil which solidified on standing to leave a yellow solid, m.p. <60° C.

[1041]¹H-NMR (300 MHz, CDCl₃): δ=1.84 (s, 2H), 2.84 (t, 2H), 3.68 (t, 2H), 3.89 (s, 2H), 7.45 (d, 2H), 7.65 (d, 2H).

[1042] LRMS (thermospray): m/z [MH⁺] 177.

[1043] Preparation 22

[1044] N-{[1-(2-{[tert-Butyl(dimethyl)silyl]oxy}ethyl)-4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}-N-(3-pyridinylmethyl)amine

[1045] 3-(Methylamino)pyridine (327 mg, 3.04 mmol) was added in one portion to a stirred solution of the bromide of Preparation 28 (300 mg, 0.610 mmol) in isopropanol (5 ml) at room temperature. The mixture was heated at 50° C. for 1 hour, cooled to room temperature and concentrated under reduced pressure to leave an orange oil. The crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:4:1, by volume) to provide the title compound (50 mg) as a colourless oil.

[1046]¹H-NMR (400 MHz, CDCl₃): δ=0.15 (s, 6H), 0.77 (s, 9H), 2.02 (s, 3H), 3.64 (s, 2H), 3.70 (s, 2H), 3.95 (t, 2H), 4.17 (t, 2H), 6.75 (s, 2H), 6.97 (s, 1H), 7.15 (dd, 1H), 7.53 (d, 1H), 8.47 (m, 2H).

[1047] LRMS (thermospray): m/z [MH⁺] 521.

[1048] Preparation 23

[1049] 3-Chloro-5-methyl-2,4-hexanedione

[1050] Chlorotrimethylsilane (13.4 ml, 105 mmol) was added dropwise to a stirred pale yellow solution of tetrabutylammonium iodide (566 mg, 1.53 mmol) in dry acetonitrile (100 ml) at room temperature under nitrogen. The resulting solution was cooled in ice and 5-methylhexane-2,4-dione (4.50 g, 35.1 mmol) and then dry dimethylsulphoxide (7.47 ml, 105 mmol) were added dropwise over 5 minutes producing a yellow solution which was allowed to warm slowly to room temperature with stirring over 1 hour. Tetrabutylammonium bromide (566 mg, 1.75 mmol) was then added in one portion and the reaction was stirred at room temperature for 2 hours. The mixture was diluted with water (200 ml), stirred for 10 min and then extracted with ether (3×100 ml). The combined ether layers were dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a yellow oil. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (98:2, by volume) to provide the title compound (2.00 g) as a colourless oil.

[1051]¹H-NMR (400 MHz, CDCl₃): δ=1.15 (d, 6H), 2.29 (s, 3H), 3.25 (sept, 1H), 15.60 (s, 1H).

[1052] LRMS (thermospray): m/z [MNH₄ ⁺] 180.

[1053] Preparation 24

[1054] 5-(1-Acetyl-3-methyl-2-oxobutoxy)isophthalonitrile

[1055] A mixture of the dione of Preparation 23 (1.12 g, 6.94 mmol), the phenol of Preparation 39 (1.00 g, 6.94 mmol), cesium carbonate (2.25 g, 6.94 mmol) and acetone (30 ml) was heated under reflux for 4 hours. The reaction was cooled to room temperature and concentrated under reduced pressure to leave a brown solid. The solid was dissolved in 1M aqueous hydrochloric acid (50 ml) and the solution was extracted with dichloromethane (3×30 ml). The combined organic phases were washed with brine (30 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with pentane:ethyl acetate (90:10, by volume) to provide the title compound (580 mg) as a yellow solid.

[1056]¹H-NMR (300 MHz, CDCl₃): =1.08 (d, 6H), 2.02 (s, 3H), 2.24 (sept, 1H), 7.47 (s, 2H), 7.63 (s, 1H), 14.71 (s, 1H).

[1057] LRMS (electrospray): m/z [M−H⁺] 269.

[1058] Preparation 25

[1059] 5-{[1-(2-{[tert-Butyl(dimethyl)silyl]oxy}ethyl)-3-isopropyl-5-methyl-1H-pyrazol-4-yl]oxy}isophthalonitrile

[1060] Sodium hydride (60% dispersion in oil, 45 mg, 1.12 mmol) was added to a stirred solution of 2-bromoethoxy-t-butyldimethylsilane (270 mg, 1.12 mmol) and the pyrazole of Example 95 (250 mg, 0.930 mmol) in N,N-dimethylformamide (5 ml) at 0° C. under nitrogen. The reaction was warmed to room temperature and stirred for 12 hours. The reaction mixture was quenched by the addition of water (50 ml) and the aqueous phase was extracted with ethyl acetate (3×30 ml). The combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure to leave a brown oil. The crude product was purified by flash column chromatography on silica gel eluting pentane:ethyl acetate (80:20, by volume) to provide the title compound (60 mg) as a colourless oil.

[1061]¹H-NMR (400 MHz, CDCl₃): δ=0.02 (s, 6H), 0.85 (s, 9H), 1.19 (d, 6H), 2.09 (s, 3H), 2.79 (sept, 1H), 3.99 (m, 2H), 4.10 (m, 2H), 7.39 (s, 2H), 7.57 (s, 1H).

[1062] LRMS (electrospray): m/z [MH⁺] 425.

[1063] Preparation 26

[1064] di(tert-Butyl) 2-[4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-1-yl]ethylimidodicarbonate and di(tert-butyl) 2-[4-(3,5-dichlorophenoxy)-5-ethyl-1H-pyrazol-1-yl]ethylimidodicarbonate

[1065] Di-t-butyldicarbonate (14.0 g, 64.2 mmol) and 4,4-dimethylaminopyridine (630 mg, 5.14 mmol) were added portionwise to a stirred solution of the amines of Example 283 (7.72 g, 25.7 mmol) in acetonitrile (128 ml) at room temperature under nitrogen. The reaction was stirred for 14 hours and concentrated under reduced pressure. A solution of the residue in dichloromethane (300 ml) was washed with water (100 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (99:1, by volume) to afford the title compounds (12.3 g) in a 85:15 ratio of regioisomers as a colourless oil.

[1066]¹H-NMR (400 MHz, CDCl₃): δ=1.15 (major, t, 3H), 1.15 (minor, t, 3H), 1.52 (major, s, 18H), 1.52 (minor, s, 18H), 2.47 (major, q, 2H), 2.56 (minor, q, 2H), 4.00 (major, t, 2H), 4.00 (minor, t, 2H), 4.24 (major, t, 2H), 4.24 (minor, t, 2H), 6.85 (major, s, 2H), 6.85 (minor, s, 2H), 7.00 (major, s, 1H), 7.00 (minor, s, 1H), 7.21 (major, s, 1H), 7.25 (minor, s, 1H).

[1067] LRMS (thermospray): m/z [MH⁺] 500.

[1068] Microanalysis: Found: C, 54.94; H, 6.26; N, 8.27. C₂₃H₃₁Cl₂N₃O₅ requires C, 55.20; H, 6.24; N, 8.40%.

[1069] Preparation 27

[1070] 1-(2-{[tert-Butyl(dimethyl)silyl]oxy}ethyl)-4-(3,5-dichlorophenoxy)-3,5-dimethyl-1H-pyrazole

[1071] Chloro-t-butyldimethylsilane (1.93 g, 12.8 mmol) was added in one portion to a stirred solution of the pyrazole of Example 1 (3.50 g, 11.6 mmol) and imidazole (1.03 g, 15.1 mmol) in N,N-dimethylformamide (23 ml) at room temperature under nitrogen. The reaction was stirred for 2 days and water (200 ml) was added. The aqueous phase was extracted with diethyl ether (3×200 ml) and the combined organic phases were washed with water (2×50 ml) and brine (2×50 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (80:20, by volume) to provide the title compound (4.82 g) as a colourless oil.

[1072]¹H-NMR (400 MHz, CDCl₃): δ=0.09 (s, 6H), 0.78 (s, 9H), 2.01 (s, 3H), 2.05 (s, 3H), 3.88 (q, 2H), 4.02 (q, 2H), 6.76 (s, 2H), 6.88 (s, 1H).

[1073] LRMS (thermospray): m/z [MH⁺] 415.

[1074] Preparation 28

[1075] 5-(Bromomethyl)-1-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazole

[1076] N-Bromosuccinimide (640 mg, 3.60 mmol) was added to a stirred solution of the pyrazole of Preparation 27 (1.00 g, 2.40 mmol) in carbon tetrachloride (15 ml) and azobisisobutyronitrile (20 mg) at room temperature under nitrogen. The reaction was heated under reflux for 5 hours then cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure and the crude product was purified by flash column chromatography on silica gel eluting with dichloromethane:methanol:ammonia (97:2.5:0.5, by volume) to provide the title compound (300 mg) as a colourless oil.

[1077]¹H-NMR (300 MHz, CDCl₃): δ=0.04 (s, 6H), 0.82 (s, 9H), 2.02 (s, 3H), 3.96 (m, 2H), 4.22 (m, 2H), 4.41 (s, 2H), 6.81 (s, 2H), 7.01 (s, 1H).

[1078] LRMS (thermospray): m/z [MH⁺] 495.

[1079] Preparation 29

[1080] 3-{[1-(2-{[tert-Butyl(dimethyl)silyl]oxy}ethyl)-3,5-dimethyl-1H-pyrazol-4-yl]oxy}-5-chlorobenzonitrile

[1081] Chloro-t-butyldimethylsilane (2.78 g, 18.5 mmol) was added in one portion to a stirred solution of the pyrazole of Example 114 (4.89 g, 16.8 mmol) and imidazole (1.48 g, 21.8 mmol) in N,N-dimethylformamide (30 ml) at room temperature under nitrogen. The reaction was stirred for 3 days and water (200 ml) was added. The aqueous phase was extracted with diethyl ether (3×200 ml) and the combined organic phases were washed with water (2×50 ml) and brine (2×50 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with dichloromethane to provide the title compound (5.60 g) as a yellow oil.

[1082]¹H-NMR (400 MHz, CDCl₃): 6 =-0.02 (s, 6H), 0.82 (s, 9H), 2.02 (s, 3H), 2.12 (s, 3H), 3.97 (q, 2H), 4.06 (m, 2H), 7.02 (s, 1H), 7.11 (s, 1H), 7.24 (s, 1H).

[1083] LRMS (thermospray): m/z [MH⁺] 408.

[1084] Microanalysis: Found: C, 58.95; H, 6.96; N, 10.22. C₂₀H₂₈N₃O₂ClSi requires C, 59.13; H, 6.95; N, 10.35%.

[1085] Preparation 30

[1086] 3-{[5-(Bromomethyl)-1-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-3-methyl-1H-pyrazol-4-yl]oxy}-5-chlorobenzonitrile

[1087] N-Bromosuccinimide (2.44 g, 13.7 mmol) was added to a stirred solution of the pyrazole of Preparation 29 (5,56 g, 13.7 mmol) in carbon tetrachloride (50 ml) and azobisisobutyronitrile (20 mg) at room temperature under nitrogen. The reaction was heated under reflux for 1 hour, cooled to room temperature and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with pentane:dichloromethane acetate (75:25, by volume) to provide the title compound (3.00 g) as a colourless oil.

[1088]¹H-NMR (300 MHz, CDCl₃): 6-0.02 (s, 6H), 0.83 (s, 9H), 2.04 (s, 3H), 3.97 (q, 2H), 4.25 (m, 2H), 4.43 (s, 2H), 7.09 (s, 1H), 7.18 (s, 1H), 7.33 (s, 1H).

[1089] LRMS (thermospray): m/z [MH⁺] 486.

[1090] Preparation 31

[1091] 3-{[5-(Aminomethyl)-1-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)-3-methyl-1H-pyrazol-4-yl]oxy}-5-chlorobenzonitrile

[1092] The bromide of Preparation 30 (1.58 g, 3.26 mmol) was added to a saturated solution of ammonia in isopropanol (50 ml) at 0° C. The reaction was stirred for 6 hours and allowed to slowly warm to room temperature. The mixture was concentrated under reduced pressure and the resulting yellow oil was dissolved in dichloromethane (50 ml). The solution was washed with 1M aqueous sodium carbonate solution (2×20 ml) and brine (20 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to provide the title compound (1.00 g) as a yellow oil.

[1093]¹H-NMR (300 MHz, CDCl₃): 6 =-0.23 (s, 6H), 0.62 (s, 9H), 1.22 (s, 2H), 1.82 (s, 3H), 2.56 (s, 2H), 3.78 (m, 2H), 4.02 (m, 2H), 6.85 (s, 1H), 6.96 (s, 1H), 7.06 (s, 1H).

[1094] LRMS (thermospray): m/z [MH⁺] 421.

[1095] Preparation 32

[1096] 1-Bromo-3-chloro-5-methoxybenzene

[1097] Sodium methoxide (2.20 ml of a 4.5M solution in methanol, 10.0 mmol) was added dropwise to a stirred solution of 1-fluoro-3-chloro-5-bromobenzene (1.00 g, 4.77 mmol) in methanol (28 ml) at room temperature under nitrogen. The reaction was heated under reflux for 3 days and cooled to room temperature. The mixture was concentrated under reduced pressure and the resulting yellow oil was dissolved in dichloromethane (30 ml). The resulting solution was washed with water (2×20 ml) dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel eluting with cyclohexane to provide the title compound (302 mg) as a colourless oil.

[1098]¹H-NMR (400 MHz, CDCl₃): δ=3.77 (s, 3H), 6.82 (s, 1H), 6.94 (s, 1H), 7.09 (s, 1H).

[1099] Microanalysis: Found: C, 37.94; H, 2.75. C₇H₆BrClO requires C, 37.96; H, 2.73%.

[1100] Preparation 33

[1101] 3-Fluoro-5-methoxybenzonitrile

[1102] Sodium methoxide (1.50 ml of a 4.5M solution in methanol, 7.10 mmol) was added dropwise to a stirred solution of 3,5-difluorobenzonitrile (1.00 g, 7.10 mmol) in N,N-dimethylformamide (36 ml) at 0° C. under nitrogen. The reaction was allowed to warm to room temperature and stirred for 14 hours. The reaction was diluted with ether (40 ml), washed with water (3×100 ml) and brine (100 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with cyclohexane:ethyl acetate (95:5, by volume) to provide the title compound (418 mg) as a yellow oil.

[1103]¹H-NMR (400 MHz, CDCl₃): δ=3.84 (s, 3H), 6.82 (dd, 1H), 6.95 (dd, 1H), 6.96 (s, 1H).

[1104] LRMS (thermospray): m/z [MNH₄ ⁺] 169.

[1105] Microanalysis: Found: C, 63.46; H, 3.95; N, 9.14. C₈H₆NOF requires C, 63.58; H, 4.00; N, 9.27%.

[1106] Preparation 34

[1107] 3-Fluoro-5-hydroxybenzonitrile

[1108] Boron trichloride (1.65 ml of a 1.0M solution in dichloromethane, 1.65 mmol) was added dropwise to a stirred solution of the nitrile of Preparation 33 (100 mg, 0.660 mmol) and tetrabutylammonium iodide (268 mg, 0.728 mmol) in dichloromethane (3 ml) at −78° C. The reaction was allowed to warm 0° C., stirred for 2 hours and then allowed to warm to room temperature and stirred for 14 hours. The reaction was cooled to 0° C., cautiously quenched with ice and then concentrated under reduced pressure. The residue was dissolved in ether (40 ml) and the resulting solution was washed with water (3×40 ml) and brine (40 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with cyclohexane:ethyl acetate (90:10, by volume) to provide the title compound (50 mg) as a white solid, m.p. 138-139° C.

[1109]¹H-NMR (300 MHz, CDCl₃): δ=5.81 (s, 1H), 6.80 (dd, 1H), 6.94 (dd, 1H), 6.95 (s, 1H).

[1110] Microanalysis: Found: C, 60.99; H, 3.01; N, 10.16. C₇H₄NOF requires C, 61.32; H, 2.94; N, 10.22%.

[1111] Preparation 35

[1112] 3-Chloro-5-methoxybenzonitrile

[1113] Palladiumtetrakis(triphenylphosphine) (174 mg, 0.150 mmol) was added in one portion to a stirred solution of the bromide of Preparation 32 (500 mg, 2.26 mmol) and zinc cyanide (146 mg, 1.24 mmol) in N,N-dimethylformamide (3 ml) at room temperature under nitrogen. The reaction was heated at 100° C. for 14 hours and cooled to room temperature. The mixture was concentrated under reduced pressure and the crude product was purified by flash chromatography on silica gel eluting with cyclohexane:ethyl acetate (95:5, by volume) to provide the title compound (380 mg) as a yellow oil.

[1114]¹H-NMR (300 MHz, CDCl₃): δ=3.82 (3H, s), 7.04 (s, 1H), 7.12 (s, 1H), 7.23 (s, 1H).

[1115] Microanalysis: Found: C, 57.50; H, 3.63; N, 8.16. C₈H₆NOCl requires C, 57.33; H, 3.61; N, 8.36%.

[1116] Preparation 36

[1117] 3-Chloro-5-hydroxybenzonitrile

[1118] Boron trichloride (26.0 ml of a 1.0M solution in dichloromethane, 26.0 mmol) was added dropwise to a stirred solution of the nitrile of Preparation 35 (1.80 g, 10.0 mmol) and tetrabutylammonium iodide (4.36 g, 11.0 mmol) in dichloromethane (50 ml) at −78° C. The reaction was allowed to warm to room temperature and stirred for 14 hours. The reaction was cooled to 0° C., cautiously quenched with ice and diluted with dichloromethane (100 ml). The organic phase was washed with water (3×40 ml) and brine (40 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with cyclohexane:ethyl acetate (80:20, by volume) to provide the title compound (900 mg) as a white solid.

[1119]¹H-NMR (400 MHz, d₆DMSO): δ=7.12 (m, 2H), 7.38 (s, 1H), 10.65 (s, 1H).

[1120] Microanalysis: Found: C, 54.76; H, 2.81; N, 8.94. C₇H₄NOCl requires C, 54.75; H, 2.63; N, 9.12%.

[1121] Preparation 37

[1122] 1,3-Dibromo-5-methoxybenzene

[1123] Sodium methoxide (8.80 ml of a 4.5M solution in methanol, 41.0 mmol) was added dropwise to a stirred solution of 3,5-dibromofluorobenzene (5.00 g, 19.0 mmol) in N,N-dimethylformamide (95 ml) at 0° C. under nitrogen. The reaction was allowed to warm to room temperature, stirred for 1 hour and then concentrated under reduced pressure. The residue was dissolved in ether and the resulting solution was washed with water (3×300 ml) and brine (300 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to provide the title compound (5.13 g) as a white solid.

[1124]¹H-NMR (300 MHz, CDCl₃): δ=3.79 (S, 3H), 7.00 (s, 2H), 7.26 (s, 1H).

[1125] LRMS (thermospray): m/z [MH⁺] 266.

[1126] Microanalysis: Found: C, 31.56; H, 2.29. C₇H₆OBr₂ requires C, 31.62; H, 2.27%.

[1127] Preparation 38

[1128] 3,5-Dicyanomethoxybenzene

[1129] Tris(dibenzylideneacetone)dipalladium (6.53 g, 7.15 mmol) was added in one portion to a stirred solution of the bromide of Preparation 37 (38.0 g, 143 mmol) and zinc cyanide (20.0 g, 172 mmol) in N,N-dimethylformamide (300 ml) at room temperature under nitrogen. The reaction was heated at 100° C. for 14 hours and cooled to room temperature. Water (1500 ml) was added and the mixture was extracted with ethyl acetate (3×500 ml). The combined organics were filtered and the filtrate was washed with water (500 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure. The resulting solid was triturated with toluene (1000 ml) to provide the title compound (18.0 g) as a tan solid.

[1130]¹H-NMR (300 MHz, CDCl₃): δ=3.83 (3H, s), 7.31 (2H, s), 7.48 (1H, s).

[1131] Preparation 39

[1132] 3,5-Dicyanohydroxybenzene

[1133] The nitrile of Preparation 38 (9.60 g, 60.7 mmol) was added portionwise to a stirred suspension of aluminium trichloride (32.4 g, 243 mmol) in dichloromethane (250 ml) at 0° C. under nitrogen. The suspension was heated to 45° C. and stirred for 6 days. The reaction was cooled to room temperature and cautiously poured onto ice (450 ml). Concentrated hydrochloric acid (450 ml) was added dropwise and the resulting suspension was stirred for 10 minutes at room temperature. The resulting solid was collected by filtration, washed with water and dried over phosphorus pentoxide to provide the title compound (7.83 g) as a tan solid containing approximately 11% starting material by ¹H-NMR and microanalysis.

[1134]¹H-NMR (400 MHz, CDCl₃): δ=7.36 (m, 2H), 7.56 (m, 1H).

[1135] Preparation 40

[1136] 3-Methoxy-5-methylphenyl trifluoromethanesulfonate

[1137] Trifluoromethanesulphonic anhydride (2.02 ml, 12.0 mmol) was added dropwise to a stirred solution of 3-methoxy-5-methylphenol (1.50 g, 10.9 mmol) in pyridine (20 ml) at −20° C. under nitrogen. The reaction was warmed to 0° C., stirred for 90 minutes and re-cooled to −20° C. More trifluoromethanesulphonic anhydride (1.01 ml, 6.00 mmol) was added dropwise. The reaction was allowed to warm to room temperature, stirred for 14 hours and cautiously poured into water (100 ml). The aqueous phase was extracted with ether (150 ml) and the organic phases were washed with water (3×75 ml), 0.2M hydrochloric acid (3×75 ml), 1.0M aqueous sodium carbonate solution (2×75 ml), water (75 ml) and brine (75 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to provide the title compound (2.86 g) as a pale brown oil.

[1138]¹H-NMR (400 MHz, CDCl₃): δ=2.35 (s, 3H), 3.80 (s, 3H), 6.60 (s, 1H), 6.68 (s, 1H), 6.73 (s, 1H).

[1139] Preparation 41

[1140] 3-Methoxy-5-methylbenzonitrile

[1141] The triflate of Preparation 40 (1.94 g, 7.10 mmol), dibromobis(triphenylphosphine)nickel (369 mg, 0.490 mmol), 1,1′bis(diphenylphosphino)ferrocene (331 mg, 0.590 mmol) and potassium cyanide (1.38 g, 21.3 mmol) were added consecutively to a stirred suspension of Rieke® zinc (supplied by the Aldrich chemical company as a suspension; 5 g Zinc in 100 ml tetrahydrofuran) (74 mg, 1.14 mmol) in acetonitrile (4 ml) at room temperature. The reaction was heated to 75° C. for 8 hours and then cooled to room temperature. The mixture was partitioned between ether (200 ml) and water (150 ml) and the organic phase was separated, washed with water (2×100 ml) and brine (75 ml), dried over magnesium sulphate, filtered and concentrated under reduced pressure to give a pale brown oil. The crude product was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (85:15, by volume) to provide the title compound (815 mg) as a white solid.

[1142]¹H-NMR (400 MHz, CDCl₃): δ=2.34 (s, 3H), 3.80 (s, 3H), 6.93 (s, 1H), 6.94 (s, 1H), 7.04 (s, 1H).

[1143] Preparation 42

[1144] 3-Hydroxy-5-methylbenzonitrile

[1145] Boron trichloride (17.6 ml of a 1.0M solution in dichloromethane, 17.6 mmol) was added dropwise to a stirred solution of the nitrile of Preparation 41 (866 mg, 5.88 mmol) and tetrabutylammonium iodide (2.61 g, 7.05 mmol) in dichloromethane (50 ml) at −78° C. The reaction was allowed to warm to room temperature and stirred for 20 minutes. The reaction was cooled to 0° C., cautiously quenched with ice and diluted with dichloromethane (100 ml). The organic phase was separated, dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (50:50, by volume) to provide the title compound (677 mg) as a white solid.

[1146]¹H-NMR (400 MHz, CDCl₃): δ=2.32 (s, 3H), 5.05 (s, 1H), 6.88 (s, 1H), 6.90 (s, 1H), 7.04 (s, 1H).

[1147] Preparations 43 to 46

[1148] The compounds of the following tabulated Preparations of the general formula:

[1149] were prepared by a similar method to that of Preparation 9 using the appropriate phenol starting material and the chloride of Preparation 2. Preparation No. (Phenol No.) R LRMS Analytical Data 43 F m/z [MNH₄ ⁺] 281. ¹H-NMR(300 MHz, (Phenol (thermospray) CDCl₃): δ = 1.05(t, 6H), Preparation 34) 2.27(q, 4H), 6.89(m, 1H), 7.03(s, 1H), 7.04(m, 1H). 44 Me m/z [M − H⁺] 258. ¹H-NMR(400 MHz, (Phenol (electrospray) CDCl₃): δ = 1.09(t, 6H), Preparation 42) 2.32(q, 4H), 2.37(s, 3H), 6.96(s, 1H), 6.97(s, 1H), 7.15(s, 1H), 14.50(s, 1H). 45 CN m/z [M − H⁺] 269. ¹H-NMR(300 MHz, (Phenol (electrospray) CDCl₃): δ = 1.09(m, 6H), Preparation 39) 2.30(m, 4H), 7.42(s, 2H), 7.61(s, 1H), 14.56(s, 1H). 46 Cl m/z [MH⁺] 280. ¹H-NMR(400 MHz, (Phenol (thermospray) CDCl₃): δ = 1.08(m, 6H), Preparation 36) 2.31(q, 4H), 7.12(s, 1H), 7.19(s, 1H), 7.31(s, 1H).

[1150] Preparation 47

[1151] 1-Cyclopropyl-1,3-pentanedione

[1152] A stirred suspension of magnesium turnings (1.83 g, 75.0 mmol) in methanol (85 ml) was heated under reflux for 90 minutes. The suspension was cooled to room temperature and a solution of 3-ketopentanoic acid (17.4 g, 150.0 mmol) in methanol (15 ml) was added. The white suspension dissolved to give a pale yellow solution. The reaction was stirred at room temperature for 1 hour and then concentrated under reduced pressure to give a pale yellow solid which was dissolved in N,N-dimethylformamide (50 ml). In a separate flask carbonyldiimidazole (13.4 g, 83.0 mmol) was added portionwise to a stirred solution of cyclopropanecarboxylic acid (6.46 g, 75.0 mmol) in N,N-dimethylformamide (150 ml) at room temperature under nitrogen. The reaction was stirred for 90 minutes and then the magnesium salt previously prepared was added dropwise. The reaction was stirred for 3 days and then poured into 1.0M hydrochloric acid (150 ml). The aqueous phase was extracted with ether (3×200 ml) and the combined organic phases were dried over magnesium sulphate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (90:10, by volume) to provide the title compound (9.33 g) as a yellow oil.

[1153]¹H-NMR (400 MHz, CDCl₃): keto and enol forms present with enol as major component; enol signals δ=1.00 (m, 7H), 1.60 (m, 1H), 2.25 (m, 2H), 5.59 (s, 1H), 15.62 (s, 1H); keto signals δ=1.00 (m, 7H), 2.01 (m, 1H), 2.52 (m, 2H), 3.68 (s, 2H).

[1154] LRMS (electrospray): m/z [M−H⁺] 139.

[1155] Microanalysis: Found: C, 68.35; H, 8.72. C₈H₁₂O₂ requires C, 68.55; H, 8.63%.

[1156] Preparation 48

[1157] The compound of the following tabulated Preparation of the general formula:

[1158] was prepared by a similar method to that of Preparation 47 using the appropriate ketoacid and carboxylic acid starting materials. Preparation No. R R′ LRMS Analytical Data 48 iPr Et m/z [M − H⁺] 141. ¹H-NMR(400 MHz, (electrospray) CDCl₃): keto and enol forms present with enol major δ = 1.12 (m, 18H, keto and enol), 2.32(m, 4H, keto and enol), 2.49 (m, 2H, keto and enol), 3.61(s, 2H, keto), 5.49(s, 1H, enol), 15.52(s, 1H, enol). Microanalysis: Found: C, 67.22; H, 9.95. C₈H₁₄O₂ requires C, 67.57; H, 9.92%.

[1159] Preparations 49 to 51

[1160] The compounds of the following tabulated Preparations of the general formula:

[1161] were prepared by a similar method to that of Preparation 2 using the appropriate diketone starting material. Preparation No. (Diketone No.) R R′ LRMS Analytical Data 49 cycloPr Et m/z [M − H⁺] 173. ¹H-NMR(400 (Preparation 47) (electrospray) MHz, CDCl₃): 1.10(m, 7H), 2.41 (m, 1H), 2.61(m, 2H), 15.90(s, 1H). 50 Me Et m/z [MNH₄ ⁺] 166. ¹H-NMR(300 (Commercially (thermospray) MHz, CDCl₃): available diketone 1.19(m, 3H), 2.27 used) (s, 3H), 2.67(q, 2H), 15.40(s, 1H). 51 iPr Et m/z [M − H⁺] 175. ¹H-NMR(400 (Preparation 48) (electrospray) MHz, CDCl₃): 1.18(m, 9H), 2.64 (q, 2H), 3.20(m, 1H), 15.80(s, 1H).

[1162] Preparations 52 to 54

[1163] The compounds of the following tabulated Preparations of the general formula:

[1164] were prepared by a similar method to that of Preparation 9 using the appropriate diketone starting material and the phenol of Preparation 39. Preparation No. (Diketone No.) R R′ LRMS Analytical Data 52 cycloPr Et m/z [M − H⁺] 282. ¹H-NMR(400 (Preparation 49) (electrospray) MHz, CDCl₃): 0.93(m, 2H), 1.12(t, 3H), 1.21 (m, 2H), 1.78(m, 1H), 2.29(q, 2H), 7.49(s, 2H), 7.61 (s, 1H), 14.87(s, 1H). 53 tBu Me m/z [MNH₄ ⁺] 301. ¹H-NMR(400 (Preparation 19) (thermospray) MHz, CDCl₃): 1.08(s, 9H), 1.84 (s, 3H), 7.30(s, 1H), 7.57(s, 2H), 15.42(s, 1H). 54 iPr Et m/z [M − H⁺]283. ¹H-NMR(400 (Preparation 51) (electrospray) MHz, CDCl₃): 1.03(m, 9H), 2.23(q, 2H), 2.58 (m, 1H), 7.41(s, 2H), 7.59(s, 1H), 14.63(s, 1H).

[1165] Preparation 55

[1166] 4-(Aminomethyl)benzamide

[1167] Powdered potassium hydroxide (340 mg, 6 mmol) was added in one portion to a stirred solution of 4-(aminomethyl)benzonitrile (200 mg, 1.5 mmol) in 2-methyl-2-propanol (20 ml) at reflux under nitrogen. The reaction was heated at reflux for 30 minutes and cooled to room temperature. The mixture was concentrated under reduced pressure and the crude product was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:ammonia (95:5:0.5, by volume) to provide the title compound (150 mg) as a white solid.

[1168]¹H-NMR (300 MHz, CD₃OD): δ=3.85 (s, 2H), 7.43 (d, 2H), 7.82 (d, 2H).

[1169] LRMS (thermospray): m/z [MH⁺] 151.

[1170] Preparation 56

[1171] 3-Oxopentanoic Acid

[1172] Sodium hydroxide (54 g, 1.35 mol) was added portionwise to a solution of 3-oxo-pentanoic acid methyl ester (80 g, 0.62 mol) in tetrahydrofuran (300 ml) and water (300 ml) at 0° C. The reaction was allowed to warm to room temperature and was stirred for 18 hours. The reaction mixture was washed with diethylether (500 ml) and the aqueous phase was acidified to pH 1 at 0° C. with concentrated hydrochloric acid (140 ml). The aqueous phase was extracted with dichloromethane (2×300 ml) and the combined organic extracts dried over magnesium sulphate and concentrated under reduced pressure to provide the title compound (44 g) as a white solid.

[1173]¹H NMR (400 MHz, CDCl₃): δ=1.12 (t, 3H), 2.59 (q, 2H), 3.49 (s, 2H).

[1174] Preparation 57

[1175] 3-(Benzyloxy)propanoic Acid

[1176] Sodium metal (249 mg, 10.8 mmol) was added to benzyl alcohol (30 g, 278 mmol) at room temperature under nitrogen and the reaction was stirred for 30 minutes. Methyl acrylate (25.9 ml, 259 mmol) was then added dropwise and the reaction was stirred at room temperature for 18 h. After quenching with saturated aqueous ammonium chloride solution (200 ml) the mixture was extracted with ethyl acetate (2×300 ml) and the combined organic extracts were washed with brine (100 ml), dried over magnesium sulphate and concentrated under reduced pressure. The residual oil was dissolved in ethanol (300 ml) and 1M aqueous sodium hydroxide solution (300 ml) was added dropwise. After 3 hours the ethanol was removed under reduced pressure and the aqueous residue was washed with dichloromethane (200 ml). The aqueous phase was then acidified with 2N aqueous hydrochloric acid (150 ml), extracted with dichloromethane (2×250 ml) and the combined organic extracts were dried over magnesium sulphate and concentrated under reduced pressure. The residual oil was dissolved in 10% aqueous potassium carbonate solution (300 ml), washed with diethylether (300 ml) and the aqueous phase was acidified to pH 1 using concentrated hydrochloric acid. The mixture was then extracted with dichloromethane (2×300 ml) and the combined organic extracts were dried over magnesium sulphate and concentrated under reduced pressure to provide the title compound (44.4 g) as a colourless oil.

[1177]¹H NMR (300 MHz, CDCl₃): δ=2.67 (t, 2H), 3.89 (t, 2H), 4.58 (s, 2H), 7.18 (m, 5H).

[1178] Preparation 58

[1179] (4Z)-1-(Benzyloxy)-5-hydroxy-4-hepten-3-one

[1180] A suspension of magnesium turnings (1.74 g, 71.6 mmol) in methanol (85 ml) was heated to reflux under nitrogen for 1.5 hours, cooled to room temperature and the β-keto acid from Preparation 56 (16.6 g, 143 mmol) was added. The reaction was stirred for 1.5 hours and the solvent was removed under reduced pressure to give the magnesium salt of the acid as a white solid. Meanwhile, the acid from Preparation 57 (12.9 g, 71.6 mmol) was dissolved in dimethylformamide (150 ml) and carbonyldiimidazole (12.8 g, 78.8 mmol) was added portionwise under nitrogen at room temperature. This was stirred for 1 hour and the magnesium salt from above was added as a solution in dimethylformamide (50 ml). Evolution of gas was noted, and the reaction was allowed to stir at room temperature for 18 hours. The mixture was concentrated under reduced pressure and the residual orange oil was dissolved in dichloromethane (300 ml), washed with 0.5M aqueous hydrochloric acid (250 ml) containing methanol (10 ml) and the aqueous phase was separated and extracted with dichloromethane (2×300 ml). The combined organic extracts were washed with brine (300 ml) containing methanol (20 ml), dried over magnesium sulphate and concentrated under reduced pressure. The residual orange oil was purified by flash chromatography on silica gel eluting with cyclohexane:ethyl acetate (80:20, by volume) to provide the title compound (12.0 g) as an orange oil.

[1181]¹H NMR (400 MHz, CDCl₃): δ=1.17 (t, 3H), 2.33 (q, 2H), 2.58 (t, 2H), 3.76 (t, 2H), 4.53 (s, 2H), 5.57 (s, 1H), 7.13 (m, 5H).

[1182] LRMS (electrospray): m/z [MNa⁺] 257.

[1183] Microanalysis: Found C, 71.77; H, 7.74. C₁₄H₁₈O₃ requires C, 71.76; H, 7.69%.

[1184] Preparation 59

[1185] (4E)-1-(Benzyloxy)-4-chloro-5-hydroxy-4-hepten-3-one

[1186] Trimethylsilyl chloride (10 ml, 51.3 mmol) was added to a solution of the enol from Preparation 58 (4.0 g, 17.1 mmol) in acetonitrile (25 ml) under nitrogen at 0° C. Dimethylsulfoxide (3.6 ml, 51.3 mmol) followed by tert-butylammonium bromide (275 mg, 0.85 mmol) were then added and the reaction was stirred at 0° C. for 2 hours. The mixture was diluted with water (100 ml), extracted with diethylether (100 ml) and the organic phase was washed with brine (50 ml), dried over magnesium sulphate and concentrated under reduced pressure. The residual pink oil was purified by flash chromatography on silica gel eluting with cyclohexane:ethyl acetate (80:20, by volume) to provide the title compound (3.76 g) as a pink oil.

[1187]¹H NMR (400 MHz, CDCl₃): δ=1.17 (t, 3H), 2.62 (q, 2H), 2.96 (t, 2H), 3.79 (t, 2H), 4.57 (s, 2H), 7.12 (m, 5H), 15.49 (s, 1H).

[1188] LRMS (electrospray): m/z [MNa⁺] 291.

[1189] Preparation 60

[1190] 3-({(1E)-1-[3-(benzyloxy)propanoyl]-2-hydroxy-1-butenyl}oxy)-5-fluorobenzonitrile

[1191] Sodium hydride (60% dispersion in oil, (1.92 g, 48.0 mmol)) was added to a stirred solution of the phenol from Preparation 34 (8.80 g, 48.0 mmol) in tetrahydrofuran (450 ml) under nitrogen at room temperature. After stirring for 1 hour, the enol from Preparation 59 (12.9 g, 48.0 mmol) was added and the reaction was stirred for 64 hours. The mixture was diluted with water (200 ml) and 2N aqueous hydrochloric acid (40 ml), extracted with ethyl acetate (2×150 ml) and the combined organic extracts were washed with brine (100 ml), dried over magnesium sulphate and concentrated under reduced pressure. The residual orange oil was purified by flash chromatography on silica gel eluting with cyclohexane:pentane (10:90, by volume) to provide the title compound (5.80 g) as an orange oil.

[1192]¹H NMR (400 MHz, CDCl₃): δ=1.08 (t, 3H), 2.31 (q, 2H), 2.59 (t, 2H), 3.75 (t, 2H), 4.45 (s, 2H), 6.92 (m, 1H), 7.02 (m, 2H), 7.29 (m, 5H), 14.50 (s, 1H).

[1193] LRMS (electrospray): m/z [MNa⁺] 392.

[1194] Preparation 61

[1195] 5-({(1E)-1-[3-(Benzyloxy)propanoyl]-2-hydroxy-1-butenyl}oxy)isophthalonitrile

[1196] Sodium hydride (60% dispersion in oil, 412 mg, 12.3 mmol) was added to a stirred solution of the phenol from Preparation 39 (1.48 g, 10.3 mmol) in tetrahydrofuran (70 ml) under nitrogen at room temperature. After stirring for 30 minutes, the enol from Preparation 59 (2.76 g, 10.3 mmol) was added and the reaction was stirred for 18 hours. Water (100 ml) and 2N aqueous hydrochloric acid (10 ml) were cautiously added and the mixture extracted with ethyl acetate (2×150 ml). The organics were combined, washed with brine (100 ml), dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with (pentane:ethyl acetate 90:10, by volume) to provide the title compound (1.00 g) as a yellow oil.

[1197] LRMS (thermospray): m/z [MH⁺] 375.

[1198] Preparation 62

[1199] 3-{[1-(2-{[tert-Butyl(dimethyl)silyl]oxy}ethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-fluorobenzonitrile

[1200] Imidazole (477 mg, 7.02 mmol) and tert-butyl-dimethyl-silyl chloride (977 mg, 6.48 mmol) were sequentially added to a solution of the alcohol from Example 117 (1.65 g, 5.40 mmol) in dimethylformamide (11 ml) at room temperature under nitrogen. The reaction was stirred for 18 hours and the mixture was diluted with water (100 ml) and extracted with diethylether (4×50 ml). The combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (99:1, by volume) to provide the title compound (2.12 g) as a colourless oil.

[1201]¹H NMR (400 MHz, CDCl₃): δ=0.03 (s, 6H), 0.84 (s, 9H), 1.10 (m, 6H), 2.42 (q, 2H), 2.56 (q, 2H), 4.00 (t, 2H), 4.09 (t, 2H), 6.86 (d, 1H), 6.99 (m, 2H).

[1202] LRMS (thermospray): m/z [MH⁺] 419.

[1203] Microanalysis: Found C, 62.73; H, 7.83; N, 9.75. C₂₂H₃₂FN₃O₂Si.0.06CH₂Cl₂ requires C, 62.68; H, 7.66; N, 9.94%.

[1204] Preparation 63

[1205] 3-({3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl}oxy)-5-fluorobenzonitrile

[1206] p-Toluene-sulphonic acid (32 mg, 0.17 mmol) was added to a solution of the alcohol from Example 117 (5.04 g, 16.6 mmol) and dihydropyran (7.57 ml, 83 mmol) in dichloromethane (65 ml) at room temperature under nitrogen. The reaction was stirred for 2 hours, but starting material still remained so a further aliquot of p-toluene-sulphonic acid (284 mg, 1.49 mmol) was added and the reaction was stirred for 1 hour. The mixture was diluted with diethylether (90 ml) and washed with a mixed aqueous solution (water (50 ml), brine (25 ml) and saturated aqueous sodium bicarbonate solution (25 ml)). The aqueous phase was extracted with diethylether (2×60 ml) and the combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound (6.31 g) as an oil.

[1207]¹H NMR (400 MHz, CDCl₃): δ=1.08 (m, 6H), 1.52 (m, 6H), 2.39 (q, 2H), 2.54 (q, 2H), 3.45 (m, 1H), 3.64 (m, 1H), 3.75 (m, 1H), 4.06 (m, 1H), 4.17 (t, 2H), 4.51 (s, 1H), 6.82 (d, 1H), 7.22 (m, 2H).

[1208] LRMS (thermospray): m/z [MH⁺] 388.

[1209] Preparation 64

[1210] 3-({3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl}oxy)-5-fluorobenzamide

[1211] Cesium carbonate (269 mg, 0.82 mmol) was added to a solution of 3-methyl-3-pyrazolin-5-one (74 mg, 0.75 mmol) in dimethylsulfoxide (1 ml) under nitrogen at room temperature and the reaction was stirred for 15 minutes. The aryl fluoride from Preparation 63 (291 mg, 0.75 mmol) dissolved in dimethylsulfoxide (1 ml) was then added and the reaction was heated to 100° C. for 18 hours. After cooling to room temperature the reaction was diluted with water (7 ml) and extracted with diethylether (12 ml). The organic phase was washed with brine (3.5 ml), dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with a solvent gradient of dichloromethane:methanol (99:1 changing to 95:5, by volume) to provide the unexpected title compound (108 mg) as an oil.

[1212]¹H NMR (400 MHz, CDCl₃): δ=1.12 (m, 6H), 1.56 (m, 6H), 2.44 (q, 2H), 2.59 (q, 2H), 3.48 (m, 1H), 3.69 (m, 1H), 3.79 (m, 1H), 4.08 (m, 1H), 4.20 (t, 2H), 4.54 (s, 1H), 6.72 (d, 1H), 7.15 (m, 2H).

[1213] LRMS (thermospray): m/z [MH⁺] 406.

[1214] Microanalysis: Found C, 60.57; H, 6.97; N, 9.97. C₂₁H₂₈FN₃O₄.0.08CH₂Cl₂.0.32H₂O requires C, 60.57; H, 6.94; N, 10.05%.

[1215] Preparation 65

[1216] 3-({3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl}oxy)-5-(1H--pyrazol-1-yl)benzonitrile

[1217] Cesium Carbonate (269 mg, 0.82 mmol) was added to a solution of pyrazole (51 mg, 0.75 mmol) in dry dimethylsulfoxide (1 ml) under nitrogen at room temperature and the reaction was stirred for 15 minutes. The aryl fluoride from Preparation 63 (291 mg, 0.75 mmol) dissolved in dry dimethylsulfoxide (1 ml) was then added and the reaction was heated to 100° C. for 18 hours. After cooling to room temperature the reaction was diluted with water (7 ml) and extracted with diethylether (10 ml). The organic phase was washed with brine (3 ml), dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with a solvent gradient of dichloromethane:methanol (100:0 changing to 90:10, by volume) to provide the title compound (55 mg).

[1218]¹H NMR (400 MHz, CDCl₃): δ=1.13 (m, 6H), 1.58 (m, 6H), 2.44 (q, 2H), 2.60 (q, 2H), 3.49 (m, 1H), 3.69 (m, 1H), 3.80 (m, 1H), 4.10 (m, 1H), 4.21 (t, 2H), 4.55 (s, 1H), 6.50 (s, 1H), 6.98 (s, 1H), 7.57 (s, 1H), 7.63 (s, 1H), 7.72 (s, 1H), 7.89 (s, 1H).

[1219] LRMS (thermospray): m/z [MH⁺] 436, [MNa⁺] 458.

[1220] HRMS: [MH⁺] Found 436.2352. C₂₄H₃₀N₅O₃ requires 436.2343

[1221] [MNa⁺] Found 458.2168. C₂₄H₂₉N₅O₃Na requires 458.2162.

[1222] Preparations 66-68

[1223] The preparation of the following tabulated Preparations of the general formula

[1224] were performed by a similar method to that of Preparation 65 using the appropriate heterocycle as the starting material. Preparation No. (Starting material preparation no.) R Analytical Data 66 (63)

¹H NMR (400 MHz, CDCl₃): δ = 1.13(m, 6H), 1.63(m, 6H), 2.44(q, 2H), 2.60(q, 2H), 3.46(m, 1H), 3.67(m, 1H), 3.79(m, 1H), 4.08(m, 1H), 4.20(t, 2H), 4.53(s, 1H), 6.26(t, 1H), 6.64(d, 1H), 7.17(s, 1H), 7.21(s, 1H), 7.34(s, 1H), 7.41(t, 1H). LRMS (thermospray): m/z [MH⁺] 463, [MNa⁺] 485. # HRMS: [MH⁺] Found 463.2353. C₂₆H₃₁N₄O₄ requires 463.2340 [MNa⁺ Found 485.2166. C₂₆H₃₀N₄O₄Na requires 485.2159. 67 (63)

¹H NMR (400 MHz, CDCl₃): δ = 1.10(m, 6H), 1.56(m, 6H), 2.41(q, 2H), 2.56(q, 2H), 3.44(m, 1H), 3.64(m, 1H), 3.75(m, 1H), 4.05(m, 1H), 4.17(t, 2H), 4.50(s, 1H), 7.00(d, 1H), 7.08(s, 1H), 7.20(m, 1H), 7.51(s, 1H), 7.64(s, 1H), 7.86(s, 1H). LRMS (thermospray): m/z [MH⁺] 464, [MNa⁺] 486. # HRMS: [MH^(+] Found 464.2297. C) ₂₅H₃₀N₅O₄ requires 464.2293 [MNa⁺ Found 486.2113. C₂₅H₂₉N₅O₄Na requires 486.2112. 68¹ (63)

¹H NMR (400 MHz, CDCl₃): δ = 1.08(m, 6H), 1.48(m, 6H), 2.23(s, 3H), 2.38(q, 2H), 2.53(q, 2H), 3.43(m, 1H), 3.63(m, 1H), 3.66(s, 3H), 3.73(m, 1H), 4.04(m, 1H), 4.15(t, 2H), 4.50(s, 1H), 5.59(s, 1H), 6.76(s, 1H), 6.88(s, 1H), 6.95(s, 1H). LRMS (thermospray): m/z [MH⁺] 480, [MNa⁺] 502.

[1225] Preparation 69

[1226] tert-Butyl 3-[4-(3,5-dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]-1-azetidinecarboxylate

[1227] Sodium hydride (60% dispersion in oil, 33 mg, 0.82 mmol) was added to a solution of the pyrazole from Example 122 (200 mg, 0.75 mmol) in dimethylformamide (3 ml) at 0° C. under nitrogen and the reaction was stirred for 10 minutes. 3-Iodo-azetidine-1-carboxylic acid tert-butyl ester (234 mg, 0.82 mmol) was added and the reaction was stirred at room temperature for 18 hours. The reaction was quenched with water (0.2 ml) and concentrated under reduced pressure. The residue was partitioned between dichloromethane (5 ml) and water (5 ml) and the organic phase was isolated using a 5 μM Whatman PTFE fritted cartridge, then concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with a solvent gradient of ethyl acetate:pentane (20:80 then 25:75 then 34:66 then 50:50 then 75:25 then 100:0, by volume) changing to ethyl acetate:methanol (10:1, by volume) then dichloromethane:methanol:0.88 ammonia (90:10:1 then 80:20:1, by volume) to provide the title compound (189 mg) as a pale yellow oil.

[1228]¹H NMR (400 MHz, CDCl₃): δ=1.03-1.17 (m, 6H), 1.49 (s, 9H), 2.39-2.52 (m, 4H), 4.32 (m, 2H), 4.50 (m, 2H), 4.94 (m, 1H), 7.38 (s, 2H), 7.56 (s, 1H).

[1229] LRMS (thermospray): m/z [MH⁺] 422, [MNa⁺] 444.

[1230] Microanalysis: Found C, 65.08; H, 6.49; N, 16.48. C₂₃H₂₇N₅O₃.0.18H₂O requires C, 65.04; H, 6.49; N, 16.49%.

[1231] Preparation 70

[1232] 5-({3,5-Diethyl-1-[3-(tetrahydro-2H-pyran-2-yloxy)propyl]-1H-pyrazol-4-yl}oxy isophthalonitrile

[1233] Sodium hydride (60% dispersion in oil, 33 mg, 0.82 mmol) was added to a solution of the pyrazole from Example 122 (200 mg, 0.75 mmol) in dimethylformamide (3 ml) at 0° C. under nitrogen and the reaction was stirred for 10 minutes. 2-(3-bromo-propoxy)-tetrahydro-pyran (184 mg, 0.82 mmol) was added and the reaction was stirred at room temperature for 18 hours. The reaction was quenched with water (0.2 ml) and concentrated under reduced pressure. The residue was partitioned between dichloromethane (5 ml) and water (5 ml) and the organic phase was isolated using a 5 μM Whatman PTFE fritted cartridge, then concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with a solvent gradient of ethyl acetate:pentane (20:80 then 25:75 then 34:66 then 50:50 then 75:25 then 100:0, by volume) changing to ethyl acetate:methanol (10:1, by volume) then dichloromethane:methanol:0.88 ammonia (90:10:1 then 80:20:1, by volume) to provide the title compound (238 mg) as a pale yellow oil.

[1234]¹H NMR (400 MHz, CDCl₃): δ=1.09 (m, 6H), 1.47-1.63 (m, 2H), 1.66-1.88 (m, 2H), 2.15 (dd, 2H), 2.38 (q, 2H), 2.53 (q, 2H), 3.37-3.55 (m, 2H), 3.75-3.90 (m, 2H), 4.11 (m, 2H), 4.56 (m, 1H), 7.37 (s, 2H), 7.55 (s, 1H).

[1235] LRMS (electro): m/z [MH⁺] 409, [MNa⁺] 421.

[1236] Microanalysis: Found C, 66.59; H, 6.91; N, 13.40. C₂₃H₂₈N₄O₃.0.36H₂O requires C, 66.57; H, 6.98; N, 13.50%.

[1237] Preparation 71

[1238] 3-[(1-Acetyl-3,5-dimethyl-1H-pyrazol-4-yl)oxy]-5-fluorobenzonitrile

[1239] The phenol from Preparation 34 (10.0 g, 72.7 mmol), 3-chloro-2,4-pentanedione (7.10 g, 72.7 mmol) and cesium carbonate (23.6 g, 72.9 mmol) were heated to reflux in acetone (100 ml) under nitrogen for 2 hours. The reaction was cooled to room temperature, 1N aqueous hydrochloric acid (50 ml) was added slowly and the mixture was extracted with ethyl acetate (3×100 ml). The combined organic extracts dried over magnesium sulphate and concentrated under reduced pressure. The residual yellow oil was dissolved in methanol (100 ml), hydrazine (5.3 ml, 109 mmol) was added and the reaction was stirred at room temperature under nitrogen for 2 hours. The solvent was removed under reduced pressure and the residue was dissolved in dimethylformamide (50 ml) at 0° C. Acetyl chloride (5.1 ml, 72.0 mmol) was added slowly followed by sodium hydride (60% dispersion in oil, 2.8 g, 72.0 mmol) portionwise. The reaction was stirred for 15 minutes and sat. ammonium chloride solution (50 ml) was added, and the reaction was allowed to warm to room temperature. The mixture was extracted with ethyl acetate (3×100 ml) and the combined organic extracts were dried over magnesium sulphate and concentrated under reduced pressure giving an oil. After standing for 18 hours, a solid had formed within the oil which was isolated by filtration, washing with diethylether (50 ml) to provide the title compound (3.50 g) as a white solid, m.p. 109-111° C.

[1240]¹H NMR (400 MHz, CDCl₃): δ=2.06 (s, 3H), 2.37 (s, 3H), 2.65 (s, 3H), 6.81 (d, 1H), 6.91 (s, 1H), 7.04 (d, 1H).

[1241] LRMS (thermospray): m/z [MH⁺] 273.

[1242] Microanalysis: Found C, 61.62; H, 4.44; N, 15.09. C₁₄H₁₂N₃O₂F requires C, 61.53; H, 4.43; N, 15.38%.

[1243] Preparations 72-74

[1244] The tabulated compounds of the general formula

[1245] were performed by a similar method to that of Preparation 71 using the appropriate phenol as the starting material. Preparation no. (Starting material preparation no.) R′ Analytical Data  72 (39) CN m.p. 204-206° C. ¹H NMR(400 MHz, CDCl₃): δ = 2.06(s, 3H), 2.38(s, 3H), 2.66(s, 3H), 7.33(s, 2H), 7.58(s, 1H). LRMS (thermospray): m/z [MH⁺] 281. Microanalysis: Found C, 63.30; H, 4.25; N, 19.59. C₁₅H₁₂N₄O₂.0.30H₂O requires C, 63.06; H, 4.45; N, 19.61%. 73¹ (42) Me m.p. 152-154° C. ¹H NMR(400 MHZ, CDCl₃): δ = 2.05(s, 3H), 2.33(s, 3H), 2.38(s, 3H), 2.66(s, 3H), 6.88(s, 1H), 6.91(s, 1H), 7.12(s, 1H). LRMS (thermospray): m/z [MH⁺] 270. Microanalysis: Found C, 66.67; H, 5.71; N, 15.25. C₁₅H₁₅N₃O₂ requires C, 66.9; H, 5.61; N, 15.60%. 74² (Commercial) H m.p. 131-133° C. ¹H NMR(400 MHz, CDCl₃): δ = 2.13(s, 3H), 2.40(s, 3H), 2.70(s, 3H), 7.15(m, 2H), 7.35 (m, 1H), 7.40(m, 1H). LRMS (thermospray): m/z [MH⁺] 278. Microanalysis: Found C, 65.87; H, 5.11; N, 16.33. C₁₄H₁₃N₃O₂ requires C, 65.87; H, 5.13; N, 14.46%.

[1246] Preparation 75

[1247] 3-{[1-Acetyl-3-(bromomethyl)-5-methyl-1H-pyrazol-4-yl]oxy}-5-fluorobenzonitrile

[1248] The pyrazole from Preparation 71 (1.00 g, 3.66 mmol) was dissolved in carbon tetrachloride (20 ml) and the solution was degassed by bubbling nitrogen through it for 20 minutes at room temperature. N-Bromosuccinimide (973 mg, 5.49 mmol) followed by 2,2′-azobisisobutyronitrile (30 mg) were added and the reaction was heated to 95° C. for 1 hour. The reaction was cooled to room temperature, concentrated under reduced pressure and purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (80:20, by volume) to provide the title compound (1.30 g) as a pale yellow oil.

[1249]¹H NMR (400 MHz, CDCl₃): δ=2.05 (s, 3H), 2.69 (s, 3H), 4.68 (s, 2H), 6.89 (d, 1H), 6.99 (s, 1H), 7.08 (d, 1H).

[1250] LRMS (thermospray): m/z [M−BrH⁺] 272.

[1251] Microanalysis: Found C, 45.08; H, 3.14; N, 11.44. C₁₄H₁₁BrN₃O₂F.1.05H₂O requires C, 45.31; H, 3.56; N, 11.32%.

[1252] Preparations 76-78

[1253] The preparation of the following tabulated Preparations of the general formula

[1254] were performed by a similar method to that of Preparation 75 using the appropriate pyrazole as the starting material. Preparation no. (Starting material preparation no.) R Analytical Data   76 (72) CN m.p. 132-134° C. ¹H NMR(400 MHz, CDCl₃): δ = 2.06(s, 3H), 2.66(s, 3H), 4.67(s, 2H), 7.40(s, 2H), 7.63(s, 1H). Microanalysis: Found C, 47.65; H, 3.03; N, 14.79. C₁₅H₁₁BrN₄O₂.0.93H₂O requires C, 47.92; H, 3.45; N, 14.90%. 77^(1,2) (73) Me m.p. 107-109° C. ¹H NMR(400 MHz, CDCl₃): δ = 2.05(s, 3H), 2.35(s, 3H), 2.70(s, 3H), 4.70(s, 2H), 6.95 (s, 1H), 6.99(s, 1H), 7.18(s, 1H). Microanalysis: Found C, 50.34; H, 3.89; N, 11.58. C₁₅H₁₄BrN₃O₂.0.40H₂O requires C, 50.69; H, 4.20; N, 11.82%. 78^(1,3) (74) H m.p. 120-124° C. ¹H NMR(400 MHz, CDCl₃): δ = 2.05(s, 3H), 2.70(s, 3H), 4.75(s, 2H), 7.20(m, 2H), 7.45(m, 1H). Microanalysis: Found C, 49.01; H, 3.47; N, 12.14. C₁₄H₁₂BrN₃O₂.0.50H₂O requires C, 49.00; H, 3.82; N, 12.24%.

[1255] Preparation 79

[1256] 3-Cyanobenzamide

[1257] 0.88 Ammonia solution (30 ml) was slowly added to a solution of 3-cyanobenzoyl chloride (10 g, 60.3 mmol) in dichloromethane (100 ml) at 0° C. under nitrogen and the reaction was stirred for 20 minutes. The mixture was filtered and the solid was washed with water (50 ml) then diethylether (50 ml), azeotroped with toluene and dried in vacuo to provide the title compound (9 g) as a white solid.

[1258]¹H NMR (400 MHz, CD₃OD): δ=7.62 (m, 1H), 7.86 (m, 1H), 8.12 (m, 1H), 8.18 (s, 1H).

[1259] Preparation 80

[1260] 3-(Aminomethyl)benzamide

[1261] The nitrile from Preparation 79 (6.4 g, 43.8 mmol) was suspended in acetic acid (60 ml) and 10% palladium on carbon (100 mg) was added. The reaction was pressurised to 60 psi at room temperature with hydrogen, and stirred for 18 hours. Starting material remained, so a further aliquot of 10% palladium on carbon (500 mg) was added and the procedure was repeated. The reaction mixture was filtered through arbocel washing with acetic acid and the filtrate was concentrated under reduced pressure. The residue was azeotroped with toluene and purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (100:0:0 changing to 90:10:1 then 85:15:1.5, by volume) to provide the title compound (5.3 g) as a colourless oil.

[1262]¹H NMR (400 MHz, CD₃OD): δ=3.83 (s, 2H), 7.39 (dd, 1H), 7.49 (d, 1H), 7.73 (d, 1H), 7.81 (s, 1H).

[1263] Preparation 81

[1264] 2-Chloro-1,3-dicyclopropyl-1,3-propanedione

[1265] Trimethylsilyl chloride (16.6 ml, 130 mmol) was added to a solution of tert-butylammonium bromide (0.70 g, 2.17 mmol) in acetonitrile (50 ml) under nitrogen at 0° C. 1,3-Dicyclopropyl-propane-1,3-dione (ref: WO98155438) (6.62 g, 43.5 mmol) in acetonitrile (15 ml) was then added followed by dimethylsulfoxide (9.25 ml, 130 mmol) dropwise, and the reaction was allowed to warm to room temperature over 4 hours. The mixture was diluted with water (75 ml), extracted with diethylether (3×35 ml) and the combined organic extracts dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with pentane:diethylether (95:5, by volume) to provide the title compound (3.76 g) as an oil, which was an 80:20 mixture of enol:keto forms.

[1266]¹H NMR (400 MHz, CDCl₃): δ=1.02 (m, 4H), 1.17 (m, 4H), 2.24 (m, 0.2H), 2.39 (m, 0.8H), 5.05 (s, 0.2H), 16.34 (s, 0.8H).

[1267] Microanalysis: Found C, 57.59; H, 5.89. C₉H₁₁CO₂.0.02CH₂Cl₂ requires C, 57.92; H, 5.94.

[1268] Preparation 82

[1269] 5-[2-Cyclopropyl-1-(cyclopropylcarbonyl)-2-oxoethoxy]isophthalonitrile

[1270] Cesium carbonate (1.97 g, 6.06 mmol) was added to a stirred solution of the phenol from Preparation 39 (0.865 g, 6.00 mmol) in acetone (24 ml) under nitrogen at reflux. After stirring for 5 minutes, the diketone from Preparation 81 (1.12 g, 6.00 mmol) in acetone (6 ml) was added and the reaction was stirred for 4 hours. After cooling the mixture was diluted with water (25 ml) and the acetone was removed under reduced pressure. The aqueous phase was acidified with 2N aqueous hydrochloric acid, extracted with dichloromethane (50 ml) and the organic phase was dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with a solvent gradient of pentane:ethyl acetate (95:5 changing to 90:10 then 80:20, by volume) to provide the title compound (1.03 g) as a white solid, which existed as the enol tautomer, m.p. 135-137° C.

[1271]¹H NMR (400 MHz, CDCl₃): δ=0.93 (m, 4H), 1.19 (m, 4H), 1.74 (m, 2H), 7.53 (s, 2H), 15.25 (s, 1H).

[1272] LRMS (electrospray): m/z [M−H⁺] 293.

[1273] Microanalysis: Found C, 69.18; H, 4.82; N, 9.35. C₁₇H₁₄N₂O₃ requires C, 69.38; H, 4.79; N, 9.52%.

[1274] Preparation 83

[1275] 3-Oxobutanoic Acid

[1276] Sodium hydroxide (37.9 g, 0.947 mol) was dissolved in water (770 ml) and added to a solution of 3-oxo-butanoic acid methyl ester (100 g, 0.861 mol) at room temperature over 20 minutes. The reaction was stirred for 18 hours, quenched with ammonium sulfate (700 g) and acidified slowly with a solution of concentrated Hydrochloric acid (21.5 ml) in water (250 ml) with ice cooling. The reaction mixture was extracted with diethylether (6×200 ml) and the combined organic extracts were dried over magnesium sulphate and concentrated under reduced pressure to provide the title compound (58.2 g) as a pale yellow oil which was a mixture of keto:enol tautomers.

[1277]¹H NMR (400 MHz, CDCl₃): δ=2.00 (s, 3H-enol), 2.30 (s, 3H-keto), 3.51 (s, 2H-keto), 5.02 (s, 1H-enol).

[1278] Preparation 84

[1279] 1-Cyclopropyl-1,3-butanedione

[1280] Magnesium turnings (3.04 g, 125 mmol) suspended in methanol (145 ml) were heated to reflux under nitrogen for 1 hour, cooled to room temperature and the β-keto acid from Preparation 83 (25.5 g, 250 mmol) dissolved in methanol (25 ml) was added dropwise with ice-cooling. The reaction was stirred for 1 hour at room temperature and the solvent was removed under reduced pressure to give the magnesium salt of the acid. Meanwhile, cyclopropane-carboxylic acid (9.91 ml, 125 mmol) was dissolved in dimethylformamide (200 ml) and carbonyldiimidazole (22.4 g, 138 mmol) was added portionwise under nitrogen at 0° C. This was stirred for 1.5 hour and the magnesium salt from above was added as a solution in dimethylformamide (100 ml) at 0° C. The reaction was allowed to stir at room temperature for 92 hours and the mixture was poured into 2M aqueous hydrochloric acid (85 ml) then diluted with water (170 ml). The mixture was extracted with diethylether (6×200 ml) and the combined organic extracts were washed with brine (3×200 ml), dried over magnesium sulphate and concentrated under reduced pressure. The residual orange oil was purified by flash chromatography on silica gel eluting with pentane:diethylether (100:0 changing to 90:10 then 80:20, by volume) to provide the title compound (7.39 g) as a yellow oil.

[1281]¹H NMR (400 MHz, CDCl₃): δ=0.83-0.95 (m, 2H), 1.06-1.10 (m, 2H), 1.54-1.63 (m, 1H), 2.00 (s, 3H).

[1282] LRMS (electrospray): m/z [MNa⁺] 149.

[1283] Preparation 85

[1284] 2-Chloro-1-cyclopropyl-1,3-butanedione

[1285] Trimethylsilyl chloride (18.9 ml, 174 mmol) was added to a solution of tert-butylammonium bromide (932 mg, 2.89 mmol) in dry acetonitrile (50 ml) under nitrogen at room temperature and the mixture was cooled to 0° C. The diketone from Preparation 84 (7.3 g, 57.9 mmol) in acetonitrile (36 ml) was then added followed by dropwise addition of dry dimethylsulfoxide (12.3 ml, 174 mmol). The reaction was stirred at 0° C. for 1.5 hours and the mixture was diluted with water (500 ml), extracted with diethylether (2×200 ml and 100 ml) and the combined organic extracts were dried over magnesium sulphate and concentrated under reduced pressure. The residual oil was purified by flash chromatography on silica gel eluting with pentane:diethylether (100:0 changing to 95:5 then 90:10, by volume) to provide the title compound (5.76 g) as a colourless oil.

[1286]¹H NMR (400 MHz, CDCl₃): δ 0.99-1.08 (m, 2H), 1.15-1.20 (m, 2H), 2.27 (s, 3H), 2.38-2.46 (m, 1H).

[1287] LRMS (electrospray): m/z [M−H⁺] 159.

[1288] Preparation 86

[1289] 3-[1-(Cyclopropylcarbonyl)-2-oxopropoxy]-5-methylbenzonitrile

[1290] Cesium carbonate (2.45 g, 8.30 mmol) and the phenol from Preparation 42 (1 g, 7.50 mmol) were added to a stirred solution of the diketone from Preparation 85 (1.3 g, 8.30 mmol) in acetone (44 ml) under nitrogen at 60° C. and the reaction was stirred for 5 hours. After cooling the mixture was quenched with water and the acetone was removed under reduced pressure. The aqueous phase was acidified with 1N aqueous hydrochloric acid, extracted with ethyl acetate and the organic phase was dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (85:15, by volume) to provide the title compound (1.03 g) as a pale red solid.

[1291]¹H NMR (400 MHz, CDCl₃): δ=0.85 (m, 2H), 1.12 (m, 2H), 1.86 (m, 1H), 1.94 (s, 3H), 2.35 (s, 3H), 6.99 (m, 2H), 7.10 (s, 1H).

[1292] LRMS (electrospray) m/z [M−H⁺] 256.

[1293] Preparation 87

[1294] 4-(3,5-Difluorophenoxy)-3,5-diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazole

[1295] p-Toluene-sulphonic acid (360 mg, 1.89 mmol) was added to a solution of the alcohol from Example 38 (5.6 g, 18.9 mmol) and dihydropyran (8.62 ml, 94.5 mmol) in dichloromethane (75 ml) at room temperature under nitrogen. The reaction was stirred for 2 hours, diluted with diethylether (100 ml) and washed with a mixed aqueous solution (water (60 ml), brine (30 ml) and saturated aqueous sodium bicarbonate solution (30 ml)). The aqueous phase was extracted with diethylether (2×60 ml) and the combined organic extracts were dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (98:2, by volume) to provide the title compound (6.31 g) as an oil.

[1296]¹H NMR (400 MHz, CDCl₃): δ=1.09 (m, 6H), 1.57 (m, 6H), 2.40 (q, 2H), 2.55 (q, 2H), 3.44 (m, 1H), 3.62 (m, 1H), 3.73 (m, 1H), 4.05 (m, 1H), 4.16 (t, 2H), 4.50 (s, 1H), 6.39 (m, 3H).

[1297] LRMS (thermospray): m/z [MH⁺] 381.

[1298] Microanalysis: Found C, 62.16; H, 6.92; N, 7.16. C₂₀H₂₆N₂O₃.0.09CH₂Cl₂ requires C, 62.18; H, 6.80; N, 7.22%.

[1299] Preparation 88

[1300] 4-[3,5-Di(1H-pyrazol-1-yl)phenoxy]-3,5-diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazole

[1301] and

[1302] Preparation 89

[1303] 3,5-Diethyl-4-[3-fluoro-5-(1H-pyrazol-1-yl)phenoxy]-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazole

[1304] Cesium Carbonate (538 mg, 1.65 mmol) was added to a solution of pyrazole (102 mg, 1.50 mmol) in dry dimethylsulfoxide (2 ml) under nitrogen at room temperature and the reaction was stirred for 15 minutes. The aryl difluoride from Preparation 87 (570 mg, 1.50 mmol) dissolved in dry dimethylsulfoxide (2 ml) was then added and the reaction was heated to 100° C. for 18 hours. After cooling to room temperature the reaction was diluted with water (20 ml) and extracted with diethylether (2×20 ml). The organic phase was washed with brine (10 ml), dried over magnesium sulphate, concentrated under reduced pressure. Some starting material remained, so the residue was dissolved in dimethylsulfoxide (12 ml), pyrazole (510 mg, 7.50 mmol) followed by cesium carbonate (2.5 g, 7.66 mmol) were added and the reaction was heated to 100° C. for 18 hours. After cooling to room temperature the reaction was diluted with water (6 ml), extracted with diethylether (20 ml) and the organic phase was washed with brine (10 ml), dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with a solvent gradient of dichloromethane:methanol (100:0 changing to 96:4, by volume). This gave two fractions, the first of which was a single product (least polar) and the other a mixture of two products. The second fraction was re-purified eluting with dichloromethane:acetonitrile (93:7 changing to 90:10, by volume) to provide the most polar product.

[1305] Least Polar Product—Preparation 88 (254 mg)

[1306]¹H NMR (400 MHz, CDCl₃): δ=1.11 (m, 6H), 1.50 (m, 6H), 2.46 (q, 2H), 2.58 (q, 2H), 3.43 (m, 1H), 3.64 (m, 1H), 3.75 (m, 1H), 4.04 (m, 1H), 4.18 (t, 2H), 4.50 (s, 1H), 6.42 (s, 2H), 7.15 (s, 2H), 7.67 (s, 3H), 7.90 (s, 2H).

[1307] LRMS (electrospray): m/z [MH⁺] 477, [MNa⁺] 499.

[1308] HRMS: [MH⁺] Found 477.2612. C₂₆H₃₃N₆O₃ requires 477.2609.

[1309] Most Polar Product—Preparation 89 (37.7 mg)

[1310]¹H NMR (400 MHz, CDCl₃): δ=1.11 (m, 6H), 1.46 (m, 6H), 2.43 (q, 2H), 2.57 (q, 2H), 3.43 (m, 1H), 3.64 (m, 1H), 3.75 (m, 1H), 4.05 (m, 1H), 4.17 (t, 2H), 4.51 (s, 1H), 6.42 (m, 2H), 7.07 (m, 2H), 7.66 (s, 1H), 7.82 (s, 1H).

[1311] LRMS (thermospray): m/z [MH⁺] 429.

[1312] Preparation 90

[1313] 3-({3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl}oxy)-5-methoxybenzonitrile

[1314] Sodium methoxide (25% w/v in methanol, 230 μl, 1.00 mmol) was added dropwise to a solution of the aryl fluoride from Preparation 63 (387 mg, 1.00 mmol) and in dimethylformamide (5 ml) at room temperature under nitrogen. The reaction was stirred for 5 hours, diluted with water (10 ml) and extracted with diethylether (50 ml). The organic phase was dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (97:3, by volume) to provide the title compound (400 mg) as an oil.

[1315]¹H NMR (400 MHz, CDCl₃): δ=1.09 (m, 6H), 1.49 (m, 6H), 2.41 (q, 2H), 2.55 (q, 2H), 3.46 (m, 1H), 3.66 (m, 1H), 3.77 (m+s, 4H), 4.07 (m, 1H), 4.19 (t, 2H), 4.52 (m, 1H), 6.66 (s, 1H), 6.69 (s, 1H), 6.77 (s, 1H).

[1316] LRMS (thermospray): m/z [MH⁺] 400.

[1317] Microanalysis: Found C, 65.59; H, 7.32; N, 10.42. C₂₂H₂₉N₃O₄.0.04CH₂Cl₂ requires C, 65.71; H, 7.28; N, 10.43%.

[1318] Preparation 91

[1319] 3- (1-Acetyl-3-methyl-2-oxobutoxy)-5-methylbenzonitrile

[1320] Cesium carbonate (1.50 g, 4.61 mmol) and the phenol from Preparation 42 (609 mg, 4.61 mmol) were added to a stirred solution of the diketone from Preparation 23 (750 mg, 4.61 mmol) in acetone (23 ml) under nitrogen at 50° C. and the reaction was stirred for 3 hours. After cooling the mixture was quenched with water (10 ml) and the acetone was removed under reduced pressure. The aqueous phase was extracted with dichloromethane (4×25 ml) and the combined organic extracts were dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (90:10, by volume) to provide the title compound (544 mg).

[1321]¹H NMR (400 MHz, CDCl₃): δ=1.10 (m, 6H), 209 (s, 3H), 2.42 (s, 3H), 2.69 (m, 1H), 7.00 (s, 2H), 7.19 (s, 1H).

[1322] LRMS (thermospray): m/z [MNH₄ ⁺] 277.

[1323] Preparation 92

[1324] [4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]acetic Acid

[1325] The pyrazole of Example 208 (400 mg, 1.41 mmol) was stirred at 110° C. for 14 hours in concentrated hydrochloric acid (20 ml). The mixture was cooled to room temperature and the solvent removed under reduced pressure to give a yellow solid. The solid was dissolved in dichloromethane (50 ml) and 1N aqueous hydrochloric acid (50 ml) and the organic layer was separated. The organics were washed with 1 N aqueous hydrochloric acid (50 ml), dried over magnesium sulphate, filtered and the solvent removed under reduced pressure to provide the title compound (400 mg) as pale yellow solid, m.p. 156-158° C.

[1326]¹H NMR (400 MHz, CD₃OD): δ=2.02 (s, 3H), 4.89 (s, 2H), 6.82 (s, 2H), 7.02 (s, 1H).

[1327] LRMS (thermospray): m/z [MH⁺] 303.

[1328] Microanalysis: Found C, 47.50; H, 3.50; N, 9.46. C₁₂H₁₀Cl₂N₂O₃ requires C, 47.86; H, 3.35; N, 9.30%.

[1329] Preparation 93

[1330] 3-({3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl}oxy)-5-(methylsulfanyl)benzonitrile

[1331] Sodium thiomethoxide (180 mg, 2 mmol) was added to a stirred solution of the aryl fluoride from Preparation 63 (774 mg, 2.00 mmol) in dimethylformamide (10 ml) at room temperature under nitrogen. The reaction mixture was stirred for 5 hours before being heated at 100° C. for 18 hours. A second portion of sodium thiomethoxide (90 mg, 1 mmol) was added and the reaction mixture was heated at 100° C. for a further 5 hours. After cooling to room temperature the mixture was diluted with water (10 ml) and extracted with diethylether (2×50 ml). The organic phase was dried over magnesium sulphate, concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (97:3, by volume) to provide the title compound (700 mg) as an oil.

[1332]¹H NMR (400 MHz, CDCl₃): δ=1.14 (m, 6H), 1.52 (m, 6H), 2.44 (q, 2H), 2.49 (s, 3H), 2.59 (q, 3H), 3.50 (m, 1H), 3.70 (m, 1H), 3.80 (m, 1H), 4.10 (m, 1H), 4.23 (m, 2H), 4.55 (m, 1H), 6.82 (s, 1H), 7.01 (s, 1H), 7.09 (s, 1H).

[1333] LRMS (APCI+): m/z [MH⁺] 416.

[1334] Preparation 94

[1335] 3-({3,5-Diethyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl}oxy-5-[2-(dimethylamino)ethoxy]benzonitrile

[1336] To a stirred solution of N,N-dimethylethanolamine (83 μl, 0.83 mmol) in dimethylformamide (2 ml) was added sodium hydride (36 mg of 60% by weight dispersion in oil, 0.90 mmol). After 10 minutes a solution of the aryl fluoride from Preparation 63 (291 mg, 0.75 mmol) in dimethylformamide (2 ml) was added and the reaction mixture was stirred at room temperature for 18 hours. The mixture was diluted with 10% aqueous potassium carbonate solution (12 ml) and extracted with diethyl ether (2×7 ml). The combined organic components were dried over magnesium sulphate and concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (a gradient from 99:1 to 90:10, by volume) to provide the title compound (180 mg) as an oil.

[1337]¹H NMR (400 MHz, CDCl₃): δ=1.09 (m, 6H), 1.50 (m, 6H), 2.39 (q, 2H), 2.47 (s, 6H), 2.55 (q, 2H), 2.87 (m, 2H), 3.47 (m, 1H), 3.67 (m, 1H), 3.78 (m, 1H), 4.05 (m, 1H), 4.17 (m, 4H), 4.52 (m, 1H), 6.70 (s, 2H), 6.79 (s, 1H).

[1338] LRMS (electrospray): m/z [MH⁺] 457.

[1339] HRMS: [MH⁺] 457.2810. C₂₅H₃₇N₄O₄ requires 457.2810.

[1340] Preparations 95-97

[1341] The preparation of the following tabulated Preparations of the general formula

[1342] were performed by a similar method to that of Preparation 94 using the appropriate alcohol as the starting material. Preparation no. (Starting material preparation no) R Analytical Data 95 (63) CH₂CH₂NHMe ¹H NMR(400 MHz, CDCl₃): δ = 1.09(m, 6H), 1.50(m, 6H), 2.39(q, 2H), 2.54(m, 5H), 3.04(t, 2H), 3.46(m, 1H), 3.66(m, 1H), 3.78(m, 1H), 4.05(m, 1H), 4.11(t, 2H), 4.17 (t, 2H), 4.52(s, 1H), 6.70 (s, 2H), 6.81(s, 1H). LRMS (electrospray): m/z [MH⁺] 443 HRMS: [MH⁺] 443.2654. C₂₄H₃₅N₄O₄ requires 443.2653. 96 (63) CH₂CONH₂ ¹H NMR(400 MHz, CDCl₃): δ = 1.11(m, 6H), 1.48(m, 6H), 2.43(q, 2H), 2.58(q, 2H), 3.46(m, 1H), 3.67(m, 1H), 3.80(m, 1H), 4.08 (m, 1H), 4.25(m, 2H), 4.45(s, 2H), 4.52(m, 1H), 5.54(broad s, 1H), 6.37(broad s, 1H), 6.72(s, 1H), 6.85(s, 2H). LRMS (electrospray): m/z 465 (MH⁺) HRMS: [MH⁺] 443.2282. C₂₃H₃₁N₄O₅ requires 443.2289. 97 (63) CH₂CH₂OCH₃ ¹H NMR(400 MHz, CDCl₃): δ = 1.10(m, 6H), 1.50(m, 6H), 2.41(q, 2H), 2.55(q, 2H), 3.41(s, 3H), 3.47 (m, 1H), 3.70(m, 3H), 3.79(m, 1H), 4.06(m, 3H), 4.20(m, 2H), 4.52(s, 1H), 6.70(s, 2H), 6.79(s, 1H). LRMS (electrospray): m/z 466 (MH⁺) HRMS: [MH⁺] 443.2282. C₂₄H₃₄N₃O₅ requires 443.2289.

[1343] Preparation 98

[1344] 5-Methyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-3-(trifluoromethyl)-1H-pyrazol-4-ol

[1345] To a stirred solution of 1-(2-hydroxyethyl)-5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-ol (600 mg, 2.86 mmol; Kenkyu Hokoku—Asahi Garasu Kogyo Gijutsu Shoreikai, 1988, 51,139-49) in dichloromethane (10 ml) and ethyl acetate (4 ml) was added para-toluenesulphonic acid (27 mg, 0.14 mmol) followed by 3,4-dihydro-2H-pyran (340 μl, 3.7 mmol). The reaction mixture was stirred at room temperature for 3 hours before being concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (60:40, by volume) to provide the title compound (560 mg) as white solid.

[1346]¹H NMR (400 MHz, CDCl₃): δ=1.60 (m, 6H), 2.23 (s, 3H), 3.44 (m, 1H), 3.60 (m, 1H), 3.72 (m, 1H), 4.04 (m, 1H), 4.18 (m, 2H), 4.50 (broad s, 1H).

[1347] LRMS (electrospray): m/z [M−H⁺] 293.

[1348] Preparation 99

[1349] 3-Fluoro-5-{[5-methyl-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-3-(trifluoromethyl)-1H-pyrazol-4-yl]oxy}benzonitrile

[1350] To a stirred solution of the pyrazole (214 mg, 0.73 mmol) from Preparation 98 in dimethylformamide (0.7 ml) was added 3,5-diflurobenzonitrile (304 mg, 2.2 mmol) and potassium carbonate (304 mg, 2.2 mmol). The reaction mixture was heated at 90° C. for 7 hours. After cooling to room temperature brine (20 ml) was added and the mixture was extracted with ethyl acetate (20 ml). The organic component was separated, washed with brine (20 ml), dried over magnesium sulphate and concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (80:20, by volume) to provide the title compound (267 mg) as a colourless oil.

[1351]¹H NMR (400 MHz, CDCl₃): δ=1.61 (m, 6H), 2.18 (s, 3H), 3.48 (m, 1H), 3.64 (m, 1H), 3.75 (m, 1H), 4.30 (t, 2H), 4.50 (broad s, 1H), 6.85 (d, 1H), 6.94 (s, 1H), 7.05 (d, 1H).

[1352] LRMS (electrospray): m/z [M−H⁺] 412.

[1353] Preparation 100

[1354] 3-Cyano-5-[(3,5-diethyl-1-{2-[(2-methoxyethoxy)methoxy]ethyl}-1H-pyrazol-4-yl)oxy]benzamide

[1355] To a stirred solution of the pyrazole from Example 261 (193 mg, 0.49 mmol) in tetrahydrofuran (2 ml) was added 2M aqueous sodium hydroxide solution (8.7 μl, 0.49 mmol) and the reaction mixture was heated at 65° C. for 24 hours. After cooling to room temperature a second portion of 2M sodium hydroxide solution (8.7μ, 0.49 mmol) was added and the mixture was heated at 65° C. for 24 hours. 6M aqueous sodium hydroxide solution (100 μl) was added and the mixture was heated at 65° C. for 24 hours. The reaction mixture was concentrated under reduced pressure, diluted with water (75 ml), neutralised to pH 7 using 2M aqueous hydrochloric acid solution and extracted with dichloromethane (2×25 ml). The combined organic components were dried over magnesium sulphate and concentrated under reduced pressure to give a crude product mixture which was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (100:0, 98:2, 96.5:3.5 then 95:5, by volume) to provide the title compound (60 mg) as a colourless oil.

[1356]¹H NMR (400 MHz, CDCl₃): δ=1.10 (m, 6H), 2.40 (q, 2H), 2.55 (q, 2H), 3.36 (s, 3H), 3.50 (q, 2H), 3.59 (q, 2H), 3.94 (q, 2H), 4.20 (q, 2H), 4.64 (s, 2H), 7.30 (s, 1H), 7.59 (s, 1H), 7.70 (s, 1H).

[1357] Preparation 101

[1358] 5-[(1-Acetyl-3,5-diethyl-1H-pyrazol-4-yl) oxy]isophthalonitrile

[1359] To a stirred solution of the pyrazole from Example 122 (3.0 g, 11.3 mmol) in dimethylformamide (45 ml) at 0° C. was added acetyl chloride (1.2 ml, 17.0 mmol), followed by sodium hydride portionwise (678 mg of 60% by weight dispersion in oil, 17.0 mmol). The cooling bath was removed and the reaction mixture was stirred at room temperature for 40 minutes. The reaction was quenched by addition of saturated aqueous ammonium chloride solution (4 ml) and concentrated under reduced pressure to give an orange residue. This material was partitioned between ethyl acetate (200 ml) and water (200 ml). The organic component was washed with water (100 ml), brine (75 ml) and then dried over magnesium sulphate before being concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (100:0, 99:1, then 98:2, by volume) to provide the title compound (2.67 g) as a white solid.

[1360]¹H NMR (400 MHz, CDCl₃): δ=1.15 (t, 3H), 1.19 (t, 3H), 2.43 (q, 2H), 2.72 (s, 3H), 3.85 (q, 2H), 7.38 (s, 2H), 7.61 (s, 1H).

[1361] LRMS (electrospray): m/z 331 [M+Na⁺].

[1362] Preparation 102

[1363] 5-{[1-Acetyl-3-(1-bromoethyl)-5-ethyl-1H-pyrazol-4-yl]oxy}isophthalonitrile

[1364] A solution of the pyrazole from Preparation 101 (881 mg, 2.86 mmol) in carbontetrachloride (12 ml) was degassed by passing a stream of nitrogen through the solution for 20 minutes. N-bromosuccinimide (763 mg, 4.28 mmol) was added followed by AIBN (30 mg) and the reaction mixture was heated at 85° C. for 4 hours. After cooling to room temperature the mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with pentane:ethyl acetate (a gradient from 100:0 to 67:33, by volume) to provide the title compound (348 mg) as a colourless oil.

[1365]¹H NMR (400 MHz, CDCl₃): δ=1.10 (t, 3 h), 2.00 (d, 3H), 2.70 (s, 3H), 2.80 (m, 2H), 4.95 (q, 1H), 7.42 (s, 2H), 7.60 (s, 1H).

[1366] LRMS (electrospray): m/z 283 [MH⁺].

[1367] Preparation 103

[1368] 5-({5-Ethyl-3-(1-hydroxyethyl)-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl}oxy) isophthalonitrile

[1369] To a stirred solution of the pyrazole from Example 263 (197 mg, 0.70 mmol) in dimethylformamide (3 ml) at 0° C. was added 2-(2-bromoethoxy)tetrahydro-2H-pyran (105 μl, 0.70 mmol) followed by sodium hydride (31 mg, 0.77 mmol). After 15 minutes the cooling bath was removed and the mixture was stirred at room temperature for 60 hours. The reaction mixture was quenched by addition of saturated aqueous ammonium chloride solution (0.5 ml) and then concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (a gradient from 100:0 to 95:5, by volume) to provide the title compound (84 mg) as a white foam which reverts to an oil on standing.

[1370]¹H NMR (400 MHz, CDCl₃): δ=1.11 (t, 3H), 1.45 (d, 3H), 1.65 (m, 6H), 2.59 (q, 2H), 3.50 (m, 1H), 3.70 (m, 1H), 3.81 (m, 1H), 4.11 (m, 1H), 4.25 (t, 2H), 4.56 (m, 1H), 4.76 (m, 1H), 7.40 (s, 2H), 7.55 (s, 1H).

[1371] LRMS (electrospray): m/z 411 [MH⁺].

[1372] Preparation 104

[1373] 3-Cyano-5-[(3,5-diethyl-1-{2-[(2-methoxyethoxy)methoxy]ethyl}-1H-pyrazol-4-yl)oxy]-N′-hydroxybenzenecarboximidamide

[1374] To a stirred solution of the pyrazole from Example 261 (1.5 g, 3.76 mmol) in ethanol (7.5 ml) was added a solution of sodium carbonate (200 mg, 1.88 mmol) and hydroxylamine hydrochloride (262 mg, 3.76 mmol) in water (7.5 ml). After stirring for 5 hours at room temperature the reaction mixture was concentrated under reduced pressure and the residue was partitioned between dichloromethane (50 ml) and water (40 ml). The aqueous phase was separated and extracted with dichloromethane (30 ml). The organic components were combined, dried over magnesium sulphate and concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (a gradient from 100:0 to 96:4, by volume) to provide the title compound (1.13 mg) as a colourless oil.

[1375]¹H NMR (400 MHz, CDCl₃): δ=1.11 (m, 6H), 2.42 (q, 2H), 2.58 (q, 2H), 3.41 (s, 3H), 3.59 (m, 4H), 3.95 (t, 2H), 4.17 (t, 2H), 4.61 (s, 2H), 4.77 (broad s, 2H), 7.38 (m, 1H), 7.49 (m, 2H).

[1376] LRMS (electrospray): m/z 432 [MH⁺].

[1377] Microanalysis: Found C, 57.50; H, 6.71; N, 16.01. C₂₁H₂₆N₄O₄+0.4H₂O requires C, 57.50; H, 6.85; N, 15.96%.

[1378] Preparation 105

[1379] 3-[(3,5-Diethyl-1-{2-[(2-methoxyethoxy)methoxy]ethyl}-1H-pyrazol-4-yl)oxy]-5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzonitrile

[1380] To a stirred solution of the amidoxime from Preparation 104 (300 mg, 0.70 mmol) in pyridine (3 ml) was added trifluoroacetic anhydride (118 μl, 0.83 mmol). After stirring at room temperature for 2 hours the reaction mixture was heated at 110° C. for 18 hours. After cooling to room temperature the mixture was concentrated under reduced pressure and the residue was partitioned between 2M aqueous HCl solution (6 ml) and dichloromethane (6 ml). The organic phase was separated and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol (a gradient from 100:0 to 90:10, by volume) to provide the title compound (259 mg) as a colourless oil.

[1381]¹H NMR (400 MHz, CDCl₃): δ=1.14 (m, 6H), 2.46 (q, 2H), 2.59 (q, 2H), 3.39 (s, 3H), 3.53 (q, 2H), 3.59 (q, 2H), 3.95 (q, 2H), 4.29 (q, 2H), 4.68 (s, 2H), 7.34 (s, 1H), 7.87 (s, 1H), 8.04 (s, 1H).

[1382] LRMS (APCI): m/z 532 (MH⁺)

[1383] Preparations 106-108

[1384] The preparation of the following tabulated Preparations of the general formula

[1385] were performed by a similar method to that of Preparation 105 using the appropriate acid chloride as the acylating agent in place of trifluoroacetic anhydride. Preparation no. R Analytical Data 106 Me ¹H NMR(400 MHz, CDCl₃): δ = 1.14(m, 6H), 2.46 (q, 2H), 2.59(q, 2H), 2.67(s, 3H), 3.39(s, 3H), 3.55 (q, 2H), 3.59(q, 2H), 3.95(q, 2H), 4.22(q, 2H), 4.68 (s, 2H), 7.27(s, 1H), 7.82(s, 1H), 8.00(s, 1H). LRMS (electrospray): m/z 478 [M + Na⁺] Microanalysis: Found C, 59.91; H, 6.27; N, 15.38. C₂₃H₂₉N₅O₅ + 0.3H₂O requires C, 59.94; H, 6.475; N, 15.19%. 107 Et ¹H NMR(400 MHz, CDCl₃): δ = 1.14(m, 6H), 1.44(t, 3H), 2.42(q, 2H), 2.48(q, 2H), 2.98(q, 2H), 3.39(s, 3H), 3.53(q, 2H), 3.59(q, 2H), 3.95(q, 2H), 4.20(q, 2H), 4.48(s, 2H), 7.30(s, 1H), 7.84(s, 1H), 8.01(s, 1H). LRMS (electrospray): m/z 492 (M + Na⁺) 108 ^(i)Pr ¹H NMR(400 MHz, CDCl₃): δ = 1.11(m, 6H), 1.49(d, 6H), 2.44(q, 2H), 2.49(q, 2H), 3.30(sept, 1H), 3.39(s, 3H), 3.54(m, 2H), 3.59(m, 2H), 3.95(t, 2H), 4.23(t, 2H), 4.91(s, 2H), 7.22(m, 1H), 7.83(m, 1H), 8.02(m, 1H). LRMS (electrospray): m/z 506 (M + Na⁺) Microanalysis: Found C, 61.87; H, 6.76; N, 14.62. C₂₅H₃₃N₅O₅ requires C, 62.10; H, 6.88; N, 14.48%.

[1386] Preparation 109

[1387] Ethyl 5-{[(tert-butoxycarbonyl)amino]methyl}nicotinate

[1388] To a stirred solution of ethyl-5-cyanonicotinate (3.0 g, 17.0 mmol; Annalen Der Chemie, 1959, 621, 106-136) in ethanol (200 ml) was added concentrated hydrochloric acid (3.4 ml) followed by 5% palladium on carbon (300 mg). The reaction mixture was stirred at room temperature under an hydrogen atmosphere (50 psi) for 18 hours. The reaction mixture was filtered through Arbocel® and concentrated under reduced pressure. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.880 ammonia (a gradient from 95:5:0.5 to 85:5:1.5, by volume) to provide the intermediate amine (2.1 g) as a yellow oily solid. This material (2.1 g, 11.7 mmol) was suspended in dichloromethane (22 ml) to which was added triethylamine (1.8 ml, 13.0 mmol) followed by di-tert-butyl dicarbonate (2.84 g, 13 mmol). After 48 hours the reaction mixture was diluted with dichloromethane (50 ml) and washed with water (50 ml). The organic component was dried over magnesium sulphate and concentrated under reduced pressure before being purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (a gradient from 100:0:0 to 95:5:0.5, by volume) to provide the title compound (2.0 g) as a yellow oil

[1389]¹H NMR (400 MHz, CDCl₃): δ=1.40 (m, 12H), 4.42 (m, 4H), 8.22 (s, 1H), 8.71 (s, 1H), 9.12 (s, 1H).

[1390] LRMS (APCI): m/z 279 (M−H⁺)

[1391] Preparation 110

[1392] 5-{[(tert-Butoxycarbonyl)amino]methyl}nicotinic Acid

[1393] To a stirred solution of the ester from Preparation 109 (2.00 g, 7.10 mmol) in 1 M aqueous sodium hydroxide solution (15 ml, 15 mmol) was added methanol (15 ml). The reaction mixture was stirred at room temperature for 18 hours, after which time the methanol was removed under reduced pressure. The aqueous solution was washed with diethyl ether (2×25 ml), cooled to 0° C. and neutralised to pH 7 by addition of 2M aqueous hydrochloric acid solution (7.5 ml). The mixture was concentrated under reduced pressure to give a yellow oil (1.5 g).

[1394]¹H NMR (400 MHz, (CD₃)₂SO): δ=1.37 (s, 9H), 4.16 (d, 2H), 7.51 (m, 1H), 8.07 (s, 1H), 8.50 (s, 1H), 8.88 (s, 1H).

[1395] LRMS (APCI): m/z 251 (M−H⁺)

[1396] Preparation 111

[1397] 5-(Aminomethyl)nicotinamide

[1398] To a stirred solution of the acid from Preparation 110 (770 mg, 3.10 mmol) in dimethylformamide (15 ml) was added carbonyldiimidazole (600 mg, 3.70 mmol). After 10 minutes 0.880 ammonia (1 ml) was added. After a further 1 hour the reaction mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (a gradient from 95:5:0.5 to 80:20:1, by volume) to provide the boc-protected intermediate. To a stirred solution of this material in dichloromethane (20 ml) was added trifluroacetic acid (6 ml). After 18 hours a second portion of trifluoroacetic acid (6 ml) was added and the reaction mixture was stirred at room temperature for 24 hours. The solution was concentrated under reduced pressure to give an oily residue which was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (100:0:0 then 90:10:1 then 80:20:1, by volume) to provide the title compound (650 mg) as a yellow oil.

[1399]¹H NMR (400 MHz, (CD₃)₂SO): δ=4.11 (s, 2H), 7.5 (broad s), 7.59 (broad s), 8.14 (broad s), 8.31 (m, 1H), 8.72 (m, 1H), 8.90 (m, 1H).

[1400] LRMS (electrospray): m/z 152 (MH⁺)

[1401] HRMS: [MH⁺] 152.0819. C₇H₁₀N₃O requires 152.0818

[1402] Preparation 112

[1403] Ethyl 2-{[(tert-butoxycarbonyl)amino]methyl}isonicotinate

[1404] To a stirred solution of ethyl 2-cyanoisonicotinate (2.00 g, 110 mmol, J. Med. Chem., 1976,19, 483) in ethanol (20 ml) was added 2M aqueous hydrochloric acid solution (7.5 ml) followed by 5% palladium on carbon (200 mg). The reaction mixture was stirred at room temperature under a hydrogen atmosphere (60 psi) for 48 hours. The mixture was filtered through arbocel and the filtrate was concentrated under reduced pressure. The residue was dried by azeotropic distillation using toluene under reduced pressure. To a stirred solution of the residue (3.00 g) in dichloromethane (22 ml) was added triethylamine (4.6 ml, 33 mmol) followed by di-tert-butyl dicarbonate (2.62 g, 12.0 mmol). After stirring for 1 hour at room temperature the reaction mixture was diluted with dichloromethane (100 ml) and washed with water (50 ml). The organic component was washed with brine (50 ml), dried over magnesium sulphate and concentrated under reduced pressure to give a brown oily solid. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (98:2:0.2 then 97:3:0.3, by volume) to provide the title compound (2.20 g) as a yellow oil.

[1405]¹H NMR (400 MHz, CDCl₃): δ=1.38 (t, 3H), 1.45 (s, 9H), 4.38 (q, 2H), 4.50 (m, 2H), 5.50 (broad s, 1H), 7.73 (d, 1H), 7.81 (s, 1H), 8.65 (d, 1H).

[1406] LRMS (electrospray): m/z 281 (MH⁺)

[1407] Preparation 113

[1408] 2-{[(tert-Butoxycarbonyl)amino]methyl}isonicotinic Acid

[1409] To a stirred solution of the ester from Preparation 112 (1.50 g, 5.35 mmol) in methanol (10 ml) was added 1M aqueous sodium hydroxide solution (10 ml). After 1 hour the reaction mixture was cooled to 0° C. and neutralised by addition of 2M aqueous hydrochloric acid solution (5 ml). The reaction mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.880 ammonia (80:20:1, by volume) to provide the title compound (1.30 g) as a yellow foam.

[1410]¹H NMR (400 MHz, (CD₃OD): δ=1.43 (s, 9H), 4.36, (s, 2H), 7.68 (m, 1H), 7.81 (s, 1H), 8.47 (m, 1H).

[1411] LRMS (electrospray): m/z 251 (M−H⁺)

[1412] HRMS: [MH⁺] 253.1179. C₁₂H₁₇N₂O₄ requires 253.1183

[1413] Preparation 114

[1414] tert-Butyl [4-(aminocarbonyl)-2-pyridinyl]methylcarbamate

[1415] To a stirred solution of the acid from Preparation 113 (1.3 g, 5.20 mmol) in dimethylformamide (10 ml) was added 1-hydroxybenzotriazole (950 mg, 6.20 mmol) followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride salt (1.20 g, 6.20 mmol). After 1 hour 0.880 ammonia (5 ml) was added and the reaction mixture was stirred at room temperature for 1.5 hours. The mixture was concentrated under reduced pressure and dried by azeotropic distillation using toluene under reduced pressure to give a yellow semi-solid. The crude product mixture was purified by flash chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia (95:5:0.5, by volume) to provide the title compound (1.1 g) as a clear oil which crystallised on standing. This material was further purified by triturating with diethyl ether (10 ml) which gave a sample of the desired product (1.0 g) white powder/.

[1416]¹H NMR (400 MHz, D6-DMSO): δ=1.39 (s, 9H), 4.25 (m, 2H), 7.44 (m, 1H), 7.61 (m, 1H), 7.66 (broad s, 2H), 8.21 (broad s, 1H), 8.59 (d, 1H).

[1417] LRMS (electrospray): m/z 250 (M−H⁺)

[1418] Microanalysis: Found C, 57.26; H, 6.86; N, 16.65. C₁₂H₁₇N₃O₃ requires C, 57.36; H, 6.82; N, 16.72%.

[1419] Preparation 115

[1420] 2-(Aminomethyl)isonicotinamide

[1421] To a stirred solution of the pyridine from Preparation 114 (1.00 g, 3.98 mmol) in dichloromethane (50 ml) was added trifluoroacetic acid (15 ml). After stirring at room temperature for 18 hours the reaction mixture was concentrated under reduced pressure and purified by ion-exchange chromatography on Dowex 50-X8-200 eluting with water followed by 0.880 ammonia:methanol:water (5:5:90, by volume) to provide the title compound (265 mg) as a white solid.

[1422]¹H NMR (400 MHz, D6-DMSO): δ=2.1 (broad s, 1H), 3.4 (broad s, 1H), 3.85 (2H, s), 7.57 (m, 1H), 7.60 (broad s, 1H), 7.80 (m, 1H), 8.16 (broad s, 1H), 8.59 (m, 1H).

[1423] LRMS (APCI): m/z 152 (MH⁺) 

What is claimed is:
 1. A compound of formula (I)

or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein: either: R¹ is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl, benzyl, halo, —CN, —OR⁷, —CO₂R¹⁰, —CONR⁵R¹⁰, R⁸ or R⁹, said C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl and benzyl being unsubstituted or substituted by halo, —CN, —OR¹⁰, S(O)_(x)R¹⁰, —CO₂R¹⁰, —CONR⁵R¹⁰, —OCONR⁵R¹⁰, —NR⁵CO₂R¹⁰, —NR¹⁰R¹¹, —NR⁵COR¹⁰, —SO₂NR⁵R¹⁰, —NR⁵CONR⁵R¹⁰, —NR⁵SO₂R¹⁰ or R¹⁰; and R² is H, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, C₃-C₇ cycloalkyl, C₃-C₇ cycloalkenyl, phenyl, benzyl, R⁸ or R⁹, said C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl and benzyl being unsubstituted or substituted by halo, —OR⁵, —OR¹², —CN, —CO₂R⁷, —OCONR⁵R⁵, —CONR⁵R⁵, —C(═NR⁵)NR⁵OR⁵, —CONR⁵NR⁵R⁵, —NR⁶R⁶, —NR⁵R¹², —NR⁵COR⁵, —NR⁵COR⁸, —NR⁵COR¹², —NR⁵CO₂R⁵, —NR⁵CONR⁵R⁵, —SO₂NR⁵R⁵, —NR⁵SO₂R⁵, —NR⁵SO₂NR⁵R⁵, R⁸ or R⁹; or R¹ and R², when taken together, represent an unbranched C₃-C₄ alkylene, unsubstituted or substituted by oxo, wherein one methylene group of said C₃-C₄ alkylene may be replaced by an oxygen atom or a nitrogen atom, said nitrogen atom being unsubstituted or substituted by R¹⁰; R³ is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl, benzyl, halo, —CN, —OR⁷, —CO₂R⁵, —CONR⁵R⁵, R⁸ or R⁹, said C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl and benzyl being unsubstituted or substituted by halo, —CN, —OR⁵, —CO₂R⁵, —CONR⁵R⁵, —OCONR⁵R⁵, —NR⁵CO₂R⁵, —NR⁶R⁶, —NR⁵COR⁵, —SO₂NR⁵R⁵, —NR⁵CONR⁵R⁵, —NR⁵SO₂R⁵, R⁸ or R⁹; R⁴ is phenyl, naphthyl or pyridyl, each being unsubstituted or substituted by R⁸, halo, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl, C₁-C₆ alkoxy, —CONR⁵R⁵, OR¹³, SO_(x)R⁶, O—(C₁-C₆ alkylene)-CONR⁵R⁵, O—(C₁-C₆ alkylene)-NR⁵R⁵, or O—(C₁-C₆ alkylene)-OR⁶; each R⁵ is independently either H, C₁-C₆ alkyl or C₃-C₇ cycloalkyl or, when two R⁵ groups are attached to the same nitrogen atom, those two groups taken together with the nitrogen atom to which they are attached represent azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl or morpholinyl, said azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl and morpholinyl being unsubstituted or substituted by C₁-C₆ alkyl or C₃-C₇ cycloalkyl; each R⁶ is independently either H, C₁-C₆ alkyl or C₃-C₇ cycloalkyl; R⁷ is C₁-C₆ alkyl or C₃-C₇ cycloalkyl; R⁸ is a five or six-membered, aromatic heterocyclic group containing (i) from 1 to 4 nitrogen heteroatom(s) or (ii) 1 or 2 nitrogen heteroatom(s) and 1 oxygen or 1 sulphur heteroatom or (iii) 1 or 2 oxygen or sulphur heteroatom(s), said heterocyclic group being unsubstituted or substituted by halo, oxo, —CN, —COR⁵, —CONR⁵R⁵, —SO₂NR⁵R⁵, —NR⁵SO₂R⁵, —OR⁵, —NR⁵R⁵, —(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, fluoro(C₁-C₆)alkyl or C₃-C₇ cycloalkyl; R⁹ is a four to seven-membered, saturated or partially unsaturated heterocyclic group containing (i) 1 or 2 nitrogen heteroatom(s) or (ii) 1 nitrogen heteroatom and 1 oxygen or 1 sulphur heteroatom or (iii) 1 oxygen or sulphur heteroatom, said heterocyclic group being unsubstituted or substituted by oxo, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, —SO₂R⁵, —CONR⁵R⁵, —COOR⁵, —CO—(C₁-C₆ alkylene)-OR⁵ or —COR⁵ and unsubstituted or substituted on a carbon atom which is not adjacent to a heteroatom by halo, —OR⁵, —NR⁵R⁵, —NR⁵COR⁵, —NR⁵COOR⁵, —NR⁵CONR⁵R⁵, —NR⁵SO₂R⁵ or —CN; R¹⁰ is H, R⁸, R⁹, R¹³, C₁-C₆ alkyl, C₃-C₇ cycloalkyl or —(C₁-C₆ alkyl)-(C₃-C₇ cycloalkyl), said C₁-C₆ alkyl and C₃-C₇ cycloalkyl being unsubstituted or substituted by —OR⁵, —OR¹³, R⁸, R⁹, R¹³ or —COR¹³; R¹¹ is H, C₁-C₆ alkyl or C₃-C₇ cycloalkyl, said C₁-C₆ alkyl and C₃-C₇ cycloalkyl being unsubstituted or substituted by —OR⁵, —NR⁵R⁵, —NR⁵COR⁵, —CONR⁵R⁵, R⁸ or R⁹; R¹² is C₁-C₆ alkyl substituted by R⁸, R⁹, —OR⁵, —CONR⁵R⁵, —NR⁵COR⁵ or —NR⁵R⁵; R¹³ is phenyl unsubstituted or substituted by halo, —CN, —COR⁵, —CONR⁵R⁵, —SO₂NR⁵R⁵, —NR⁵SO₂R⁵, —OR⁵, —NR⁵R⁵, —(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, halo(C₁-C₆)alkyl or C₃-C₇ cycloalkyl; and x is 0, 1 or 2; with the proviso that: (a) when R¹ and R³ are both phenyl, R² is not methyl; and (b) when R¹ is ethoxy and R³ is ethoxycarbonyl, R² is not phenyl.
 2. A compound of formula (I)

or a pharmaceutically acceptable salt thereof, wherein: either: R¹ is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl, benzyl, halo, —CN, —OR⁷, —CO₂R¹⁰, —CONR⁵R¹⁰, R⁸ or R⁹, said C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl and benzyl being unsubstituted or substituted by halo, —CN, —OR¹⁰, S(O)_(x)R¹⁰, —CO₂R¹⁰, —CONR⁵R¹⁰, —OCONR⁵R¹⁰, —NR⁵CO₂R¹⁰, —NR¹⁰R¹¹, —NR⁵COR¹⁰, SO₂NR⁵R¹⁰, —NR⁵CONR⁵R¹⁰, —NR⁵SO₂R¹⁰ or R¹⁰; and R² is H, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, C₃-C₇ cycloalkyl, C₃-C₇ cycloalkenyl, phenyl, benzyl, R⁸ or R⁹, said C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl and benzyl being unsubstituted or substituted by halo, —OR⁵, —OR¹², —CN, —CO₂R⁷, —OCONR⁵R⁵, —CONR⁵R⁵, —C(═NR⁵)NR⁵OR⁵, —CONR⁵NR⁵R⁵, —NR⁶R⁶, —NR⁵R¹², —NR⁵COR⁵, —NR⁵COR⁸, —NR⁵COR¹², —NR⁵CO₂R⁵, —NR⁵CONR⁵R⁵, —SO₂NR⁵R⁵, —NR⁵SO₂R⁵, —NR⁵SO₂NR⁵R⁵, R⁸ or R⁹; or R¹ and R², when taken together, represent an unbranched C₃-C₄ alkylene, unsubstituted or substituted by oxo, wherein one methylene group of said C₃-C₄ alkylene may be replaced by an oxygen atom or a nitrogen atom, said nitrogen atom being unsubstituted or substituted by R¹⁰; R³ is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl, benzyl, halo, —CN, —OR⁷, —CO₂R⁵, —CONR⁵R⁵, R⁸ or R⁹, said C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl and benzyl being unsubstituted or substituted by halo, —CN, —OR⁵, —CO₂R⁵, —CONR⁵R⁵, —OCONR⁵R⁵, —NR⁵CO₂R⁵, —NR⁶R⁶, —NR⁵COR⁵, —SO₂NR⁵R⁵, —NR⁵CONR⁵R⁵, —NR⁵SO₂R⁵, R⁸ or R⁹; R⁴ is phenyl, naphthyl or pyridyl, each being unsubstituted or substituted by R⁸, halo, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl, C₁-C₆ alkoxy, —CONR⁵R⁵, OR¹³, SO_(x)R⁶, O—(C₁-C₆ alkylene)-CONR⁵R⁵, O—(C₁-C₆ alkylene)-NR⁵R⁵, or O—(C₁-C₆ alkylene)-OR⁶; each R⁵ is independently either H, C₁-C₆ alkyl or C₃-C₇ cycloalkyl or, when two R⁵ groups are attached to the same nitrogen atom, those two groups taken together with the nitrogen atom to which they are attached represent azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl or morpholinyl, said azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl and morpholinyl being unsubstituted or substituted by C₁-C₆ alkyl or C₃-C₇ cycloalkyl; each R⁶ is independently either H, C₁-C₆ alkyl or C₃-C₇ cycloalkyl; R⁷ is C₁-C₆ alkyl or C₃-C₇ cycloalkyl; R⁸ is a five or six-membered, aromatic heterocyclic group containing (i) from 1 to 4 nitrogen heteroatom(s) or (ii) 1 or 2 nitrogen heteroatom(s) and 1 oxygen or 1 sulphur heteroatom or (iii) 1 or 2 oxygen or sulphur heteroatom(s), said heterocyclic group being unsubstituted or substituted by halo, oxo, —CN, —COR⁵, —CONR⁵R⁵, —SO₂NR⁵R⁵, —NR⁵SO₂R⁵, —OR⁵, —NR⁵R⁵, —(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, fluoro(C₁-C₆)alkyl or C₃-C₇ cycloalkyl; R⁹ is a four to seven-membered, saturated or partially unsaturated heterocyclic group containing (i) 1 or 2 nitrogen heteroatom(s) or (ii) 1 nitrogen heteroatom and 1 oxygen or 1 sulphur heteroatom or (iii) 1 oxygen or sulphur heteroatom, said heterocyclic group being unsubstituted or substituted by oxo, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, —SO₂R⁵, —CONR⁵R⁵, —COOR⁵, —CO—(C₁-C₆ alkylene)-OR⁵ or —COR⁵ and unsubstituted or substituted on a carbon atom which is not adjacent to a heteroatom by halo, —OR⁵, —NR⁵R⁵, —NR⁵COR⁵, —NR⁵COOR⁵, —NR⁵CONR⁵R⁵, —NR⁵SO₂R⁵ or —CN; R¹⁰ is H, R⁸, R⁹, R¹³, C₁-C₆ alkyl, C₃-C₇ cycloalkyl or —(C₁-C₆ alkyl)-(C₃-C₇ cycloalkyl), said C₁-C₆ alkyl and C₃-C₇ cycloalkyl being unsubstituted or substituted by —OR⁵, —OR¹³, R⁸, R⁹, R¹³ or —COR¹³; R¹¹ is H, C₁-C₆ alkyl or C₃-C₇ cycloalkyl, said C₁-C₆ alkyl and C₃-C₇ cycloalkyl being unsubstituted or substituted by —OR⁵, —NR⁵R⁵, —NR⁵COR⁵, —CONR⁵R⁵, R⁸ or R⁹; R¹² is C₁-C₆ alkyl substituted by R⁸, R⁹, —OR⁵, —CONR⁵R⁵, —NR⁵COR⁵ or —NR⁵R⁵; R¹³ is phenyl unsubstituted or substituted by halo, —CN, —COR⁵, —CONR⁵R⁵, —SO₂NR⁵R⁵, —NR⁵SO₂R⁵, —OR⁵, —NR⁵R⁵, —(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, halo(C₁-C₆)alkyl or C₃-C₇ cycloalkyl; and x is 0, 1 or 2; with the proviso that: (a) when R¹ and R³ are both phenyl, R² is not methyl; and (b) when R¹ is ethoxy and R³ is ethoxycarbonyl, R² is not phenyl.
 3. A compound according to claim 1 or 2 wherein R¹, when taken separately, is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl or —OR⁷, said C₁-C₆ alkyl and C₃-C₇ cycloalkyl being unsubstituted or substituted by halo, —CN, —OR¹⁰, S(O)_(x)R¹⁰, —CO₂R¹⁰, —CONR⁵R¹⁰, —OCONR⁵R¹⁰, —NR⁵CO₂R¹⁰, —NR¹⁰R¹¹, —NR⁵COR¹⁰, —SO₂NR⁵R¹⁰, —NR⁵CONR⁵R¹⁰, —NR⁵SO₂R¹⁰ or R¹⁰.
 4. A compound according to any one of claims 1 to 3 wherein R¹, when taken separately, is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl or —OR⁷, said C₁-C₆ alkyl being unsubstituted or substituted by halo, —OR¹⁰, —NR¹⁰R¹¹, —NR⁵COR¹⁰ or R¹⁰.
 5. A compound according to any one of claims 1 to 4 wherein R², when taken separately, is H, C₁-C₆ alkyl, C₃-C₆ alkenyl or R⁹, said C₁-C₆ alkyl being unsubstituted or substituted by halo, —OR⁵, —OR¹², —CN, —CO₂R⁷, —OCONR⁵R⁵,—CONR⁵R⁵, —C(═NR⁵)NR⁵OR⁵, —CONR⁵NR⁵R⁵, —NR⁶R⁶, —NR⁵R¹², —NR⁵COR⁵, —NR⁵COR⁸, —NR⁵COR¹², —NR⁵CO₂R⁵, —NR⁵CONR⁵R⁵, —SO₂NR⁵R⁵, —NR⁵SO₂R⁵, R⁸ or R⁹.
 6. A compound according to any one of claims 1 to 5 wherein R², when taken separately, is H, C₁-C₆ alkyl, C₃-C₆ alkenyl or R⁹, said C₁-C₆ alkyl being unsubstituted or substituted by —OR⁵, —OR¹², —CN, —CO₂R⁷, —CONR⁵R⁵, —C(═NR⁵)NR⁵OR⁵, —CONR⁵NR⁵R⁵, —NR⁶R⁶, —NR⁵R¹², —NR⁵COR⁸, —NR⁵COR¹², —NR⁵CO₂R⁵, R⁸ or R⁹.
 7. A compound according to claim 1 or 2 wherein R¹ and R², when taken together, represent an unbranched C₃-C₄ alkylene, unsubstituted or substituted by oxo, wherein one methylene group of said C₃-C₄ alkylene is replaced by an oxygen atom or a nitrogen atom, said nitrogen atom being unsubstituted or substituted by R¹⁰.
 8. A compound according to any one of claim 1, 2 or 7 wherein R¹ and R², when taken together, represent unbranched propylene wherein one methylene group is replaced by an oxygen atom or unbranched butylene wherein one methylene group is replaced by a nitrogen atom, said propylene and butylene being unsubstituted or substituted by oxo and said nitrogen atom being unsubstituted or substituted by R¹⁰.
 9. A compound according to any one of claims 1 to 8 wherein R³ is H or C₁-C₆ alkyl, said C₁-C₆ alkyl being unsubstituted or substituted by halo, —CN, —OR⁵, —CO₂R⁵, —CONR⁵R⁵, —OCONR⁵R⁵, —NR⁵CO₂R⁵, —NR⁶R⁶, —NR⁵COR⁵, —SO₂NR⁵R⁵, —NR⁵CONR⁵R⁵, —NR⁵SO₂R⁵, R⁸ or R⁹.
 10. A compound according to any one of claims 1 to 9 wherein R³ is H or C₁-C₆ alkyl.
 11. A compound according to any one of claims 1 to 10 wherein R⁴ is phenyl unsubstituted or substituted by R⁸, halo, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl, C₁-C₆ alkoxy, —CONR⁵R⁵, OR¹³, SO_(x)R⁶, O—(C₁-C₆ alkylene)-CONR⁵R⁵, O—(C₁-C₆ alkylene)-NR⁵R⁵, or O—(C₁-C₆ alkylene)-OR⁶; or naphthyl.
 12. A compound according to any one of claims 1 to 11 wherein R⁴ is phenyl substituted by R⁸, halo, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl, C₁-C₆-alkoxy, —CONR⁵R⁵, OR¹³, SO_(x)R⁶, O—(C₁-C₆ alkylene)-CONR⁵R⁵, O—(C₁-C₆ alkylene)—NR⁵R⁵, or O—(C₁-C₆ alkylene)-OR⁶.
 13. A compound according to any one of claims 1 to 12 wherein R⁴ is phenyl substituted by R⁸, halo, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl or C₁-C₆ alkoxy.
 14. A compound according to any one of claims 1 to 13 wherein R⁴ is phenyl substituted by halo, —CN or C₁-C₆ alkyl.
 15. A compound according to any one of claims 1 to 14 wherein R⁸ is pyrrolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, furanyl, thienyl, pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl, each being unsubstituted or substituted by halo, —CN, —COR⁵, —CONR⁵R⁵, —SO₂NR⁵R⁵, —NR⁵SO₂R⁵, —OR⁵, —NR⁵R⁵, —(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, fluoro(C₁-C₆)alkyl or C₃-C₇ cycloalkyl.
 16. A compound according to any one of claims 1 to 15 wherein R⁸ is imidazolyl, pyrazolyl, 1,2,4-triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrazinyl or pyrimidinyl, each being unsubstituted or substituted by halo, —CN, —COR⁵, —CONR⁵R⁵, —SO₂NR⁵R⁵, —NR⁵SO₂R⁵, —OR⁵, —NR⁵R⁵, —(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, fluoro(C₁-C₆)alkyl or C₃-C₇ cycloalkyl.
 17. A compound according to any one of claims 1 to 16 wherein R⁸ is imidazolyl, pyrazolyl, 1,2,4-triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrazinyl or pyrimidinyl, each being unsubstituted or substituted by —OR⁵, —NR⁵R⁵ or C₁-C₆ alkyl.
 18. A compound according to any one of claims 1 to 17 wherein R⁹ is azetidinyl, tetrahydropyrrolyl, piperidinyl, azepinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, oxepinyl, morpholinyl, piperazinyl or diazepinyl, each being unsubstituted or substituted by oxo, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, —SO₂R⁵, —CONR⁵R⁵, —COOR⁵, —CO—(C₁-C₆ alkylene)-OR⁵ or —COR⁵ and unsubstituted or substituted on a carbon atom which is not adjacent to a heteroatom by halo, —OR⁵, —NR⁵R⁵, —NR⁵COR⁵, —NR⁵COOR⁵, —NR⁵CONR⁵R⁵, —NR⁵SO₂R⁵ or —CN.
 19. A compound according to any one of claims 1 to 18 wherein R⁹ is azetidinyl, piperidinyl, tetrahydrofuranyl, piperazinyl or morpholinyl, each being unsubstituted or substituted by oxo, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, —SO₂R⁵, —CONR⁵R⁵, —COOR⁵, —CO—(C₁-C₆ alkylene)-OR⁵ or —COR⁵ and unsubstituted or substituted on a carbon atom which is not adjacent to a heteroatom by halo, —OR⁵, —NR⁵R⁵, —NR⁵COR⁵, —NR⁵COOR⁵, NR⁵CONR⁵R⁵, —NR⁵SO₂R⁵ or —CN.
 20. A compound according to any one of claims 1 to 19 wherein R⁹ is azetidinyl, piperidinyl, tetrahydrofuranyl, piperazinyl or morpholinyl, each being unsubstituted or substituted by C₁-C₆ alkyl, —SO₂R⁵, —CONR⁵R⁵, —COOR⁵, —CO—(C₁-C₆ alkylene)-OR⁵ or —COR⁵ and unsubstituted or substituted on a carbon atom which is not adjacent to a heteroatom by —OR⁵ or —NR⁵COR⁵.
 21. A compound according to any one of claims 1 to 20 wherein R¹⁰ is H, R⁸, R⁹, R¹³, C₁-C₆ alkyl or —(C₁-C₆ alkyl)-(C₃-C₇ cycloalkyl), said C₁-C₆ alkyl being unsubstituted or substituted by —OR⁵, —OR¹³, R⁸, R⁹, R¹³ or —COR¹³.
 22. A compound according to any one of claims 1 to 21 wherein R¹⁰ is H, R⁸, R⁹, R¹³, C₁-C₆ alkyl or —(C₁-C₆ alkyl)-(C₃-C₇ cycloalkyl), said C₁-C₆ alkyl being unsubstituted or substituted by —OR⁵ or R¹³.
 23. A compound according to any one of claims 1 to 22 wherein R¹¹ is H or C₁-C₆ alkyl, said C₁-C₆ alkyl being unsubstituted or substituted by —OR⁵, —NR⁵R⁵, —NR⁵COR⁵, —CONR⁵R⁵, R⁸ or R⁹.
 24. A compound according to any one of claims 1 to 23 wherein R¹¹ is H or C₁-C₆ alkyl, said C₁-C₆ alkyl being unsubstituted or substituted by —OR⁵ or —NR⁵COR⁵.
 25. A compound according to any one of claims 1 to 24 wherein R¹² is C₁-C₄ alkyl substituted by R⁸, R⁹, —OR⁵, —CONR⁵R⁵, —NR⁵COR⁵ or —NR⁵R⁵.
 26. A compound according to any one of claims 1 to 25 wherein R¹² is C₁-C₄ alkyl substituted by R⁹, —OR⁵, —NR⁵COR⁵ or —NR⁵R⁵.
 27. A compound according to any one of claims 1 to 26 wherein R¹³ is phenyl substituted by halo, —CN, —COR⁵, —CONR⁵R⁵, —SO₂NR⁵R⁵R⁵, —NR⁵SO₂R⁵, —OR⁵, —NR⁵R⁵, —(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, halo(C₁-C₆)alkyl or C₃-C₇ cycloalkyl.
 28. A compound according to any one of claims 1 to 27 wherein R¹³ is phenyl substituted by halo, —CN, —CONR⁵R⁵, —SO₂NR⁵R⁵ or —OR⁵.
 29. A compound selected from the group consisting of: 2-[4-(3,5-Dichlorophenoxy)-3,5-dimethyl-1H-pyrazol-1-yl]ethanol; 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol; 4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazole; [4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetonitrile; 5-{[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl}-1H-pyrazol-3-ol; 6-{[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl}-2-methyl-4 (3H)-pyrimidinone; 2-Amino-6-{[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl}-4 (3H)-pyrimidinone; 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]-N-hydroxyethanimidamide; Methyl [4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetate; 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetamide; 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetohydrazide; 5-{[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl}-1,3,4-oxadiazol-2(3H)-one; 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethylamine; 3-{[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl}-1,2,4-oxadiazol-5-ol; 5-{[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl}-1,3,4-oxadiazol-2-amine; N-{2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl}-2-methoxyacetamide; N-{2-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl}-2-pyridinecarboxamide; N-{2-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl}-2-pyrazinecarboxamide; 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}benzonitrile; 4-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-3,5-dimethylbenzonitrile; 3-chloro-4-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}benzonitrile; 5-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-2-fluorobenzonitrile; 2-[4-(4-chlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol; 2-[4-(3-chlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol; 2-[4-(2-chlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol; 2-[4-(2,6-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol; 2-[4-(2,3-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol; 2-[4-(2,4-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol; 2-[3,5-diethyl-4-(2-fluorophenoxy)-1H-pyrazol-1-yl]ethanol; 2-[3,5-diethyl-4-(3-fluorophenoxy)-1H-pyrazol-1-yl]ethanol; 2-[4-(3,5-dimethylphenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol; 2-[3,5-diethyl-4-(4-fluoro-3-methylphenoxy)-1H-pyrazol-1-yl]ethanol; 2-[4-(2,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol; 2-[4-(2,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol; 2-[4-(3,4-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol; 2-[4-(2,6-difluorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol; 2-[4-(2,5-difluorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol; 2-[4-(3,5-difluorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethanol; 4-(3,5-Dichlorophenoxy)-3,5-diethyl-1-(2-methoxyethyl)-1H-pyrazole; 4-(3,5-dichlorophenoxy)-3,5-diethyl-1-(methoxymethyl)-1H-pyrazole; 4-(3,5-dichlorophenoxy)-3,5-diethyl-1-methyl-1H-pyrazole; 4-(3,5-Dichlorophenoxy)-3-ethyl-1H-pyrazole; 4-{2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl}morpholine; N-{2-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl}-N-(2-methoxyethyl)amine; 1-(1-{2-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl}-4-piperidinyl)ethanone; N-{2-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl}-N,N-dimethylamine; N-[2-({2-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl}amino)ethyl]acetamide; N-{2-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl}-N-methylamine; N-{2-[4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl}-N-(tetrahydro-2-furanylmethyl)amine; 3-{[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]methyl}morpholine; 1-(3-Azetidinyl)-4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazole; 7-(3,5-Dichlorophenoxy)-6-ethyl-2,3-dihydropyrazolo[5, 1-b][1,3]oxazole; 4-(3,5-Dichlorophenoxy)-3,5-dimethyl-1H-pyrazole; 1-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]-2-propanol; 2-{2-[4-(3,5-Dichlorophenxoy)-3,5-diethyl-1H-pyrazol-1-yl)ethoxy}ethanamine; 4-{[4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}morpholine; 4-(3,5-Dichlorophenoxy)-3-methyl-5-[(2-methyl-1H-imidazol-1-yl)methyl]-1H-pyrazole; 2-[4-(3,5-Dichlorophenoxy)-3-ethyl-5-methoxy-1H-pyrazol-1-yl]ethanol; 1-{[4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}-1H-1,2,4-triazole; 3-[(3,5-Diethyl-1H-pyrazol-4-yl)oxy]benzonitrile; 3-{[1-(2-Aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}benzonitrile; 2-[4-(3-Cyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetamide; Ethyl [4-(3-cyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetate; 1-Allyl-4-(3,5-dichlorophenoxy)-3,5-diethyl-1H-pyrazole; N-{[4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}-N-(4-methoxybenzyl)amine; N-(cyclopropylmethyl)[4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methanamine; [4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]-N,N-dimethylmethanamine; [4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]-N-methylmethanamine; 1-{[4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}-4-methylpiperazine; 1-{[4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}-4-piperidinecarboxamide; N-{[4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}-2-methoxyethanamine; 1-acetyl-4-{[4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}piperazine; N-[2-({[4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}amino)ethyl]acetamide; N-(1-{[4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}-4-piperidinyl)acetamide; 1-{[4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}-4-methoxypiperidine; 3-Chloro-5-[(3,5-dimethyl-1H-pyrazol-4-yl)oxy]benzonitrile; 3-{[5-(Aminomethyl)-3-methyl-1H-pyrazol-4-yl]oxy}-5-chlorobenzonitrile; 3-Chloro-5-{[3-methyl-5-(1-piperazinylmethyl)-1H-pyrazol-4-yl]oxy}benzonitrile; 3-Chloro-5-[(5-{[(4-cyanobenzyl)amino]methyl}-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-[(3-methyl-5-{[4-(methylsulfonyl)-1-piperazinyl]methyl}-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-[(5-{[4-(methoxyacetyl)-1-piperazinyl]methyl}-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile; Methyl 4-{[4-(3-chloro-5-cyanophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}-1-piperazinecarboxylate; 4-[({[4-(3-Chloro-5-cyanophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}amino)methyl]benzenesulfonamide; 4-(3,5-Dichlorophenoxy)-5-(methoxymethyl)-3-methyl-1H-pyrazole; 3- tert-Butyl-4-(3,5-dichlorophenoxy)-5-methyl-1H-pyrazole; 4-(3,5-Dichlorophenoxy)-3-ethyl-5-methyl-1H-pyrazole; 4-Cyano-N-{[4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}benzamide; 3-Cyano-N-{[4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}benzamide; N-{[4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}-N-(3-pyridinylmethyl)amine; 3-({5-[(4-Acetyl-1-piperazinyl)methyl]-3-methyl-1H-pyrazol-4-yl}oxy)-5-chlorobenzonitrile; 3-Chloro-5-[(5-{[(4-cyanobenzyl)(methyl)amino]methyl}-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-[(5-{[(4-cyanobenzyl)(2-hydroxyethyl)amino]methyl}-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-({3-methyl-5-[(2-methyl-1H-imidazol-1-yl)methyl]-1H-pyrazol-4-yl}oxy)benzonitrile; 2-(4-(3,5-Dichlorophenoxy)-3-methyl-5-{[(3-pyridinylmethyl)amino]methyl}-1H-pyrazol-1-yl)ethanol; 5-[(3-Isopropyl-5-methyl-1H-pyrazol-4-yl)oxy]isophthalonitrile; 5-{[1-(2-Hydroxyethyl)-3-isopropyl-5-methyl-1H-pyrazol-4-yl]oxy}isophthalonitrile; 3-(3,5-Dichlorophenoxy)-2-ethyl-6,7-dihydropyrazolo[1,5-a]pyrazin-4 (5H)-one; 3-(3,5-Dichlorophenoxy)-2-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine; 3-(3,5-Dichlorophenoxy)-2-ethyl-5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine; 4-[(3-(3,5-Dichlorophenoxy)-2-ethyl-6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)methyl]benzonitrile; 3-(3,5-Dichlorophenoxy)-2-ethyl-5-(4-methoxybenzyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine; [1-(2-Aminoethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-5-yl]methanol; 2-[4-(3,5-Dichlorophenoxy)-5-(ethoxymethyl)-3-ethyl-1H-pyrazol-1-yl]ethylamine; 2-[4-(3,5-dichlorophenoxy)-3-ethyl-5-(1H-pyrazol-1-ylmethyl)-1H-pyrazol-1-yl]ethylamine; N-{[1-(2-aminoethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-5-yl]methyl}-N-(4-methoxybenzyl)amine; 4-[({[1-(2-aminoethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-5-yl]methyl}amino)methyl]benzonitrile; 2-[5-[(4-Acetyl-1-piperazinyl)methyl]-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-1-yl]ethylamine; N-[2-({[1-(2-Aminoethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-5-yl]methyl}amino)ethyl]acetamide; [4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methanamine hydrobromide; N-{[4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}-N-(4-fluorobenzyl)amine; 4-[({[4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}amino)methyl]benzonitrile; 3-Chloro-5-[(1,3,5-trimethyl-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-[(5-{[(4-cyanobenzyl)amino]methyl}-1,3-dimethyl-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-{[1-(2-hydroxyethyl)-3,5-dimethyl-1H-pyrazol-4-yl]oxy}benzonitrile; 3-Chloro-5-{[5-{[(4-cyanobenzyl)amino]methyl}-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy}benzonitrile; 4-[({[4-(3-Chloro-5-cyanophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}amino)methyl]benzamide; 3-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-fluorobenzonitrile; 3-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile; 5-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile; 3-chloro-5-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}benzonitrile; 3-[(3,5-diethyl-1H-pyrazol-4-yl)oxy]-5-fluorobenzonitrile; 5-[(3,5-diethyl-1H-pyrazol-4-yl)oxy]isophthalonitrile; 3-[(3,5-diethyl-1H-pyrazol-4-yl)oxy]-5-methylbenzonitrile; 3-chloro-5-[(3,5-diethyl-1H-pyrazol-4-yl)oxy]benzonitrile; 3-{[1-(2-aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile; 3-{[1-(2-aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-chlorobenzonitrile; 5-{[1-(2-aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}isophthalonitrile; 3-{[1-(2-aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-fluorobenzonitrile; 5-[(3-cyclopropyl-5-ethyl-1H-pyrazol-4-yl)oxy]isophthalonitrile; 5-[(3-tert-butyl-5-methyl-1H-pyrazol-4-yl)oxy]isophthalonitrile; 5-[(5-ethyl-3-isopropyl-1H-pyrazol-4-yl)oxy]isophthalonitrile; 4-(3,5-Dichlorophenoxy)-3,5-diethyl-1-(1-methyl-3-azetidinyl)-1H-pyrazole; 2-[4-(3,5-Dichlorophenoxy)-3-ethyl-1H-pyrazol-1-yl]ethylamine; 2-[4-(3,5-Dichlorophenoxy)-5-ethyl-1H-pyrazol-1-yl]ethylamine; tert-Butyl 2-[4-(3,5-dichlorophenoxy)-3-ethyl-5-(hydroxymethyl)-1H-pyrazol-1-yl]ethylcarbamate; tert-Butyl 2-[4-(3,5-dichlorophenoxy)-5-(ethoxymethyl)-3-ethyl-1H-pyrazol-1-yl]ethylcarbamate; tert-Butyl 2-[5-(bromomethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-1-yl]ethylcarbamate; tert-Butyl 2-[5-(aminomethyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-1-yl]ethylcarbamate; tert-Butyl 2-[5-[(4-acetyl-1-piperazinyl)methyl]-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-1-yl]ethylcarbamate; tert-Butyl 2-[4-(3,5-dichlorophenoxy)-3-ethyl-5-(1H-pyrazol-1-ylmethyl)-1H-pyrazol-1-yl]ethylcarbamate; tert-Butyl 2-[5-({[2-(acetylamino)ethyl]amino}methyl)-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-1-yl]ethylcarbamate; tert-Butyl 2-(4-(3,5-dichlorophenoxy)-3-ethyl-5-{[(4-methoxybenzyl)amino]methyl}-1H-pyrazol-1-yl)ethylcarbamate; tert-Butyl 2-[5-{[(4-cyanobenzyl)amino]methyl}-4-(3,5-dichlorophenoxy)-3-ethyl-1H-pyrazol-1-yl]ethylcarbamate; 3-{[5-(Bromomethyl)-1,3-dimethyl-1H-pyrazol-4-yl]oxy}-5-chlorobenzonitrile; 3-[(3,5-Diethyl-1-methyl-1H-pyrazol-4-yl)oxy]benzonitrile; 3-{[3,5-Diethyl-1-(2-methoxyethyl)-1H-pyrazol-4-yl]oxy}benzonitrile; 3-({5-[2-(Benzyloxy)ethyl]-3-ethyl-1H-pyrazol-4-yl}oxy)-5-fluorobenzonitrile; 3-{[3-Ethyl-5-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-fluorobenzonitrile; 3-({5-[2-(4-Cyanophenoxy)ethyl]-3-ethyl-1H-pyrazol-4-yl}oxy)-5-fluorobenzonitrile; 3-[(3-Ethyl-5-{2-[(2-methyl-3-pyridinyl)oxy]ethyl}-1H-pyrazol-4-yl)oxy]-5-fluorobenzonitrile; 3-({3-Ethyl-5-[2-(3-pyridinyloxy)ethyl]-1H-pyrazol-4-yl}oxy)-5-fluorobenzonitrile; 3-[(5-{2-[(2-Amino-3-pyridinyl)oxy]ethyl}-3-ethyl-1H-pyrazol-4-yl)oxy]-5-fluorobenzonitrile; 5-({5-[2-(benzyloxy)ethyl]-3-ethyl-1H-pyrazol-4-yl}oxy)isophthalonitrile; 5-{[3-Ethyl-5-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile; 3-{[5-(Aminomethyl)-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy}-5-chlorobenzonitrile; 5-[(1-Allyl-3-tert-butyl-5-methyl-1H-pyrazol-4-yl)oxy]isophthalonitrile; 5-{[3-tert-Butyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy}isophthalonitrile; 5-{[1-(2-Aminoethyl)-3-tert-butyl-5-methyl-1H-pyrazol-4-yl]oxy}isophthalonitrile; 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(1H-1,2,4-triazol-1-yl)benzonitrile; 3-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(4-oxo-1 (4H)-pyridinyl)benzonitrile; 3-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(1H-1,2,3-triazol-1-yl)benzonitrile; 3-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(2H-1,2,3-triazol-2-yl)benzonitrile; 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-fluorobenzamide; 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(1H-pyrazol-1-yl)benzamide; 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(2-oxo-1 (2H)-pyridinyl)benzamide; 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(6-oxo-1 (6H)-pyridazinyl)benzamide; 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(2,3-dimethyl-5-oxo-2,5-dihydro-1H-pyrazol-1-yl)benzamide; 5-{[3-Cyclopropyl-5-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile; 5-{[5-Cyclopropyl-3-ethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile; 5-{[5-Ethyl-1-(2-hydroxyethyl)-3-isopropyl-1H-pyrazol-4-yl]oxy}isophthalonitrile; 5-{[3-Ethyl-1-(2-hydroxyethyl)-5-isopropyl-1H-pyrazol-4-yl]oxy}isophthalonitrile; 2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl carbamate; N-{2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl}sulfamide; N-{2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl}-2-methoxyacetamide; 5-{[1-(3-Azetidinyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}isophthalonitrile; 5-{[3,5-Diethyl-1-(3-hydroxypropyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile; 5-[(3,5-Diethyl-1-methyl-1H-pyrazol-4-yl)oxy]isophthalonitrile; 5-{[3,5-Diethyl-1-(2-methoxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile; 5-{[1-(3-Aminopropyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}isophthalonitrile; methyl [4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetate; 2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]acetamide; 5-{[3,5-Diethyl-1-(hydroxymethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile; 3-[({[4-(3-cyano-5-fluorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}amino)methyl]benzamide; 4-[({(4-(3-Cyano-5-fluorophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}amino)methyl]benzamide; 4-[({[4-(3,5-Dicyanophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}amino)methyl]benzamide; 3-[({[4-(3-Chloro-5-cyanophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}amino)methyl]benzamide; 4-[({[4-(3-Cyano-5-methylphenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}amino)methyl]benzamide; 4-[({[4-(3-Cyanophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}amino)methyl]benzamide; 5-[(3,5-Dicyclopropyl-1H-pyrazol-4-yl)oxy]isophthalonitrile; 5-{[3,5-Dicyclopropyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile; 5-{[1-(2-Aminoethyl)-3,5-dicyclopropyl-1H-pyrazol-4-yl]oxy}isophthalonitrile; 3-{[3-cyclopropyl-1-(2-hydroxyethyl)-5-methyl-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile; 3-{[5-cyclopropyl-1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile; 3-[3-Cyclopropyl-1-(2-amino-ethyl)-5-methyl-1H-pyrazol-4-yloxy]-5-methyl-benzonitrile; 3-[(3-Cyclopropyl-5-methyl-1H-pyrazol-4-yl)oxy]-5-methylbenzonitrile; 3-{[1-(3-Aminopropyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile; 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-4-methoxybenzonitrile; 2-[3,5-Diethyl-4-(1-naphthyloxy)-1H-pyrazol-1-yl]ethanol; 2-[3,5-Diethyl-4-(2-naphthyloxy)-1H-pyrazol-1-yl]ethanol; 2-{4-[3,5-Di(1H-pyrazol-1-yl)phenoxy]-3,5-diethyl-1H-pyrazol-1-yl}ethanol; 2-{3,5-Diethyl-4-[3-fluoro-5-(1H-pyrazol-1-yl)phenoxy]-1H-pyrazol-1-yl}ethanol; 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-methoxybenzonitrile; 2-[4-(3,5-Difluorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethylamine; 3-{[1-(2-Aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-fluorobenzamide; 3-[(3-Isopropyl-5-methyl-1H-pyrazol-4-yl)oxy]-5-methylbenzonitrile; 3-{[1-(2-Aminoethyl)-3-isopropyl-5-methyl-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile; 2-[4-(3,5-Dichlorophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]-N-(2-pyridinylmethyl)acetamide; [4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]acetonitrile; 1-{[4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]acetyl}piperidine; (3R)-1-{[4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]acetyl}-3-piperidinol; N-(2,4-Dichlorobenzyl)-2-[4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]acetamide; 2-[4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]-N-(6-methyl-2-pyridinyl)acetamide; 2-[4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]-N-[4-(trifluoromethyl)benzyl]acetamide; N-(3-Chlorobenzyl)-2-[4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]acetamide; 2-[4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]-N-[2-(trifluoromethyl)benzyl]acetamide; 2-[4-(3,5-Dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]-N-(4-fluorobenzyl)acetamide; N-Benzyl-2-[4-(3,5-dichlorophenoxy)-3-methyl-1H-pyrazol-5-yl]-N-methylacetamide; 3-chloro-5-[(5-{[(2-chlorobenzyl)amino]methyl}-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile; 3-({5-[(Benzylamino)methyl]-3-methyl-1H-pyrazol-4-yl}oxy)-5-chlorobenzonitrile; 3-[(5-{[Benzyl(methyl)amino]methyl}-3-methyl-1H-pyrazol-4-yl)oxy]-5-chlorobenzonitrile; 3-Chloro-5-{[5-({[(5-chloro-2-pyridinyl)methy]amino}methyl)-3-methyl-1H-pyrazol-4-yl]oxy}benzonitrile; 3-Chloro-5-[(3-methyl-5-{[(4-pyridinylmethyl)amino]methyl}-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-[(3-methyl-5-{[(4-methylbenzyl)amino]methyl}-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-[(5-{[(3-methoxypropyl)amino]methyl}-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile; 4-[2-({[4-(3-Chloro-5-cyanophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}amino)ethyl]benzenesulfonamide; 3-Chloro-5-{[3-methyl-5-({[(1S)-1-phenylethyl]amino}methyl)-1H-pyrazol-4-yl]oxy}benzonitrile; 3-Chloro-5-[(5-{[(4-chlorobenzyl)amino]methyl}-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-[(3-methyl-5-{[methyl(2-phenylethyl)amino]methyl}-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-({3-methyl-5-[(1H-pyrazol-3-ylamino)methyl]-1H-pyrazol-4-yl}oxy)benzonitrile; N-[2-({[4-(3-Chloro-5-cyanophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}amino)ethyl]acetamide; 3-Chloro-5-[(5-{[(3-chlorobenzyl)amino]methyl}-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-{[5-({[3-fluoro-5-(trifluoromethyl)benzyl]amino}methyl)-3-methyl-1H-pyrazol-4-yl]oxy}benzonitrile; 3-Chloro-5-[(3-methyl-5-{[(6-methyl-2-pyridinyl)amino]methyl}-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-[(5-{[(4-hydroxy-6-methyl-2-pyrimidinyl)amino]methyl}-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-[(5-{[(4-fluorobenzyl)amino]methyl}-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-{[5-({[(1R)-2-hydroxy-1-phenylethyl]amino}methyl)-3-methyl-1H-pyrazol-4-yl]oxy}benzonitrile; 3-({5-[(Benzylamino)methyl]-3-methyl-1H-pyrazol-4-yl}oxy)-5-chlorobenzonitrile; 3-Chloro-5-[(5-{[(3-methoxybenzyl)amino]methyl}-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-{[3-methyl-5-({[4-(trifluoromethyl)benzyl]amino}methyl)-1H-pyrazol-4-yl]oxy)benzonitrile; 3-Chloro-5-{[5-({[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino}methyl)-3-methyl-1H-pyrazol-4-yl]oxy}benzonitrile; 3-Chloro-5-[(5-{[(2-methoxybenzyl)amino]methyl}-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-{[3-methyl-5-(([2-(2-thienyl)ethyl]amino}methyl)-1H-pyrazol-4-yl]oxy)benzonitrile; 3-Chloro-5-[(3-methyl-5-{[(3-pyridinylmethyl)amino]methyl}-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-{[3-methyl-5-({[2-(trifluoromethyl)benzyl]amino}methyl)-1H-pyrazol-4-yl]oxy}benzonitrile; 3-Chloro-5-[(5-{[(2,4-dichlorobenzyl)amino]methyl)-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-[(3-methyl-5-{[(2-pyridinylmethyl)amino]methyl}-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-[(5-{[(3,4-dichlorobenzyl)amino]methyl}-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-[(3-methyl-5-{[(3-phenylpropyl)amino]methyl}-1H-pyrazol-4-yl)oxy]benzonitrile; 3-Chloro-5-[(5-{[(4-methoxybenzyl)amino]methyl}-3-methyl-1H-pyrazol-4-yl)oxy]benzonitrile; 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(methylsulfanyl)benzonitrile; 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(methylsulfinyl)benzonitrile; 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(methylsulfonyl)benzonitrile; 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-[2-(dimethylamino)ethoxy]benzonitrile; 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-[2-(methylamino)ethoxy]benzonitrile; 2-(3-Cyano-5-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}phenoxy)acetamide; 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(2-methoxyethoxy)benzonitrile; 3-{[1-(2-Aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-methoxybenzonitrile; 3-{[1-(2-Aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-(1H-pyrazol-1-yl)benzonitrile; 3,5-Dichlorophenyl-3-methyl-5-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-1H-pyrazol-4-yl ether; 3-Fluoro-5-{[1-(2-hydroxyethyl)-5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]oxy}benzonitrile; 5-[(3,5-Diethyl-1-{2-[(2-methoxyethoxy)methoxy]ethyl}-1H-pyrazol-4-yl)oxy]isophthalonitrile; 3-Cyano-5-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}benzamide; 5-{[5-Ethyl-3-(1-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile; 5-{[5-Ethyl-3-(1-hydroxyethyl)-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile; 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(5-trifluoromethyl-1,2,4-oxadiazol-3-yl)benzonitrile; 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(5-methyl-1,2,4-oxadiazol-3-yl)benzonitrile; 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(5-ethyl-1,2,4-oxadiazol-3-yl)benzonitrile; 3-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-(5-isopropyl-1,2,4-oxadiazol-3-yl)benzonitrile; 5-[({[4-(3-Chloro-5-cyanophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}amino)methyl]nicotinamide; 2-[({[4-(3-Chloro-5-cyanophenoxy)-3-methyl-1H-pyrazol-5-yl]methyl}amino)methyl]isonicotinamide; Di(tert-butyl) 2-[4-(3,5-dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl phosphate; 2-[4-(3,5-Dicyanophenoxy)-3,5-diethyl-1H-pyrazol-1-yl]ethyl dihydrogen phosphate; 5-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile sulfate salt; 5-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile; 5-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile tosylate salt; 5-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile mesylate salt; 3-([1-(2-Aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile bis-mesylate salt; 3-([1-(2-Aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile phosphate salt; 3-{[1-(2-Aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile (L) tartrate salt; 3-{[1-(2-Aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile succinate salt; and 3-{[1-(2-Aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile (L) citrate salt; or a pharmaceutically acceptable salt, solvate or derivative thereof.
 30. A compound selected from the group consisting of: 3-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-fluorobenzonitrile; 3-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile; 5-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}isophthalonitrile; 3-chloro-5-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}benzonitrile; 5-[(3,5-diethyl-1H-pyrazol-4-yl)oxy]isophthalonitrile; 3-[(3,5-diethyl-1H-pyrazol-4-yl)oxy]-5-methylbenzonitrile; 3-chloro-5-[(3,5-diethyl-1H-pyrazol-4-yl)oxy]benzonitrile; 3-{[1-(2-aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-methylbenzonitrile; 3-{[1-(2-aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}-5-chlorobenzonitrile; and 5-{[1-(2-aminoethyl)-3,5-diethyl-1H-pyrazol-4-yl]oxy}isophthalonitrile; or a pharmaceutically acceptable salt, solvate or derivative thereof.
 31. A compound of formula (I):

or a pharmaceutically acceptable salt or solvate thereof, wherein: R¹ is H, C₁-C₆ alkyl, —O(C₁-C₆ alkyl), —O(C₃-C₇ cycloalkyl), said C₁-C₆ alkyl being unsubstituted or substituted by R¹⁵; R² is H, C₁-C₃ alkyl, propenyl or C-linked R¹⁵, said C₁-C₃ alkyl being unsubstituted or substituted by —OH, —OCH₃, —OCH₂CH₂NH₂, —CN, —CO₂CH₃, —CONH₂, —C(═NH)NH₂, —CONHNH₂, —NH₂, —NHCH₃, —N(CH₃)₂, —NHCH₂CH₂NHCOCH₃, —NHCH₂CH₂OCH₃, —NHCH₂R¹⁵, —NHCOR¹⁵, —NHCOCH₂OCH₃, or R¹⁵; R¹⁵ is azetidinyl, tetrahydrofuranyl, morpholinyl, piperazinyl, pyrazolyl, oxadiazolyl, pyridinyl or pyrimidinyl each being unsubstituted or substituted by —OH, —NH₂, oxo or C₁-C₆ alkyl or —CO(C₁-C₆ alkyl); R³ is C₁-C₆ alkyl; and R⁴ is phenyl unsubstituted or substituted by halo, —CN, C₁-C₆ alkyl, C₁-C₆-haloalkyl, C₃-C₇ cycloalkyl or C₁-C₆ alkoxy.
 32. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, according to any one of claims 1 to 31, together with one or more pharmaceutically acceptable excipients, diluents or carriers.
 33. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 31, together with one or more pharmaceutically acceptable excipients, diluents or carriers.
 34. A pharmaceutical composition according to claim 31 or 32, further comprising one or more additional therapeutic agents.
 35. A method of inhibiting or modulating expression of a reverse transcriptase comprising contacting the reverse transcriptase with a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any one of claims 1 to 31, or a pharmaceutical composition according to any one of claims 32 to
 34. 36. A method of treating an HIV, or genetically-related retroviral, infection or a resulting acquired immune deficiency syndrome comprising administering a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any one of claims 1 to 31, or a pharmaceutical composition according to any one of claims 32 to
 34. 37. A method of treating an HIV, or genetically-related retroviral, infection or a resulting acquired immune deficiency syndrome comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 31, or a pharmaceutical composition according to any one of claims 32 to
 34. 38. A method of treating a mammal in need of reverse transcriptase inhibition or modulation treatment comprising administering to said mammal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any one of claims 1 to 31, or a pharmaceutical composition according to any one of claims 32 to
 34. 39. A method of treating a mammal in need of reverse transcriptase inhibition or modulation treatment comprising administering to said mammal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 31, or a pharmaceutical composition according to any one of claims 32 to
 34. 40. A method of treating a mammal afflicted with an HIV, genetically-related retroviral infection, or a resulting acquired immune deficiency comprising administering to said mammal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof according to any one of claims 1 to 31, or a pharmaceutical composition according to any one of claims 32 to
 34. 41. A method of treating a mammal afflicted with an HIV, genetically-related retroviral infection, or a resulting acquired immune deficiency comprising administering to said mammal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 31, or a pharmaceutical composition according to any one of claims 32 to
 34. 42. A process for preparing a compound of formula (I) or a salt, solvate or pharmaceutically acceptable derivative thereof according to any one of claims 1 to 31, comprising: (A) except where either R¹ or R³ is halo, —OR⁸ or —CN, condensing a compound of formula (II), (VI) or (VII):

with a compound of formula (V): H₂NNHR²  (V) or a salt or hydrate thereof; (B) for preparing a compound of formula (I) in which R¹ or R³ is —OR⁸, reacting a compound of formula (XIII) or (XIV);

wherein L¹, L² and L³ are each suitable leaving groups; with an alcohol of formula (XXI); R⁸OH  (XXI) in the presence of a suitable palladium catalyst and carbon monoxide; (C) for preparing a compound of formula (I) in which R¹ or R³ is —OR⁸, reacting a compound of formula (XV) or (XVI);

with a compound of formula (XXI); R⁸OH  (XXI) under dehydrating conditions; or (D) for preparing a compound of formula (I) in which R¹ or R³ is halo, reacting a compound of formula (XV) or (XVI);

with a halogenating agent; or (E) interconverting a compound of formula (I) into another compound of formula (I); or (F) deprotecting a protected derivative of a compound of formula (I); and optionally converting a compound of formula (I) prepared by any one of processes (A) to (F) into a pharmaceutically acceptable salt, solvate or derivative thereof.
 43. A compound of formula (II), (VI), (VII), (XIII) or (XIV):

wherein: either: R¹ is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl, benzyl, halo, —CN, —OR⁷, —CO₂R¹⁰, —CONR⁵R¹⁰, R⁸ or R⁹, said C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl and benzyl being unsubstituted or substituted by halo, —CN, —OR¹⁰, S(O)_(x)R¹⁰, —CO₂R¹⁰, —CONR⁵R¹⁰, —OCONR⁵R¹⁰, —NR⁵CO₂R¹¹, —NR¹⁰R¹¹, —NR⁵COR¹⁰, —SO₂NR⁵R¹¹, —NR⁵CONR⁵R¹⁰, —NR⁵SO₂R¹⁰ or R¹⁰; and R² is H, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, C₃-C₇ cycloalkyl, C₃-C₇ cycloalkenyl, phenyl, benzyl, R⁸ or R⁹, said C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl and benzyl being unsubstituted or substituted by halo, —OR⁵, —OR¹², —CN, —CO₂R⁷, —OCONR⁵R⁵, —CONR⁵R⁵, —C(═NR⁵)NR⁵OR⁵, —CONR⁵NR⁵R⁵, —NR⁶R⁶, —NR⁵R¹², —NR⁵COR⁵, —NR⁵COR⁸, —NR⁵COR¹², —NR⁵CO₂R⁵, —NR⁵CONR⁵R⁵, —SO₂NR⁵R⁵, —NR⁵SO₂R⁵, —NR⁵SO₂NR⁵R⁵, R⁸ or R⁹; or R¹ and R², when taken together, represent unbranched C₃-C₄ alkylene, unsubstituted or substituted by oxo, wherein one methylene group of said C₃-C₄ alkylene may be replaced by an oxygen atom or a nitrogen atom, said nitrogen atom being unsubstituted or substituted by R¹⁰; R³ is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl, benzyl, halo, —CN, —OR⁷, —CO₂R⁵, —CONR⁵R⁵, R⁸ or R⁹, said C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl and benzyl being unsubstituted or substituted by halo, —CN, —OR⁵, —CO₂R⁵, —CONR⁵R⁵, —OCONR⁵R⁵, —NR⁵CO₂R⁵, —NR⁶R⁶, —NR⁵COR⁵, —SO₂NR⁵R⁵, —NR⁵CONR⁵R⁵, —NR⁵SO₂R⁵, R⁸ or R⁹; R⁴ is phenyl, naphthyl or pyridyl, each being unsubstituted or substituted by R⁸, halo, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl, C₁-C₆ alkoxy, —CONR⁵R⁵, OR¹³, SO_(x)R⁶, O—(C₁-C₆ alkylene)-CONR⁵R⁵, O—(C₁-C₆ alkylene)-NR⁵R⁵, or O—(C₁-C₆ alkylene)-OR⁶; each R⁵ is independently either H, C₁-C₆ alkyl or C₃-C₇ cycloalkyl or, when two R⁵ groups are attached to the same nitrogen atom, those two groups taken together with the nitrogen atom to which they are attached represent azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl or morpholinyl, said azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl and morpholinyl being optionally substituted by C₁-C₆ alkyl or C₃-C₇ cycloalkyl; each R⁶ is independently either H, C₁-C₆ alkyl or C₃-C₇ cycloalkyl; R⁷ is C₁-C₆ alkyl or C₃-C₇ cycloalkyl; R⁸ is a five or six-membered, aromatic heterocyclic group containing (i) from 1 to 4 nitrogen heteroatom(s) or (ii) 1 or 2 nitrogen heteroatom(s) and 1 oxygen or 1 sulphur heteroatom or (iii) 1 or 2 oxygen or sulphur heteroatom(s), said heterocyclic group being unsubstituted or substituted by halo, oxo, —CN, —COR⁵, —CONR⁵R⁵, —SO₂NR⁵R⁵, —NR⁵SO₂R⁵, —OR⁵, —NR⁵R⁵, —(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, fluoro(C₁-C₆)alkyl or C₃-C₇ cycloalkyl; R⁹ is a four to seven-membered, saturated or partially unsaturated heterocyclic group containing (i) 1 or 2 nitrogen heteroatom(s) or (ii) 1 nitrogen heteroatom and 1 oxygen or 1 sulphur heteroatom or (iii) 1 oxygen or sulphur heteroatom, said heterocyclic group being unsubstituted or substituted by oxo, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, —SO₂R⁵, —CONR⁵R⁵, —COOR⁵, —CO—(C₁-C₆ alkylene)-OR⁵ or —COR⁵ and unsubstituted or substituted on a carbon atom which is not adjacent to a heteroatom by halo, —OR⁵, —NR⁵R⁵, —NR⁵COR⁵, —NR⁵COOR⁵, —NR⁵CONR⁵R⁵, —NR⁵SO₂R⁵ or —CN; R¹⁰ is H, R⁸, R⁹, R¹³, C₁-C₆ alkyl, C₃-C₇ cycloalkyl or —(C₁-C₆ alkyl)-(C₃-C₇ cycloalkyl), said C₁-C₆ alkyl and C₃-C₇ cycloalkyl being unsubstituted or substituted by —OR⁵, —OR¹³, R⁸, R⁹, R¹³ or —COR¹³; R¹¹ is H, C₁-C₆ alkyl or C₃-C₇ cycloalkyl, said C₁-C₆ alkyl and C₃-C₇ cycloalkyl being unsubstituted or substituted by —OR⁵, —NR⁵R⁵, —NR⁵COR⁵, —CONR⁵R⁵, R⁸ or R⁹; R¹² is C₁-C₆ alkyl substituted by R⁸, R⁹, —OR⁵, —CONR⁵R⁵, —NR⁵COR⁵ or —NR⁵R⁵; R¹³ is phenyl unsubstituted or substituted by halo, —CN, —COR⁵, —CONR⁵R⁵, —SO₂NR⁵R⁵, —NR⁵SO₂R⁵, —OR⁵, —NR⁵R⁵, —(C₁-C₆ alkylene)-NR⁵R⁵, C₁-C₆ alkyl, halo(C₁-C₆)alkyl or C₃-C₇ cycloalkyl; and x is 0, 1 or 2; with the proviso that: (a) when R¹ and R³ are both phenyl, R² is not methyl; and (b) when R¹ is ethoxy and R³ is ethoxycarbonyl, R² is not phenyl; and L¹, L² and L³ are each suitable leaving groups. 